{"PMC7094407": [["INTRODUCTIONHealth problems can be thought of as phenotypic expressions of the complex relationships between genes, environments, and phenomes as a whole (Houle et al., 2010).", [["INTRODUCTIONHealth problems", "PROBLEM", 0, 27]]], ["Although modern dairy population medicine has focused extensively on establishing genetic associations to understand phenotypes related to productivity, disease states, and mortality (De Vries, 2017), these associations tend to explain only a small proportion of phenotypic variance (Houle, 2010).", [["modern dairy population medicine", "TREATMENT", 9, 41], ["phenotypes", "PROBLEM", 117, 127], ["disease states", "PROBLEM", 153, 167]]], ["Detailed records and evaluations of data related to phenotypic expressions of illness are required to characterize important biological outcomes, including morbidity and mortality (Houle et al., 2010; Giebel et al., 2012; Gangsei et al., 2016).INTRODUCTIONEfforts to document dairy mortality have primarily focused on adult cow death (Thomsen and Houe, 2006; McConnel et al., 2015; Shahid et al., 2015; Compton et al., 2017).", [["illness", "DISEASE", 78, 85], ["cow death", "DISEASE", 324, 333], ["cow", "ORGANISM_SUBDIVISION", 324, 327], ["cow", "SPECIES", 324, 327], ["cow", "SPECIES", 324, 327], ["evaluations of data", "TEST", 21, 40], ["illness", "PROBLEM", 78, 85]]], ["Research into heifer health problems tends to distill disease into preweaning or postweaning gastrointestinal (GI) or respiratory disease (Gorden and Plummer, 2010; Stanton et al., 2012; Klein-J\u00f6bstl et al., 2014; USDA, 2017).", [["gastrointestinal", "ANATOMY", 93, 109], ["GI", "ANATOMY", 111, 113], ["respiratory", "ANATOMY", 118, 129], ["postweaning gastrointestinal (GI) or respiratory disease", "DISEASE", 81, 137], ["gastrointestinal", "ORGANISM_SUBDIVISION", 93, 109], ["respiratory disease", "PROBLEM", 118, 137], ["gastrointestinal", "ANATOMY", 93, 109], ["respiratory", "ANATOMY", 118, 129], ["disease", "OBSERVATION", 130, 137]]], ["It is estimated that over 8% of nulliparous heifers die, with producer-derived surveys implicating infectious calf diarrhea as a cause of more than half (56.4%) of all preweaning calf mortality and respiratory problems as a cause of over half (58.9%) of postweaning deaths (USDA, 2017).", [["diarrhea", "DISEASE", 115, 123], ["respiratory problems", "DISEASE", 198, 218], ["deaths", "DISEASE", 266, 272], ["heifers", "ORGANISM", 44, 51], ["calf", "ORGANISM_SUBDIVISION", 110, 114], ["calf", "ORGANISM_SUBDIVISION", 179, 183], ["calf", "SPECIES", 110, 114], ["calf", "SPECIES", 179, 183], ["infectious calf diarrhea", "PROBLEM", 99, 123], ["all preweaning calf mortality", "PROBLEM", 164, 193], ["respiratory problems", "PROBLEM", 198, 218], ["infectious", "OBSERVATION_MODIFIER", 99, 109], ["diarrhea", "OBSERVATION", 115, 123], ["calf", "ANATOMY", 179, 183], ["respiratory problems", "OBSERVATION", 198, 218]]], ["However, diagnostic detail and accuracy is hindered by a lack of necropsies and additional laboratory work-up.", [["additional laboratory work", "TEST", 80, 106]]], ["Across US dairies, it is estimated that only 11% of farms necropsy heifers at all and <5% of dead heifers are necropsied as part of a postmortem examination of cause of death (USDA, 2017).INTRODUCTIONWithout necropsies, it is often impossible to clarify underlying disease processes and treatment efficacy.", [["death", "DISEASE", 169, 174], ["heifers", "ORGANISM", 98, 105], ["a postmortem examination", "TEST", 132, 156], ["death", "PROBLEM", 169, 174], ["necropsies", "TREATMENT", 208, 218], ["underlying disease processes", "PROBLEM", 254, 282], ["treatment efficacy", "TREATMENT", 287, 305], ["disease", "OBSERVATION", 265, 272]]], ["Furthermore, inconsistencies in cause of death definitions and disease data presentation hinder descriptions, comparisons, and investigations into animal health (Kelton et al., 1998; Giebel et al., 2012).", [["death", "DISEASE", 41, 46], ["death definitions", "PROBLEM", 41, 58]]], ["Standardizing health event nomenclature based on postmortem findings in simple and consistent terms can provide useful information not only for the analysis of deaths but for other health-related questions as well (McConnel and Garry, 2017).", [["deaths", "DISEASE", 160, 166], ["postmortem findings", "TEST", 49, 68]]], ["Without standardized methods of classification, what little information is available is often wasted (McConnel et al., 2010; Compton et al., 2017).INTRODUCTIONThe correlation between suspected causes of death in heifers and causes of death verified through postmortem evaluations has been assessed to a very limited degree within Scandinavia (Gulliksen et al., 2009) and has not been evaluated at a meaningful level within the United States.", [["death", "DISEASE", 203, 208], ["death", "DISEASE", 234, 239], ["death", "PROBLEM", 203, 208], ["death", "PROBLEM", 234, 239], ["postmortem evaluations", "TEST", 257, 279]]], ["Gulliksen et al. (2009) found that pneumonia was the most common cause of death among 65 necropsied calves on 35 Norwegian dairy farms but that enteritis was the most frequent postmortem diagnoses in the youngest calves.", [["pneumonia", "DISEASE", 35, 44], ["death", "DISEASE", 74, 79], ["enteritis", "DISEASE", 144, 153], ["calves", "ORGANISM", 100, 106], ["calves", "ORGANISM", 213, 219], ["calves", "SPECIES", 100, 106], ["calves", "SPECIES", 213, 219], ["pneumonia", "PROBLEM", 35, 44], ["death", "PROBLEM", 74, 79], ["enteritis", "PROBLEM", 144, 153], ["pneumonia", "OBSERVATION", 35, 44], ["enteritis", "OBSERVATION", 144, 153]]], ["Given that <5% of dead heifers are necropsied in the United States, the reality is that many dairy calf mortalities are poorly categorized, with causes of death based solely upon previous treatment history rather than diagnostic input.", [["death", "DISEASE", 155, 160], ["heifers", "ORGANISM", 23, 30], ["calf", "ORGANISM_SUBDIVISION", 99, 103], ["calf", "SPECIES", 99, 103], ["many dairy calf mortalities", "PROBLEM", 88, 115], ["death", "PROBLEM", 155, 160], ["diagnostic input", "TEST", 218, 234]]], ["The absence of diagnostic input is important because current estimations of the frequency of disease are then dependent upon standard treatment protocols serving as a proxy for unsubstantiated underlying disease.", [["disease", "PROBLEM", 93, 100], ["standard treatment protocols", "TREATMENT", 125, 153], ["unsubstantiated underlying disease", "PROBLEM", 177, 211], ["disease", "OBSERVATION", 93, 100], ["disease", "OBSERVATION", 204, 211]]], ["This lack of insight into heifer health problems is a major liability for efforts to accurately record disease phenotypes.", [["disease phenotypes", "PROBLEM", 103, 121]]], ["Without a clearer understanding of the relationship between treatment and disease, approximations of treatment failures versus diagnostic inaccuracies are left unknown.", [["treatment", "TREATMENT", 60, 69], ["disease", "PROBLEM", 74, 81], ["treatment failures", "TREATMENT", 101, 119], ["diagnostic inaccuracies", "TEST", 127, 150], ["left", "ANATOMY_MODIFIER", 155, 159]]], ["Ultimately, understanding the timing and fates of animals that die on farms can be informative in their reflection of management conditions and production efficiencies and provide a foundation for improved understanding of animal health and features of farm management that present risks of poor outcomes.INTRODUCTIONWith that in mind, the objective of this project was to utilize necropsies, standardized death certificates listing attributable causes of death (underlying, contributing, immediate), and additional diagnostics to clarify calf mortality phenotypes for a better understanding and recording of the underlying burden of disease.", [["death", "DISEASE", 406, 411], ["death", "DISEASE", 456, 461], ["calf", "ORGANISM_SUBDIVISION", 539, 543], ["calf", "SPECIES", 539, 543], ["management conditions", "TREATMENT", 118, 139], ["production efficiencies", "PROBLEM", 144, 167], ["farm management", "TREATMENT", 253, 268], ["necropsies", "TREATMENT", 381, 391], ["death", "PROBLEM", 456, 461], ["calf mortality phenotypes", "PROBLEM", 539, 564], ["disease", "PROBLEM", 634, 641], ["disease", "OBSERVATION", 634, 641]]], ["Comparisons were made between standard treatment-based versus on-farm necropsy-based cause-of-death diagnoses with or without additional diagnostics at the Washington Animal Disease Diagnostic Laboratory (WADDL; College of Veterinary Medicine, Washington State University, Pullman).", [["death", "DISEASE", 94, 99], ["standard treatment", "TREATMENT", 30, 48]]], ["We hypothesized that classifying dairy calf mortality phenotypes via a systematic postmortem analysis would identify differences in cause of death diagnoses compared with those derived from treatments alone.Study Population ::: MATERIALS AND METHODSThis cross-sectional study was carried out on a dairy calf ranch in the western United States between June 20 and September 14, 2017.", [["death", "DISEASE", 141, 146], ["calf", "ORGANISM_SUBDIVISION", 39, 43], ["calf", "ORGANISM_SUBDIVISION", 303, 307], ["calf", "SPECIES", 39, 43], ["calf", "SPECIES", 303, 307], ["dairy calf mortality phenotypes", "PROBLEM", 33, 64], ["a systematic postmortem analysis", "TEST", 69, 101], ["death diagnoses", "PROBLEM", 141, 156], ["treatments", "TREATMENT", 190, 200], ["METHODSThis cross-sectional study", "TEST", 242, 275], ["a dairy calf ranch", "TREATMENT", 295, 313]]], ["The ranch housed approximately 25,000 heifer calves from multiple dairies through 200 d of age.", [["calves", "ORGANISM", 45, 51], ["calves", "SPECIES", 45, 51]]], ["Historical mortality levels approximated 2% of carrying capacity per month, with 90% of those deaths occurring at \u226490 d of age.", [["deaths", "DISEASE", 94, 100], ["Historical mortality levels", "TEST", 0, 27]]], ["This study focused on deaths of calves \u226490 d of age to concentrate efforts within the high-risk period for calf mortality.Study Population ::: MATERIALS AND METHODSColostrum was fed to calves at the dairy of birth and approximately 40% of calves had serum total protein levels assessed at the ranch within the first week of life using a Brix refractometer.", [["serum", "ANATOMY", 250, 255], ["deaths", "DISEASE", 22, 28], ["calves", "ORGANISM", 32, 38], ["calf", "ORGANISM_SUBDIVISION", 107, 111], ["calves", "ORGANISM", 185, 191], ["calves", "ORGANISM", 239, 245], ["serum", "ORGANISM_SUBSTANCE", 250, 255], ["calves", "SPECIES", 32, 38], ["calf", "SPECIES", 107, 111], ["calves", "SPECIES", 185, 191], ["calves", "SPECIES", 239, 245], ["This study", "TEST", 0, 10], ["calf mortality", "PROBLEM", 107, 121], ["METHODSColostrum", "TREATMENT", 157, 173], ["serum total protein levels", "TEST", 250, 276], ["a Brix refractometer", "TREATMENT", 335, 355], ["calf", "ANATOMY", 107, 111], ["mortality", "OBSERVATION", 112, 121]]], ["Calves were fed 2 L of a custom milk blend twice daily from 1 to 52 d of age.", [["milk", "ANATOMY", 32, 36], ["Calves", "ORGANISM", 0, 6], ["milk", "ORGANISM_SUBSTANCE", 32, 36], ["Calves", "SPECIES", 0, 6], ["a custom milk blend", "TREATMENT", 23, 42]]], ["The milk blend consisted of pasteurized waste milk and milk replacer targeting 13% solids, 22 to 24% fat, and 28% protein.", [["milk", "ANATOMY", 4, 8], ["milk", "ANATOMY", 46, 50], ["milk", "ANATOMY", 55, 59], ["milk", "ORGANISM_SUBSTANCE", 4, 8], ["milk", "ORGANISM_SUBSTANCE", 46, 50], ["milk", "ORGANISM_SUBSTANCE", 55, 59], ["fat", "TISSUE", 101, 104], ["The milk blend", "TREATMENT", 0, 14], ["pasteurized waste milk", "TREATMENT", 28, 50], ["milk replacer", "TREATMENT", 55, 68], ["13% solids", "TREATMENT", 79, 89]]], ["A grain mix consisting of pellets, molasses, and whole corn was offered from d 3 of age and steadily increased to approximately 2.25 kg by d 30 with free choice thereafter.", [["corn", "ORGANISM_SUBDIVISION", 55, 59], ["corn", "SPECIES", 55, 59], ["corn", "SPECIES", 55, 59], ["A grain mix", "TREATMENT", 0, 11], ["molasses", "TREATMENT", 35, 43], ["grain mix", "OBSERVATION", 2, 11]]], ["An intranasal viral respiratory vaccine (Vista Once SQ, Intervet Inc., Merck Animal Health, Omaha, NE) and enteric clostridial vaccine (Ultrabac CD, Zoetis Inc., Kalamazoo MI) were administered at arrival.", [["An intranasal viral respiratory vaccine", "TREATMENT", 0, 39], ["Omaha, NE)", "TREATMENT", 92, 102], ["enteric clostridial vaccine", "TREATMENT", 107, 134], ["Ultrabac CD", "TREATMENT", 136, 147], ["Zoetis", "TREATMENT", 149, 155], ["Kalamazoo MI", "TREATMENT", 162, 174], ["enteric clostridial", "ANATOMY", 107, 126]]], ["A booster dose of the respiratory vaccine was administered at 21 d of age, and a 7-way clostridial vaccine (Ultrabac 7, Zoetis Inc.) was administered at 45 d of age.", [["respiratory", "ANATOMY", 22, 33], ["A booster dose", "TREATMENT", 0, 14], ["the respiratory vaccine", "TREATMENT", 18, 41], ["a 7-way clostridial vaccine (Ultrabac", "TREATMENT", 79, 116]]], ["Calves were kept in hutches through approximately 90 d of age.Calf Health Records ::: MATERIALS AND METHODSTwo on-farm veterinarians oversaw calf health management and treatment protocols.", [["Calves", "ORGANISM", 0, 6], ["calf", "ORGANISM_SUBDIVISION", 141, 145], ["Calves", "SPECIES", 0, 6], ["calf", "SPECIES", 141, 145], ["calf health management", "TREATMENT", 141, 163], ["treatment protocols", "TREATMENT", 168, 187]]], ["Upon entry to the ranch all calves were ear notched and tested for bovine viral diarrhea virus (BVDV) using PCR.", [["ear", "ANATOMY", 40, 43], ["bovine viral diarrhea", "DISEASE", 67, 88], ["calves", "ORGANISM", 28, 34], ["ear", "ORGAN", 40, 43], ["bovine viral diarrhea virus", "ORGANISM", 67, 94], ["BVDV", "ORGANISM", 96, 100], ["calves", "SPECIES", 28, 34], ["bovine", "SPECIES", 67, 73], ["viral diarrhea virus", "SPECIES", 74, 94], ["bovine viral diarrhea virus", "SPECIES", 67, 94], ["BVDV", "SPECIES", 96, 100], ["bovine viral diarrhea virus", "PROBLEM", 67, 94], ["PCR", "TEST", 108, 111], ["ranch", "ANATOMY_MODIFIER", 18, 23], ["all calves", "ANATOMY", 24, 34], ["ear notched", "ANATOMY", 40, 51]]], ["Health problems were diagnosed and treated based on input from calf health managers' clinical assessments, and health records included broad disease diagnoses and associated treatments.", [["calf", "ORGANISM_SUBDIVISION", 63, 67], ["calf", "SPECIES", 63, 67], ["clinical assessments", "TEST", 85, 105], ["broad disease diagnoses", "PROBLEM", 135, 158], ["associated treatments", "TREATMENT", 163, 184]]], ["Morbidity and mortality records were managed on-farm using DairyComp 305 (Valley Agricultural Software, Tulare CA) with record oversight and health data compilation provided through The HEALTHSUM Syndicate LLC (Sunnyside, WA).", [["LLC", "ANATOMY", 206, 209]]], ["Plausible causes of death were recorded by 3 calf health managers without input from this study's systematic postmortem analysis, and were coded as standardized, generic disease remarks (diarrhea, pneu, resp, injury, bloat) within a \u201cdied\u201d event.Study Protocol ::: MATERIALS AND METHODSCalves that died overnight between 1700 and 0700 h and were \u226490 d of age were gathered and delivered by 1000 h to a dedicated, biosecure necropsy site.", [["death", "DISEASE", 20, 25], ["diarrhea", "DISEASE", 187, 195], ["pneu", "DISEASE", 197, 201], ["calf", "SPECIES", 45, 49], ["death", "PROBLEM", 20, 25], ["this study", "TEST", 85, 95], ["systematic postmortem analysis", "TEST", 98, 128], ["diarrhea", "PROBLEM", 187, 195], ["pneu", "PROBLEM", 197, 201], ["injury", "PROBLEM", 209, 215], ["bloat", "PROBLEM", 217, 222], ["resp", "ANATOMY", 203, 207]]], ["Time and personnel constraints dictated that necropsies were performed 2 to 3 times per week on up to 10 calves.", [["calves", "ORGANISM", 105, 111], ["calves", "SPECIES", 105, 111], ["necropsies", "TEST", 45, 55]]], ["If more than 10 calves were available for necropsy, a coin flip was used to determine the 10 calves to be necropsied.", [["calves", "ORGANISM", 16, 22], ["calves", "ORGANISM", 93, 99], ["calves", "SPECIES", 16, 22], ["calves", "SPECIES", 93, 99], ["necropsy", "TREATMENT", 42, 50], ["a coin flip", "TREATMENT", 52, 63]]], ["Only calves that had died the previous night were necropsied in an effort to avoid autolysis due to summer daytime temperatures.", [["calves", "ORGANISM", 5, 11], ["calves", "SPECIES", 5, 11], ["autolysis", "PROBLEM", 83, 92], ["summer daytime temperatures", "PROBLEM", 100, 127], ["calves", "OBSERVATION", 5, 11]]], ["Necropsies were performed following a study protocol (Supplemental Figure S1; https://doi.org/10.3168/jds.2018-15527) outlining the standardized procedures for calf necropsies (Severidt et al., 2002), tissue sampling and tissue submission guidelines, and representative digital images.", [["tissue", "ANATOMY", 201, 207], ["tissue", "ANATOMY", 221, 227], ["tissue", "TISSUE", 201, 207], ["tissue", "TISSUE", 221, 227], ["calf", "SPECIES", 160, 164], ["Necropsies", "TEST", 0, 10], ["a study protocol", "TEST", 36, 52], ["Supplemental Figure S1", "TREATMENT", 54, 76], ["the standardized procedures", "TEST", 128, 155], ["calf necropsies", "TEST", 160, 175], ["tissue sampling", "TEST", 201, 216], ["representative digital images", "TEST", 255, 284], ["calf", "ANATOMY", 160, 164]]], ["Once or twice per week, a coin flip was used to identify a subset of up to 6 necropsied calves to be sampled for additional diagnostics at WADDL.", [["calves", "ORGANISM", 88, 94], ["calves", "SPECIES", 88, 94], ["a coin flip", "TREATMENT", 24, 35]]], ["The minimum number of calves to be included overall was based on experiential evidence, and data related to diagnostic inaccuracies suggesting that on-farm treatment-based causes of death would agree with WADDL diagnostic results in up to 60% of cases (Gulliksen et al., 2009).", [["death", "DISEASE", 182, 187], ["calves", "ORGANISM", 22, 28], ["calves", "SPECIES", 22, 28], ["diagnostic inaccuracies", "TEST", 108, 131], ["farm treatment", "TREATMENT", 151, 165], ["death", "PROBLEM", 182, 187], ["minimum", "OBSERVATION_MODIFIER", 4, 11]]], ["These potential differences suggested that a minimum sample size of 82 cases (compared against themselves) would allow for detection of at least a 20% difference in classification agreement with a power of 80% and a significance level of 0.05.Study Protocol ::: MATERIALS AND METHODSNecropsies were performed initially by the on-farm veterinarians and principal investigator (CSM), with help from 2 undergraduate summer interns.", [["a minimum sample size", "TEST", 43, 64], ["METHODSNecropsies", "TREATMENT", 276, 293]]], ["Within 2 wk of the study's commencement, the interns performed necropsies with or without a veterinarian present following the prescribed protocols.", [["the study", "TEST", 15, 24], ["the prescribed protocols", "TREATMENT", 123, 147]]], ["For all cases, a set of standard digital images was taken, demonstrating both thoracic and abdominal cavities.", [["thoracic", "ANATOMY", 78, 86], ["abdominal cavities", "ANATOMY", 91, 109], ["thoracic", "MULTI-TISSUE_STRUCTURE", 78, 86], ["abdominal cavities", "MULTI-TISSUE_STRUCTURE", 91, 109], ["standard digital images", "TEST", 24, 47], ["both", "ANATOMY_MODIFIER", 73, 77], ["thoracic", "ANATOMY", 78, 86], ["abdominal cavities", "ANATOMY", 91, 109]]], ["Additional images were taken to highlight specific pathologies and irregularities of interest.", [["Additional images", "TEST", 0, 17], ["specific pathologies", "PROBLEM", 42, 62], ["irregularities of interest", "PROBLEM", 67, 93], ["pathologies", "OBSERVATION", 51, 62]]], ["All images were uploaded into a group messenger application for smartphones (2017 WhatsApp Inc.; https://www.whatsapp.com/) and delivered to participating investigators for comment and discussion regarding lesions and relevant historical attributes.", [["lesions", "ANATOMY", 206, 213], ["lesions", "CANCER", 206, 213], ["All images", "TEST", 0, 10], ["lesions", "PROBLEM", 206, 213]]], ["Images related to cases submitted to WADDL for further diagnostics were catalogued electronically at Washington State University for evaluation by the veterinary pathologists on record.Dairy Calf Certificate of Death and Causes of Death ::: MATERIALS AND METHODSA death certificate (Supplemental Figure S2; https://doi.org/10.3168/jds.2018-15527) was modified from one created to document adult cows deaths (McConnel and Garry, 2017).", [["Death", "DISEASE", 211, 216], ["Death", "DISEASE", 231, 236], ["death", "DISEASE", 264, 269], ["deaths", "DISEASE", 400, 406], ["further diagnostics", "TEST", 47, 66], ["evaluation", "TEST", 133, 143], ["Calf", "ANATOMY", 191, 195]]], ["It was completed by the interns and veterinarians for each necropsied calf on the day of the necropsy and included details related to relevant treatments, necropsy findings, significant postnatal issues, or conditions contributing to the mortality phenotype, and attributable causes of death (underlying, contributing, immediate).", [["death", "DISEASE", 286, 291], ["calf", "ORGANISM_SUBDIVISION", 70, 74], ["calf", "SPECIES", 70, 74], ["relevant treatments", "TREATMENT", 134, 153], ["necropsy findings", "TEST", 155, 172], ["significant postnatal issues", "PROBLEM", 174, 202], ["the mortality phenotype", "PROBLEM", 234, 257], ["death", "PROBLEM", 286, 291], ["significant", "OBSERVATION_MODIFIER", 174, 185]]], ["No information was available from the calves' dairies of origin regarding potential difficulties during the birthing process or maternal characteristics such as vaccination status.", [["calves", "ORGANISM", 38, 44], ["calves", "SPECIES", 38, 44], ["potential difficulties", "PROBLEM", 74, 96]]], ["The death certificate was included as part of the WADDL submission form along with a screenshot of the DairyComp 305 CowCard, to provide a standardized accounting of treatment histories and pathological findings that helped WADDL pathologists and microbiologists determine the most logical ancillary bacteriologic and molecular diagnostics to perform.Dairy Calf Certificate of Death and Causes of Death ::: MATERIALS AND METHODSMortality phenotypes were diagnosed for cases with and without a WADDL workup according to the most pertinent available data from the 3 levels of diagnostic information: on-farm treatment-based records alone, necropsy-based postmortem findings in addition to treatment records, and WADDL diagnostic results in addition to all other information.", [["death", "DISEASE", 4, 9], ["Death", "DISEASE", 377, 382], ["Death", "DISEASE", 397, 402], ["a WADDL workup", "TEST", 491, 505], ["Calf", "ANATOMY", 357, 361]]], ["The WADDL-based diagnoses were determined on a case-by-case basis by the pathologist of record following completion of ancillary diagnostics including histopathology.", [["ancillary diagnostics", "TEST", 119, 140], ["histopathology", "TEST", 151, 165]]], ["Resultant mortality phenotypes were then categorized broadly by the principal investigator for each of the 3 levels of information according to a modified categorization scheme for dairy calf causes of death using a calf death loss flowchart (Figure 1; Lombard et al., 2019).", [["death", "DISEASE", 202, 207], ["death loss", "DISEASE", 221, 231], ["calf", "ORGANISM_SUBDIVISION", 187, 191], ["calf", "ORGANISM_SUBDIVISION", 216, 220], ["calf", "SPECIES", 187, 191], ["calf", "SPECIES", 216, 220], ["Resultant mortality phenotypes", "PROBLEM", 0, 30], ["death", "PROBLEM", 202, 207], ["a calf death loss flowchart", "PROBLEM", 214, 241], ["calf", "ANATOMY", 216, 220]]], ["Although no information was available from the time of parturition, a category for calving problems was included to appropriately document trauma such as fractured ribs or pathology due to apparent hypoxic changes such as centrilobular hepatic necrosis within calves \u226448 h of age.", [["ribs", "ANATOMY", 164, 168], ["centrilobular hepatic", "ANATOMY", 222, 243], ["trauma", "DISEASE", 139, 145], ["centrilobular hepatic necrosis", "DISEASE", 222, 252], ["ribs", "ORGAN", 164, 168], ["hepatic", "ORGAN", 236, 243], ["calves", "ORGANISM", 260, 266], ["calves", "SPECIES", 260, 266], ["calving problems", "PROBLEM", 83, 99], ["trauma", "PROBLEM", 139, 145], ["fractured ribs or pathology", "PROBLEM", 154, 181], ["apparent hypoxic changes", "PROBLEM", 189, 213], ["centrilobular hepatic necrosis", "PROBLEM", 222, 252], ["ribs", "ANATOMY", 164, 168], ["hypoxic", "OBSERVATION", 198, 205], ["centrilobular", "ANATOMY_MODIFIER", 222, 235], ["hepatic", "ANATOMY", 236, 243], ["necrosis", "OBSERVATION", 244, 252]]], ["Aside from those calves with lesions apparently associated with calving problems or due to a congenital defect or accident, all deaths \u226424 h of age were assigned to a postnatal death category as per the flowchart.", [["lesions", "ANATOMY", 29, 36], ["calving problems", "DISEASE", 64, 80], ["congenital defect", "DISEASE", 93, 110], ["deaths", "DISEASE", 128, 134], ["death", "DISEASE", 177, 182], ["calves", "ORGANISM", 17, 23], ["lesions", "PATHOLOGICAL_FORMATION", 29, 36], ["calves", "SPECIES", 17, 23], ["lesions", "PROBLEM", 29, 36], ["calving problems", "PROBLEM", 64, 80], ["a congenital defect", "PROBLEM", 91, 110], ["lesions", "OBSERVATION", 29, 36], ["congenital", "OBSERVATION_MODIFIER", 93, 103], ["defect", "OBSERVATION", 104, 110]]], ["Postmortem evaluations of the postnatal deaths provided insight into whether the underlying cause of death was something more specific than an ill-defined maladaptation to life.", [["deaths", "DISEASE", 40, 46], ["death", "DISEASE", 101, 106], ["Postmortem evaluations", "TEST", 0, 22], ["death", "PROBLEM", 101, 106], ["maladaptation", "OBSERVATION", 155, 168]]], ["Additional categories for causes of death were as follows and depended upon the relevant treatments, timing and phenotypic expression of disease or injury: accident, diarrhea, diarrhea and respiratory, respiratory, joint or navel, lameness or injury, other digestive, other known reasons, and unknown reason.Comparisons of Causes of Death ::: MATERIALS AND METHODSAlthough the generalities of treatment-based causes of death frequently failed to identify the same level of phenotypic detail as necropsy- or WADDL-based diagnoses, each case was assessed based on the merit of the varying levels of information to classify the cause of death within the broad categories provided within the calf death loss flowchart (Figure 1).", [["respiratory", "ANATOMY", 189, 200], ["respiratory", "ANATOMY", 202, 213], ["joint", "ANATOMY", 215, 220], ["navel", "ANATOMY", 224, 229], ["digestive", "ANATOMY", 257, 266], ["death", "DISEASE", 36, 41], ["accident", "DISEASE", 156, 164], ["diarrhea", "DISEASE", 166, 174], ["diarrhea", "DISEASE", 176, 184], ["respiratory, respiratory, joint or navel", "DISEASE", 189, 229], ["lameness", "DISEASE", 231, 239], ["Death", "DISEASE", 333, 338], ["death", "DISEASE", 419, 424], ["death", "DISEASE", 634, 639], ["death", "DISEASE", 693, 698], ["joint", "MULTI-TISSUE_STRUCTURE", 215, 220], ["navel", "ORGANISM_SUBDIVISION", 224, 229], ["digestive", "ORGAN", 257, 266], ["calf", "ORGANISM_SUBDIVISION", 688, 692], ["calf", "SPECIES", 688, 692], ["death", "PROBLEM", 36, 41], ["the relevant treatments", "TREATMENT", 76, 99], ["disease", "PROBLEM", 137, 144], ["injury", "PROBLEM", 148, 154], ["diarrhea", "PROBLEM", 166, 174], ["diarrhea", "PROBLEM", 176, 184], ["respiratory, respiratory, joint or navel", "PROBLEM", 189, 229], ["lameness", "PROBLEM", 231, 239], ["injury", "PROBLEM", 243, 249], ["treatment", "TREATMENT", 393, 402], ["death", "PROBLEM", 419, 424], ["necropsy", "TEST", 494, 502], ["death", "PROBLEM", 634, 639], ["respiratory", "ANATOMY", 189, 200], ["respiratory", "ANATOMY", 202, 213], ["joint", "ANATOMY", 215, 220], ["navel", "ANATOMY", 224, 229], ["injury", "OBSERVATION", 243, 249], ["calf", "ANATOMY", 688, 692]]], ["For example, a case of bronchopneumonia had the same underlying cause of death (respiratory) listed across sources even though the extent of disease only could be exposed through postmortem analysis.", [["respiratory", "ANATOMY", 80, 91], ["bronchopneumonia", "DISEASE", 23, 39], ["death", "DISEASE", 73, 78], ["bronchopneumonia", "PROBLEM", 23, 39], ["death", "PROBLEM", 73, 78], ["disease", "PROBLEM", 141, 148], ["postmortem analysis", "TEST", 179, 198], ["bronchopneumonia", "OBSERVATION", 23, 39], ["disease", "OBSERVATION", 141, 148]]], ["Compare this to a case of necrotizing, ulcerative typhlitis (cecal inflammation) variably categorized as diarrhea, diarrhea and respiratory, and other digestive for treatment-, necropsy-, and WADDL-based mortality phenotypes, respectively.", [["cecal", "ANATOMY", 61, 66], ["respiratory", "ANATOMY", 128, 139], ["typhlitis", "DISEASE", 50, 59], ["cecal inflammation", "DISEASE", 61, 79], ["diarrhea", "DISEASE", 105, 113], ["diarrhea", "DISEASE", 115, 123], ["cecal", "ORGANISM_SUBDIVISION", 61, 66], ["necrotizing, ulcerative typhlitis", "PROBLEM", 26, 59], ["cecal inflammation", "PROBLEM", 61, 79], ["diarrhea", "PROBLEM", 105, 113], ["diarrhea", "PROBLEM", 115, 123], ["treatment", "TREATMENT", 165, 174], ["necropsy", "TEST", 177, 185], ["necrotizing", "OBSERVATION_MODIFIER", 26, 37], ["ulcerative", "OBSERVATION_MODIFIER", 39, 49], ["typhlitis", "OBSERVATION", 50, 59], ["cecal", "ANATOMY", 61, 66], ["inflammation", "OBSERVATION", 67, 79], ["respiratory", "ANATOMY", 128, 139], ["mortality phenotypes", "OBSERVATION", 204, 224]]], ["Although the underlying issue was demonstrably aligned along a comparable pathologic spectrum ranging from diarrhea to sepsis, each diagnostic level identified novel phenotypic expressions of illness and death (e.g., lung pathology, intestinal necrosis and ulcerative lesions, peritonitis) that ultimately led to reclassifications of the cause of death.Comparisons of Causes of Death ::: MATERIALS AND METHODSCauses of deaths based on the broad categorization scheme were compared between levels of information using descriptive statistics (Excel 2013, Microsoft Corp., Redmond, WA) and Cohen's kappa (\u03ba) according to Landis and Koch (1977): \u03ba = (pa \u2212 p\u03b5)/(1 \u2212 p\u03b5), where pa represents the proportion of observations in agreement and p\u03b5 the proportion in agreement due to chance.", [["lung", "ANATOMY", 217, 221], ["intestinal", "ANATOMY", 233, 243], ["ulcerative lesions", "ANATOMY", 257, 275], ["diarrhea", "DISEASE", 107, 115], ["sepsis", "DISEASE", 119, 125], ["illness", "DISEASE", 192, 199], ["death", "DISEASE", 204, 209], ["intestinal necrosis", "DISEASE", 233, 252], ["ulcerative lesions", "DISEASE", 257, 275], ["peritonitis", "DISEASE", 277, 288], ["death", "DISEASE", 347, 352], ["Death", "DISEASE", 378, 383], ["deaths", "DISEASE", 419, 425], ["lung", "ORGAN", 217, 221], ["intestinal", "ORGAN", 233, 243], ["ulcerative lesions", "PATHOLOGICAL_FORMATION", 257, 275], ["a comparable pathologic spectrum", "PROBLEM", 61, 93], ["diarrhea", "PROBLEM", 107, 115], ["sepsis", "PROBLEM", 119, 125], ["illness", "PROBLEM", 192, 199], ["death", "PROBLEM", 204, 209], ["lung pathology", "PROBLEM", 217, 231], ["intestinal necrosis", "PROBLEM", 233, 252], ["ulcerative lesions", "PROBLEM", 257, 275], ["peritonitis", "PROBLEM", 277, 288], ["death", "PROBLEM", 347, 352], ["deaths", "PROBLEM", 419, 425], ["sepsis", "OBSERVATION", 119, 125], ["lung", "ANATOMY", 217, 221], ["intestinal", "ANATOMY", 233, 243], ["necrosis", "OBSERVATION", 244, 252], ["ulcerative", "OBSERVATION_MODIFIER", 257, 267], ["lesions", "OBSERVATION", 268, 275], ["peritonitis", "OBSERVATION", 277, 288]]], ["The value of \u03ba determined the level of agreement as follows: less than chance agreement (\u03ba < 0), slight agreement (\u03ba = 0.01\u20130.20), fair agreement (\u03ba = 0.21\u20130.40), moderate agreement (\u03ba = 0.41\u20130.60), substantial agreement (\u03ba = 0.61\u20130.80), and almost perfect agreement (\u03ba = 0.81\u20130.99).", [["The value", "TEST", 0, 9]]], ["Because the bulk of treatment-based diagnoses fell within 3 main categories (diarrhea, diarrhea and respiratory, and respiratory), these categories were used for comparison along with all other categories collapsed together.", [["respiratory", "ANATOMY", 100, 111], ["diarrhea", "DISEASE", 77, 85], ["diarrhea", "DISEASE", 87, 95], ["diarrhea", "PROBLEM", 77, 85], ["diarrhea", "PROBLEM", 87, 95], ["bulk", "OBSERVATION_MODIFIER", 12, 16], ["respiratory", "ANATOMY", 100, 111], ["respiratory", "ANATOMY", 117, 128], ["collapsed", "OBSERVATION", 205, 214]]], ["For all cases, comparisons of diagnostic agreement were made between the standard treatment-based records with and without input from on-farm necropsy-based postmortem analyses.", [["postmortem analyses", "TEST", 157, 176]]], ["For cases submitted to WADDL, additional comparisons were made between treatment records and on-farm postmortem evaluations with and without input from WADDL results.", [["postmortem evaluations", "TEST", 101, 123]]], ["For a particular pathologic outcome of interest (necrotizing, ulcerative enterocolitis and typhlitis), a \u03c72 test for association was calculated based on pathogen exposure.RESULTSA total of 210 dairy calves were necropsied during this study, with a minimum of 1 and a maximum of 10 calves necropsied on a given day.", [["ulcerative enterocolitis", "DISEASE", 62, 86], ["typhlitis", "DISEASE", 91, 100], ["calves", "ORGANISM", 199, 205], ["calves", "ORGANISM", 281, 287], ["calves", "SPECIES", 199, 205], ["calves", "SPECIES", 281, 287], ["necrotizing, ulcerative enterocolitis", "PROBLEM", 49, 86], ["typhlitis", "PROBLEM", 91, 100], ["a \u03c72 test", "TEST", 103, 112], ["pathogen exposure", "PROBLEM", 153, 170], ["this study", "TEST", 229, 239], ["necrotizing", "OBSERVATION_MODIFIER", 49, 60], ["ulcerative", "OBSERVATION_MODIFIER", 62, 72], ["enterocolitis", "OBSERVATION", 73, 86], ["typhlitis", "OBSERVATION", 91, 100]]], ["Of those necropsied, 88% (184) were \u226430 d of age, 9% (19) were >30 but \u226460 d of age, and 3% (7) were weaned and >60 d old.", [["age", "TEST", 45, 48]]], ["Of those submitted to WADDL, 89% (109) were \u226430 d of age, 9% (11) were >30 but \u226460 d of age, and 2% (2) were weaned and >60 d old but \u226490 d of age.RESULTSTreatment-based diagnoses of causes of death based on input from calf health managers and relevant treatment records categorized almost two-thirds (65%; 137/210) of the deaths due to diarrhea or diarrhea and respiratory (Table 1).", [["death", "DISEASE", 193, 198], ["deaths", "DISEASE", 323, 329], ["diarrhea", "DISEASE", 337, 345], ["diarrhea", "DISEASE", 349, 357], ["calf", "ORGANISM_SUBDIVISION", 219, 223], ["calf", "SPECIES", 219, 223], ["WADDL", "TEST", 22, 27], ["age", "TEST", 53, 56], ["death", "PROBLEM", 193, 198], ["diarrhea", "PROBLEM", 337, 345], ["diarrhea", "PROBLEM", 349, 357], ["diarrhea", "OBSERVATION", 337, 345]]], ["An additional 16% (34) of the total deaths were attributed to respiratory disease alone.", [["respiratory", "ANATOMY", 62, 73], ["deaths", "DISEASE", 36, 42], ["respiratory disease", "DISEASE", 62, 81], ["the total deaths", "PROBLEM", 26, 42], ["respiratory disease", "PROBLEM", 62, 81], ["respiratory disease", "OBSERVATION", 62, 81]]], ["Of the other categories for dairy calf deaths, 10% (20) of deaths fell under postnatal death, 4% (8) were unknown, and \u22642% (\u22644) were accounted for by each of the categories \u201ccongenital defects,\u201d \u201cjoint or navel,\u201d \u201cother digestive,\u201d and \u201cother known,\u201d in contrast to the findings with causes of death based on additional input from on-farm necropsy-based postmortem analysis without input from WADDL.", [["joint", "ANATOMY", 196, 201], ["navel", "ANATOMY", 205, 210], ["digestive", "ANATOMY", 220, 229], ["deaths", "DISEASE", 39, 45], ["deaths", "DISEASE", 59, 65], ["death", "DISEASE", 87, 92], ["congenital defects", "DISEASE", 174, 192], ["death", "DISEASE", 294, 299], ["calf", "ORGANISM_SUBDIVISION", 34, 38], ["digestive", "ORGAN", 220, 229], ["calf", "SPECIES", 34, 38], ["dairy calf deaths", "PROBLEM", 28, 45], ["deaths", "PROBLEM", 59, 65], ["postnatal death", "PROBLEM", 77, 92], ["congenital defects", "PROBLEM", 174, 192], ["navel", "PROBLEM", 205, 210], ["death", "PROBLEM", 294, 299], ["postmortem analysis", "TEST", 354, 373], ["calf", "ANATOMY", 34, 38], ["congenital defects", "OBSERVATION", 174, 192], ["joint", "ANATOMY", 196, 201], ["navel", "ANATOMY", 205, 210]]], ["Overall, necropsy-based postmortem diagnoses categorized 21% (44/210) of deaths due to diarrhea or diarrhea and respiratory disease.", [["respiratory", "ANATOMY", 112, 123], ["deaths", "DISEASE", 73, 79], ["diarrhea", "DISEASE", 87, 95], ["diarrhea", "DISEASE", 99, 107], ["respiratory disease", "DISEASE", 112, 131], ["diarrhea", "PROBLEM", 87, 95], ["diarrhea", "PROBLEM", 99, 107], ["respiratory disease", "PROBLEM", 112, 131], ["diarrhea", "OBSERVATION", 99, 107], ["respiratory disease", "OBSERVATION", 112, 131]]], ["Respiratory disease alone was indicated in only 6% (13) of all cases.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory disease", "DISEASE", 0, 19], ["Respiratory disease", "PROBLEM", 0, 19], ["disease", "OBSERVATION", 12, 19]]], ["However, the \u201cother digestive\u201d category captured almost 50% (104) of cases primarily because of diagnosing necrotizing, ulcerative enteritis and typhlitis.", [["digestive", "ANATOMY", 20, 29], ["ulcerative", "ANATOMY", 120, 130], ["ulcerative enteritis", "DISEASE", 120, 140], ["typhlitis", "DISEASE", 145, 154], ["digestive", "ORGAN", 20, 29], ["necrotizing", "PROBLEM", 107, 118], ["ulcerative enteritis", "PROBLEM", 120, 140], ["typhlitis", "PROBLEM", 145, 154], ["necrotizing", "OBSERVATION_MODIFIER", 107, 118], ["ulcerative", "OBSERVATION_MODIFIER", 120, 130], ["enteritis", "OBSERVATION", 131, 140], ["typhlitis", "OBSERVATION", 145, 154]]], ["For those 122 cases with diagnostic input from WADDL, the percent of deaths attributed to diarrhea or diarrhea and respiratory fell to 16% (19), and respiratory disease alone accounted for only 3% of deaths (4).", [["respiratory", "ANATOMY", 115, 126], ["respiratory", "ANATOMY", 149, 160], ["deaths", "DISEASE", 69, 75], ["diarrhea", "DISEASE", 90, 98], ["diarrhea", "DISEASE", 102, 110], ["respiratory disease", "DISEASE", 149, 168], ["deaths", "DISEASE", 200, 206], ["diagnostic input", "TEST", 25, 41], ["diarrhea", "PROBLEM", 90, 98], ["diarrhea", "PROBLEM", 102, 110], ["respiratory disease", "PROBLEM", 149, 168], ["diarrhea", "OBSERVATION", 90, 98], ["diarrhea", "OBSERVATION", 102, 110], ["respiratory disease", "OBSERVATION", 149, 168]]], ["On the other hand, \u201cother digestive\u201d deaths rose to 56% (68) due to additional histopathologic diagnoses of necrotizing, ulcerative GI lesions.", [["digestive", "ANATOMY", 26, 35], ["ulcerative GI lesions", "ANATOMY", 121, 142], ["deaths", "DISEASE", 37, 43], ["digestive", "ORGAN", 26, 35], ["ulcerative GI lesions", "PATHOLOGICAL_FORMATION", 121, 142], ["necrotizing, ulcerative GI lesions", "PROBLEM", 108, 142], ["necrotizing", "OBSERVATION_MODIFIER", 108, 119], ["ulcerative", "OBSERVATION_MODIFIER", 121, 131], ["GI", "ANATOMY", 132, 134], ["lesions", "OBSERVATION", 135, 142]]], ["Based on postmortem evaluation, each of the other categories for dairy calf deaths contained \u22644% of cases, both with (\u22645) and without (\u22648) input from WADDL, aside from the 9% of cases assigned to postnatal death both with (11) and without (19) input from WADDL.RESULTSComparative results of diagnostic agreement between the standard treatment-based records with and without input from on-farm necropsy-based postmortem analyses are presented in Table 2(part a).", [["deaths", "DISEASE", 76, 82], ["death", "DISEASE", 206, 211], ["calf", "ORGANISM_SUBDIVISION", 71, 75], ["calf", "SPECIES", 71, 75], ["postmortem evaluation", "TEST", 9, 30], ["dairy calf deaths", "PROBLEM", 65, 82], ["postnatal death", "PROBLEM", 196, 211], ["postmortem analyses", "TEST", 408, 427]]], ["The proportion of observations in agreement (pa = 80) and calculated to be in agreement due to chance (p\u03b5 = 44.2) equated to a value of Cohen's \u03ba (\u03ba = 0.22; 95% CI: 0.15\u20130.28) indicating fair agreement between the levels of information.", [["pa", "TEST", 45, 47], ["p\u03b5", "TEST", 103, 105], ["CI", "TEST", 161, 163]]], ["The addition of diagnostic results from WADDL to the postmortem evaluations (Table 2, part b), led to only slight agreement with treatment-based records (\u03ba = 0.13; 95% CI: 0.06\u20130.21).", [["the postmortem evaluations", "TEST", 49, 75], ["CI", "TEST", 168, 170]]], ["On the other hand, there was almost perfect agreement (\u03ba = 0.86; 95% CI: 0.76\u20130.97) between dairy calf deaths categorized by necropsy-based postmortem findings with and without input from WADDL (Table 2, part c).RESULTSThe primary driver of discrepancies between treatment-based diagnoses and those established following postmortem evaluations had to do with the reassignment of cases from diarrhea or diarrhea and respiratory to the category \u201cother digestive\u201d (Table 1).", [["digestive", "ANATOMY", 450, 459], ["deaths", "DISEASE", 103, 109], ["diarrhea", "DISEASE", 390, 398], ["diarrhea", "DISEASE", 402, 410], ["calf", "ORGANISM_SUBDIVISION", 98, 102], ["digestive", "ORGAN", 450, 459], ["calf", "SPECIES", 98, 102], ["CI", "TEST", 69, 71], ["dairy calf deaths", "PROBLEM", 92, 109], ["postmortem evaluations", "TEST", 321, 343], ["diarrhea", "PROBLEM", 390, 398], ["diarrhea", "PROBLEM", 402, 410], ["calf", "ANATOMY", 98, 102]]], ["Only occasional treatment-based diagnoses entirely failed to account for the pathophysiologic system underlying the mortality phenotype identified through postmortem evaluations.", [["the pathophysiologic system", "PROBLEM", 73, 100], ["the mortality phenotype", "PROBLEM", 112, 135], ["postmortem evaluations", "TEST", 155, 177]]], ["For those few cases, treatment-based diagnoses such as diarrhea or unknown overlooked issues such as esophageal tubing injuries (accidents) or omphalitis (joint or navel).RESULTSMany of the cases that presented clinically with and were treated for diarrhea and potentially respiratory distress ultimately proved to suffer from specific lesions and infections that could only be diagnosed by necropsy or histopathology (Table 3).", [["esophageal", "ANATOMY", 101, 111], ["joint", "ANATOMY", 155, 160], ["navel", "ANATOMY", 164, 169], ["respiratory", "ANATOMY", 273, 284], ["lesions", "ANATOMY", 336, 343], ["diarrhea", "DISEASE", 55, 63], ["esophageal tubing injuries", "DISEASE", 101, 127], ["accidents", "DISEASE", 129, 138], ["omphalitis", "DISEASE", 143, 153], ["diarrhea", "DISEASE", 248, 256], ["respiratory distress", "DISEASE", 273, 293], ["infections", "DISEASE", 348, 358], ["joint", "MULTI-TISSUE_STRUCTURE", 155, 160], ["navel", "ORGANISM_SUBDIVISION", 164, 169], ["lesions", "PATHOLOGICAL_FORMATION", 336, 343], ["treatment", "TREATMENT", 21, 30], ["diarrhea", "PROBLEM", 55, 63], ["unknown overlooked issues", "PROBLEM", 67, 92], ["esophageal tubing injuries", "PROBLEM", 101, 127], ["omphalitis (joint or navel)", "PROBLEM", 143, 170], ["diarrhea", "PROBLEM", 248, 256], ["respiratory distress", "PROBLEM", 273, 293], ["specific lesions", "PROBLEM", 327, 343], ["infections", "PROBLEM", 348, 358], ["esophageal", "ANATOMY", 101, 111], ["tubing injuries", "OBSERVATION", 112, 127], ["joint", "ANATOMY", 155, 160], ["navel", "ANATOMY", 164, 169], ["respiratory distress", "OBSERVATION", 273, 293], ["lesions", "OBSERVATION", 336, 343], ["infections", "OBSERVATION", 348, 358]]], ["This was especially apparent for 83 cases of necrotizing, ulcerative enterocolitis and typhlitis that fell within the \u201cother digestive\u201d category because they typically demonstrated severe peritonitis with obvious macroscopic, perforating ulcerative lesions.", [["digestive", "ANATOMY", 125, 134], ["ulcerative lesions", "ANATOMY", 238, 256], ["necrotizing", "DISEASE", 45, 56], ["ulcerative enterocolitis", "DISEASE", 58, 82], ["typhlitis", "DISEASE", 87, 96], ["peritonitis", "DISEASE", 188, 199], ["ulcerative", "PATHOLOGICAL_FORMATION", 58, 68], ["enterocolitis", "PATHOLOGICAL_FORMATION", 69, 82], ["digestive", "ORGAN", 125, 134], ["perforating", "PATHOLOGICAL_FORMATION", 226, 237], ["ulcerative lesions", "PATHOLOGICAL_FORMATION", 238, 256], ["necrotizing", "PROBLEM", 45, 56], ["ulcerative enterocolitis", "PROBLEM", 58, 82], ["typhlitis", "PROBLEM", 87, 96], ["severe peritonitis", "PROBLEM", 181, 199], ["obvious macroscopic, perforating ulcerative lesions", "PROBLEM", 205, 256], ["necrotizing", "OBSERVATION_MODIFIER", 45, 56], ["ulcerative", "OBSERVATION_MODIFIER", 58, 68], ["enterocolitis", "OBSERVATION", 69, 82], ["typhlitis", "OBSERVATION", 87, 96], ["severe", "OBSERVATION_MODIFIER", 181, 187], ["peritonitis", "OBSERVATION", 188, 199], ["obvious", "OBSERVATION_MODIFIER", 205, 212], ["macroscopic", "OBSERVATION_MODIFIER", 213, 224], ["perforating", "OBSERVATION_MODIFIER", 226, 237], ["ulcerative", "OBSERVATION_MODIFIER", 238, 248], ["lesions", "OBSERVATION", 249, 256]]], ["When submitted to WADDL, those cases had consistent histologic evidence of severe intestinal necrosis with histologic diagnoses such as fibrinonecrotic, transmural, ulcerative enterocolitis or typhlitis.", [["intestinal", "ANATOMY", 82, 92], ["fibrinonecrotic", "ANATOMY", 136, 151], ["transmural", "ANATOMY", 153, 163], ["intestinal necrosis", "DISEASE", 82, 101], ["ulcerative enterocolitis", "DISEASE", 165, 189], ["typhlitis", "DISEASE", 193, 202], ["intestinal", "ORGAN", 82, 92], ["severe intestinal necrosis", "PROBLEM", 75, 101], ["histologic diagnoses", "PROBLEM", 107, 127], ["fibrinonecrotic, transmural, ulcerative enterocolitis", "PROBLEM", 136, 189], ["typhlitis", "PROBLEM", 193, 202], ["evidence of", "UNCERTAINTY", 63, 74], ["severe", "OBSERVATION_MODIFIER", 75, 81], ["intestinal", "ANATOMY", 82, 92], ["necrosis", "OBSERVATION", 93, 101], ["transmural", "OBSERVATION_MODIFIER", 153, 163], ["ulcerative", "OBSERVATION_MODIFIER", 165, 175], ["enterocolitis", "OBSERVATION", 176, 189], ["typhlitis", "OBSERVATION", 193, 202]]], ["Moreover, WADDL further elucidated the problem by demonstrating that of those necrotizing, ulcerative cases submitted for molecular diagnostics, 98% (44/45) had Rotavirus detected by PCR, whereas only 31% (14/45) had Coronavirus and 2% (1/45) had Cryptosporidium spp. detected by PCR (Table 4).", [["Rotavirus", "DISEASE", 161, 170], ["Cryptosporidium spp", "DISEASE", 247, 266], ["ulcerative", "PATHOLOGICAL_FORMATION", 91, 101], ["Coronavirus", "CANCER", 217, 228], ["Cryptosporidium spp", "ORGANISM", 247, 266], ["WADDL", "PROTEIN", 10, 15], ["those necrotizing, ulcerative cases", "PROBLEM", 72, 107], ["molecular diagnostics", "TEST", 122, 143], ["Rotavirus", "PROBLEM", 161, 170], ["PCR", "TEST", 183, 186], ["Coronavirus", "TEST", 217, 228], ["Cryptosporidium spp", "PROBLEM", 247, 266], ["necrotizing", "OBSERVATION_MODIFIER", 78, 89], ["ulcerative", "OBSERVATION", 91, 101], ["Cryptosporidium spp", "OBSERVATION", 247, 266]]], ["When compared against nonulcerative cases submitted to WADDL for molecular diagnostics, the evidence suggested that necrotizing, ulcerative cases were 3.0 times more likely to be diagnosed with Rotavirus alone than with no Rotavirus or Rotavirus in combination with either or both Coronavirus or Cryptosporidium spp. (odds ratio = 3.0; 95% CI: 1.2\u20137.8; Pearson \u03c72P-value = 0.02).", [["ulcerative", "DISEASE", 129, 139], ["Rotavirus", "DISEASE", 194, 203], ["Rotavirus", "DISEASE", 223, 232], ["Rotavirus", "DISEASE", 236, 245], ["Cryptosporidium spp", "DISEASE", 296, 315], ["ulcerative", "PATHOLOGICAL_FORMATION", 129, 139], ["Cryptosporidium spp", "ORGANISM", 296, 315], ["molecular diagnostics", "TEST", 65, 86], ["necrotizing, ulcerative cases", "PROBLEM", 116, 145], ["Rotavirus", "PROBLEM", 194, 203], ["Rotavirus", "PROBLEM", 223, 232], ["Rotavirus", "PROBLEM", 236, 245], ["both Coronavirus", "PROBLEM", 276, 292], ["Cryptosporidium spp", "PROBLEM", 296, 315], ["odds ratio", "TEST", 318, 328], ["CI", "TEST", 340, 342], ["Pearson", "TEST", 353, 360], ["value", "TEST", 365, 370], ["necrotizing", "OBSERVATION_MODIFIER", 116, 127], ["ulcerative", "OBSERVATION_MODIFIER", 129, 139], ["Rotavirus", "OBSERVATION", 236, 245], ["Cryptosporidium spp", "OBSERVATION", 296, 315]]], ["Although those necrotizing, ulcerative cases arguably had clinical signs and lesions aligned along a pathophysiologic continuum from GI injury to sepsis, the lack of detail inherent to standard treatment-based causes of death led to different categorizations along the calf death loss flowchart and failed to identify meaningful characteristics necessary for understanding the progression of disease and pathways for intervention.RESULTSInformative phenotypic detail across the spectrum of dairy calf death categories was provided by postmortem evaluations founded on necropsies with input from WADDL when available (Table 3).", [["lesions", "ANATOMY", 77, 84], ["calf", "ANATOMY", 269, 273], ["GI injury", "DISEASE", 133, 142], ["sepsis", "DISEASE", 146, 152], ["death", "DISEASE", 220, 225], ["death", "DISEASE", 274, 279], ["death", "DISEASE", 501, 506], ["lesions", "PATHOLOGICAL_FORMATION", 77, 84], ["GI", "ORGANISM_SUBDIVISION", 133, 135], ["calf", "ORGANISM_SUBDIVISION", 269, 273], ["calf", "ORGANISM_SUBDIVISION", 496, 500], ["calf", "SPECIES", 269, 273], ["calf", "SPECIES", 496, 500], ["those necrotizing, ulcerative cases", "PROBLEM", 9, 44], ["clinical signs", "PROBLEM", 58, 72], ["lesions", "PROBLEM", 77, 84], ["a pathophysiologic continuum", "PROBLEM", 99, 127], ["GI injury", "PROBLEM", 133, 142], ["sepsis", "PROBLEM", 146, 152], ["standard treatment", "TREATMENT", 185, 203], ["death", "PROBLEM", 220, 225], ["different categorizations", "PROBLEM", 233, 258], ["the calf death loss flowchart", "PROBLEM", 265, 294], ["disease", "PROBLEM", 392, 399], ["intervention", "TREATMENT", 417, 429], ["dairy calf death categories", "PROBLEM", 490, 517], ["postmortem evaluations", "TEST", 534, 556], ["necrotizing", "OBSERVATION_MODIFIER", 15, 26], ["ulcerative", "OBSERVATION_MODIFIER", 28, 38], ["lesions", "OBSERVATION", 77, 84], ["GI", "ANATOMY", 133, 135], ["injury", "OBSERVATION", 136, 142], ["sepsis", "OBSERVATION", 146, 152], ["calf", "ANATOMY", 269, 273]]], ["Aside from the specific lesions and infectious agents detailed within the \u201cother digestive\u201d category, most cases assigned to the other broad categories also benefited from insight into aspects of disease progression, severity, duration, and infection.", [["lesions", "ANATOMY", 24, 31], ["infection", "DISEASE", 241, 250], ["lesions", "PATHOLOGICAL_FORMATION", 24, 31], ["the specific lesions", "PROBLEM", 11, 31], ["infectious agents", "TREATMENT", 36, 53], ["disease progression", "PROBLEM", 196, 215], ["severity", "PROBLEM", 217, 225], ["infection", "PROBLEM", 241, 250], ["specific", "OBSERVATION_MODIFIER", 15, 23], ["lesions", "OBSERVATION", 24, 31], ["infectious", "OBSERVATION", 36, 46], ["disease", "OBSERVATION", 196, 203], ["severity", "OBSERVATION_MODIFIER", 217, 225], ["infection", "OBSERVATION", 241, 250]]], ["For example, enterocolitis could be found across categories (diarrhea, diarrhea and respiratory, other digestive), but associated pathology (e.g., bronchopneumonia, peritonitis, septicemia) and level of severity (e.g., mild, suppurative, ulcerative) ultimately dictated how a case aligned within the calf death loss categorization scheme.", [["respiratory", "ANATOMY", 84, 95], ["digestive", "ANATOMY", 103, 112], ["enterocolitis", "DISEASE", 13, 26], ["diarrhea", "DISEASE", 61, 69], ["diarrhea", "DISEASE", 71, 79], ["bronchopneumonia", "DISEASE", 147, 163], ["peritonitis", "DISEASE", 165, 176], ["septicemia", "DISEASE", 178, 188], ["ulcerative", "DISEASE", 238, 248], ["death", "DISEASE", 305, 310], ["digestive", "ORGAN", 103, 112], ["calf", "ORGANISM_SUBDIVISION", 300, 304], ["calf", "SPECIES", 300, 304], ["enterocolitis", "PROBLEM", 13, 26], ["diarrhea", "PROBLEM", 61, 69], ["diarrhea", "PROBLEM", 71, 79], ["respiratory, other digestive)", "PROBLEM", 84, 113], ["associated pathology", "PROBLEM", 119, 139], ["bronchopneumonia", "PROBLEM", 147, 163], ["peritonitis", "PROBLEM", 165, 176], ["septicemia", "PROBLEM", 178, 188], ["level of severity (e.g., mild, suppurative, ulcerative)", "PROBLEM", 194, 249], ["the calf death loss categorization scheme", "PROBLEM", 296, 337], ["enterocolitis", "OBSERVATION", 13, 26], ["respiratory", "ANATOMY", 84, 95], ["pathology", "OBSERVATION", 130, 139], ["bronchopneumonia", "OBSERVATION", 147, 163], ["peritonitis", "OBSERVATION", 165, 176], ["septicemia", "OBSERVATION", 178, 188], ["mild", "OBSERVATION_MODIFIER", 219, 223], ["suppurative", "OBSERVATION_MODIFIER", 225, 236], ["ulcerative", "OBSERVATION", 238, 248], ["calf", "ANATOMY", 300, 304]]], ["The specificity of the mortality phenotypes stood in stark contrast to the otherwise generic cause of death diagnoses derived from treatments alone and provided meaningful insight into pathophysiological processes capable of informing therapeutic and preventive practices.", [["death", "DISEASE", 102, 107], ["the mortality phenotypes", "PROBLEM", 19, 43], ["treatments", "TREATMENT", 131, 141], ["preventive practices", "TREATMENT", 251, 271]]], ["This held true even for those cases that were assigned to the postnatal death category as a straightforward function of the timing of death (\u226424 h of age).", [["death", "DISEASE", 72, 77], ["death", "DISEASE", 134, 139]]], ["Specific pathologic findings and infections still spoke to consequential problems beyond an ill-defined maladaptation to life.", [["infections", "DISEASE", 33, 43], ["Specific pathologic findings", "PROBLEM", 0, 28], ["infections", "PROBLEM", 33, 43], ["consequential problems", "PROBLEM", 59, 81], ["pathologic", "OBSERVATION", 9, 19], ["infections", "OBSERVATION", 33, 43], ["maladaptation", "OBSERVATION", 104, 117]]], ["In fact, postmortem evaluations were informative even for the 1% (3/210) of cases for which a cause of death remained unknown, to the extent that the findings documented the absence of specific issues of concern.DISCUSSIONAn accurate description of dairy mortality is needed to reduce economic and animal welfare costs, as well as the reputational risk posed to the industry by preventable deaths (Compton et al., 2017).", [["death", "DISEASE", 103, 108], ["deaths", "DISEASE", 390, 396], ["dairy", "ORGANISM_SUBDIVISION", 249, 254], ["postmortem evaluations", "TEST", 9, 31], ["death", "PROBLEM", 103, 108]]], ["Necropsies are warranted when morbidity or mortality exceeds historic or comfortable levels, when there is a perceived treatment failure, for acquiring information necessary for confirmation of a tentative clinical diagnosis, when presenting signs are dramatic or unusual, or to characterize a disease process when no antemortem observation has been made (Mason and Madden, 2007; Thomsen et al., 2012).", [["Necropsies", "TREATMENT", 0, 10], ["morbidity", "PROBLEM", 30, 39], ["mortality", "PROBLEM", 43, 52], ["a perceived treatment failure", "PROBLEM", 107, 136], ["a disease process", "PROBLEM", 292, 309], ["antemortem observation", "TEST", 318, 340]]], ["Information derived from a necropsy and associated diagnostics should be viewed in conjunction with background information related to management factors such as the nutritional regimen, and clinical history, including treatments, to form a systematic postmortem evaluation.", [["management factors", "TREATMENT", 134, 152], ["the nutritional regimen", "TREATMENT", 161, 184], ["treatments", "TREATMENT", 218, 228], ["a systematic postmortem evaluation", "TEST", 238, 272]]], ["The findings from this study support the hypothesis that classifying dairy calf mortality phenotypes via a systematic postmortem analysis can identify differences in cause-of-death diagnoses compared with those derived from treatments alone.", [["death", "DISEASE", 175, 180], ["dairy", "ORGANISM_SUBDIVISION", 69, 74], ["calf", "ORGANISM_SUBDIVISION", 75, 79], ["calf", "SPECIES", 75, 79], ["this study", "TEST", 18, 28], ["dairy calf mortality phenotypes", "PROBLEM", 69, 100], ["a systematic postmortem analysis", "TEST", 105, 137]]], ["Differences in the characterization of underlying pathologies highlighted the value of on-farm necropsies and laboratory-based diagnostics to (1) detect antemortem disease misclassifications, (2) provide detail regarding disease processes and mortality phenotypes, and (3) direct disease mitigation strategies related to prevention and treatment.DISCUSSIONThis study adapted a calf death loss flowchart and dairy calf death categorization scheme (Lombard et al., 2019) to compare 3 levels of diagnostic information: on-farm treatment-based records alone, necropsy-based postmortem findings in addition to treatment records, and WADDL diagnostic results in addition to all other information.", [["death loss", "DISEASE", 382, 392], ["death", "DISEASE", 418, 423], ["calf", "ORGANISM_SUBDIVISION", 377, 381], ["calf", "ORGANISM_SUBDIVISION", 413, 417], ["calf", "SPECIES", 377, 381], ["calf", "SPECIES", 413, 417], ["underlying pathologies", "PROBLEM", 39, 61], ["antemortem disease misclassifications", "PROBLEM", 153, 190], ["disease processes", "PROBLEM", 221, 238], ["mortality phenotypes", "PROBLEM", 243, 263], ["direct disease mitigation strategies", "PROBLEM", 273, 309], ["treatment", "TREATMENT", 336, 345], ["a calf death loss flowchart", "PROBLEM", 375, 402], ["dairy calf death", "PROBLEM", 407, 423], ["calf", "ANATOMY", 377, 381]]], ["This categorization scheme is particularly useful in that it discriminates between uncomplicated diarrhea and other specific digestive ailments such as GI ulceration and peritonitis, and acknowledges the fact that many calf deaths present with ante- and postmortem evidence suggestive of both GI and lung pathology.", [["digestive", "ANATOMY", 125, 134], ["GI", "ANATOMY", 152, 154], ["GI", "ANATOMY", 293, 295], ["lung", "ANATOMY", 300, 304], ["diarrhea", "DISEASE", 97, 105], ["digestive ailments", "DISEASE", 125, 143], ["GI ulceration", "DISEASE", 152, 165], ["peritonitis", "DISEASE", 170, 181], ["deaths", "DISEASE", 224, 230], ["digestive", "ORGANISM_SUBDIVISION", 125, 134], ["calf", "ORGANISM", 219, 223], ["GI", "ORGANISM_SUBDIVISION", 293, 295], ["lung", "ORGAN", 300, 304], ["calf", "SPECIES", 219, 223], ["uncomplicated diarrhea", "PROBLEM", 83, 105], ["other specific digestive ailments", "PROBLEM", 110, 143], ["GI ulceration", "PROBLEM", 152, 165], ["peritonitis", "PROBLEM", 170, 181], ["many calf deaths", "PROBLEM", 214, 230], ["both GI and lung pathology", "PROBLEM", 288, 314], ["uncomplicated", "OBSERVATION_MODIFIER", 83, 96], ["diarrhea", "OBSERVATION", 97, 105], ["GI", "ANATOMY", 152, 154], ["ulceration", "OBSERVATION", 155, 165], ["peritonitis", "OBSERVATION", 170, 181], ["calf", "ANATOMY", 219, 223], ["deaths", "OBSERVATION", 224, 230], ["suggestive of", "UNCERTAINTY", 274, 287], ["both", "ANATOMY_MODIFIER", 288, 292], ["GI", "ANATOMY", 293, 295], ["lung", "ANATOMY", 300, 304], ["pathology", "OBSERVATION", 305, 314]]], ["In total, treatment-based records attributed 65% (137) of the 210 deaths evaluated in this study to diarrhea with or without respiratory problems, and 16% (34) were attributed to respiratory disease alone.", [["respiratory", "ANATOMY", 125, 136], ["respiratory", "ANATOMY", 179, 190], ["deaths", "DISEASE", 66, 72], ["diarrhea", "DISEASE", 100, 108], ["respiratory problems", "DISEASE", 125, 145], ["respiratory disease", "DISEASE", 179, 198], ["this study", "TEST", 86, 96], ["diarrhea", "PROBLEM", 100, 108], ["respiratory problems", "PROBLEM", 125, 145], ["respiratory disease alone", "PROBLEM", 179, 204], ["respiratory disease", "OBSERVATION", 179, 198]]], ["Only 4% (8) had an unknown reason for the cause of death based on treatment records.", [["death", "DISEASE", 51, 56], ["death", "PROBLEM", 51, 56]]], ["Given that this study was 97% (203) populated with preweaning calves \u226460 d of age, these findings are similar to results from the USDA National Animal Health Monitoring System (NAHMS) Dairy 2014 study, which indicated that preweaning heifer deaths were predominantly attributed by producers to a generic category encompassing diarrhea or other digestive problems (56%).", [["digestive", "ANATOMY", 344, 353], ["deaths", "DISEASE", 241, 247], ["diarrhea", "DISEASE", 326, 334], ["calves", "ORGANISM", 62, 68], ["digestive", "ORGAN", 344, 353], ["calves", "SPECIES", 62, 68], ["this study", "TEST", 11, 21], ["preweaning heifer deaths", "PROBLEM", 223, 247], ["a generic category encompassing diarrhea", "PROBLEM", 294, 334], ["other digestive problems", "PROBLEM", 338, 362]]], ["Respiratory problems accounted for approximately one-fourth (24%) of producer-attributed preweaning heifer deaths, and producers reported that only 6% of preweaning heifer deaths were due to unknown causes (USDA, 2017).", [["Respiratory problems", "DISEASE", 0, 20], ["deaths", "DISEASE", 107, 113], ["deaths", "DISEASE", 172, 178], ["Respiratory problems", "PROBLEM", 0, 20]]], ["The similarity between the current study's treatment-based causes of death and those recorded in the NAHMS study was not unexpected given that only 11% of US operations performed necropsies on heifers and only 5% of dead heifers were necropsied (USDA, 2017).DISCUSSIONCertain aspects of operational management such as the restricted milk feeding in this study may not correspond across calf rearing systems and undoubtedly influence calf health differentially; however, within a given contextual framework, a necropsy can discriminate clinical signs, such as respiratory distress due to concurrent GI disease and debility, from a distinct pathology, such as bacterial bronchopneumonia.", [["milk", "ANATOMY", 333, 337], ["respiratory", "ANATOMY", 559, 570], ["GI", "ANATOMY", 598, 600], ["death", "DISEASE", 69, 74], ["respiratory distress", "DISEASE", 559, 579], ["GI disease", "DISEASE", 598, 608], ["bronchopneumonia", "DISEASE", 668, 684], ["heifers", "ORGANISM", 221, 228], ["milk", "ORGANISM_SUBDIVISION", 333, 337], ["calf", "ORGANISM_SUBDIVISION", 386, 390], ["calf", "ORGANISM_SUBDIVISION", 433, 437], ["calf", "SPECIES", 386, 390], ["calf", "SPECIES", 433, 437], ["the current study", "TEST", 23, 40], ["death", "PROBLEM", 69, 74], ["the NAHMS study", "TEST", 97, 112], ["US operations", "TEST", 155, 168], ["necropsies", "TEST", 179, 189], ["heifers", "TREATMENT", 193, 200], ["operational management", "TREATMENT", 287, 309], ["the restricted milk feeding", "TREATMENT", 318, 345], ["this study", "TEST", 349, 359], ["a necropsy", "TEST", 507, 517], ["clinical signs", "PROBLEM", 535, 549], ["respiratory distress", "PROBLEM", 559, 579], ["concurrent GI disease", "PROBLEM", 587, 608], ["debility", "PROBLEM", 613, 621], ["a distinct pathology", "PROBLEM", 628, 648], ["bacterial bronchopneumonia", "PROBLEM", 658, 684], ["GI", "ANATOMY", 598, 600], ["disease", "OBSERVATION", 601, 608], ["debility", "OBSERVATION", 613, 621], ["distinct", "OBSERVATION_MODIFIER", 630, 638], ["pathology", "OBSERVATION", 639, 648], ["bacterial", "OBSERVATION_MODIFIER", 658, 667], ["bronchopneumonia", "OBSERVATION", 668, 684]]], ["Disease processes operate along a continuum with the potential to affect multiple organ systems and manifest across the clinical spectrum.", [["organ", "ANATOMY", 82, 87], ["organ", "ORGAN", 82, 87], ["Disease processes", "PROBLEM", 0, 17], ["multiple organ systems", "PROBLEM", 73, 95]]], ["Without the benefit of information provided by necropsies as part of systematic postmortem evaluations, it is difficult to ascribe meaningful detail to causes of death.", [["death", "DISEASE", 162, 167], ["systematic postmortem evaluations", "TEST", 69, 102], ["death", "PROBLEM", 162, 167]]], ["As demonstrated within the current study, the additional detail allowed for scrutiny of antemortem diagnostic accuracy and clarification of phenotypic expressions of illness and death.", [["illness", "DISEASE", 166, 173], ["death", "DISEASE", 178, 183], ["the current study", "TEST", 23, 40], ["antemortem diagnostic accuracy", "TEST", 88, 118], ["illness", "PROBLEM", 166, 173], ["death", "PROBLEM", 178, 183]]], ["This was especially apparent concerning the surprising number of cases of necrotizing, ulcerative enterocolitis and typhlitis that particularly reduced agreement between levels of information (Table 2).", [["necrotizing", "DISEASE", 74, 85], ["ulcerative enterocolitis", "DISEASE", 87, 111], ["typhlitis", "DISEASE", 116, 125], ["necrotizing", "PROBLEM", 74, 85], ["ulcerative enterocolitis", "PROBLEM", 87, 111], ["typhlitis", "PROBLEM", 116, 125], ["necrotizing", "OBSERVATION_MODIFIER", 74, 85], ["ulcerative", "OBSERVATION_MODIFIER", 87, 97], ["enterocolitis", "OBSERVATION", 98, 111], ["typhlitis", "OBSERVATION", 116, 125]]], ["The clinical presentations and treatment regimens documented for those cases belied the specificity and severity of the pathophysiologic causal pathway.", [["treatment regimens", "TREATMENT", 31, 49]]], ["Without the detail provided by extensive postmortem evaluations that integrate gross, histological, and microbiological findings, those cases would have been relegated to categories that failed to acknowledge the particular pathology.", [["extensive postmortem evaluations", "TEST", 31, 63]]], ["As with human cases of necrotizing enterocolitis, the exact role of microbes in bovine cases remains incompletely understood and the apparent dysbiosis associated with the lesions certainly does not imply cause and effect (Coggins et al., 2015; Adaska et al., 2017).", [["lesions", "ANATOMY", 172, 179], ["necrotizing enterocolitis", "DISEASE", 23, 48], ["dysbiosis", "DISEASE", 142, 151], ["human", "ORGANISM", 8, 13], ["bovine", "ORGANISM", 80, 86], ["lesions", "PATHOLOGICAL_FORMATION", 172, 179], ["human", "SPECIES", 8, 13], ["bovine", "SPECIES", 80, 86], ["human", "SPECIES", 8, 13], ["necrotizing enterocolitis", "PROBLEM", 23, 48], ["the apparent dysbiosis", "PROBLEM", 129, 151], ["the lesions", "PROBLEM", 168, 179], ["necrotizing", "OBSERVATION_MODIFIER", 23, 34], ["enterocolitis", "OBSERVATION", 35, 48], ["dysbiosis", "OBSERVATION", 142, 151], ["lesions", "OBSERVATION", 172, 179]]], ["However, the notion that a specific pathogen such as Rotavirus might have played a role in a rarely identified pattern of lesions potentially linked to stress-induced metabolic, immunologic, and microbial GI disturbances (Mitchell et al., 1981; Aoki-Yoshida et al., 2016) provides support for additional nutritional, therapeutic, and diagnostic investigations.DISCUSSIONCertainly, not all deaths in this study were clearly aligned with diagnostic pathology.", [["lesions", "ANATOMY", 122, 129], ["GI", "ANATOMY", 205, 207], ["Rotavirus", "DISEASE", 53, 62], ["deaths", "DISEASE", 389, 395], ["Rotavirus", "ORGANISM", 53, 62], ["lesions", "PATHOLOGICAL_FORMATION", 122, 129], ["a specific pathogen", "PROBLEM", 25, 44], ["Rotavirus", "PROBLEM", 53, 62], ["lesions", "PROBLEM", 122, 129], ["microbial GI disturbances", "PROBLEM", 195, 220], ["diagnostic investigations", "TEST", 334, 359], ["this study", "TEST", 399, 409], ["diagnostic pathology", "TEST", 436, 456], ["lesions", "OBSERVATION", 122, 129]]], ["In a small subset of cases (3), the cause of death remained unknown (Table 1).", [["death", "DISEASE", 45, 50], ["death", "PROBLEM", 45, 50], ["small", "OBSERVATION_MODIFIER", 5, 10], ["subset", "OBSERVATION_MODIFIER", 11, 17]]], ["There were also cases (7%; 8/122) for which the necropsy- and WADDL-based mortality phenotypes differed even though there was almost perfect overall agreement between the 2 levels of information (Table 2, part c).", [["the necropsy", "TEST", 44, 56], ["WADDL", "TREATMENT", 62, 67], ["based mortality phenotypes", "PROBLEM", 68, 94]]], ["It should be noted as well that the limited diagnostic agreement between treatment-based and necropsy-based postmortem findings was undoubtedly influenced by necropsy practices, including tissue selection and death certificate content.", [["tissue", "ANATOMY", 188, 194], ["death", "DISEASE", 209, 214], ["tissue", "TISSUE", 188, 194], ["treatment", "TREATMENT", 73, 82], ["tissue selection", "TREATMENT", 188, 204]]], ["Nonetheless, the postmortem evaluation as a whole proved informative for the majority of cases and provided insight into many deaths that would otherwise have remained poorly or inaccurately classified.", [["deaths", "DISEASE", 126, 132], ["the postmortem evaluation", "TEST", 13, 38]]], ["In the end, postmortem evaluations provided the detail required to describe specific lesions and pathogens and corroborated the accuracy of antemortem diagnoses and efficacy of therapeutic interventions.DISCUSSIONFor ongoing reference and education, the truncated categorizations of disease and death in on-farm record systems can be complemented with additional documentation of postmortem findings and relevant perspective through the use of death certificates, necropsy photos, and other diagnostic results.", [["lesions", "ANATOMY", 85, 92], ["death", "DISEASE", 295, 300], ["death", "DISEASE", 444, 449], ["lesions", "PATHOLOGICAL_FORMATION", 85, 92], ["postmortem evaluations", "TEST", 12, 34], ["specific lesions", "PROBLEM", 76, 92], ["pathogens", "PROBLEM", 97, 106], ["antemortem diagnoses", "TEST", 140, 160], ["therapeutic interventions", "TREATMENT", 177, 202], ["disease", "PROBLEM", 283, 290], ["death", "PROBLEM", 295, 300], ["necropsy photos", "TEST", 464, 479], ["lesions", "OBSERVATION", 85, 92]]], ["Describing the process leading to a death and mortality phenotype helps provide a narrative with the ability to convey complex and multi-layered ideas in a simple and memorable form to culturally diverse audiences.", [["death", "DISEASE", 36, 41], ["a death", "PROBLEM", 34, 41], ["mortality phenotype", "PROBLEM", 46, 65]]], ["The power of the causal narrative is its ability to stimulate interest in a problem, facilitate learning, influence communication and cross-cultural understanding, and drive change within a farm (Snowden, 1999, 2000a,b).DISCUSSIONFormulating a narrative based on systematic postmortem evaluations therefore provides an avenue for exploring common sense solutions to otherwise complex problems, and affords an opportunity for real-time intervention in the form of employee education.", [["systematic postmortem evaluations", "TEST", 263, 296], ["real-time intervention", "TREATMENT", 425, 447], ["employee education", "TREATMENT", 463, 481], ["power", "OBSERVATION_MODIFIER", 4, 9]]], ["Rather than viewing an individual calf death as a demoralizing end-point, the narrative provides an understanding from which to elicit change across the population.", [["death", "DISEASE", 39, 44], ["calf", "ORGANISM_SUBDIVISION", 34, 38], ["calf", "SPECIES", 34, 38], ["an individual calf death", "PROBLEM", 20, 44], ["calf", "ANATOMY", 34, 38], ["death", "OBSERVATION", 39, 44]]], ["Rearing dairy replacement heifers should focus on limiting environmental impact, protecting animal welfare, and minimizing required inputs while returning the most profitable outputs (Hoffman and Funk, 1992; Heinrichs et al., 2017).", [["Rearing dairy replacement heifers", "TREATMENT", 0, 33]]], ["As such, reducing economic costs and impairment to animal welfare through improved understanding of dairy calf mortality provides a critical control point for accelerating whole-farm efficiency and sustainability.DISCUSSION\u201cThe promises of a diagnosis, even if speculative, are always more welcome than the absolute certainties of an autopsy\u201d (Nichols, 2017).", [["dairy", "ORGANISM_SUBDIVISION", 100, 105], ["calf", "ORGANISM_SUBDIVISION", 106, 110], ["calf", "SPECIES", 106, 110], ["dairy", "SPECIES", 100, 105], ["reducing economic costs", "PROBLEM", 9, 32], ["dairy calf mortality", "TREATMENT", 100, 120]]], ["The NAHMS Dairy 2014 study indicated that very few (<5%) dead heifers are necropsied as part of a postmortem examination.", [["heifers", "ORGANISM", 62, 69], ["a postmortem examination", "TEST", 96, 120]]], ["Yet without information provided from postmortem examinations, a dairy calf health management team is limited in their assessment of outcomes related to antemortem clinical diagnoses and treatments.", [["calf", "ORGANISM_SUBDIVISION", 71, 75], ["calf", "SPECIES", 71, 75], ["postmortem examinations", "TEST", 38, 61], ["a dairy calf health management", "TREATMENT", 63, 93], ["treatments", "TREATMENT", 187, 197]]], ["Rather than wading through the complexities of treatment records and making decisions founded on speculation, evidence-based veterinary medicine would suggest that necropsies and additional laboratory-based diagnostics should be used as part of a systematic postmortem examination of dairy heifer causes of death.", [["death", "DISEASE", 307, 312], ["a systematic postmortem examination", "TEST", 245, 280], ["death", "PROBLEM", 307, 312]]]], "38e8343c1894b79471d3c61b976fbc96dfa78aeb": [["Corona Virus Disease 2019 (COVID- 19) , first discovered in Wuhan City, Hubei 2 Province, China on December 31st 2019 [7] , has established itself as the most 3 devastating global pandemic todate.", [["COVID- 19", "CHEMICAL", 27, 36], ["Corona Virus", "ORGANISM", 0, 12], ["COVID- 19", "ORGANISM", 27, 36], ["Corona Virus Disease 2019 (COVID- 19", "SPECIES", 0, 36], ["Corona Virus Disease", "PROBLEM", 0, 20], ["COVID", "TEST", 27, 32], ["Virus Disease", "OBSERVATION", 7, 20]]], ["The disease has not respected borders, 4 socio-economic developments of countries or states, and personal status.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11]]], ["COVID-19 5 caused by Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has 6 spread worldwide [1] .", [["COVID-19 5", "CHEMICAL", 0, 10], ["Acute Respiratory Syndrome Corona Virus", "DISEASE", 28, 67], ["SARS-CoV-2", "CHEMICAL", 71, 81], ["COVID-19 5", "ORGANISM", 0, 10], ["SARS-CoV-2", "ORGANISM", 71, 81], ["Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2", "SPECIES", 21, 81], ["COVID", "TEST", 0, 5], ["Severe Acute Respiratory Syndrome", "PROBLEM", 21, 54], ["Corona Virus", "PROBLEM", 55, 67], ["Severe", "OBSERVATION_MODIFIER", 21, 27], ["Acute", "OBSERVATION_MODIFIER", 28, 33], ["Respiratory Syndrome", "OBSERVATION", 34, 54]]], ["Globally, 9 the number of cases confirmed to the disease has surpassed 3.5 million people with over 10 248,313 deaths (CFR: 7% ) and 1,157,014 recoveries [5] .", [["deaths", "DISEASE", 111, 117], ["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89], ["the disease", "PROBLEM", 45, 56], ["CFR", "TEST", 119, 122], ["disease", "OBSERVATION", 49, 56]]], ["With USA showing the highest death toll 68,602 persons 14 (with 5.8% Case fatality rate), as of May 4th, 2020 [5] .", [["death", "DISEASE", 29, 34], ["persons", "SPECIES", 47, 54], ["fatality rate", "TEST", 74, 87]]], ["In Africa, an estimated 44,483 15 confirmed cases; 1,801 death, with case fatality rate of 4% and 14,921 recoveries have 16 occurred, as of May 4th, 2020 [23] .", [["death", "DISEASE", 57, 62], ["case fatality rate", "TEST", 69, 87]]], ["Countries that have not reported COVID-19 cases 17 as of, May 4th, 2020 include: Kiribati, Lesotho, Marshall Islands, Micronesia, Nauru, 18 North Korea, Palau, Samoa, Solomon Islands, Tonga, Turkmenistan, Tuvalu, 19 Vanuatu [25] .", [["COVID", "TEST", 33, 38], ["Marshall Islands", "OBSERVATION", 100, 116]]], ["The pandemic however, has both direct and indirect effects and 20 ramifications in all sectors of life including health, economy, trade, travel, education and 21 governance.", [["pandemic", "OBSERVATION", 4, 12]]], ["Despite immediate 23 lock down and intense public health interventions including contact tracing, the country 24 has registered eighty-nine (89) cases as of May 4th, 2020 [5] .", [["intense public health interventions", "TREATMENT", 35, 70], ["contact tracing", "TEST", 81, 96]]], ["The total 26 number of foreign truck drivers who have tested positive for COVID-19 is thirty (30), of 27 these nineteen have returned to their respective countries whereas eleven are admitted 28 at different hospitals in Uganda [6] .", [["COVID", "TEST", 74, 79]]], ["The community transmission through contacts has 29 emerged and the extent of which remains unknown since many of those who traveled updates as of May 4th, 2020 indicate that a total of thirty nine thousand, two hundred 36 thirty two (39,232) persons have been tested, of whom eighty nine (89) are confirmed 37 cases, eight hundred sixty one (861) have been discharged from institutional quarantine, 38 four hundred forty six (446) are under institutional quarantine, one thousand three 39 hundred two (1,302) are contacts listed, eight hundred eight (808) are under follow up, 40 141 are under self quarantine, eighteen (18) are active cases and fifty two (52) have fully 41 recovered following successful treatment [3, 6] .", [["persons", "ORGANISM", 242, 249], ["persons", "SPECIES", 242, 249]]], ["The distribution of COVID-19 confirmed 42 cases by residence is shown in [6] .", [["COVID-19", "DNA", 20, 28], ["COVID", "TEST", 20, 25]]]], "17f76ad05e3858dd355a62d95dd6a541e4db40c2": [["BackgroundUnderstanding how, when and in what types of settings SARS-CoV-2 spreads between people is critical to developing effective public health and infection prevention measures to break chains of transmission.", [["SARS", "DISEASE", 64, 68], ["infection", "DISEASE", 152, 161], ["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["infection prevention measures", "TREATMENT", 152, 181], ["infection", "OBSERVATION", 152, 161]]], ["1 Current evidence suggests SARS-CoV-2 is primarily transmitted via respiratory droplets and aerosols; and can occur between pre-symptomatic or symptomatic infected individuals to others in close contact.BackgroundSARS-CoV-2 has been shown to contaminate and survive on certain surfaces, but currently, no reports have directly demonstrated fomite to human transmission.", [["respiratory droplets", "ANATOMY", 68, 88], ["SARS-CoV-2", "ORGANISM", 28, 38], ["BackgroundSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 204, 224], ["human", "ORGANISM", 351, 356], ["human", "SPECIES", 351, 356], ["SARS-CoV", "SPECIES", 28, 36], ["human", "SPECIES", 351, 356], ["SARS", "PROBLEM", 28, 32], ["symptomatic infected individuals", "PROBLEM", 144, 176], ["BackgroundSARS", "TEST", 204, 218], ["suggests", "UNCERTAINTY", 19, 27], ["SARS", "OBSERVATION", 28, 32], ["respiratory droplets", "OBSERVATION", 68, 88], ["symptomatic", "OBSERVATION_MODIFIER", 144, 155], ["infected", "OBSERVATION", 156, 164]]], ["SARS-CoV-2 has also been detected in the feces of some patients which taken together with fomite transmission suggest the possibility that SARS-CoV-2 could transmit via the orofecal route.", [["feces", "ANATOMY", 41, 46], ["orofecal", "ANATOMY", 173, 181], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 139, 143], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["feces", "ORGANISM_SUBDIVISION", 41, 46], ["patients", "ORGANISM", 55, 63], ["SARS-CoV-2", "ORGANISM", 139, 149], ["patients", "SPECIES", 55, 63], ["SARS", "PROBLEM", 139, 143]]], ["\"Orofecal\" describes a route of transmission where the virus in fecal particles can pass from one person to the mouth of another.", [["mouth", "ANATOMY", 112, 117], ["mouth", "ORGANISM_SUBDIVISION", 112, 117], ["person", "SPECIES", 98, 104], ["the virus in fecal particles", "PROBLEM", 51, 79], ["virus", "OBSERVATION", 55, 60], ["fecal", "ANATOMY", 64, 69]]], ["Fecal contamination of food is another form of orofecal transmission.MethodsWe are undertaking an open evidence review investigating factors and circumstances that impact on the transmission of SARS-CoV-2, based on our published protocol .", [["Fecal", "ANATOMY", 0, 5], ["orofecal", "ANATOMY", 47, 55], ["SARS", "DISEASE", 194, 198], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["orofecal", "CANCER", 47, 55], ["SARS-CoV-2", "ORGANISM", 194, 204], ["SARS-CoV", "SPECIES", 194, 202], ["Fecal contamination of food", "PROBLEM", 0, 27], ["our published protocol", "TREATMENT", 215, 237], ["contamination", "OBSERVATION", 6, 19], ["orofecal transmission", "OBSERVATION", 47, 68]]], ["We conduct an ongoing search using LitCovid, medRxiv, Google Scholar and Google for Covid-19 for keywords and associated synonyms.", [["LitCovid", "TREATMENT", 35, 43]]], ["One reviewer extracts data from the included studies that is then checked by a second reviewer and a summary is uploaded to an accessible Evidence Explorer at https://www.cebm.net/evidence-synthesis/transmission-dynamics-of-covid-19/ From included studies we extract information on the study characteristics, the population, the funding and the main methods, reported mode of transmissions and associated outcomes, We assess study quality based on five criteria and report important findings on an ongoing basis.", [["the study", "TEST", 282, 291], ["study quality", "TEST", 425, 438]]], ["Where necessary we write to authors of included studies for further details or clarification on the content of their articles.Results:We found 59 studies: nine reviews and 51 primary studies or reports (one study undertook a cohort study and included a review) examining the potential role of orofecal transmission of SARS-CoV-2 (see Table 1 of references w1-w59 ).", [["orofecal", "ANATOMY", 293, 301], ["SARS", "DISEASE", 318, 322], ["SARS-CoV", "SPECIES", 318, 326], ["studies", "TEST", 48, 55], ["primary studies", "TEST", 175, 190], ["a cohort study", "TEST", 223, 237], ["SARS", "PROBLEM", 318, 322], ["CoV", "TEST", 323, 326]]], ["Study Characteristics ) thirty seven studies reported positive fecal samples for SARS-CoV-2 based on RT-PCR results (n=1,034 patients).", [["fecal samples", "ANATOMY", 63, 76], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["SARS-CoV", "SPECIES", 81, 89], ["thirty seven studies", "TEST", 24, 44], ["fecal samples", "TEST", 63, 76], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89], ["RT-PCR", "TEST", 101, 107]]], ["Six ( Jeong , Wang W , Xiao F, Tang M , Xiao F, Sun J , Yoa H and Zhang Y 2020 ) report isolating the virus.", [["the virus", "PROBLEM", 98, 107]]], ["Eleven studies report on fecal samples in sewage. (see Study Characteristics ) Three studies were done in laboratories ( Lamers , Zang and Zhou J ), and two sampled bathrooms and toilets for viruses ( Ding Z , Ong ) .Results:Overall the quality of the evidence was low to moderate mainly due to a lack of standardisation of techniques, omissions in reporting and a failure to account for biases in the research process. (see Table 3 Quality of Included Studies).SARS-COV-2 excretion and detection via the orofecal route -evidence from reviewsThe main findings of each study are summarised in Table 4 .", [["fecal samples", "ANATOMY", 25, 38], ["SARS", "DISEASE", 462, 466], ["fecal samples", "ORGANISM_SUBSTANCE", 25, 38], ["Eleven studies", "TEST", 0, 14], ["fecal samples", "TEST", 25, 38], ["Three studies", "TEST", 79, 92], ["viruses", "PROBLEM", 191, 198], ["a failure", "PROBLEM", 363, 372], ["biases in the research process", "PROBLEM", 388, 418], ["Studies", "TEST", 453, 460], ["SARS", "TEST", 462, 466], ["each study", "TEST", 563, 573], ["failure", "OBSERVATION", 365, 372], ["main", "OBSERVATION_MODIFIER", 546, 550]]], ["We found nine reviews with overlapping studies that assessed the excretion and detection of SARS-COV-2: six in mixed adults and children [ Parasa , w31 Amirian , W2 Cheung , W 10 A fourth review with 26 articles included in the final analysis with 824 patients included across the studies and 540 tested for fecal viral RNA: 291 (54%) had positive fecal RT-PCR tests .", [["SARS", "DISEASE", 92, 96], ["children", "ORGANISM", 128, 136], ["patients", "ORGANISM", 252, 260], ["fecal viral RNA", "RNA", 308, 323], ["children", "SPECIES", 128, 136], ["patients", "SPECIES", 252, 260], ["overlapping studies", "TEST", 27, 46], ["the excretion", "TEST", 61, 74], ["SARS", "PROBLEM", 92, 96], ["COV", "TEST", 97, 100], ["Parasa", "TEST", 139, 145], ["the final analysis", "TEST", 224, 242], ["the studies", "TEST", 277, 288], ["fecal viral RNA", "TEST", 308, 323], ["positive fecal RT-PCR tests", "PROBLEM", 339, 366], ["fecal", "ANATOMY", 348, 353]]], ["W15 Of the 199 patients who tested positive for fecal viral RNA and who were followed up with stool testing, 125 (63%) had persistent shedding of virus in the stool samples after a negative nasopharyngeal swab.", [["stool samples", "ANATOMY", 159, 172], ["nasopharyngeal swab", "ANATOMY", 190, 209], ["patients", "ORGANISM", 15, 23], ["fecal", "ORGANISM_SUBSTANCE", 48, 53], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 190, 209], ["patients", "SPECIES", 15, 23], ["fecal viral RNA", "PROBLEM", 48, 63], ["stool testing", "TEST", 94, 107], ["persistent shedding of virus", "PROBLEM", 123, 151], ["a negative nasopharyngeal swab", "PROBLEM", 179, 209], ["virus", "OBSERVATION", 146, 151], ["nasopharyngeal", "ANATOMY", 190, 204], ["swab", "OBSERVATION", 205, 209]]], ["The duration of fecal shedding of viral RNA after clearance of respiratory samples ranged from 1 to 33 days and in one patient up to 47 days from symptom onset.", [["fecal", "ANATOMY", 16, 21], ["respiratory samples", "ANATOMY", 63, 82], ["fecal", "ORGANISM_SUBSTANCE", 16, 21], ["patient", "ORGANISM", 119, 126], ["viral RNA", "RNA", 34, 43], ["patient", "SPECIES", 119, 126], ["fecal shedding of viral RNA", "PROBLEM", 16, 43], ["respiratory samples", "TEST", 63, 82], ["symptom onset", "PROBLEM", 146, 159], ["fecal", "ANATOMY", 16, 21], ["viral RNA", "OBSERVATION", 34, 43]]], ["Only one study tested the viability of fecally excreted viruses.", [["one study", "TEST", 5, 14], ["fecally excreted viruses", "PROBLEM", 39, 63], ["viruses", "OBSERVATION", 56, 63]]], ["Of 153 stool specimens tested in this study, four were tested for viability and two (50%) were viable.SARS-COV-2 excretion and detection via the orofecal route -evidence from reviewsTian et al W39 reviewed 15 included studies with data from 2,023 patients (mainly from China) and showed that gastrointestinal symptoms are common in Covid-19 patients and were reported with increased prevalence as the epidemic progressed in China.", [["stool specimens", "ANATOMY", 7, 22], ["gastrointestinal", "ANATOMY", 292, 308], ["SARS", "DISEASE", 102, 106], ["gastrointestinal symptoms", "DISEASE", 292, 317], ["patients", "ORGANISM", 247, 255], ["gastrointestinal", "ORGAN", 292, 308], ["patients", "ORGANISM", 341, 349], ["patients", "SPECIES", 247, 255], ["patients", "SPECIES", 341, 349], ["stool specimens", "TEST", 7, 22], ["this study", "TEST", 33, 43], ["viability", "TEST", 66, 75], ["SARS", "TEST", 102, 106], ["studies with data", "TEST", 218, 235], ["gastrointestinal symptoms", "PROBLEM", 292, 317], ["gastrointestinal", "ANATOMY", 292, 308]]], ["Among 2,033 Covid-19 patients, gastrointestinal symptoms were observed in 3% (1/41) to 79% (159/201) of the cases.", [["gastrointestinal", "ANATOMY", 31, 47], ["gastrointestinal symptoms", "DISEASE", 31, 56], ["patients", "ORGANISM", 21, 29], ["gastrointestinal", "ORGAN", 31, 47], ["patients", "SPECIES", 21, 29], ["Covid", "TEST", 12, 17], ["gastrointestinal symptoms", "PROBLEM", 31, 56], ["gastrointestinal", "ANATOMY", 31, 47]]], ["Symptoms included anorexia 40%; diarrhoea 2%; vomiting 3.6%; nausea 1% ; abdominal pain 2.2%; and gastrointestinal bleeding 4%.SARS-COV-2 excretion and detection via the orofecal route -evidence from reviewsDiarrhoea was the most common gastrointestinal symptom in children and adults, with a mean duration of 4.1 \u00b1 2.5 days, and was observed before and after diagnosis.", [["abdominal", "ANATOMY", 73, 82], ["gastrointestinal", "ANATOMY", 98, 114], ["gastrointestinal", "ANATOMY", 237, 253], ["anorexia", "DISEASE", 18, 26], ["diarrhoea", "DISEASE", 32, 41], ["vomiting", "DISEASE", 46, 54], ["nausea", "DISEASE", 61, 67], ["abdominal pain", "DISEASE", 73, 87], ["gastrointestinal bleeding", "DISEASE", 98, 123], ["SARS", "DISEASE", 127, 131], ["Diarrhoea", "DISEASE", 207, 216], ["abdominal", "ORGANISM_SUBDIVISION", 73, 82], ["gastrointestinal", "ORGANISM_SUBDIVISION", 98, 114], ["gastrointestinal", "ORGAN", 237, 253], ["children", "ORGANISM", 265, 273], ["children", "SPECIES", 265, 273], ["Symptoms", "PROBLEM", 0, 8], ["anorexia", "PROBLEM", 18, 26], ["diarrhoea", "PROBLEM", 32, 41], ["vomiting", "PROBLEM", 46, 54], ["nausea", "PROBLEM", 61, 67], ["abdominal pain", "PROBLEM", 73, 87], ["gastrointestinal bleeding", "PROBLEM", 98, 123], ["SARS", "TEST", 127, 131], ["the orofecal route", "TEST", 166, 184], ["Diarrhoea", "PROBLEM", 207, 216], ["abdominal", "ANATOMY", 73, 82], ["gastrointestinal", "ANATOMY", 98, 114], ["bleeding", "OBSERVATION", 115, 123], ["most common", "OBSERVATION_MODIFIER", 225, 236]]], ["Vomiting was more prominent in children.", [["Vomiting", "DISEASE", 0, 8], ["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["Vomiting", "PROBLEM", 0, 8], ["more prominent", "OBSERVATION_MODIFIER", 13, 27]]], ["Fecal PCR testing was as accurate as respiratory specimen PCR detection, and fecal excretion persisted after sputum excretion in 23% of the patients for 1 to 11 days.SARS-COV-2 excretion and detection via the orofecal route -evidence from reviewsA systematic review of four case series (36 children, 15 boys and 21 girls, aged 56 to 91 months) aimed to investigate differences in viral shedding in respiratory and fecal samples from children with Covid-19 .", [["Fecal", "ANATOMY", 0, 5], ["respiratory specimen", "ANATOMY", 37, 57], ["fecal", "ANATOMY", 77, 82], ["sputum", "ANATOMY", 109, 115], ["respiratory", "ANATOMY", 398, 409], ["fecal samples", "ANATOMY", 414, 427], ["SARS", "DISEASE", 166, 170], ["Fecal", "ORGANISM_SUBSTANCE", 0, 5], ["fecal", "ORGANISM_SUBSTANCE", 77, 82], ["sputum", "ORGANISM_SUBSTANCE", 109, 115], ["patients", "ORGANISM", 140, 148], ["COV-2", "CELL", 171, 176], ["children", "ORGANISM", 290, 298], ["fecal samples", "ORGANISM_SUBSTANCE", 414, 427], ["children", "ORGANISM", 433, 441], ["patients", "SPECIES", 140, 148], ["children", "SPECIES", 290, 298], ["boys", "SPECIES", 303, 307], ["girls", "SPECIES", 315, 320], ["children", "SPECIES", 433, 441], ["Fecal PCR testing", "TEST", 0, 17], ["respiratory specimen PCR detection", "TEST", 37, 71], ["fecal excretion", "TEST", 77, 92], ["sputum excretion", "TEST", 109, 125], ["SARS", "TEST", 166, 170], ["viral shedding", "PROBLEM", 380, 394], ["Covid", "TEST", 447, 452], ["respiratory", "ANATOMY", 398, 409]]], ["W34 Three times as many children had SARS-CoV-2 shedding in stools after 14 days of symptoms onset compared to respiratory samples, RR= 3.2 (95%CI 1.2 to 8.9).", [["respiratory samples", "ANATOMY", 111, 130], ["SARS", "DISEASE", 37, 41], ["children", "ORGANISM", 24, 32], ["CoV-2", "ORGANISM", 42, 47], ["stools", "ORGANISM", 60, 66], ["children", "SPECIES", 24, 32], ["SARS", "PROBLEM", 37, 41], ["CoV", "PROBLEM", 42, 45], ["2 shedding in stools", "PROBLEM", 46, 66], ["symptoms onset", "PROBLEM", 84, 98], ["respiratory samples", "TEST", 111, 130], ["RR", "TEST", 132, 134], ["CI", "TEST", 144, 146]]], ["The review authors were unsure whether the fecally shed viruses were viable and hence infectious.SARS-COV-2 excretion and detection via the orofecal route -evidence from reviewsA short review by Don\u00e0 et al. W14 including six studies of children reports the orofecal route is an alternative route of transmission, regardless of presenting Covid-19 symptomatology.", [["SARS", "DISEASE", 97, 101], ["children", "ORGANISM", 236, 244], ["children", "SPECIES", 236, 244], ["the fecally shed viruses", "PROBLEM", 39, 63], ["SARS", "TEST", 97, 101], ["infectious", "OBSERVATION", 86, 96]]], ["Citing evidence from the SARS-CoV-1 outbreak that fecal excretion could be ongoing even after 30 days from symptom onset, the review authors recommend that exclusion of SARS-CoV-2 infection by single time point nasopharyngeal swabs should not be used in children.SARS-COV-2 excretion and detection via the orofecal route -evidence from reviewsA review on the potential for foodborne transmission of SARs-CoV-2 found no published studies of SARS-CoV-2 survival in or on food products .", [["fecal", "ANATOMY", 50, 55], ["nasopharyngeal swabs", "ANATOMY", 211, 231], ["SARS", "DISEASE", 25, 29], ["SARS", "DISEASE", 169, 173], ["infection", "DISEASE", 180, 189], ["SARS", "DISEASE", 263, 267], ["SARS", "DISEASE", 440, 444], ["fecal", "ORGANISM_SUBSTANCE", 50, 55], ["SARS-CoV-2", "ORGANISM", 169, 179], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 211, 231], ["children", "ORGANISM", 254, 262], ["children", "SPECIES", 254, 262], ["SARS-CoV-1", "SPECIES", 25, 35], ["SARS-CoV", "SPECIES", 169, 177], ["the SARS", "PROBLEM", 21, 29], ["fecal excretion", "PROBLEM", 50, 65], ["symptom onset", "PROBLEM", 107, 120], ["SARS", "PROBLEM", 169, 173], ["CoV", "PROBLEM", 174, 177], ["2 infection", "PROBLEM", 178, 189], ["nasopharyngeal swabs", "TREATMENT", 211, 231], ["SARS", "TEST", 263, 267], ["SARs", "PROBLEM", 399, 403], ["CoV", "TEST", 404, 407], ["published studies", "TEST", 419, 436], ["SARS", "PROBLEM", 440, 444], ["CoV", "TEST", 445, 448]]], ["W20Live SARS-COV-2 excretion by the fecal routeSix studies ( Jeong , w18 , Wang W , w41 Xiao F Tang M , w47 Xiao F Sun J , w48 Yoa H , w51 and Zhang Y w58 ) reported isolating the virus from nine patients: one study Qian , w33 reported virions in rectal tissue under electron microscopy; and a laboratory study by Lamers w21 found that SARS-CoV-2 productively infected human small intestinal organoids.Live SARS-COV-2 excretion by the fecal routeViable SARS-CoV-2 was isolated from naso/oropharyngeal swabs and saliva of Covid-19 patients, as well as nasal washes of ferrets inoculated with patient urine or stool. w18 Wang W et al w41 detected SARS-CoV-2 in the feces of 44 of 153 (29%) specimens collected from 205 patients with Covid-19 from three hospitals in the Hubei and Shandong provinces and Beijing.", [["virions", "ANATOMY", 236, 243], ["rectal tissue", "ANATOMY", 247, 260], ["small intestinal organoids", "ANATOMY", 375, 401], ["oropharyngeal swabs", "ANATOMY", 487, 506], ["saliva", "ANATOMY", 511, 517], ["nasal", "ANATOMY", 551, 556], ["urine", "ANATOMY", 599, 604], ["stool", "ANATOMY", 608, 613], ["feces", "ANATOMY", 663, 668], ["specimens", "ANATOMY", 688, 697], ["COV-2", "GENE_OR_GENE_PRODUCT", 13, 18], ["patients", "ORGANISM", 196, 204], ["rectal tissue", "TISSUE", 247, 260], ["SARS-CoV-2", "ORGANISM", 336, 346], ["human", "ORGANISM", 369, 374], ["intestinal organoids", "TISSUE", 381, 401], ["COV-2", "GENE_OR_GENE_PRODUCT", 412, 417], ["fecal routeViable SARS-CoV-2", "ORGANISM", 435, 463], ["naso", "ORGANISM_SUBDIVISION", 482, 486], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 487, 506], ["saliva", "ORGANISM_SUBSTANCE", 511, 517], ["patients", "ORGANISM", 530, 538], ["nasal", "ORGANISM_SUBDIVISION", 551, 556], ["ferrets", "ORGANISM", 567, 574], ["patient", "ORGANISM", 591, 598], ["urine", "ORGANISM_SUBSTANCE", 599, 604], ["stool", "ORGANISM_SUBSTANCE", 608, 613], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 645, 655], ["feces", "ORGANISM", 663, 668], ["specimens", "CANCER", 688, 697], ["patients", "ORGANISM", 717, 725], ["human small intestinal organoids", "CELL_TYPE", 369, 401], ["patients", "SPECIES", 196, 204], ["human", "SPECIES", 369, 374], ["SARS-CoV", "SPECIES", 453, 461], ["patients", "SPECIES", 530, 538], ["ferrets", "SPECIES", 567, 574], ["patient", "SPECIES", 591, 598], ["patients", "SPECIES", 717, 725], ["human", "SPECIES", 369, 374], ["SARS-CoV", "SPECIES", 453, 461], ["ferrets", "SPECIES", 567, 574], ["SARS", "TEST", 8, 12], ["COV", "TEST", 13, 16], ["electron microscopy", "TEST", 267, 286], ["a laboratory study", "TEST", 292, 310], ["SARS", "PROBLEM", 336, 340], ["CoV", "TEST", 341, 344], ["2 productively infected human small intestinal organoids", "PROBLEM", 345, 401], ["Live SARS", "TEST", 402, 411], ["COV", "TEST", 412, 415], ["the fecal routeViable SARS", "TEST", 431, 457], ["CoV", "TEST", 458, 461], ["naso/oropharyngeal swabs", "TREATMENT", 482, 506], ["Covid", "TREATMENT", 521, 526], ["nasal washes of ferrets", "TREATMENT", 551, 574], ["patient urine", "TEST", 591, 604], ["SARS", "TEST", 645, 649], ["CoV", "TEST", 650, 653], ["specimens", "TEST", 688, 697], ["Covid", "TEST", 731, 736], ["fecal", "ANATOMY", 36, 41], ["rectal tissue", "ANATOMY", 247, 260], ["SARS", "OBSERVATION", 336, 340], ["infected", "OBSERVATION", 360, 368], ["small intestinal organoids", "OBSERVATION", 375, 401], ["fecal", "ANATOMY", 435, 440], ["oropharyngeal swabs", "ANATOMY", 487, 506], ["stool", "OBSERVATION", 608, 613], ["feces", "ANATOMY", 663, 668]]], ["RNA was extracted by RT-PCR targeting the open reading frame 1ab gene of SARS-CoV-2.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 73, 83], ["RNA", "RNA", 0, 3], ["open reading frame 1ab gene", "DNA", 42, 69], ["SARS-CoV-2", "DNA", 73, 83], ["SARS-CoV", "SPECIES", 73, 81], ["RT", "TEST", 21, 23], ["PCR", "TEST", 24, 27], ["SARS", "TEST", 73, 77], ["CoV", "TEST", 78, 81]]], ["A cycle threshold value less than 40 was interpreted as positive for SARS-CoV-2 RNA.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 69, 79], ["SARS-CoV-2 RNA", "RNA", 69, 83], ["SARS-CoV", "SPECIES", 69, 77], ["A cycle threshold value", "TEST", 0, 23], ["SARS", "PROBLEM", 69, 73], ["CoV", "TEST", 74, 77]]], ["Four positive fecal specimens with high copy numbers were then cultured, and electron microscopy performed to detect live virus.", [["fecal specimens", "ANATOMY", 14, 29], ["electron microscopy", "TEST", 77, 96], ["live virus", "PROBLEM", 117, 127], ["positive", "OBSERVATION_MODIFIER", 5, 13], ["fecal specimens", "OBSERVATION", 14, 29]]], ["Live SARS-CoV-2 virus was observed in the stool sample of two patients who did not have diarrhea.Live SARS-COV-2 excretion by the fecal routeXiao F, Sun J et al. w48 undertook a case-series of 28 hospitalised patients with severe Covid-19. for whom feces samples were available.", [["stool sample", "ANATOMY", 42, 54], ["feces samples", "ANATOMY", 249, 262], ["diarrhea", "DISEASE", 88, 96], ["Live SARS-CoV-2 virus", "ORGANISM", 0, 21], ["patients", "ORGANISM", 62, 70], ["patients", "ORGANISM", 209, 217], ["feces", "ORGANISM", 249, 254], ["CoV-2 virus", "SPECIES", 10, 21], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 209, 217], ["SARS-CoV-2 virus", "SPECIES", 5, 21], ["Live SARS", "TEST", 0, 9], ["CoV-2 virus", "PROBLEM", 10, 21], ["diarrhea", "PROBLEM", 88, 96], ["Live SARS", "TEST", 97, 106], ["severe Covid", "PROBLEM", 223, 235], ["whom feces samples", "TEST", 244, 262], ["diarrhea", "OBSERVATION", 88, 96], ["fecal", "ANATOMY", 130, 135]]], ["Among the specimens collected 12 were positive for viral RNA at least one-time point.", [["specimens", "ANATOMY", 10, 19], ["viral RNA", "RNA", 51, 60], ["the specimens", "TEST", 6, 19], ["viral RNA", "PROBLEM", 51, 60]]], ["SARS-CoV-2 virus was successfully isolated from two of the viral RNA-positive patients.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2 virus", "ORGANISM", 0, 16], ["patients", "ORGANISM", 78, 86], ["CoV-2 virus", "SPECIES", 5, 16], ["patients", "SPECIES", 78, 86], ["SARS-CoV-2 virus", "SPECIES", 0, 16], ["SARS-CoV-2 virus", "PROBLEM", 0, 16], ["the viral RNA", "TEST", 55, 68], ["viral RNA", "OBSERVATION", 59, 68]]], ["Viral particles that were visible were spherical and had distinct surface spike protein projections, consistent with a previously published SARS-CoV2 image.", [["surface", "ANATOMY", 66, 73], ["Viral", "ORGANISM", 0, 5], ["Viral particles", "PROBLEM", 0, 15], ["distinct surface spike protein projections", "PROBLEM", 57, 99], ["particles", "OBSERVATION", 6, 15], ["distinct", "OBSERVATION_MODIFIER", 57, 65], ["surface", "OBSERVATION_MODIFIER", 66, 73], ["consistent with", "UNCERTAINTY", 101, 116]]], ["Four serial feces samples from a seriously ill 78-year old patient with Covid-19 all tested positive for viral RNA; the patient subsequently died.", [["feces samples", "ANATOMY", 12, 25], ["feces", "ORGANISM", 12, 17], ["patient", "ORGANISM", 59, 66], ["patient", "ORGANISM", 120, 127], ["viral RNA", "RNA", 105, 114], ["patient", "SPECIES", 59, 66], ["patient", "SPECIES", 120, 127], ["Four serial feces samples", "TEST", 0, 25], ["Covid", "TEST", 72, 77], ["viral RNA", "PROBLEM", 105, 114], ["viral RNA", "OBSERVATION", 105, 114]]], ["Viral antigen was also detected in gastrointestinal epithelial cells of a biopsy sample, from this 78-year old Covid-19 patient.Live SARS-COV-2 excretion by the fecal routeAn assessment of viral RNA in feces from 71 hospitalized patients with SARS-CoV-2 reported that viral RNA and viral nucleocapsid protein in gastrointestinal tissues was extracted from one patient. w47 Immunofluorescent data showed that ACE2 protein (a cell receptor for SARS-CoV-2) is expressed in the glandular cells of gastric, duodenal, and rectal epithelia, supporting the entry into the host cells.", [["gastrointestinal epithelial cells", "ANATOMY", 35, 68], ["biopsy sample", "ANATOMY", 74, 87], ["feces", "ANATOMY", 202, 207], ["gastrointestinal tissues", "ANATOMY", 312, 336], ["cell", "ANATOMY", 424, 428], ["glandular cells", "ANATOMY", 474, 489], ["gastric", "ANATOMY", 493, 500], ["duodenal", "ANATOMY", 502, 510], ["rectal epithelia", "ANATOMY", 516, 532], ["cells", "ANATOMY", 569, 574], ["SARS", "DISEASE", 243, 247], ["Viral", "ORGANISM", 0, 5], ["gastrointestinal epithelial cells", "CELL", 35, 68], ["biopsy sample", "CANCER", 74, 87], ["patient", "ORGANISM", 120, 127], ["COV-2", "GENE_OR_GENE_PRODUCT", 138, 143], ["feces", "ORGANISM_SUBDIVISION", 202, 207], ["patients", "ORGANISM", 229, 237], ["gastrointestinal tissues", "TISSUE", 312, 336], ["patient", "ORGANISM", 360, 367], ["ACE2", "GENE_OR_GENE_PRODUCT", 408, 412], ["a cell receptor", "GENE_OR_GENE_PRODUCT", 422, 437], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 442, 452], ["glandular cells", "CELL", 474, 489], ["gastric", "MULTI-TISSUE_STRUCTURE", 493, 500], ["duodenal", "MULTI-TISSUE_STRUCTURE", 502, 510], ["rectal epithelia", "TISSUE", 516, 532], ["host cells", "CELL", 564, 574], ["Viral antigen", "PROTEIN", 0, 13], ["gastrointestinal epithelial cells", "CELL_TYPE", 35, 68], ["viral RNA", "RNA", 189, 198], ["viral RNA", "RNA", 268, 277], ["viral nucleocapsid protein", "PROTEIN", 282, 308], ["ACE2 protein", "PROTEIN", 408, 420], ["glandular cells", "CELL_TYPE", 474, 489], ["host cells", "CELL_TYPE", 564, 574], ["patient", "SPECIES", 120, 127], ["patients", "SPECIES", 229, 237], ["patient", "SPECIES", 360, 367], ["SARS-CoV", "SPECIES", 243, 251], ["Viral antigen", "TEST", 0, 13], ["a biopsy sample", "TEST", 72, 87], ["Live SARS", "TEST", 128, 137], ["the fecal routeAn assessment", "TEST", 157, 185], ["viral RNA in feces", "PROBLEM", 189, 207], ["SARS", "PROBLEM", 243, 247], ["CoV", "TEST", 248, 251], ["viral RNA", "PROBLEM", 268, 277], ["viral nucleocapsid protein in gastrointestinal tissues", "PROBLEM", 282, 336], ["Immunofluorescent data", "TEST", 373, 395], ["ACE2 protein", "TEST", 408, 420], ["a cell receptor", "TEST", 422, 437], ["SARS", "TEST", 442, 446], ["CoV", "TEST", 447, 450], ["gastric, duodenal, and rectal epithelia", "PROBLEM", 493, 532], ["gastrointestinal epithelial cells", "OBSERVATION", 35, 68], ["fecal", "ANATOMY", 161, 166], ["viral RNA", "OBSERVATION", 189, 198], ["viral RNA", "OBSERVATION", 268, 277], ["viral nucleocapsid protein", "OBSERVATION", 282, 308], ["gastrointestinal tissues", "ANATOMY", 312, 336], ["glandular cells", "ANATOMY", 474, 489], ["gastric", "ANATOMY", 493, 500], ["duodenal", "ANATOMY", 502, 510], ["rectal epithelia", "ANATOMY", 516, 532], ["host cells", "OBSERVATION", 564, 574]]], ["Viral nucleocapsid protein was found intracellularly in gastric, duodenal, and rectal epithelia.Live SARS-COV-2 excretion by the fecal routeYoa H et al. w51 obtained 11 SARS-CoV-2 viral isolates from patients admitted to Zhejiang University-affiliated hospitals in Hangzhou, China.", [["gastric", "ANATOMY", 56, 63], ["duodenal", "ANATOMY", 65, 73], ["rectal epithelia", "ANATOMY", 79, 95], ["gastric", "MULTI-TISSUE_STRUCTURE", 56, 63], ["duodenal", "MULTI-TISSUE_STRUCTURE", 65, 73], ["rectal epithelia", "TISSUE", 79, 95], ["COV-2", "GENE_OR_GENE_PRODUCT", 106, 111], ["SARS-CoV-2", "ORGANISM", 169, 179], ["patients", "ORGANISM", 200, 208], ["Viral nucleocapsid protein", "PROTEIN", 0, 26], ["patients", "SPECIES", 200, 208], ["Viral nucleocapsid protein", "TEST", 0, 26], ["intracellularly in gastric, duodenal, and rectal epithelia", "PROBLEM", 37, 95], ["Live SARS", "TEST", 96, 105], ["SARS", "TEST", 169, 173], ["CoV", "TEST", 174, 177], ["nucleocapsid protein", "OBSERVATION", 6, 26], ["gastric", "ANATOMY", 56, 63], ["duodenal", "ANATOMY", 65, 73], ["rectal epithelia", "ANATOMY", 79, 95], ["fecal", "ANATOMY", 129, 134]]], ["Three of the viable viral isolates were extracted from stool samples, indicating that the SARS-CoV-2 is capable of replicating in stool samples.", [["stool samples", "ANATOMY", 55, 68], ["stool samples", "ANATOMY", 130, 143], ["SARS", "DISEASE", 90, 94], ["stool samples", "ORGANISM_SUBSTANCE", 55, 68], ["SARS-CoV-2", "ORGANISM", 90, 100], ["stool samples", "ORGANISM_SUBSTANCE", 130, 143], ["SARS-CoV", "SPECIES", 90, 98], ["the viable viral isolates", "PROBLEM", 9, 34], ["stool samples", "TEST", 55, 68], ["the SARS", "TEST", 86, 94], ["stool samples", "TEST", 130, 143], ["viral isolates", "OBSERVATION", 20, 34]]], ["At 24 hours post-infection significant decreases in cycle threshold value for all of the viral isolates were observed.Live SARS-COV-2 excretion by the fecal routeZhang Y w58 isolated live virus from the stools of one severe pneumonia case, pointing to a possible orofecal spread.", [["orofecal", "ANATOMY", 263, 271], ["pneumonia", "DISEASE", 224, 233], ["COV-2", "GENE_OR_GENE_PRODUCT", 128, 133], ["Zhang Y w58 isolated live virus", "SPECIES", 162, 193], ["significant decreases in cycle threshold value", "PROBLEM", 27, 73], ["the viral isolates", "PROBLEM", 85, 103], ["Live SARS", "TEST", 118, 127], ["one severe pneumonia case", "PROBLEM", 213, 238], ["orofecal spread", "PROBLEM", 263, 278], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["decreases", "OBSERVATION_MODIFIER", 39, 48], ["fecal", "ANATOMY", 151, 156], ["severe", "OBSERVATION_MODIFIER", 217, 223], ["pneumonia", "OBSERVATION", 224, 233], ["possible", "UNCERTAINTY", 254, 262], ["orofecal spread", "OBSERVATION", 263, 278]]], ["There were unclear and sparse clinical details in the study report.Live SARS-COV-2 excretion by the fecal routeA patient admitted to Zhongnan Hospital of Wuhan University for treatment of a rectal adenocarcinoma had samples taken from enteric sections, mucosa of rectum and ileum. w33 Typical coronavirus virions in rectal tissue were observed under electron microscopy with abundant lymphocytes and macrophages (some SARS-CoV-2 positive) infiltrating the lamina propria.", [["rectal adenocarcinoma", "ANATOMY", 190, 211], ["samples", "ANATOMY", 216, 223], ["sections", "ANATOMY", 243, 251], ["mucosa", "ANATOMY", 253, 259], ["rectum", "ANATOMY", 263, 269], ["ileum", "ANATOMY", 274, 279], ["virions", "ANATOMY", 305, 312], ["rectal tissue", "ANATOMY", 316, 329], ["lymphocytes", "ANATOMY", 384, 395], ["macrophages", "ANATOMY", 400, 411], ["lamina propria", "ANATOMY", 456, 470], ["rectal adenocarcinoma", "DISEASE", 190, 211], ["COV-2", "GENE_OR_GENE_PRODUCT", 77, 82], ["patient", "ORGANISM", 113, 120], ["rectal adenocarcinoma", "CANCER", 190, 211], ["enteric sections", "MULTI-TISSUE_STRUCTURE", 235, 251], ["mucosa", "MULTI-TISSUE_STRUCTURE", 253, 259], ["rectum", "MULTI-TISSUE_STRUCTURE", 263, 269], ["ileum", "ORGAN", 274, 279], ["coronavirus", "ORGANISM", 293, 304], ["rectal tissue", "TISSUE", 316, 329], ["lymphocytes", "CELL", 384, 395], ["macrophages", "CELL", 400, 411], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 418, 428], ["lamina propria", "TISSUE", 456, 470], ["lymphocytes", "CELL_TYPE", 384, 395], ["macrophages", "CELL_TYPE", 400, 411], ["patient", "SPECIES", 113, 120], ["the study", "TEST", 50, 59], ["Live SARS", "TEST", 67, 76], ["treatment", "TREATMENT", 175, 184], ["a rectal adenocarcinoma", "PROBLEM", 188, 211], ["Typical coronavirus virions in rectal tissue", "PROBLEM", 285, 329], ["electron microscopy", "TEST", 350, 369], ["macrophages", "TEST", 400, 411], ["some SARS", "TEST", 413, 422], ["CoV", "TEST", 423, 426], ["fecal", "ANATOMY", 100, 105], ["rectal", "ANATOMY", 190, 196], ["adenocarcinoma", "OBSERVATION", 197, 211], ["mucosa", "ANATOMY", 253, 259], ["rectum", "ANATOMY", 263, 269], ["ileum", "ANATOMY", 274, 279], ["coronavirus virions", "OBSERVATION", 293, 312], ["rectal tissue", "ANATOMY", 316, 329], ["abundant lymphocytes", "OBSERVATION", 375, 395], ["macrophages", "ANATOMY", 400, 411], ["lamina propria", "ANATOMY", 456, 470]]], ["Virions were found in the cytoplasm of intestinal epithelial cells and at electron microscopy.", [["cytoplasm", "ANATOMY", 26, 35], ["intestinal epithelial cells", "ANATOMY", 39, 66], ["Virions", "GENE_OR_GENE_PRODUCT", 0, 7], ["cytoplasm", "ORGANISM_SUBSTANCE", 26, 35], ["intestinal epithelial cells", "CELL", 39, 66], ["Virions", "PROTEIN", 0, 7], ["intestinal epithelial cells", "CELL_TYPE", 39, 66], ["Virions", "PROBLEM", 0, 7], ["electron microscopy", "TEST", 74, 93], ["cytoplasm", "ANATOMY_MODIFIER", 26, 35], ["intestinal epithelial", "ANATOMY", 39, 60], ["cells", "OBSERVATION", 61, 66]]], ["SARS-CoV-2 antigens were confirmed to be expressed on intestinal epithelial cells, lymphocytes and macrophages in the lamina propria.Live SARS-COV-2 excretion by the fecal routeZang R et al. w54 undertook a laboratory study that reported that human enterocytes express high ACE2 receptor levels, which could support infection with SARS-CoV-2, and Lamers et al. w21 found that SARS-CoV-2 productively infected Human small intestinal organoids (hSIOs) assessed by qRT-PCR for viral sequences and by live virus titrations on VeroE6 cells.Timing of fecal sheddingA retrospective study of 133 hospitalised Covid-19 patients identified 22 whose sputum or fecal samples tested positive, after pharyngeal swabs became negative.", [["intestinal epithelial cells", "ANATOMY", 54, 81], ["lymphocytes", "ANATOMY", 83, 94], ["macrophages", "ANATOMY", 99, 110], ["lamina propria", "ANATOMY", 118, 132], ["enterocytes", "ANATOMY", 249, 260], ["small intestinal organoids", "ANATOMY", 415, 441], ["hSIOs", "ANATOMY", 443, 448], ["VeroE6 cells", "ANATOMY", 522, 534], ["fecal", "ANATOMY", 545, 550], ["sputum", "ANATOMY", 639, 645], ["fecal samples", "ANATOMY", 649, 662], ["pharyngeal swabs", "ANATOMY", 686, 702], ["infection", "DISEASE", 316, 325], ["SARS", "DISEASE", 331, 335], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 0, 19], ["intestinal epithelial cells", "CELL", 54, 81], ["lymphocytes", "CELL", 83, 94], ["macrophages", "CELL", 99, 110], ["lamina propria", "TISSUE", 118, 132], ["COV-2", "GENE_OR_GENE_PRODUCT", 143, 148], ["human", "ORGANISM", 243, 248], ["enterocytes", "CELL", 249, 260], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 274, 287], ["SARS-CoV-2", "ORGANISM", 331, 341], ["SARS-CoV-2", "ORGANISM", 376, 386], ["Human", "ORGANISM", 409, 414], ["intestinal organoids", "CELL", 421, 441], ["hSIOs", "CELL", 443, 448], ["VeroE6 cells", "CELL", 522, 534], ["fecal", "ORGANISM_SUBSTANCE", 545, 550], ["patients", "ORGANISM", 610, 618], ["fecal samples", "ORGANISM_SUBSTANCE", 649, 662], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 686, 702], ["SARS-CoV-2 antigens", "PROTEIN", 0, 19], ["intestinal epithelial cells", "CELL_TYPE", 54, 81], ["lymphocytes", "CELL_TYPE", 83, 94], ["macrophages", "CELL_TYPE", 99, 110], ["human enterocytes", "CELL_TYPE", 243, 260], ["ACE2", "PROTEIN", 274, 278], ["Human small intestinal organoids", "CELL_TYPE", 409, 441], ["viral sequences", "DNA", 474, 489], ["VeroE6 cells", "CELL_LINE", 522, 534], ["human", "SPECIES", 243, 248], ["Human", "SPECIES", 409, 414], ["patients", "SPECIES", 610, 618], ["human", "SPECIES", 243, 248], ["SARS-CoV", "SPECIES", 331, 339], ["Human", "SPECIES", 409, 414], ["SARS-CoV-2 antigens", "TEST", 0, 19], ["intestinal epithelial cells", "TEST", 54, 81], ["Live SARS", "TEST", 133, 142], ["COV", "TEST", 143, 146], ["a laboratory study", "TEST", 205, 223], ["human enterocytes", "PROBLEM", 243, 260], ["high ACE2 receptor levels", "PROBLEM", 269, 294], ["infection", "PROBLEM", 316, 325], ["CoV", "TEST", 336, 339], ["SARS", "PROBLEM", 376, 380], ["CoV", "TEST", 381, 384], ["productively infected Human small intestinal organoids", "PROBLEM", 387, 441], ["PCR", "TEST", 466, 469], ["viral sequences", "TEST", 474, 489], ["VeroE6 cells", "TREATMENT", 522, 534], ["fecal shedding", "TEST", 545, 559], ["A retrospective study", "TEST", 559, 580], ["Covid", "TEST", 601, 606], ["whose sputum", "TEST", 633, 645], ["fecal samples", "TEST", 649, 662], ["pharyngeal swabs", "TEST", 686, 702], ["intestinal", "ANATOMY", 54, 64], ["epithelial cells", "OBSERVATION", 65, 81], ["lymphocytes", "ANATOMY", 83, 94], ["macrophages", "OBSERVATION", 99, 110], ["lamina propria", "ANATOMY", 118, 132], ["fecal", "ANATOMY", 166, 171], ["infection", "OBSERVATION", 316, 325], ["small", "OBSERVATION_MODIFIER", 415, 420], ["intestinal organoids", "ANATOMY", 421, 441], ["fecal", "ANATOMY", 649, 654]]], ["[ Chen w7 ] Cheung et al. w10 reported in a cohort of 59 patients that fecal discharge continues long after respiratory shedding of Covid-19 has ceased.", [["fecal", "ANATOMY", 71, 76], ["respiratory", "ANATOMY", 108, 119], ["Covid-19", "CHEMICAL", 132, 140], ["patients", "ORGANISM", 57, 65], ["fecal", "ORGANISM_SUBSTANCE", 71, 76], ["patients", "SPECIES", 57, 65], ["Chen w7 ] Cheung et al. w10", "TREATMENT", 2, 29], ["fecal discharge", "PROBLEM", 71, 86]]], ["Gupta et al. w15 reported that the duration for fecal shedding of viral RNA after clearance of respiratory samples ranged from 1 to 33 days and in one patient was up to 47 days from symptom onset.Timing of fecal sheddingIn the review by Tian et al. W39 fecal PCR testing was shown to be as accurate as respiratory specimen PCR detection, and fecal excretion persisted after sputum excretion in 23% patients for 1 to 11 days.", [["fecal", "ANATOMY", 48, 53], ["respiratory samples", "ANATOMY", 95, 114], ["fecal", "ANATOMY", 206, 211], ["respiratory specimen", "ANATOMY", 302, 322], ["fecal", "ANATOMY", 342, 347], ["sputum", "ANATOMY", 374, 380], ["fecal", "ORGANISM_SUBSTANCE", 48, 53], ["patient", "ORGANISM", 151, 158], ["fecal", "ORGANISM_SUBSTANCE", 206, 211], ["fecal", "ORGANISM_SUBSTANCE", 342, 347], ["sputum", "ORGANISM_SUBSTANCE", 374, 380], ["patients", "ORGANISM", 398, 406], ["viral RNA", "RNA", 66, 75], ["patient", "SPECIES", 151, 158], ["patients", "SPECIES", 398, 406], ["fecal shedding of viral RNA", "PROBLEM", 48, 75], ["respiratory samples", "TEST", 95, 114], ["fecal shedding", "PROBLEM", 206, 220], ["fecal PCR testing", "TEST", 253, 270], ["respiratory specimen PCR detection", "TEST", 302, 336], ["fecal excretion", "TEST", 342, 357], ["sputum excretion", "TEST", 374, 390], ["viral RNA", "OBSERVATION", 66, 75], ["fecal", "ANATOMY", 206, 211], ["shedding", "OBSERVATION", 212, 220]]], ["Don\u00e0 et al. W14 cites evidence from the SARS-CoV-1 outbreak that fecal excretion could be ongoing even after 30 days from symptom onset, the review authors recommend that exclusion of SARS-CoV-2 infection by single time point nasopharyngeal swabs should not be used in children.Detection in bathrooms of Acute Healthcare SettingsFrom January 24th to February 4th, three infected patients in airborne infection isolation rooms with anterooms and bathrooms had surface environmental samples taken at 26 sites.", [["fecal", "ANATOMY", 65, 70], ["nasopharyngeal swabs", "ANATOMY", 226, 246], ["surface", "ANATOMY", 459, 466], ["samples", "ANATOMY", 481, 488], ["SARS", "DISEASE", 40, 44], ["SARS", "DISEASE", 184, 188], ["infection", "DISEASE", 195, 204], ["infection", "DISEASE", 400, 409], ["fecal", "ORGANISM_SUBSTANCE", 65, 70], ["SARS-CoV-2", "ORGANISM", 184, 194], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 226, 246], ["children", "ORGANISM", 269, 277], ["patients", "ORGANISM", 379, 387], ["W14", "PROTEIN", 12, 15], ["children", "SPECIES", 269, 277], ["patients", "SPECIES", 379, 387], ["SARS-CoV-1", "SPECIES", 40, 50], ["SARS-CoV", "SPECIES", 184, 192], ["the SARS", "PROBLEM", 36, 44], ["fecal excretion", "PROBLEM", 65, 80], ["symptom onset", "PROBLEM", 122, 135], ["SARS", "PROBLEM", 184, 188], ["CoV", "PROBLEM", 189, 192], ["2 infection", "PROBLEM", 193, 204], ["nasopharyngeal swabs", "TREATMENT", 226, 246], ["surface environmental samples", "PROBLEM", 459, 488], ["Acute", "OBSERVATION_MODIFIER", 304, 309], ["infected", "OBSERVATION_MODIFIER", 370, 378], ["airborne infection", "OBSERVATION", 391, 409]]], ["Ong et al. w29 In two symptomatic patients rooms, after routine cleaning all samples were negative.", [["samples", "ANATOMY", 77, 84], ["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["routine cleaning all samples", "TEST", 56, 84]]], ["In the third patient's room, samples were collected before routine cleaning and were found to be positive for 13 out of 15 (87%) sites (including air outlet fans) and three of five toilet sites (toilet bowl, sink, and door handle) tested positive.", [["samples", "ANATOMY", 29, 36], ["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["routine cleaning", "TEST", 59, 75], ["air outlet fans", "TEST", 146, 161], ["air outlet", "OBSERVATION", 146, 156]]], ["One patient had upper respiratory tract involvement and two positive stool samples for SARS-CoV-2 on RT-PCR despite not having diarrhoea. w29 A study in February 2020 randomly sampled the 3-bed isolation rooms of the Covid-19 designated infectious diseases hospital wards, Nanjing, China.", [["upper respiratory tract", "ANATOMY", 16, 39], ["stool samples", "ANATOMY", 69, 82], ["SARS", "DISEASE", 87, 91], ["diarrhoea", "DISEASE", 127, 136], ["infectious diseases", "DISEASE", 237, 256], ["patient", "ORGANISM", 4, 11], ["upper respiratory", "ORGANISM_SUBDIVISION", 16, 33], ["tract", "ORGANISM_SUBDIVISION", 34, 39], ["patient", "SPECIES", 4, 11], ["SARS-CoV", "SPECIES", 87, 95], ["upper respiratory tract involvement", "PROBLEM", 16, 51], ["stool samples", "TEST", 69, 82], ["SARS", "PROBLEM", 87, 91], ["CoV", "TEST", 92, 95], ["RT-PCR", "TEST", 101, 107], ["diarrhoea", "PROBLEM", 127, 136], ["A study", "TEST", 142, 149], ["upper", "ANATOMY_MODIFIER", 16, 21], ["respiratory tract", "ANATOMY", 22, 39], ["diarrhoea", "OBSERVATION", 127, 136], ["infectious", "OBSERVATION_MODIFIER", 237, 247]]], ["[ Ding Z w13 ] Environmental sampling was also carried out in four isolation rooms, a nursing station, a corridor, an air-conditioning system and other spaces in the airborne infectious-disease zone on the fifth floor of the hospital.", [["infectious-disease", "DISEASE", 175, 193], ["Ding Z w", "TREATMENT", 2, 10], ["Environmental sampling", "TEST", 15, 37], ["an air-conditioning system", "TREATMENT", 115, 141], ["other spaces", "PROBLEM", 146, 158], ["disease zone", "PROBLEM", 186, 198], ["airborne", "OBSERVATION_MODIFIER", 166, 174], ["infectious", "OBSERVATION", 175, 185]]], ["Sampling procedures are described accurately and the air sampler twice needed to be quarantined despite wearing full PPE.", [["Sampling procedures", "TEST", 0, 19], ["the air sampler", "TREATMENT", 49, 64], ["full PPE", "TREATMENT", 112, 120]]], ["Airflow was also assessed between 4th and 5th floors in the building using a smoke tracer.", [["Airflow", "TEST", 0, 7]]], ["Of the 107 surface samples (37 from toilets, 34 from other surfaces in isolation rooms and 36 from other surfaces outside isolation rooms).", [["surface samples", "ANATOMY", 11, 26], ["the 107 surface samples", "TEST", 3, 26], ["toilets", "TEST", 36, 43]]], ["Four samples were positive (two ward door door-handles, one bathroom toilet toilet-seat cover and one bathroom door door-handle).", [["samples", "ANATOMY", 5, 12], ["Four samples", "TEST", 0, 12]]], ["Three were weakly positive from a bathroom toilet seat, one bathroom washbasin tap lever and one bathroom ceiling exhaust louvre.", [["weakly", "OBSERVATION_MODIFIER", 11, 17], ["positive", "OBSERVATION", 18, 26]]], ["One of the 46 corridor air samples was weakly positive.Detection in SewageAhmed et al. w1 obtained samples taken from two treatment plants and pumping stations around Brisbane, Queensland, Eastern Australia starting on the 24th of February until 13th of April with more frequent sampling as the epidemic curve got higher.", [["corridor air samples", "ANATOMY", 14, 34], ["samples", "ANATOMY", 99, 106], ["air samples", "CANCER", 23, 34], ["corridor air samples", "TEST", 14, 34], ["the epidemic curve", "TEST", 291, 309], ["positive", "OBSERVATION", 46, 54]]], ["Some 22% of the samples from one sampling point were positive.", [["samples", "ANATOMY", 16, 23], ["samples", "CANCER", 16, 23], ["the samples", "TEST", 12, 23]]], ["The estimated number of infections and prevalence were strongly correlated with the log10 SARS-CoV-2 RNA copies in stool, followed by the RNA copies detected in wastewater and log10/g of feces/person/day.", [["stool", "ANATOMY", 115, 120], ["infections", "DISEASE", 24, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 90, 100], ["stool", "ORGANISM_SUBSTANCE", 115, 120], ["feces", "ORGANISM", 187, 192], ["SARS-CoV-2 RNA copies", "RNA", 90, 111], ["RNA copies", "RNA", 138, 148], ["person", "SPECIES", 193, 199], ["infections", "PROBLEM", 24, 34], ["CoV", "TEST", 95, 98], ["number", "OBSERVATION_MODIFIER", 14, 20], ["infections", "OBSERVATION", 24, 34]]], ["Cahill et al. w3 review of available evidence of the orofecal transmission and its possible relation to wastewater management reported that SARS-CoV-2 has been detected in faeces and wastewater over recent months.Detection in SewageConcentration and detection of SARS coronavirus was found in sewage concentrates in China in two hospitals receiving SARS patients prior to disinfection, and occasionally after disinfection (no live SARS-CoV was detected in these assays).", [["orofecal", "ANATOMY", 53, 61], ["faeces", "ANATOMY", 172, 178], ["SARS-CoV-2", "CHEMICAL", 140, 150], ["SARS coronavirus", "DISEASE", 263, 279], ["SARS", "DISEASE", 349, 353], ["SARS-CoV-2", "ORGANISM", 140, 150], ["faeces", "ORGANISM_SUBSTANCE", 172, 178], ["SARS coronavirus", "ORGANISM", 263, 279], ["patients", "ORGANISM", 354, 362], ["patients", "SPECIES", 354, 362], ["SARS coronavirus", "SPECIES", 263, 279], ["SARS-CoV", "SPECIES", 431, 439], ["the orofecal transmission", "PROBLEM", 49, 74], ["wastewater management", "TREATMENT", 104, 125], ["SARS coronavirus", "PROBLEM", 263, 279], ["disinfection", "TREATMENT", 372, 384], ["disinfection", "TREATMENT", 409, 421], ["live SARS", "PROBLEM", 426, 435], ["CoV", "PROBLEM", 436, 439]]], ["The authors reported that the virus may be able to survive for 14 days in sewage at 4\u00b0C, 2 days at 20\u00b0C; its RNA could be detected for eight days although the virus had been inactivated.", [["the virus", "PROBLEM", 26, 35], ["the virus", "PROBLEM", 155, 164]]], ["[ Wang XW w42 ] Sentinel surveillance of SARS-CoV-2 in wastewater was shown to anticipate the occurrence of Covid-19 cases.", [["SARS", "DISEASE", 41, 45], ["SARS-CoV-2", "ORGANISM", 41, 51], ["SARS", "TEST", 41, 45], ["CoV", "TEST", 46, 49], ["Covid", "TEST", 108, 113]]], ["SARS-CoV-2 was detected in sewage 41 days before the declaration of the first Covid-19 case in Spain and in frozen samples dating back to 12 March 2019.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10]]], ["If confirmed, the results hypothesise that SARS CoV-2 has been around much longer than considered.", [["SARS", "DISEASE", 43, 47], ["SARS CoV", "TEST", 43, 51]]], ["Environmental screening may, therefore, be a sensitive tool to gauge viral presence before clinical symptoms become apparent.", [["Environmental screening", "TEST", 0, 23], ["clinical symptoms", "PROBLEM", 91, 108]]], ["SARS-CoV-2 was detected in the sewage of five sites a week after the first Covid-19 case in the Netherlands: identification of viral antigens occurred when the COVID-19 prevalence was around or even below 1 case per 100,000.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["viral antigens", "PROTEIN", 127, 141], ["SARS-CoV", "SPECIES", 0, 8], ["viral antigens", "PROBLEM", 127, 141], ["the COVID", "TEST", 156, 165], ["viral", "OBSERVATION", 127, 132]]], ["[ Medema G w27 ]Detection in SewageA systematic review of what is known of the presence and survival of coronaviridae in various water settings included twelve articles.", [["Medema G w", "TREATMENT", 2, 12], ["coronaviridae", "TREATMENT", 104, 117]]], ["La Rosa et al. w22 noted the methods of concentration and collection for these viridae may not be appropriate.", [["these viridae", "TREATMENT", 73, 86]]], ["Coroviridae have been isolated in different types of liquids from waste to surface water but in general, they appear to be unstable.", [["Coroviridae", "CHEMICAL", 0, 11], ["Coroviridae", "SIMPLE_CHEMICAL", 0, 11], ["Coroviridae", "TREATMENT", 0, 11], ["unstable", "OBSERVATION", 123, 131]]], ["Chlorination and higher temperatures lead to their inactivation.", [["Chlorination", "TREATMENT", 0, 12], ["higher temperatures", "PROBLEM", 17, 36], ["their inactivation", "PROBLEM", 45, 63]]], ["Chlorine was considered far more effective against SARS-CoV-2 than other microorganisms because of its lytic action on the envelope.Detection in SewageA study in the First Affiliated Hospital of Zhejiang University, China found that strict disinfection and hand hygiene could decrease the hospital-associated Covid-19 infection risk of the staff in isolation wards.", [["hand", "ANATOMY", 257, 261], ["Chlorine", "CHEMICAL", 0, 8], ["SARS", "DISEASE", 51, 55], ["infection", "DISEASE", 318, 327], ["Chlorine", "CHEMICAL", 0, 8], ["Chlorine", "SIMPLE_CHEMICAL", 0, 8], ["SARS-CoV-2", "ORGANISM", 51, 61], ["hand", "ORGANISM_SUBDIVISION", 257, 261], ["SARS-CoV", "SPECIES", 51, 59], ["Chlorine", "TREATMENT", 0, 8], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["other microorganisms", "PROBLEM", 67, 87], ["its lytic action", "PROBLEM", 99, 115], ["SewageA study", "TEST", 145, 158], ["strict disinfection", "TREATMENT", 233, 252], ["hand hygiene", "TREATMENT", 257, 269], ["lytic", "OBSERVATION", 103, 108], ["infection", "OBSERVATION", 318, 327]]], ["The study monitored the presence of SARS-Cov-2 among hospital environment surfaces, sewage, and personal protective equipment (PPE) of staff.", [["SARS", "DISEASE", 36, 40], ["The study", "TEST", 0, 9], ["SARS", "PROBLEM", 36, 40]]], ["During the study period, 33 patients were hospitalized in isolation wards, and no SARS-Cov-2 RNA was detected among the 36 objects surface samples and nine staff PPE samples.", [["surface samples", "ANATOMY", 131, 146], ["samples", "ANATOMY", 166, 173], ["SARS", "DISEASE", 82, 86], ["patients", "ORGANISM", 28, 36], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 82, 92], ["SARS-Cov-2 RNA", "RNA", 82, 96], ["patients", "SPECIES", 28, 36], ["SARS", "PROBLEM", 82, 86], ["Cov", "TEST", 87, 90], ["nine staff PPE samples", "TEST", 151, 173], ["no", "UNCERTAINTY", 79, 81]]], ["Wang J (b) et al. w41 surfaces were wiped with 1000 mg/L chlorine-containing disinfectant every 4 hours in the isolation ICU ward and every 8 hours in general isolation wards.", [["chlorine", "CHEMICAL", 57, 65], ["chlorine", "CHEMICAL", 57, 65], ["chlorine", "SIMPLE_CHEMICAL", 57, 65], ["Wang J (b) et al. w41 surfaces", "TREATMENT", 0, 30], ["chlorine", "TREATMENT", 57, 65]]], ["Preprocessing disinfection equipment was added before sewage drainage from the isolation wards into the final sewage disinfection pool.", [["Preprocessing disinfection equipment", "TREATMENT", 0, 36], ["sewage drainage", "TREATMENT", 54, 69], ["the isolation wards", "TREATMENT", 75, 94], ["sewage disinfection", "OBSERVATION", 110, 129]]], ["The sewage samples from the inlet pool were found to be positive, and from the outlet of the preprocessing pool weakly positive, but the sewage samples from the last disinfection pool were negative.", [["sewage samples", "ANATOMY", 4, 18], ["samples", "ANATOMY", 144, 151], ["sewage samples", "ORGANISM_SUBSTANCE", 4, 18], ["The sewage samples", "TEST", 0, 18], ["the inlet pool", "TEST", 24, 38], ["the sewage samples", "TEST", 133, 151], ["the last disinfection pool", "TEST", 157, 183]]], ["No viable virus was detected by culture.DiscussionWe found nine reviews and 51 primary studies or reports examining the potential role of orofecal transmission of SARS-CoV-2.", [["orofecal", "ANATOMY", 138, 146], ["SARS", "DISEASE", 163, 167], ["orofecal", "ORGANISM_SUBDIVISION", 138, 146], ["SARS-CoV-2", "ORGANISM", 163, 173], ["SARS-CoV", "SPECIES", 163, 171], ["viable virus", "PROBLEM", 3, 15], ["culture", "TEST", 32, 39], ["primary studies", "TEST", 79, 94], ["viable", "OBSERVATION_MODIFIER", 3, 9], ["virus", "OBSERVATION", 10, 15]]], ["Thirty seven studies reported positive fecal samples for SARS-CoV-2 based on RT-PCR results of 1,034 patients.", [["fecal samples", "ANATOMY", 39, 52], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["SARS-CoV", "SPECIES", 57, 65], ["Thirty seven studies", "TEST", 0, 20], ["fecal samples", "TEST", 39, 52], ["SARS", "TEST", 57, 61], ["CoV", "TEST", 62, 65], ["RT-PCR", "TEST", 77, 83]]], ["Six studies reported isolating the virus from fecal samples of nine patients and one study from rectal tissue.", [["fecal samples", "ANATOMY", 46, 59], ["rectal tissue", "ANATOMY", 96, 109], ["fecal samples", "ORGANISM_SUBSTANCE", 46, 59], ["patients", "ORGANISM", 68, 76], ["rectal tissue", "TISSUE", 96, 109], ["patients", "SPECIES", 68, 76], ["Six studies", "TEST", 0, 11], ["the virus", "PROBLEM", 31, 40], ["fecal samples", "TEST", 46, 59], ["one study", "TEST", 81, 90], ["rectal tissue", "ANATOMY", 96, 109]]], ["Eleven studies report on fecal samples found in sewage, and two collected samples from bathrooms and toilets.How this fits with knowledge of other CoronavirusesMERS-CoV has been shown to infect human primary intestinal epithelial cells, small intestine explants and intestinal organoids.", [["fecal samples", "ANATOMY", 25, 38], ["samples", "ANATOMY", 74, 81], ["primary intestinal epithelial cells", "ANATOMY", 200, 235], ["small intestine explants", "ANATOMY", 237, 261], ["intestinal organoids", "ANATOMY", 266, 286], ["fecal samples", "ORGANISM_SUBSTANCE", 25, 38], ["CoronavirusesMERS-CoV", "ORGANISM", 147, 168], ["human", "ORGANISM", 194, 199], ["intestinal epithelial cells", "CELL", 208, 235], ["small intestine explants", "TISSUE", 237, 261], ["intestinal organoids", "TISSUE", 266, 286], ["human primary intestinal epithelial cells", "CELL_TYPE", 194, 235], ["intestinal organoids", "CELL_TYPE", 266, 286], ["human", "SPECIES", 194, 199], ["CoronavirusesMERS-CoV", "SPECIES", 147, 168], ["human", "SPECIES", 194, 199], ["Eleven studies", "TEST", 0, 14], ["fecal samples", "TEST", 25, 38], ["other CoronavirusesMERS", "PROBLEM", 141, 164], ["CoV", "PROBLEM", 165, 168], ["small intestine explants", "PROBLEM", 237, 261], ["intestinal organoids", "PROBLEM", 266, 286], ["intestinal", "ANATOMY", 208, 218], ["epithelial cells", "OBSERVATION", 219, 235], ["small", "OBSERVATION_MODIFIER", 237, 242], ["intestine", "ANATOMY", 243, 252], ["intestinal", "ANATOMY", 266, 276], ["organoids", "OBSERVATION", 277, 286]]], ["8 MERS-CoV has been detected in 42% of milk samples collected from lactating camels where it can survive for a prolonged period.", [["milk samples", "ANATOMY", 39, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 2, 10], ["milk samples", "ORGANISM_SUBSTANCE", 39, 51], ["camels", "ORGANISM_SUBDIVISION", 77, 83], ["MERS-CoV", "SPECIES", 2, 10], ["CoV", "PROBLEM", 7, 10], ["milk samples", "TEST", 39, 51]]], ["A study of human primary intestinal epithelial cells and small intestine explants of MERS-CoV patterns identified the viral replication intermediates in stool specimens.", [["primary intestinal epithelial cells", "ANATOMY", 17, 52], ["small intestine explants", "ANATOMY", 57, 81], ["stool specimens", "ANATOMY", 153, 168], ["human", "ORGANISM", 11, 16], ["intestinal epithelial cells", "CELL", 25, 52], ["small intestine explants", "TISSUE", 57, 81], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 85, 93], ["stool specimens", "ORGANISM_SUBSTANCE", 153, 168], ["human primary intestinal epithelial cells", "CELL_TYPE", 11, 52], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["MERS-CoV", "SPECIES", 85, 93], ["A study", "TEST", 0, 7], ["human primary intestinal epithelial cells", "PROBLEM", 11, 52], ["small intestine explants of MERS", "PROBLEM", 57, 89], ["CoV patterns", "TEST", 90, 102], ["the viral replication intermediates", "PROBLEM", 114, 149], ["stool specimens", "TEST", 153, 168], ["intestinal", "ANATOMY", 25, 35], ["epithelial cells", "OBSERVATION", 36, 52], ["small", "OBSERVATION_MODIFIER", 57, 62], ["intestine", "ANATOMY", 63, 72], ["viral replication", "OBSERVATION", 118, 135]]], ["MERS-CoV was found to be resistant to fed-state gastrointestinal fluids but less tolerant to the high acidic fasted-state gastric fluid.How this fits with knowledge of other CoronavirusesIn 1977 the prolonged excretion of coronaviruses in feces was first observed.", [["gastrointestinal fluids", "ANATOMY", 48, 71], ["gastric fluid", "ANATOMY", 122, 135], ["feces", "ANATOMY", 239, 244], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["gastric fluid", "MULTI-TISSUE_STRUCTURE", 122, 135], ["CoronavirusesIn 1977", "ORGANISM", 174, 194], ["coronaviruses", "ORGANISM", 222, 235], ["feces", "ORGANISM_SUBSTANCE", 239, 244], ["MERS-CoV", "SPECIES", 0, 8], ["the prolonged excretion of coronaviruses in feces", "PROBLEM", 195, 244], ["gastrointestinal", "ANATOMY", 48, 64], ["gastric", "ANATOMY", 122, 129], ["fluid", "OBSERVATION", 130, 135], ["coronaviruses", "OBSERVATION", 222, 235]]], ["10 In the SARS-CoV-1 outbreak in 2002-03, a significant portion of patients had enteric involvement.", [["SARS", "DISEASE", 10, 14], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["SARS-CoV-1", "SPECIES", 10, 20], ["CoV", "TEST", 15, 18], ["enteric involvement", "PROBLEM", 80, 99], ["enteric", "ANATOMY", 80, 87], ["involvement", "OBSERVATION", 88, 99]]], ["In the Toronto outbreak in 2003, 6% of 144 patients had diarrhoea on presentation.", [["diarrhoea", "DISEASE", 56, 65], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["diarrhoea", "PROBLEM", 56, 65]]], ["11 Also among 138 patients with SARS in Hong Kong, 20% presented with watery diarrhoea and 38% had symptoms of diarrhoea during the illness.", [["SARS", "DISEASE", 32, 36], ["watery diarrhoea", "DISEASE", 70, 86], ["diarrhoea", "DISEASE", 111, 120], ["illness", "DISEASE", 132, 139], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["SARS", "PROBLEM", 32, 36], ["watery diarrhoea", "PROBLEM", 70, 86], ["symptoms", "PROBLEM", 99, 107], ["diarrhoea", "PROBLEM", 111, 120], ["the illness", "PROBLEM", 128, 139], ["diarrhoea", "OBSERVATION", 111, 120]]], ["Intestinal biopsy specimens showed the presence of active viral replication, and SARS-CoV RNA was detected in the stool of some patients for more than ten weeks after symptom onset.", [["Intestinal biopsy specimens", "ANATOMY", 0, 27], ["stool", "ANATOMY", 114, 119], ["Intestinal biopsy specimens", "CANCER", 0, 27], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 81, 89], ["stool", "ORGANISM_SUBSTANCE", 114, 119], ["patients", "ORGANISM", 128, 136], ["SARS-CoV RNA", "RNA", 81, 93], ["patients", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 81, 89], ["Intestinal biopsy specimens", "TEST", 0, 27], ["active viral replication", "PROBLEM", 51, 75], ["SARS", "PROBLEM", 81, 85], ["CoV RNA", "PROBLEM", 86, 93], ["symptom onset", "PROBLEM", 167, 180], ["active", "OBSERVATION_MODIFIER", 51, 57], ["viral replication", "OBSERVATION", 58, 75]]], ["12 A retrospective study on specimens from 154 patients in Hong Kong with laboratory-confirmed SARS found the viral load to be the highest in stool specimens.", [["specimens", "ANATOMY", 28, 37], ["stool specimens", "ANATOMY", 142, 157], ["SARS", "DISEASE", 95, 99], ["specimens", "CANCER", 28, 37], ["patients", "ORGANISM", 47, 55], ["stool specimens", "ORGANISM_SUBSTANCE", 142, 157], ["patients", "SPECIES", 47, 55], ["A retrospective study", "TEST", 3, 24], ["specimens", "TEST", 28, 37], ["SARS", "PROBLEM", 95, 99], ["the viral load", "PROBLEM", 106, 120], ["stool specimens", "TEST", 142, 157]]], ["13 Up to 70% of 75 patients in a community outbreak in Hong Kong developed watery diarrhea.", [["watery diarrhea", "DISEASE", 75, 90], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["watery diarrhea", "PROBLEM", 75, 90], ["watery diarrhea", "OBSERVATION", 75, 90]]], ["14 This outbreak was linked to a faulty sewage system in the Amoy Gardens apartment complex, further suggesting orofecal transmission might be a route for transmission.", [["orofecal", "ANATOMY", 112, 120], ["orofecal transmission", "PROBLEM", 112, 133]]], ["15 The human gastrointestinal tract can act as a primary infection site for SARS-CoV.", [["gastrointestinal tract", "ANATOMY", 13, 35], ["infection", "DISEASE", 57, 66], ["SARS", "DISEASE", 76, 80], ["human", "ORGANISM", 7, 12], ["gastrointestinal tract", "ORGAN", 13, 35], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 7, 12], ["SARS-CoV", "SPECIES", 76, 84], ["The human gastrointestinal tract", "PROBLEM", 3, 35], ["a primary infection site", "PROBLEM", 47, 71], ["SARS", "PROBLEM", 76, 80], ["gastrointestinal tract", "ANATOMY", 13, 35], ["infection", "OBSERVATION", 57, 66]]], ["Ding et al used a monoclonal antibody specific for the SARS -CoV nucleoprotein, and probes for the RNA polymerase gene fragment in four patients who died from SARS -CoV-1.", [["SARS", "DISEASE", 159, 163], ["SARS -CoV", "GENE_OR_GENE_PRODUCT", 55, 64], ["patients", "ORGANISM", 136, 144], ["SARS -CoV-1", "ORGANISM", 159, 170], ["monoclonal antibody", "PROTEIN", 18, 37], ["SARS -CoV nucleoprotein", "RNA", 55, 78], ["RNA polymerase gene fragment", "DNA", 99, 127], ["patients", "SPECIES", 136, 144], ["SARS -CoV", "SPECIES", 55, 64], ["SARS -CoV-1", "SPECIES", 159, 170], ["a monoclonal antibody", "TEST", 16, 37], ["the SARS", "TEST", 51, 59], ["CoV nucleoprotein", "TREATMENT", 61, 78], ["the RNA polymerase gene fragment", "PROBLEM", 95, 127], ["SARS", "PROBLEM", 159, 163], ["fragment", "OBSERVATION_MODIFIER", 119, 127]]], ["16 Virus was detected in the stomach, small intestine, distal convoluted renal tubule, sweat gland, parathyroid, pituitary, pancreas, adrenal, liver and cerebrum.", [["stomach", "ANATOMY", 29, 36], ["small intestine", "ANATOMY", 38, 53], ["distal convoluted renal tubule", "ANATOMY", 55, 85], ["sweat gland", "ANATOMY", 87, 98], ["parathyroid", "ANATOMY", 100, 111], ["pituitary", "ANATOMY", 113, 122], ["pancreas", "ANATOMY", 124, 132], ["adrenal", "ANATOMY", 134, 141], ["liver", "ANATOMY", 143, 148], ["cerebrum", "ANATOMY", 153, 161], ["Virus", "ORGANISM", 3, 8], ["stomach", "ORGAN", 29, 36], ["small intestine", "MULTI-TISSUE_STRUCTURE", 38, 53], ["convoluted renal tubule", "MULTI-TISSUE_STRUCTURE", 62, 85], ["sweat gland", "MULTI-TISSUE_STRUCTURE", 87, 98], ["parathyroid", "ORGAN", 100, 111], ["pituitary", "ORGAN", 113, 122], ["pancreas", "ORGAN", 124, 132], ["adrenal", "ORGAN", 134, 141], ["liver", "ORGAN", 143, 148], ["cerebrum", "ORGAN", 153, 161], ["Virus", "PROBLEM", 3, 8], ["distal convoluted renal tubule, sweat gland, parathyroid, pituitary, pancreas, adrenal, liver and cerebrum", "PROBLEM", 55, 161], ["Virus", "OBSERVATION", 3, 8], ["stomach", "ANATOMY", 29, 36], ["small intestine", "ANATOMY", 38, 53], ["distal", "ANATOMY_MODIFIER", 55, 61], ["convoluted", "ANATOMY_MODIFIER", 62, 72], ["renal", "ANATOMY", 73, 78], ["tubule", "ANATOMY_MODIFIER", 79, 85], ["sweat gland", "ANATOMY", 87, 98], ["parathyroid", "ANATOMY", 100, 111], ["pituitary", "ANATOMY", 113, 122], ["pancreas", "ANATOMY", 124, 132], ["adrenal", "ANATOMY", 134, 141], ["liver", "ANATOMY", 143, 148], ["cerebrum", "ANATOMY", 153, 161]]], ["The authors discussed that viruses in contaminated food and water may enter the human body through epithelial cells covering the surface of the gastrointestinal tract, although there was no direct evidence to show that foodborne transmission had occurred.", [["body", "ANATOMY", 86, 90], ["epithelial cells", "ANATOMY", 99, 115], ["surface", "ANATOMY", 129, 136], ["gastrointestinal tract", "ANATOMY", 144, 166], ["foodborne transmission", "DISEASE", 219, 241], ["food", "ORGANISM_SUBDIVISION", 51, 55], ["human", "ORGANISM", 80, 85], ["body", "DEVELOPING_ANATOMICAL_STRUCTURE", 86, 90], ["epithelial cells", "CELL", 99, 115], ["surface", "CELLULAR_COMPONENT", 129, 136], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 144, 166], ["epithelial cells", "CELL_TYPE", 99, 115], ["human", "SPECIES", 80, 85], ["human", "SPECIES", 80, 85], ["viruses", "PROBLEM", 27, 34], ["epithelial cells", "TREATMENT", 99, 115], ["foodborne transmission", "PROBLEM", 219, 241], ["viruses", "OBSERVATION", 27, 34], ["epithelial cells", "OBSERVATION", 99, 115], ["surface", "ANATOMY_MODIFIER", 129, 136], ["gastrointestinal tract", "ANATOMY", 144, 166], ["no direct evidence", "UNCERTAINTY", 187, 205]]], ["A study from the sewage of two hospitals receiving SARS patients in Beijing found no infectious SARS-CoV contamination in any of the samples collected, but did detect the nucleic acid in the sewage from the two hospitals before disinfection -providing further evidence that SARS-CoV-1 can be excreted by feces into the sewage system.", [["samples", "ANATOMY", 133, 140], ["SARS", "DISEASE", 51, 55], ["SARS", "DISEASE", 96, 100], ["nucleic acid", "CHEMICAL", 171, 183], ["SARS-CoV-1", "CHEMICAL", 274, 284], ["patients", "ORGANISM", 56, 64], ["nucleic acid", "SIMPLE_CHEMICAL", 171, 183], ["CoV-1", "ORGANISM", 279, 284], ["feces", "ORGANISM_SUBSTANCE", 304, 309], ["patients", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 96, 104], ["A study", "TEST", 0, 7], ["infectious SARS", "PROBLEM", 85, 100], ["CoV contamination", "PROBLEM", 101, 118], ["the samples", "TEST", 129, 140], ["the nucleic acid", "PROBLEM", 167, 183], ["disinfection", "TREATMENT", 228, 240], ["SARS", "PROBLEM", 274, 278], ["no", "UNCERTAINTY", 82, 84], ["infectious", "OBSERVATION_MODIFIER", 85, 95], ["sewage system", "OBSERVATION", 319, 332]]], ["17 While human coronaviruses are considered not to transmit fecally this is not the case in animals.", [["human", "ORGANISM", 9, 14], ["coronaviruses", "ORGANISM", 15, 28], ["human", "SPECIES", 9, 14], ["human coronaviruses", "SPECIES", 9, 28]]], ["Feline coronavirus, for instance, is typically shed in feces of healthy cats and transmitted by the orofecal route to other cats .", [["feces", "ANATOMY", 55, 60], ["orofecal", "ANATOMY", 100, 108], ["Feline coronavirus", "DISEASE", 0, 18], ["Feline coronavirus", "ORGANISM", 0, 18], ["feces", "ORGANISM_SUBDIVISION", 55, 60], ["cats", "ORGANISM", 72, 76], ["cats", "ORGANISM", 124, 128], ["Feline coronavirus", "SPECIES", 0, 18], ["cats", "SPECIES", 72, 76], ["cats", "SPECIES", 124, 128], ["Feline coronavirus", "SPECIES", 0, 18], ["Feline coronavirus", "PROBLEM", 0, 18], ["coronavirus", "OBSERVATION", 7, 18]]], ["19 Pigs are also infected by the transmissible gastroenteritis coronavirus via the fecal-oral route .", [["oral", "ANATOMY", 89, 93], ["gastroenteritis coronavirus", "DISEASE", 47, 74], ["Pigs", "ORGANISM", 3, 7], ["gastroenteritis coronavirus", "ORGANISM", 47, 74], ["fecal", "ORGANISM_SUBDIVISION", 83, 88], ["oral", "ORGANISM_SUBDIVISION", 89, 93], ["Pigs", "SPECIES", 3, 7], ["transmissible gastroenteritis coronavirus", "SPECIES", 33, 74], ["Pigs", "SPECIES", 3, 7], ["transmissible gastroenteritis coronavirus", "SPECIES", 33, 74], ["Pigs", "TREATMENT", 3, 7], ["the transmissible gastroenteritis coronavirus", "PROBLEM", 29, 74], ["infected", "OBSERVATION", 17, 25], ["transmissible", "OBSERVATION_MODIFIER", 33, 46], ["gastroenteritis coronavirus", "OBSERVATION", 47, 74], ["fecal", "ANATOMY", 83, 88]]], ["20 Bat coronavirus infects the gastrointestinal and respiratory tracts of bats seemingly without causing disease.", [["gastrointestinal", "ANATOMY", 31, 47], ["respiratory tracts", "ANATOMY", 52, 70], ["coronavirus infects the gastrointestinal and respiratory tracts", "DISEASE", 7, 70], ["20", "ORGANISM", 0, 2], ["Bat coronavirus", "ORGANISM", 3, 18], ["gastrointestinal", "ORGAN", 31, 47], ["bats", "ORGANISM", 74, 78], ["Bat coronavirus infects", "SPECIES", 3, 26], ["Bat coronavirus", "SPECIES", 3, 18], ["Bat coronavirus infects the gastrointestinal and respiratory tracts of bats", "PROBLEM", 3, 78], ["disease", "PROBLEM", 105, 112], ["coronavirus infects", "OBSERVATION", 7, 26], ["gastrointestinal", "ANATOMY", 31, 47], ["respiratory tracts", "OBSERVATION", 52, 70], ["without", "UNCERTAINTY", 89, 96]]], ["21 Transmission following exposure to camel feces has also been considered to be biologically plausible, although no evidence indicates whether this is possible.", [["camel", "ORGANISM", 38, 43], ["feces", "ORGANISM_SUBSTANCE", 44, 49], ["camel", "SPECIES", 38, 43], ["camel", "SPECIES", 38, 43], ["no evidence indicates", "UNCERTAINTY", 114, 135]]], ["22 There is, however, evidence that SARS-CoV-2 can survive adverse conditions in the gastrointestinal system.", [["gastrointestinal system", "ANATOMY", 85, 108], ["SARS-CoV-2", "ORGANISM", 36, 46], ["gastrointestinal", "ORGAN", 85, 101], ["system", "ANATOMICAL_SYSTEM", 102, 108], ["SARS", "PROBLEM", 36, 40], ["adverse conditions in the gastrointestinal system", "PROBLEM", 59, 108], ["gastrointestinal system", "ANATOMY", 85, 108]]], ["It has been identified in endoscopic specimens of the esophagus, stomach, duodenum, and rectum of Covid-19 patients; substantial amounts of SARS-CoV-2 RNA have been consistently detected in stool specimens.", [["specimens", "ANATOMY", 37, 46], ["esophagus", "ANATOMY", 54, 63], ["stomach", "ANATOMY", 65, 72], ["duodenum", "ANATOMY", 74, 82], ["rectum", "ANATOMY", 88, 94], ["stool specimens", "ANATOMY", 190, 205], ["SARS", "DISEASE", 140, 144], ["esophagus", "ORGAN", 54, 63], ["stomach", "ORGAN", 65, 72], ["duodenum", "ORGAN", 74, 82], ["rectum", "ORGAN", 88, 94], ["patients", "ORGANISM", 107, 115], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 140, 150], ["stool specimens", "ORGANISM_SUBSTANCE", 190, 205], ["SARS-CoV-2 RNA", "RNA", 140, 154], ["patients", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 140, 148], ["Covid", "TEST", 98, 103], ["SARS", "PROBLEM", 140, 144], ["CoV-2 RNA", "PROBLEM", 145, 154], ["stool specimens", "TEST", 190, 205], ["esophagus", "ANATOMY", 54, 63], ["stomach", "ANATOMY", 65, 72], ["duodenum", "ANATOMY", 74, 82], ["rectum", "ANATOMY", 88, 94], ["substantial", "OBSERVATION_MODIFIER", 117, 128], ["amounts", "OBSERVATION_MODIFIER", 129, 136], ["SARS", "OBSERVATION", 140, 144]]], ["The Ding S et al. w12 review cited evidence that SARS-CoV-2 can survive the adverse conditions in the gastrointestinal system.", [["gastrointestinal system", "ANATOMY", 102, 125], ["SARS", "DISEASE", 49, 53], ["SARS-CoV-2", "ORGANISM", 49, 59], ["gastrointestinal", "ORGAN", 102, 118], ["system", "ANATOMICAL_SYSTEM", 119, 125], ["SARS", "PROBLEM", 49, 53], ["the adverse conditions in the gastrointestinal system", "PROBLEM", 72, 125], ["gastrointestinal system", "ANATOMY", 102, 125]]], ["Heavy glycosylation of the large spike S protein has been shown to lead to resistance to the proteases, the low pH and bile salts found in the gastrointestinal system.", [["gastrointestinal system", "ANATOMY", 143, 166], ["bile salts", "CHEMICAL", 119, 129], ["bile salts", "CHEMICAL", 119, 129], ["large spike S protein", "GENE_OR_GENE_PRODUCT", 27, 48], ["bile salts", "SIMPLE_CHEMICAL", 119, 129], ["gastrointestinal", "ORGAN", 143, 159], ["system", "ANATOMICAL_SYSTEM", 160, 166], ["large spike S protein", "PROTEIN", 27, 48], ["proteases", "PROTEIN", 93, 102], ["the large spike S protein", "PROBLEM", 23, 48], ["the proteases", "TEST", 89, 102], ["the low pH", "PROBLEM", 104, 114], ["bile salts", "PROBLEM", 119, 129], ["glycosylation", "OBSERVATION", 6, 19], ["large", "OBSERVATION_MODIFIER", 27, 32], ["spike", "OBSERVATION_MODIFIER", 33, 38], ["bile", "ANATOMY", 119, 123], ["gastrointestinal system", "ANATOMY", 143, 166]]], ["Some gastric processes may actually facilitate viral entry into the enterocytes: in bovine coronavirus, one specific site on the S glycoprotein has to be cleaved by an intracellular protease or trypsin to activate viral infectivity and cell fusion.", [["gastric", "ANATOMY", 5, 12], ["enterocytes", "ANATOMY", 68, 79], ["intracellular", "ANATOMY", 168, 181], ["cell", "ANATOMY", 236, 240], ["gastric", "ORGAN", 5, 12], ["enterocytes", "CELLULAR_COMPONENT", 68, 79], ["bovine coronavirus", "ORGANISM", 84, 102], ["S glycoprotein", "GENE_OR_GENE_PRODUCT", 129, 143], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 168, 181], ["trypsin", "GENE_OR_GENE_PRODUCT", 194, 201], ["cell", "CELL", 236, 240], ["enterocytes", "CELL_TYPE", 68, 79], ["S glycoprotein", "PROTEIN", 129, 143], ["intracellular protease", "PROTEIN", 168, 190], ["trypsin", "PROTEIN", 194, 201], ["bovine", "SPECIES", 84, 90], ["coronavirus", "SPECIES", 91, 102], ["bovine coronavirus", "SPECIES", 84, 102], ["Some gastric processes", "PROBLEM", 0, 22], ["bovine coronavirus", "PROBLEM", 84, 102], ["the S glycoprotein", "TREATMENT", 125, 143], ["an intracellular protease", "TREATMENT", 165, 190], ["trypsin", "TREATMENT", 194, 201], ["viral infectivity", "PROBLEM", 214, 231], ["cell fusion", "TREATMENT", 236, 247], ["gastric", "ANATOMY", 5, 12], ["viral", "OBSERVATION", 47, 52], ["enterocytes", "ANATOMY", 68, 79], ["bovine coronavirus", "OBSERVATION", 84, 102], ["viral infectivity", "OBSERVATION", 214, 231], ["cell fusion", "OBSERVATION", 236, 247]]], ["3LimitationsThe limitations in this review are mainly related to the quality of the included studies.", [["the included studies", "TEST", 80, 100]]], ["Many were small, did not provide a protocol that established a priori methods, they were often poorly reported and often did not take into account biases.", [["a protocol", "TREATMENT", 33, 43], ["small", "OBSERVATION_MODIFIER", 10, 15]]], ["These limitations prevent firm conclusions being drawn on the magnitude of the estimates but these studies do provide largely consistent evidence on the main conclusions that SARS-CoV-2 is excreted fecally, is found in sewage and can be cultured.Implications for PolicyPolicy should emphasise routine surveillance of food, wastewaters and effluent.", [["SARS", "DISEASE", 175, 179], ["SARS-CoV-2", "ORGANISM", 175, 185], ["firm conclusions", "PROBLEM", 26, 42], ["these studies", "TEST", 93, 106], ["SARS", "PROBLEM", 175, 179], ["CoV", "TEST", 180, 183], ["PolicyPolicy", "TREATMENT", 263, 275], ["firm", "OBSERVATION", 26, 30], ["effluent", "OBSERVATION", 339, 347]]], ["The importance of strict personal hygiene measures, chlorine-based disinfection of surfaces in locations with presumed or known SARS CoV-2 activity should form part of public policy and education campaigns.", [["chlorine", "CHEMICAL", 52, 60], ["SARS", "DISEASE", 128, 132], ["chlorine", "CHEMICAL", 52, 60], ["chlorine", "SIMPLE_CHEMICAL", 52, 60], ["strict personal hygiene measures", "TREATMENT", 18, 50], ["chlorine-based disinfection of surfaces", "TREATMENT", 52, 91], ["known SARS CoV", "PROBLEM", 122, 136]]], ["Stool testing should be carried out in dischargees from the hospital or other holding facilities well before discharge date and discharge should be conditional either on cessation of fecal excretion or strict quarantine and personal hygiene measures in those still excreting viral particles by stool independently from respiratory excretion.Implications for Further ResearchEach outbreak should be investigated and a report be made publicly available rapidly.", [["fecal", "ANATOMY", 183, 188], ["respiratory", "ANATOMY", 319, 330], ["fecal", "ORGANISM_SUBSTANCE", 183, 188], ["stool", "ORGANISM_SUBSTANCE", 294, 299], ["Stool testing", "TEST", 0, 13], ["fecal excretion", "TREATMENT", 183, 198], ["strict quarantine", "TREATMENT", 202, 219], ["personal hygiene measures", "TREATMENT", 224, 249], ["respiratory excretion", "TEST", 319, 340], ["Further ResearchEach outbreak", "TREATMENT", 358, 387], ["viral particles", "OBSERVATION", 275, 290], ["respiratory excretion", "OBSERVATION", 319, 340]]], ["Testing of stools should be carried out in all people involved in the outbreak.", [["stools", "ORGANISM_SUBSTANCE", 11, 17], ["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["Testing of stools", "PROBLEM", 0, 17], ["stools", "OBSERVATION", 11, 17]]], ["As there is coherent evidence of ingestion, penetration of enterocytes and excretion of live SARs-CoV-2 in possible analogy with SARs and MERS agents, we believe this working hypothesis should be tested by conducting case-control studies during the investigation of outbreaks following a set protocol.", [["enterocytes", "ANATOMY", 59, 70], ["enterocytes", "MULTI-TISSUE_STRUCTURE", 59, 70], ["CoV-2", "GENE_OR_GENE_PRODUCT", 98, 103], ["ingestion", "PROBLEM", 33, 42], ["penetration of enterocytes", "PROBLEM", 44, 70], ["CoV", "TEST", 98, 101], ["SARs", "PROBLEM", 129, 133], ["MERS agents", "TREATMENT", 138, 149], ["the investigation", "TEST", 245, 262], ["a set protocol", "TREATMENT", 286, 300], ["evidence of", "UNCERTAINTY", 21, 32], ["ingestion", "OBSERVATION", 33, 42]]], ["For such investigations, cases would be cases of Covid-19 (categorised by symptom presence and severity) either fecally excreting virions or not (cases and contacts) and controls would be healthy matches.", [["such investigations", "TEST", 4, 23], ["Covid", "TEST", 49, 54], ["fecally excreting virions", "PROBLEM", 112, 137]]], ["Exposure to potentially fecally contaminated materials and protective measures taken would be elicited at interview.", [["fecally contaminated materials", "TREATMENT", 24, 54], ["protective measures", "TREATMENT", 59, 78]]], ["To minimise the play of recall and ascertainment bias, interviewers should be blind to fecal excretion status and the interview should take place as soon as possible after the event.Implications for Further ResearchViability of fecal isolates and their possible pathogenicity should be tested in outbreaks, irrespective of the presence of symptoms or nasal swab positivity.ConclusionThe various observational and mechanistic evidence supports the hypothesis that SARS-CoV-2 can infect and be shed from the human gastrointestinal tract.", [["fecal", "ANATOMY", 87, 92], ["nasal swab", "ANATOMY", 351, 361], ["gastrointestinal tract", "ANATOMY", 512, 534], ["SARS", "DISEASE", 463, 467], ["fecal", "ORGANISM_SUBSTANCE", 87, 92], ["SARS-CoV-2", "ORGANISM", 463, 473], ["human", "ORGANISM", 506, 511], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 512, 534], ["human", "SPECIES", 506, 511], ["human", "SPECIES", 506, 511], ["blind to fecal excretion status", "PROBLEM", 78, 109], ["fecal isolates", "TREATMENT", 228, 242], ["pathogenicity", "PROBLEM", 262, 275], ["symptoms", "PROBLEM", 339, 347], ["nasal swab positivity", "PROBLEM", 351, 372], ["the hypothesis", "PROBLEM", 443, 457], ["SARS", "PROBLEM", 463, 467], ["nasal", "ANATOMY", 351, 356], ["gastrointestinal tract", "ANATOMY", 512, 534]]], ["This has important implications for policy that should emphasise routine surveillance of food, wastewaters and effluent, and emphasize the importance of strict personal hygiene measures, chlorine-based disinfection of surfaces in locations with presumed or known SARS CoV-2 activity.Funding:This review received funding support from the National Institute of Health Research School of Primary Care Research (NIHR SPCR) Evidence Synthesis Working Group Project 380. and Funding from the David and Maria Willetts Foundation.", [["chlorine", "CHEMICAL", 187, 195], ["chlorine", "CHEMICAL", 187, 195], ["chlorine", "SIMPLE_CHEMICAL", 187, 195], ["CoV-2", "GENE_OR_GENE_PRODUCT", 268, 273], ["SARS CoV", "SPECIES", 263, 271], ["strict personal hygiene measures", "TREATMENT", 153, 185], ["chlorine", "TREATMENT", 187, 195], ["known SARS CoV", "PROBLEM", 257, 271]]]], "PMC7172144": [["IntroductionPorcine reproductive and respiratory syndrome (PRRS) is caused by an enveloped positive-stranded RNA virus, PRRSV, belonging to the family Arteriviridae (Benfield et al., 1992, Cavanagh, 1997, Nelsen et al., 1999, Wensvoort et al., 1991).", [["IntroductionPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["PRRS", "DISEASE", 59, 63], ["PRRSV", "ORGANISM", 120, 125], ["PRRS", "SPECIES", 59, 63], ["PRRSV", "SPECIES", 120, 125], ["IntroductionPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome", "PROBLEM", 37, 57], ["an enveloped positive-stranded RNA virus", "PROBLEM", 78, 118], ["respiratory syndrome", "OBSERVATION", 37, 57], ["stranded RNA virus", "OBSERVATION", 100, 118]]], ["Other members of the arterivirus group include lactate dehydrogenase-elevating virus (LDV) of mice, equine arteritis virus (EAV), and simian hemorrhagic fever virus (SHFV; for review see Plagemann, 1996).", [["lactate", "CHEMICAL", 47, 54], ["equine arteritis", "DISEASE", 100, 116], ["simian hemorrhagic fever", "DISEASE", 134, 158], ["lactate", "CHEMICAL", 47, 54], ["lactate dehydrogenase-elevating virus", "ORGANISM", 47, 84], ["LDV", "ORGANISM", 86, 89], ["mice", "ORGANISM", 94, 98], ["equine arteritis virus", "ORGANISM", 100, 122], ["EAV", "ORGANISM", 124, 127], ["simian hemorrhagic fever virus", "ORGANISM", 134, 164], ["lactate dehydrogenase", "PROTEIN", 47, 68], ["mice", "SPECIES", 94, 98], ["equine arteritis virus", "SPECIES", 100, 122], ["simian hemorrhagic fever virus", "SPECIES", 134, 164], ["LDV", "SPECIES", 86, 89], ["mice", "SPECIES", 94, 98], ["equine arteritis virus", "SPECIES", 100, 122], ["EAV", "SPECIES", 124, 127], ["simian hemorrhagic fever virus", "SPECIES", 134, 164], ["SHFV", "SPECIES", 166, 170], ["lactate dehydrogenase", "TEST", 47, 68], ["elevating virus", "PROBLEM", 69, 84], ["equine arteritis virus", "PROBLEM", 100, 122], ["simian hemorrhagic fever virus", "PROBLEM", 134, 164], ["equine arteritis virus", "OBSERVATION", 100, 122], ["hemorrhagic", "OBSERVATION_MODIFIER", 141, 152]]], ["The arteriviruses, toroviruses, roniviruses and coronaviruses form a single order, Nidovirales.", [["arteriviruses", "ANATOMY", 4, 17], ["arteriviruses", "GENE_OR_GENE_PRODUCT", 4, 17], ["toroviruses", "GENE_OR_GENE_PRODUCT", 19, 30], ["roniviruses", "GENE_OR_GENE_PRODUCT", 32, 43], ["The arteriviruses", "TREATMENT", 0, 17], ["toroviruses", "TREATMENT", 19, 30], ["roniviruses", "TREATMENT", 32, 43], ["coronaviruses", "PROBLEM", 48, 61], ["Nidovirales", "TREATMENT", 83, 94]]], ["Arteriviruses structurally resemble togaviruses, but similar to coronaviruses, replicate via a nested 3\u2032-co-terminal set of subgenomic mRNAs that possesses a common leader and a poly-A tail (reviewed in Snijder and Mulenberg, 1998).", [["togaviruses", "ANATOMY", 36, 47], ["togaviruses", "CANCER", 36, 47], ["subgenomic mRNAs", "RNA", 124, 140], ["poly-A tail", "DNA", 178, 189], ["coronaviruses", "PROBLEM", 64, 77], ["subgenomic mRNAs", "PROBLEM", 124, 140], ["subgenomic mRNAs", "OBSERVATION", 124, 140]]], ["The arteriviruses exhibit several important properties relevant to the study of viral pathogenesis, including cytopathic replication in macrophages, the capacity to establish and maintain an asymptomatic infection, as well as cause severe and fatal disease (Plagemann, 1996).IntroductionInfection of adult pigs with PRRSV usually produces a non-fatal disease, characterized by flu-like symptoms, a transient elevation in temperature and inappetance (reviewed in Benfield et al., 1999, Christianson et al., 1992).", [["arteriviruses", "ANATOMY", 4, 17], ["macrophages", "ANATOMY", 136, 147], ["infection", "DISEASE", 204, 213], ["PRRSV", "DISEASE", 316, 321], ["flu-like symptoms", "DISEASE", 377, 394], ["arteriviruses", "CANCER", 4, 17], ["macrophages", "CELL", 136, 147], ["pigs", "ORGANISM", 306, 310], ["PRRSV", "ORGANISM", 316, 321], ["macrophages", "CELL_TYPE", 136, 147], ["pigs", "SPECIES", 306, 310], ["PRRSV", "SPECIES", 316, 321], ["pigs", "SPECIES", 306, 310], ["PRRSV", "SPECIES", 316, 321], ["the study", "TEST", 67, 76], ["viral pathogenesis", "PROBLEM", 80, 98], ["cytopathic replication in macrophages", "PROBLEM", 110, 147], ["an asymptomatic infection", "PROBLEM", 188, 213], ["severe and fatal disease", "PROBLEM", 232, 256], ["PRRSV", "PROBLEM", 316, 321], ["a non-fatal disease", "PROBLEM", 339, 358], ["flu-like symptoms", "PROBLEM", 377, 394], ["a transient elevation in temperature", "PROBLEM", 396, 432], ["cytopathic", "OBSERVATION_MODIFIER", 110, 120], ["asymptomatic", "OBSERVATION_MODIFIER", 191, 203], ["infection", "OBSERVATION", 204, 213], ["fatal", "OBSERVATION_MODIFIER", 243, 248], ["adult pigs", "OBSERVATION", 300, 310], ["non-fatal disease", "OBSERVATION", 341, 358], ["transient", "OBSERVATION_MODIFIER", 398, 407], ["elevation", "OBSERVATION_MODIFIER", 408, 417]]], ["The reproductive form of PRRS occurs following the infection of late gestation pregnant gilts or sows.", [["PRRS", "DISEASE", 25, 29], ["infection", "DISEASE", 51, 60], ["PRRS", "ORGANISM", 25, 29], ["gilts", "ORGANISM_SUBDIVISION", 88, 93], ["sows", "ORGANISM_SUBDIVISION", 97, 101], ["PRRS", "SPECIES", 25, 29], ["PRRS", "PROBLEM", 25, 29], ["the infection", "PROBLEM", 47, 60], ["PRRS", "OBSERVATION", 25, 29], ["infection", "OBSERVATION", 51, 60]]], ["Natural infection of the fetus with PRRSV is initiated with the infection of gilts and sows at 90 days gestation.", [["fetus", "ANATOMY", 25, 30], ["infection", "DISEASE", 8, 17], ["infection", "DISEASE", 64, 73], ["fetus", "ORGANISM", 25, 30], ["PRRSV", "ORGANISM", 36, 41], ["gilts", "ORGANISM", 77, 82], ["sows", "ORGANISM_SUBDIVISION", 87, 91], ["PRRSV", "SPECIES", 36, 41], ["Natural infection of the fetus", "PROBLEM", 0, 30], ["PRRSV", "PROBLEM", 36, 41], ["the infection of gilts", "PROBLEM", 60, 82], ["infection", "OBSERVATION", 8, 17], ["fetus", "ANATOMY", 25, 30], ["PRRSV", "OBSERVATION", 36, 41], ["infection", "OBSERVATION", 64, 73]]], ["After productive replication on the maternal side, the virus crosses the placenta and productively infects the fetus.", [["placenta", "ANATOMY", 73, 81], ["fetus", "ANATOMY", 111, 116], ["placenta", "ORGAN", 73, 81], ["fetus", "ORGAN", 111, 116], ["productive replication on the maternal side", "TREATMENT", 6, 49], ["the virus", "PROBLEM", 51, 60], ["productive", "OBSERVATION_MODIFIER", 6, 16], ["replication", "OBSERVATION", 17, 28], ["virus", "OBSERVATION", 55, 60], ["placenta", "ANATOMY", 73, 81], ["fetus", "ANATOMY", 111, 116]]], ["The mechanism of transplacental infection is unknown, but could be similar to the infected \u201cTrojan Horse\u201d macrophage, described for LDV (Cafruny and Bradley, 1996).", [["macrophage", "ANATOMY", 106, 116], ["transplacental infection", "DISEASE", 17, 41], ["Horse\u201d macrophage", "CELL", 99, 116], ["LDV", "ORGANISM", 132, 135], ["LDV", "SPECIES", 132, 135], ["transplacental infection", "PROBLEM", 17, 41], ["transplacental", "OBSERVATION_MODIFIER", 17, 31], ["infection", "OBSERVATION", 32, 41], ["infected", "OBSERVATION_MODIFIER", 82, 90]]], ["Since the pig fetus becomes immunocompetent at about 70 days of gestation, PRRSV infection occurs in an immune environment containing functional B and T cells.IntroductionAccordingly, virus-induced reproductive failure can present clinically as delayed returns to estrus, as well as abortions, mummified fetuses, stillborn and weak-born pigs (Benfield et al., 1999, Christianson et al., 1993, Collins et al., 1992, Mengeling et al., 1994, Rossow et al., 1999, Rowland et al., 2003).", [["fetus", "ANATOMY", 14, 19], ["B", "ANATOMY", 145, 146], ["T cells", "ANATOMY", 151, 158], ["fetuses", "ANATOMY", 304, 311], ["PRRSV infection", "DISEASE", 75, 90], ["reproductive failure", "DISEASE", 198, 218], ["abortions", "DISEASE", 283, 292], ["pig", "ORGANISM", 10, 13], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 14, 19], ["PRRSV", "ORGANISM", 75, 80], ["B", "CELL", 145, 146], ["T cells", "CELL", 151, 158], ["fetuses", "ORGANISM_SUBDIVISION", 304, 311], ["pigs", "ORGANISM", 337, 341], ["functional B and T cells", "CELL_TYPE", 134, 158], ["pig", "SPECIES", 10, 13], ["pigs", "SPECIES", 337, 341], ["pig", "SPECIES", 10, 13], ["PRRSV", "SPECIES", 75, 80], ["immunocompetent", "PROBLEM", 28, 43], ["PRRSV infection", "PROBLEM", 75, 90], ["IntroductionAccordingly", "TREATMENT", 159, 182], ["virus", "PROBLEM", 184, 189], ["reproductive failure", "PROBLEM", 198, 218], ["mummified fetuses", "PROBLEM", 294, 311], ["immunocompetent", "OBSERVATION", 28, 43], ["infection", "OBSERVATION", 81, 90]]], ["Surviving neonates can exhibit the severest form of respiratory disease with mortality sometimes reaching 100% within three weeks after birth (Feng et al., 2001, Rossow et al., 1994, Rossow, 1998).", [["respiratory", "ANATOMY", 52, 63], ["respiratory disease", "DISEASE", 52, 71], ["neonates", "ORGANISM", 10, 18], ["respiratory disease", "PROBLEM", 52, 71], ["respiratory disease", "OBSERVATION", 52, 71]]], ["The complex pathology following exposure to PRRSV in utero represents a unique form of the disease referred to as congenital PRRS (Rowland et al., 2003).", [["PRRSV", "DISEASE", 44, 49], ["congenital PRRS", "DISEASE", 114, 129], ["PRRSV", "ORGANISM", 44, 49], ["PRRSV", "SPECIES", 44, 49], ["The complex pathology", "PROBLEM", 0, 21], ["PRRSV", "TREATMENT", 44, 49], ["the disease", "PROBLEM", 87, 98], ["congenital PRRS", "PROBLEM", 114, 129], ["complex", "OBSERVATION_MODIFIER", 4, 11], ["pathology", "OBSERVATION", 12, 21], ["disease", "OBSERVATION", 91, 98]]], ["The purpose of this study was to characterize the interaction between PRRSV and the pig fetus by (1) identifying sites of virus replication, (2) measuring immune and inflammatory cytokines in different compartments, and (3) evaluating the response of lymph nodes.Virus and infection ::: Materials and methodsExperiments involving animals were approved by the Kansas State University IACU Committee.", [["fetus", "ANATOMY", 88, 93], ["sites", "ANATOMY", 113, 118], ["compartments", "ANATOMY", 202, 214], ["lymph nodes", "ANATOMY", 251, 262], ["infection", "DISEASE", 273, 282], ["PRRSV", "ORGANISM", 70, 75], ["pig", "ORGANISM", 84, 87], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 88, 93], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 251, 262], ["Virus", "ORGANISM", 263, 268], ["animals", "ORGANISM", 330, 337], ["inflammatory cytokines", "PROTEIN", 166, 188], ["PRRSV", "SPECIES", 70, 75], ["pig", "SPECIES", 84, 87], ["PRRSV", "SPECIES", 70, 75], ["pig", "SPECIES", 84, 87], ["this study", "TEST", 15, 25], ["virus replication", "TREATMENT", 122, 139], ["measuring immune and inflammatory cytokines in different compartments", "PROBLEM", 145, 214], ["lymph nodes", "PROBLEM", 251, 262], ["Virus", "PROBLEM", 263, 268], ["infection", "PROBLEM", 273, 282], ["pig fetus", "ANATOMY", 84, 93], ["virus replication", "OBSERVATION", 122, 139], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178], ["lymph nodes", "OBSERVATION", 251, 262], ["infection", "OBSERVATION", 273, 282]]], ["Pregnant sows, obtained from a closely monitored PRRSV-negative herd, were challenged at 90 days gestation with a sixth passage isolate of SD-23983, a typical North American field isolate (Rowland et al., 2001).", [["sows", "ANATOMY", 9, 13], ["SD-23983", "CHEMICAL", 139, 147], ["sows", "ORGANISM", 9, 13], ["PRRSV", "ORGANISM", 49, 54], ["herd", "ORGANISM", 64, 68], ["SD-23983", "CELL", 139, 147], ["sows", "SPECIES", 9, 13], ["SD-23983", "SPECIES", 139, 147]]], ["The methods for the preparation of the PRRSV inoculum on MARC-145 cells and infection of pigs are described in Rowland et al. (2003).", [["MARC-145 cells", "ANATOMY", 57, 71], ["MARC-145", "CHEMICAL", 57, 65], ["infection", "DISEASE", 76, 85], ["PRRSV", "ORGANISM", 39, 44], ["MARC-145 cells", "CELL", 57, 71], ["pigs", "ORGANISM", 89, 93], ["MARC-145 cells", "CELL_LINE", 57, 71], ["pigs", "SPECIES", 89, 93], ["PRRSV", "SPECIES", 39, 44], ["pigs", "SPECIES", 89, 93], ["The methods", "TREATMENT", 0, 11], ["the PRRSV inoculum", "TREATMENT", 35, 53], ["infection", "PROBLEM", 76, 85], ["PRRSV inoculum", "OBSERVATION", 39, 53], ["145 cells", "OBSERVATION_MODIFIER", 62, 71]]], ["Virus was cultivated on MARC-145 cells in MEM supplemented with antibiotics (pen/step) and 7% FBS.", [["MARC-145 cells", "ANATOMY", 24, 38], ["FBS", "ANATOMY", 94, 97], ["MARC-145", "CHEMICAL", 24, 32], ["MEM", "CHEMICAL", 42, 45], ["Virus", "ORGANISM", 0, 5], ["MARC-145 cells", "CELL", 24, 38], ["FBS", "ORGANISM_SUBSTANCE", 94, 97], ["MARC-145 cells", "CELL_LINE", 24, 38], ["Virus", "PROBLEM", 0, 5], ["antibiotics", "TREATMENT", 64, 75]]], ["Dams, at 90 days gestation were challenged with approximately 105 TCID50 of virus diluted in 5 ml of culture medium.", [["Dams", "ORGANISM", 0, 4], ["virus", "TREATMENT", 76, 81], ["culture medium", "TEST", 101, 115]]], ["One half of the inoculum was administered by intramuscular injection in the neck.", [["intramuscular", "ANATOMY", 45, 58], ["neck", "ANATOMY", 76, 80], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 58], ["neck", "ORGANISM_SUBDIVISION", 76, 80], ["the inoculum", "TREATMENT", 12, 24], ["inoculum", "OBSERVATION", 16, 24], ["neck", "ANATOMY", 76, 80]]], ["Mock-infected sows were challenged with medium recovered from MARC-145 cells.", [["MARC-145 cells", "ANATOMY", 62, 76], ["sows", "ORGANISM", 14, 18], ["MARC-145 cells", "CELL", 62, 76], ["MARC-145 cells", "CELL_LINE", 62, 76], ["MARC-145", "SPECIES", 62, 70]]], ["Dams were monitored for clinical signs and blood collected weekly.", [["blood", "ANATOMY", 43, 48], ["Dams", "ORGANISM", 0, 4], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["clinical signs", "TEST", 24, 38]]], ["At between 109 and 112 days of an approximate 114 days gestation period, the dams were euthanized.", [["dams", "ORGANISM", 77, 81]]], ["The uterine horns were immediately removed and the individual fetuses with intact placenta were carefully removed and immediately necropsied.", [["uterine horns", "ANATOMY", 4, 17], ["fetuses", "ANATOMY", 62, 69], ["placenta", "ANATOMY", 82, 90], ["uterine horns", "ORGAN", 4, 17], ["fetuses", "ORGANISM", 62, 69], ["placenta", "ORGAN", 82, 90], ["uterine horns", "ANATOMY", 4, 17], ["individual", "OBSERVATION_MODIFIER", 51, 61], ["fetuses", "OBSERVATION", 62, 69], ["intact placenta", "OBSERVATION", 75, 90]]], ["A sample of amniotic fluid was collected prior to removal.", [["sample", "ANATOMY", 2, 8], ["amniotic fluid", "ANATOMY", 12, 26], ["amniotic fluid", "ORGANISM_SUBSTANCE", 12, 26], ["A sample of amniotic fluid", "TEST", 0, 26], ["removal", "TREATMENT", 50, 57], ["amniotic fluid", "OBSERVATION", 12, 26]]], ["The brachial artery of each fetus was severed and blood collected using a disposable syringe and serum stored at \u221280 \u00b0C. Maternal, accessory and fetal tissues were collected and stored in formalin for histological staining and immunohistochemistry (IHC), or storage in RNAlater (Ambion) for RT-PCR of cytokine mRNAs.", [["brachial artery", "ANATOMY", 4, 19], ["fetus", "ANATOMY", 28, 33], ["blood", "ANATOMY", 50, 55], ["serum", "ANATOMY", 97, 102], ["fetal tissues", "ANATOMY", 145, 158], ["formalin", "CHEMICAL", 188, 196], ["brachial artery", "MULTI-TISSUE_STRUCTURE", 4, 19], ["fetus", "ORGANISM", 28, 33], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["serum", "ORGANISM_SUBSTANCE", 97, 102], ["fetal tissues", "TISSUE", 145, 158], ["formalin", "SIMPLE_CHEMICAL", 188, 196], ["cytokine mRNAs", "RNA", 301, 315], ["a disposable syringe", "TREATMENT", 72, 92], ["serum", "TEST", 97, 102], ["Maternal, accessory and fetal tissues", "PROBLEM", 121, 158], ["histological staining", "TEST", 201, 222], ["immunohistochemistry", "TEST", 227, 247], ["IHC", "TEST", 249, 252], ["RT-PCR", "TEST", 291, 297], ["cytokine mRNAs", "PROBLEM", 301, 315], ["brachial artery", "ANATOMY", 4, 19], ["severed", "OBSERVATION", 38, 45], ["accessory", "ANATOMY_MODIFIER", 131, 140], ["fetal tissues", "ANATOMY", 145, 158], ["cytokine mRNAs", "OBSERVATION", 301, 315]]], ["PRRSV-specific antibody was measured in sera using the HerdCheck\u00ae PRRS ELISA (IDEXX) and performed by personnel at Kansas State University Veterinary Diagnostic Laboratory.", [["sera", "ANATOMY", 40, 44], ["PRRSV", "ORGANISM", 0, 5], ["sera", "ORGANISM_SUBSTANCE", 40, 44], ["PRRSV-specific antibody", "PROTEIN", 0, 23], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRS", "SPECIES", 66, 70], ["PRRSV", "PROBLEM", 0, 5], ["specific antibody", "TEST", 6, 23]]], ["Serology results were reported as a sample/positive (S/P) ratio.", [["Serology", "TEST", 0, 8], ["a sample/positive (S/P) ratio", "PROBLEM", 34, 63]]], ["An S/P ratio greater than 0.39 was considered positive for PRRSV antibody.Virus isolation and titration ::: Materials and methodsVirus isolation (VI) in serum and tissues was performed as described in Rowland et al. (2003).", [["serum", "ANATOMY", 153, 158], ["tissues", "ANATOMY", 163, 170], ["PRRSV", "ORGANISM", 59, 64], ["Virus", "ORGANISM", 74, 79], ["Virus", "ORGANISM", 129, 134], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["tissues", "TISSUE", 163, 170], ["PRRSV antibody", "PROTEIN", 59, 73], ["PRRSV", "SPECIES", 59, 64], ["An S/P ratio", "TEST", 0, 12], ["PRRSV antibody", "PROBLEM", 59, 73], ["Virus isolation", "TREATMENT", 74, 89], ["Materials", "TREATMENT", 108, 117], ["methodsVirus isolation", "TREATMENT", 122, 144], ["(VI) in serum and tissues", "TEST", 145, 170], ["positive for", "UNCERTAINTY", 46, 58], ["PRRSV antibody", "OBSERVATION", 59, 73], ["tissues", "ANATOMY", 163, 170]]], ["Briefly, serum was serially diluted in MEM supplemented with pen/step antibiotics and 7% FBS and placed on 96 well plates of confluent MARC-145 cells.", [["serum", "ANATOMY", 9, 14], ["FBS", "ANATOMY", 89, 92], ["MARC-145 cells", "ANATOMY", 135, 149], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["FBS", "ORGANISM_SUBSTANCE", 89, 92], ["MARC-145 cells", "CELL", 135, 149], ["confluent MARC-145 cells", "CELL_LINE", 125, 149], ["pen/step antibiotics", "TREATMENT", 61, 81], ["7% FBS", "TREATMENT", 86, 92], ["confluent MARC", "TEST", 125, 139], ["145 cells", "OBSERVATION", 140, 149]]], ["After three days, plates were fixed in 80% acetone and stained with FITC-SDOW-17 anti-nucleocapsid antibody, diluted in PBS with 5% FBS (Nelson et al., 1993).", [["acetone", "CHEMICAL", 43, 50], ["FITC-SDOW-17 anti-nucleocapsid", "CHEMICAL", 68, 98], ["acetone", "CHEMICAL", 43, 50], ["FITC", "CHEMICAL", 68, 72], ["acetone", "SIMPLE_CHEMICAL", 43, 50], ["FITC-SDOW-17", "SIMPLE_CHEMICAL", 68, 80], ["FBS", "ORGANISM_SUBSTANCE", 132, 135], ["FITC-SDOW-17 anti-nucleocapsid antibody", "PROTEIN", 68, 107], ["plates", "TEST", 18, 24], ["FITC", "TEST", 68, 72], ["SDOW", "TEST", 73, 77], ["anti-nucleocapsid antibody", "TREATMENT", 81, 107]]], ["The results were reported as the log10 of the inverse dilution of the last positive well.", [["the inverse dilution", "TEST", 42, 62]]], ["Virus isolation from tissues was the same except that tissues were weighed and homogenized in Hanks balanced salt solution and then centrifuged at 500 \u00d7g for 20 min to remove debris.PRRSV ORF5 sequencing ::: Materials and methodsThe sequencing of the hypervariable region of ORF5 is described in Rowland et al. (1999).", [["tissues", "ANATOMY", 21, 28], ["tissues", "ANATOMY", 54, 61], ["Virus", "ORGANISM", 0, 5], ["tissues", "TISSUE", 21, 28], ["tissues", "TISSUE", 54, 61], ["PRRSV", "ORGANISM", 182, 187], ["ORF5", "GENE_OR_GENE_PRODUCT", 275, 279], ["hypervariable region", "DNA", 251, 271], ["ORF5", "DNA", 275, 279], ["PRRSV", "SPECIES", 182, 187], ["PRRSV", "SPECIES", 182, 187], ["Virus isolation", "TREATMENT", 0, 15], ["Hanks balanced salt solution", "TREATMENT", 94, 122], ["debris", "PROBLEM", 175, 181], ["debris", "OBSERVATION", 175, 181], ["hypervariable", "OBSERVATION_MODIFIER", 251, 264]]], ["Total RNA was prepared from serum or infected MARC-145 cells using an RNeasy kit (Qiagen) according manufacturer's instructions.", [["serum", "ANATOMY", 28, 33], ["MARC-145 cells", "ANATOMY", 46, 60], ["serum", "ORGANISM_SUBSTANCE", 28, 33], ["MARC-145 cells", "CELL", 46, 60], ["MARC-145 cells", "CELL_LINE", 46, 60], ["MARC-145", "SPECIES", 46, 54], ["Total RNA", "TEST", 0, 9], ["an RNeasy kit", "TREATMENT", 67, 80]]], ["For PCR, cDNA was prepared using MLV reverse transcriptase (Promega) and 4MSB as the primer.", [["MLV reverse transcriptase", "GENE_OR_GENE_PRODUCT", 33, 58], ["Promega", "GENE_OR_GENE_PRODUCT", 60, 67], ["cDNA", "DNA", 9, 13], ["MLV reverse transcriptase", "PROTEIN", 33, 58], ["PCR", "TEST", 4, 7], ["cDNA", "TEST", 9, 13], ["MLV reverse transcriptase (Promega)", "TREATMENT", 33, 68], ["4MSB", "TREATMENT", 73, 77]]], ["The sense and antisense primers for the outer amplification were 4MSA, 5\u2032-CTTCGTCCCTTCTTTTCCTCGTGG, and 4MSB, 5\u2032-CCGCTCTAGAGCCAACGATAGAGTCTGC, respectively.", [["antisense primers", "DNA", 14, 31], ["antisense primers", "TREATMENT", 14, 31], ["the outer amplification", "TEST", 36, 59]]], ["The product was re-amplified with a nested set of sense and antisense primers, 04A, 5\u2032-ACCGTGTATGTTACCATCACAGCC and 04B, ACGGGAAAGATGACAAAACTCTCC.", [["a nested set of sense and antisense primers", "TREATMENT", 34, 77]]], ["Thirty-two cycles of amplification were performed for each primer pair.", [["primer pair", "DNA", 59, 70], ["amplification", "TREATMENT", 21, 34]]], ["The conditions for both amplifications included a 95 \u00b0C denaturing step (25 s), a 58 \u00b0C annealing step (10 s), and a 74 \u00b0C (25 s) polymerization step.", [["a 74 \u00b0C (25 s) polymerization step", "TREATMENT", 115, 149]]], ["The final PCR product, which contained the last 312 nucleotides of ORF4, the 10 nucleotide untranslated region (UTR), and the first 215 nucleotides of ORF5 was sequenced directly by automated DNA sequencing.", [["nucleotides", "CHEMICAL", 52, 63], ["nucleotide", "CHEMICAL", 80, 90], ["nucleotides", "CHEMICAL", 136, 147], ["ORF4", "GENE_OR_GENE_PRODUCT", 67, 71], ["ORF5", "GENE_OR_GENE_PRODUCT", 151, 155], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["ORF4", "DNA", 67, 71], ["10 nucleotide untranslated region", "DNA", 77, 110], ["UTR", "DNA", 112, 115], ["ORF5", "DNA", 151, 155], ["The final PCR product", "TEST", 0, 21], ["ORF4", "TEST", 67, 71], ["ORF5", "TREATMENT", 151, 155]]], ["PCR products were cloned into a pCR2.1 TA cloning vector (Invitrogen), propagated in Escherichia coli and individual plasmids sequenced using M13 forward and reverse primers.", [["plasmids", "ANATOMY", 117, 125], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 58, 68], ["Escherichia coli", "ORGANISM", 85, 101], ["PCR products", "DNA", 0, 12], ["pCR2.1 TA cloning vector", "DNA", 32, 56], ["plasmids", "DNA", 117, 125], ["M13 forward and reverse primers", "DNA", 142, 173], ["Escherichia coli", "SPECIES", 85, 101], ["Escherichia coli", "SPECIES", 85, 101], ["PCR products", "TREATMENT", 0, 12], ["a pCR2.1 TA cloning vector (Invitrogen)", "TREATMENT", 30, 69], ["propagated in Escherichia coli", "TREATMENT", 71, 101], ["individual plasmids", "TREATMENT", 106, 125], ["reverse primers", "TREATMENT", 158, 173], ["Escherichia coli", "OBSERVATION", 85, 101], ["reverse primers", "OBSERVATION", 158, 173]]], ["Sequences were analyzed using Gene Jockey II software.RT-PCR and ELISA for detection of porcine cytokines ::: Materials and methodsTissue samples for RT-PCR were immediately placed in RNA-Later (Ambion) and stored at \u221280 \u00b0C. Total RNA was extracted from approximately 50 \u03bcg of tissue using RNeasy kit (Qiagen) according to manufacturer's instructions.", [["Tissue samples", "ANATOMY", 131, 145], ["tissue", "ANATOMY", 277, 283], ["porcine", "ORGANISM", 88, 95], ["Tissue samples", "CANCER", 131, 145], ["Ambion", "ORGANISM", 195, 201], ["tissue", "TISSUE", 277, 283], ["Gene Jockey II software", "DNA", 30, 53], ["porcine cytokines", "PROTEIN", 88, 105], ["porcine", "SPECIES", 88, 95], ["Sequences", "TEST", 0, 9], ["RT-PCR", "TEST", 54, 60], ["ELISA", "TEST", 65, 70], ["Tissue samples", "TEST", 131, 145], ["RT-PCR", "TEST", 150, 156], ["Total RNA", "PROBLEM", 225, 234], ["RNeasy kit", "TREATMENT", 290, 300]]], ["The design of cytokine-specific primers and RT-PCR procedures were performed according to Reddy and Wilkie (2000).", [["cytokine", "PROTEIN", 14, 22], ["cytokine-specific primers", "TREATMENT", 14, 39], ["RT-PCR procedures", "TEST", 44, 61]]], ["Primer sequences are listed in Table 1.", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["RNA was diluted to a final volume of 50 \u03bcl in nuclease free water. cDNA was prepared from10 \u03bcl of total RNA by reverse transcription using Molony murine leukemia virus reverse transcriptase (Promega) and random hexamers as primers.", [["Molony murine leukemia virus", "ORGANISM", 139, 167], ["Promega", "ORGANISM", 191, 198], ["RNA", "RNA", 0, 3], ["nuclease", "PROTEIN", 46, 54], ["cDNA", "DNA", 67, 71], ["total RNA", "RNA", 98, 107], ["Molony murine leukemia virus reverse transcriptase", "PROTEIN", 139, 189], ["murine", "SPECIES", 146, 152], ["leukemia virus", "SPECIES", 153, 167], ["Molony murine leukemia virus", "SPECIES", 139, 167], ["a final volume", "TEST", 19, 33], ["total RNA", "TREATMENT", 98, 107], ["Molony murine leukemia virus", "TREATMENT", 139, 167], ["transcriptase (Promega)", "TREATMENT", 176, 199], ["random hexamers as primers", "TREATMENT", 204, 230], ["leukemia virus", "OBSERVATION", 153, 167]]], ["The amplification of \u03b22m mRNA was used as an internal control.", [["\u03b22m", "GENE_OR_GENE_PRODUCT", 21, 24], ["\u03b22m mRNA", "RNA", 21, 29], ["\u03b22m mRNA", "TREATMENT", 21, 29], ["an internal control", "TREATMENT", 42, 61]]], ["PCR amplification of cytokine and control cDNAs consisted of 35 cycles (45 s at 94 \u00b0C, 45 s at 55 \u00b0C, and 45 s at 72 \u00b0C) and DNA products electrophoresed on a 2.0% agarose gel and visualized using ethidium bromide.", [["ethidium bromide", "CHEMICAL", 197, 213], ["ethidium bromide", "CHEMICAL", 197, 213], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["agarose", "SIMPLE_CHEMICAL", 164, 171], ["ethidium bromide", "SIMPLE_CHEMICAL", 197, 213], ["cytokine and control cDNAs", "DNA", 21, 47], ["PCR amplification", "TEST", 0, 17], ["cytokine and control cDNAs", "TREATMENT", 21, 47], ["DNA products", "TREATMENT", 125, 137], ["a 2.0% agarose gel", "TREATMENT", 157, 175], ["ethidium bromide", "TREATMENT", 197, 213]]], ["The identity of the DNA products was confirmed by DNA sequencing.Histology and immunohistochemistry ::: Materials and methodsTissue samples were collected and immediately placed in 10% buffered formalin.", [["Tissue samples", "ANATOMY", 125, 139], ["formalin", "CHEMICAL", 194, 202], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["DNA", "CELLULAR_COMPONENT", 50, 53], ["Tissue samples", "CANCER", 125, 139], ["formalin", "SIMPLE_CHEMICAL", 194, 202], ["DNA products", "PROTEIN", 20, 32], ["the DNA products", "TREATMENT", 16, 32], ["DNA sequencing", "TEST", 50, 64], ["methodsTissue samples", "TEST", 118, 139]]], ["Paraffin-embedded thin sections were mounted on slides, deparaffinized and stained with hematoxylin and eosin (H and E).", [["sections", "ANATOMY", 23, 31], ["hematoxylin", "CHEMICAL", 88, 99], ["eosin", "CHEMICAL", 104, 109], ["thin sections", "CANCER", 18, 31], ["hematoxylin", "SIMPLE_CHEMICAL", 88, 99], ["eosin", "SIMPLE_CHEMICAL", 104, 109], ["Paraffin-embedded thin sections", "TREATMENT", 0, 31], ["slides", "TEST", 48, 54], ["hematoxylin", "TREATMENT", 88, 99]]], ["Immunohistochemistry (IHC) and H and E staining procedures were performed by personnel in the Kansas State Veterinary Diagnostic Laboratory.", [["Immunohistochemistry", "TEST", 0, 20], ["E staining procedures", "TEST", 37, 58]]], ["For IHC staining, thin sections were mounted on Vectabond-treated slides (Vector Laboratories) and deparaffinized and processed using an automated NexES IHC Staining Module (Ventana Medical).", [["sections", "ANATOMY", 23, 31], ["IHC staining", "PROBLEM", 4, 16], ["thin sections", "TEST", 18, 31]]], ["For the detection of PRRSV antigen, slides were incubated for 30 min with a 1:100 dilution of mAb SR-30 anti-nucleocapsid antibody (Rural Technologies).", [["PRRSV", "ORGANISM", 21, 26], ["PRRSV antigen", "PROTEIN", 21, 34], ["mAb SR-30 anti-nucleocapsid antibody", "PROTEIN", 94, 130], ["PRRSV", "SPECIES", 21, 26], ["PRRSV antigen", "PROBLEM", 21, 34], ["mAb SR", "TEST", 94, 100]]], ["Other antibodies included a polyclonal anti-human CD3 and B cell antibodies, anti-CDw75 and anti-CD79\u03b1.", [["B cell", "ANATOMY", 58, 64], ["CD3", "GENE_OR_GENE_PRODUCT", 50, 53], ["B cell antibodies", "GENE_OR_GENE_PRODUCT", 58, 75], ["anti-CDw75", "GENE_OR_GENE_PRODUCT", 77, 87], ["anti-CD79\u03b1", "GENE_OR_GENE_PRODUCT", 92, 102], ["antibodies", "PROTEIN", 6, 16], ["polyclonal anti-human CD3 and B cell antibodies", "PROTEIN", 28, 75], ["anti-CDw75", "PROTEIN", 77, 87], ["anti-CD79\u03b1", "PROTEIN", 92, 102], ["anti-human", "SPECIES", 39, 49], ["Other antibodies", "TEST", 0, 16], ["a polyclonal anti-human CD3", "TEST", 26, 53], ["B cell antibodies", "TEST", 58, 75], ["anti-CDw", "TEST", 77, 85], ["cell antibodies", "OBSERVATION", 60, 75]]], ["Bound antibody was detected with biotinylated goat anti-mouse or anti-rabbit Ig followed by avidin-HRPO and DAB chromagen (Ventana Medical).", [["Ig", "GENE_OR_GENE_PRODUCT", 77, 79], ["avidin-HRPO", "SIMPLE_CHEMICAL", 92, 103], ["DAB chromagen", "SIMPLE_CHEMICAL", 108, 121], ["Bound antibody", "PROTEIN", 0, 14], ["biotinylated goat anti-mouse", "PROTEIN", 33, 61], ["anti-rabbit Ig", "PROTEIN", 65, 79], ["avidin", "PROTEIN", 92, 98], ["goat", "SPECIES", 46, 50], ["anti-mouse", "SPECIES", 51, 61], ["anti-rabbit", "SPECIES", 65, 76], ["goat", "SPECIES", 46, 50], ["anti-rabbit", "SPECIES", 65, 76], ["Bound antibody", "TEST", 0, 14], ["biotinylated goat anti-mouse", "TREATMENT", 33, 61], ["anti-rabbit Ig", "TREATMENT", 65, 79], ["avidin-HRPO", "TREATMENT", 92, 103], ["DAB chromagen", "TREATMENT", 108, 121]]], ["Slides were counterstained with hematoxylin.Clinical signs, gross pathology and infection status ::: ResultsThe experiment incorporated four PRRSV-infected and two-mock-infected dams.", [["infection", "DISEASE", 80, 89], ["PRRSV-infected", "DISEASE", 141, 155], ["hematoxylin", "CHEMICAL", 32, 43], ["hematoxylin", "SIMPLE_CHEMICAL", 32, 43], ["PRRSV", "ORGANISM", 141, 146], ["dams", "ORGANISM", 178, 182], ["PRRSV", "SPECIES", 141, 146], ["hematoxylin", "TREATMENT", 32, 43], ["Clinical signs", "TEST", 44, 58], ["gross pathology", "PROBLEM", 60, 75], ["gross", "OBSERVATION_MODIFIER", 60, 65], ["pathology", "OBSERVATION", 66, 75], ["infection", "OBSERVATION", 80, 89], ["infected", "OBSERVATION_MODIFIER", 147, 155], ["infected", "OBSERVATION", 169, 177]]], ["All maternal serum samples were VI-negative and seronegative for PRRSV prior to infection.", [["serum samples", "ANATOMY", 13, 26], ["infection", "DISEASE", 80, 89], ["serum samples", "ORGANISM_SUBSTANCE", 13, 26], ["VI", "GENE_OR_GENE_PRODUCT", 32, 34], ["PRRSV", "ORGANISM", 65, 70], ["PRRSV", "SPECIES", 65, 70], ["All maternal serum samples", "TEST", 0, 26], ["VI", "TEST", 32, 34], ["seronegative", "PROBLEM", 48, 60], ["PRRSV", "PROBLEM", 65, 70], ["infection", "PROBLEM", 80, 89], ["infection", "OBSERVATION", 80, 89]]], ["Between one and two weeks after virus challenge, all infected sows were VI-positive in serum, confirming the presence of an active infection.", [["serum", "ANATOMY", 87, 92], ["infection", "DISEASE", 131, 140], ["sows", "ORGANISM", 62, 66], ["VI", "GENE_OR_GENE_PRODUCT", 72, 74], ["serum", "ORGANISM_SUBSTANCE", 87, 92], ["virus challenge", "TREATMENT", 32, 47], ["VI", "TEST", 72, 74], ["serum", "TEST", 87, 92], ["an active infection", "PROBLEM", 121, 140], ["active", "OBSERVATION_MODIFIER", 124, 130], ["infection", "OBSERVATION", 131, 140]]], ["By the time of necropsy, the concentration of circulating virus in the dams had dipped to below detectable levels by VI.", [["dams", "ORGANISM", 71, 75], ["necropsy", "TREATMENT", 15, 23], ["circulating virus", "PROBLEM", 46, 63], ["circulating virus", "OBSERVATION", 46, 63]]], ["A total of 44 viable fetuses were recovered from the four infected dams (see Table 2for summary).", [["fetuses", "ANATOMY", 21, 28], ["fetuses", "ORGANISM", 21, 28], ["dams", "ORGANISM", 67, 71], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Two fetuses were dead and partially autolysed and not subjected to further study.", [["fetuses", "ANATOMY", 4, 11], ["fetuses", "ORGANISM", 4, 11], ["further study", "TEST", 67, 80], ["fetuses", "OBSERVATION", 4, 11]]], ["10 (22%) of the 44 viable fetuses were positive for PRRSV by VI.", [["fetuses", "ANATOMY", 26, 33], ["fetuses", "ORGANISM", 26, 33], ["PRRSV", "ORGANISM", 52, 57], ["PRRSV", "SPECIES", 52, 57], ["PRRSV", "PROBLEM", 52, 57]]], ["Since dams were VI-negative in blood at the time of necropsy, it was concluded that the presence of virus in the fetal circulation was the result of virus replication in the fetus and not from contamination with maternal blood.", [["blood", "ANATOMY", 31, 36], ["fetal", "ANATOMY", 113, 118], ["fetus", "ANATOMY", 174, 179], ["blood", "ANATOMY", 221, 226], ["dams", "ORGANISM", 6, 10], ["VI", "GENE_OR_GENE_PRODUCT", 16, 18], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["fetal circulation", "MULTI-TISSUE_STRUCTURE", 113, 130], ["fetus", "ORGANISM", 174, 179], ["blood", "ORGANISM_SUBSTANCE", 221, 226], ["VI", "TEST", 16, 18], ["necropsy", "TREATMENT", 52, 60], ["virus in the fetal circulation", "PROBLEM", 100, 130], ["virus replication", "PROBLEM", 149, 166], ["maternal blood", "PROBLEM", 212, 226], ["negative", "OBSERVATION", 19, 27], ["virus", "OBSERVATION", 100, 105], ["fetal circulation", "ANATOMY", 113, 130], ["virus", "OBSERVATION", 149, 154]]], ["(The virus isolation technique is not subject to false positives from minute amounts of cross-contamination with viral protein or RNA.)", [["viral protein", "PROTEIN", 113, 126], ["The virus isolation technique", "TREATMENT", 1, 30], ["false positives", "PROBLEM", 49, 64], ["viral protein or RNA", "PROBLEM", 113, 133]]], ["The number of infected fetuses in each litter varied from no infected fetuses (dam no. 2) to five of 14 (36%) infected fetuses for dam no. 4.", [["fetuses", "ANATOMY", 23, 30], ["fetuses", "ANATOMY", 70, 77], ["fetuses", "ANATOMY", 119, 126], ["fetuses", "ORGANISM", 23, 30], ["fetuses", "ORGAN", 70, 77], ["fetuses", "ORGANISM", 119, 126], ["infected fetuses", "PROBLEM", 14, 30], ["infected fetuses", "PROBLEM", 61, 77], ["infected fetuses", "PROBLEM", 110, 126], ["number", "OBSERVATION_MODIFIER", 4, 10], ["infected", "OBSERVATION_MODIFIER", 14, 22], ["fetuses", "OBSERVATION", 23, 30], ["no", "UNCERTAINTY", 58, 60], ["infected", "OBSERVATION_MODIFIER", 61, 69], ["fetuses", "OBSERVATION", 70, 77], ["fetuses", "OBSERVATION", 119, 126]]], ["Fetuses that were VI-negative in serum were confirmed as PRRSV-negative by VI-negative results in placenta, lung, lymph nodes and thymus (data not shown).", [["Fetuses", "ANATOMY", 0, 7], ["serum", "ANATOMY", 33, 38], ["placenta", "ANATOMY", 98, 106], ["lung", "ANATOMY", 108, 112], ["lymph nodes", "ANATOMY", 114, 125], ["thymus", "ANATOMY", 130, 136], ["Fetuses", "ORGANISM", 0, 7], ["VI", "GENE_OR_GENE_PRODUCT", 18, 20], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["PRRSV", "ORGANISM", 57, 62], ["placenta", "MULTI-TISSUE_STRUCTURE", 98, 106], ["lung", "ORGAN", 108, 112], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 114, 125], ["thymus", "ORGAN", 130, 136], ["PRRSV", "SPECIES", 57, 62], ["Fetuses", "TEST", 0, 7], ["VI", "TEST", 18, 20], ["serum", "TEST", 33, 38], ["PRRSV", "TEST", 57, 62], ["placenta", "ANATOMY", 98, 106], ["lung", "ANATOMY", 108, 112], ["lymph nodes", "OBSERVATION", 114, 125], ["thymus", "ANATOMY", 130, 136]]], ["One fetus, 1-1, was seropositive for PRRSV (S/P ratio = 0.94).", [["fetus", "ANATOMY", 4, 9], ["fetus", "ORGANISM", 4, 9], ["PRRSV", "ORGANISM", 37, 42], ["PRRSV", "SPECIES", 37, 42], ["PRRSV", "PROBLEM", 37, 42], ["S/P ratio", "TEST", 44, 53], ["fetus", "ANATOMY", 4, 9]]], ["Since there is no maternal transfer of antibody from mother to fetus (Tizard, 1996), it was concluded that this fetus generated an antibody response to PRRSV in utero.", [["fetus", "ANATOMY", 63, 68], ["fetus", "ANATOMY", 112, 117], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 63, 68], ["fetus", "ORGANISM", 112, 117], ["PRRSV", "ORGANISM", 152, 157], ["PRRSV", "SPECIES", 152, 157], ["this fetus", "PROBLEM", 107, 117], ["an antibody response", "PROBLEM", 128, 148], ["PRRSV", "PROBLEM", 152, 157], ["no", "UNCERTAINTY", 15, 17]]], ["7 of the 10 infected fetuses showed some form of gross pathology, including growth retardation (two fetuses) or reduced amounts and/or merconium-stained amniotic fluid (five fetuses).", [["fetuses", "ANATOMY", 21, 28], ["fetuses", "ANATOMY", 100, 107], ["amniotic fluid", "ANATOMY", 153, 167], ["fetuses", "ANATOMY", 174, 181], ["growth retardation", "DISEASE", 76, 94], ["merconium", "CHEMICAL", 135, 144], ["fetuses", "ORGANISM", 21, 28], ["merconium", "SIMPLE_CHEMICAL", 135, 144], ["amniotic fluid", "ORGANISM_SUBSTANCE", 153, 167], ["fetuses", "ORGAN", 174, 181], ["the 10 infected fetuses", "PROBLEM", 5, 28], ["gross pathology", "PROBLEM", 49, 64], ["growth retardation", "PROBLEM", 76, 94], ["two fetuses)", "PROBLEM", 96, 108], ["reduced amounts", "PROBLEM", 112, 127], ["merconium-stained amniotic fluid", "PROBLEM", 135, 167], ["gross", "OBSERVATION_MODIFIER", 49, 54], ["pathology", "OBSERVATION", 55, 64], ["amniotic fluid", "OBSERVATION", 153, 167]]], ["Ongoing virus replication in the fetus as the source of these gross pathological changes is questionable, since non-infected fetuses from infected dams exhibited similar changes.", [["fetus", "ANATOMY", 33, 38], ["fetuses", "ANATOMY", 125, 132], ["fetus", "ORGAN", 33, 38], ["fetuses", "ORGANISM", 125, 132], ["dams", "ORGANISM", 147, 151], ["Ongoing virus replication", "TREATMENT", 0, 25], ["these gross pathological changes", "PROBLEM", 56, 88], ["non-infected fetuses", "PROBLEM", 112, 132], ["infected dams", "PROBLEM", 138, 151], ["virus", "OBSERVATION", 8, 13], ["gross", "OBSERVATION_MODIFIER", 62, 67], ["pathological", "OBSERVATION", 68, 80], ["infected", "OBSERVATION", 138, 146], ["similar", "OBSERVATION_MODIFIER", 162, 169]]], ["For example, fetuses from dam no. 2 (see Fig. 1) were either merconium stained (two fetuses), non-viable, possessed reduced amniotic fluid levels (four fetuses) or small (one fetus).", [["fetuses", "ANATOMY", 13, 20], ["fetuses", "ANATOMY", 84, 91], ["amniotic fluid", "ANATOMY", 124, 138], ["fetuses", "ANATOMY", 152, 159], ["fetus", "ANATOMY", 175, 180], ["merconium", "CHEMICAL", 61, 70], ["merconium", "CHEMICAL", 61, 70], ["fetuses", "ORGANISM", 13, 20], ["fetuses", "ORGANISM", 84, 91], ["amniotic fluid", "ORGANISM_SUBSTANCE", 124, 138], ["fetuses", "ORGAN", 152, 159], ["fetus", "ORGAN", 175, 180], ["reduced amniotic fluid levels", "PROBLEM", 116, 145], ["small (one fetus)", "PROBLEM", 164, 181], ["fetuses", "OBSERVATION", 13, 20], ["reduced", "OBSERVATION_MODIFIER", 116, 123], ["amniotic fluid levels", "OBSERVATION", 124, 145], ["small", "OBSERVATION_MODIFIER", 164, 169]]], ["Except for one autolysed fetus, the 23 fetuses from the two control dams showed no evidence of gross pathology (data not shown).Appearance of a novel viral sequence in dams and fetuses ::: ResultsRNA viruses frequently exist as a heterogeneous population, frequently referred to as a quasispecies.", [["fetus", "ANATOMY", 25, 30], ["fetuses", "ANATOMY", 39, 46], ["fetuses", "ANATOMY", 177, 184], ["fetus", "ORGAN", 25, 30], ["fetuses", "ORGANISM", 39, 46], ["dams", "ORGANISM", 68, 72], ["dams", "ORGANISM", 168, 172], ["fetuses", "ORGAN", 177, 184], ["novel viral sequence", "DNA", 144, 164], ["one autolysed fetus", "PROBLEM", 11, 30], ["gross pathology", "PROBLEM", 95, 110], ["a novel viral sequence", "TEST", 142, 164], ["ResultsRNA viruses", "PROBLEM", 189, 207], ["a heterogeneous population", "PROBLEM", 228, 254], ["no evidence of", "UNCERTAINTY", 80, 94], ["gross", "OBSERVATION_MODIFIER", 95, 100], ["pathology", "OBSERVATION", 101, 110], ["heterogeneous", "OBSERVATION_MODIFIER", 230, 243], ["population", "OBSERVATION", 244, 254]]], ["The appearance or disappearance of individual viral sequences within a quasispecies population is often used as evidence to support the existence of positive or negative selection during infection (Elena et al., 2000, Forns et al., 1999, Tsibris et al., 2009).", [["infection", "DISEASE", 187, 196], ["viral sequences", "DNA", 46, 61], ["individual viral sequences", "PROBLEM", 35, 61], ["a quasispecies population", "PROBLEM", 69, 94], ["positive or negative selection during infection", "PROBLEM", 149, 196], ["disappearance", "OBSERVATION_MODIFIER", 18, 31], ["individual", "OBSERVATION_MODIFIER", 35, 45], ["viral", "OBSERVATION", 46, 51]]], ["Mutations that appear in the PRRSV genome are useful as markers to identify and follow the appearance and disappearance of viruses within the population (Allende et al., 2000, Rowland et al., 1999).", [["PRRSV", "ORGANISM", 29, 34], ["PRRSV genome", "DNA", 29, 41], ["PRRSV", "SPECIES", 29, 34], ["PRRSV", "SPECIES", 29, 34], ["Mutations", "PROBLEM", 0, 9], ["viruses", "PROBLEM", 123, 130]]], ["DNA sequencing of ORF5 PCR products, amplified directly from the sera of infected dams, identified one dam, no. 4, which possessed a virus with a mutation within the hypervariable region of ORF5.", [["sera", "ANATOMY", 65, 69], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["ORF5", "GENE_OR_GENE_PRODUCT", 18, 22], ["sera", "ORGANISM_SUBSTANCE", 65, 69], ["dams", "ORGANISM", 82, 86], ["ORF5", "GENE_OR_GENE_PRODUCT", 190, 194], ["ORF5 PCR products", "PROTEIN", 18, 35], ["hypervariable region", "DNA", 166, 186], ["ORF5", "DNA", 190, 194], ["DNA sequencing", "TEST", 0, 14], ["ORF5 PCR products", "TREATMENT", 18, 35], ["a virus", "PROBLEM", 131, 138], ["a mutation", "PROBLEM", 144, 154], ["virus", "OBSERVATION", 133, 138]]], ["The change detected by sequencing the PCR product was a C to T (U for RNA) nucleotide transition at position 77 that resulted in a non-conserved amino acid change from threonine to isoleucine in GP5.", [["nucleotide", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 145, 155], ["threonine", "CHEMICAL", 168, 177], ["isoleucine", "CHEMICAL", 181, 191], ["nucleotide", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 145, 155], ["threonine", "CHEMICAL", 168, 177], ["isoleucine", "CHEMICAL", 181, 191], ["amino acid", "AMINO_ACID", 145, 155], ["threonine", "AMINO_ACID", 168, 177], ["isoleucine", "AMINO_ACID", 181, 191], ["GP5", "AMINO_ACID", 195, 198], ["GP5", "PROTEIN", 195, 198], ["the PCR product", "TEST", 34, 49], ["nucleotide transition", "PROBLEM", 75, 96], ["a non-conserved amino acid change", "TREATMENT", 129, 162], ["threonine to isoleucine in GP5", "TREATMENT", 168, 198], ["amino acid", "OBSERVATION", 145, 155]]], ["The T-77 mutation was not detected after sequencing the ORF5 PCR products from the other dams (see Table 3).", [["T-77", "GENE_OR_GENE_PRODUCT", 4, 8], ["ORF5 PCR products", "PROTEIN", 56, 73], ["T-77", "SPECIES", 4, 8], ["The T", "TEST", 0, 5], ["the ORF5 PCR", "TEST", 52, 64]]], ["PCR products were cloned into a TA plasmid and the individual plasmids sequenced.", [["plasmid", "ANATOMY", 35, 42], ["plasmids", "ANATOMY", 62, 70], ["PCR products", "DNA", 0, 12], ["TA plasmid", "DNA", 32, 42], ["plasmids", "DNA", 62, 70], ["PCR products", "TREATMENT", 0, 12], ["a TA plasmid", "TREATMENT", 30, 42], ["the individual plasmids", "TREATMENT", 47, 70]]], ["Even though T-77 was detected in the PCR product from dam no. 4, the sequence of individual clones showed that two of the five sequences possessed a C at position 77 mutation, which indicated that viruses with the wild-type ORF5 sequence were still present in the population.", [["T-77", "CHEMICAL", 12, 16], ["T-77", "GENE_OR_GENE_PRODUCT", 12, 16], ["clones", "CELL", 92, 98], ["C", "GENE_OR_GENE_PRODUCT", 149, 150], ["ORF5", "GENE_OR_GENE_PRODUCT", 224, 228], ["wild-type ORF5 sequence", "DNA", 214, 237], ["T-77", "SPECIES", 12, 16], ["T", "TEST", 12, 13], ["the sequence of individual clones", "TEST", 65, 98], ["the five sequences", "TEST", 118, 136], ["a C at position 77 mutation", "PROBLEM", 147, 174], ["viruses", "PROBLEM", 197, 204], ["the wild-type ORF5 sequence", "PROBLEM", 210, 237], ["viruses", "OBSERVATION", 197, 204]]], ["Whole PCR and plasmid-cloned PCR products were sequenced for the five infected fetuses from dam no. 4.", [["fetuses", "ANATOMY", 79, 86], ["fetuses", "ORGANISM", 79, 86], ["PCR products", "DNA", 29, 41], ["Whole PCR", "TEST", 0, 9], ["plasmid-cloned PCR products", "TREATMENT", 14, 41]]], ["The frequency of the T-77 mutation ranged from 25% (fetus 4\u201311) to 100% (fetuses 4\u201312 and 4\u201313).", [["fetuses", "ANATOMY", 73, 80], ["T-77", "GENE_OR_GENE_PRODUCT", 21, 25], ["T-77", "SPECIES", 21, 25], ["the T", "TEST", 17, 22], ["fetus", "TEST", 52, 57], ["fetuses", "TEST", 73, 80]]], ["These results indicate that the fetus is capable of selecting for a particular virus population, which either arises in the dam or fetus.", [["fetus", "ANATOMY", 32, 37], ["fetus", "ANATOMY", 131, 136], ["fetus", "ORGANISM", 32, 37], ["dam", "ORGANISM_SUBDIVISION", 124, 127], ["fetus", "ORGAN", 131, 136], ["a particular virus population", "PROBLEM", 66, 95], ["fetus", "ANATOMY", 131, 136]]], ["Therefore, fetal infection is a potential source of PRRSV diversity.The fetal thymus as the primary site of PRRSV replication ::: ResultsDuring acute infection of the postnatal pig, the largest quantity of virus and greatest number of cells supporting virus replication are found in the lung, a consequence of targeting alveolar macrophages.", [["fetal", "ANATOMY", 11, 16], ["fetal thymus", "ANATOMY", 72, 84], ["cells", "ANATOMY", 235, 240], ["lung", "ANATOMY", 287, 291], ["alveolar macrophages", "ANATOMY", 320, 340], ["fetal infection", "DISEASE", 11, 26], ["infection", "DISEASE", 150, 159], ["fetal", "ANATOMICAL_SYSTEM", 11, 16], ["PRRSV", "ORGANISM", 52, 57], ["fetal thymus", "MULTI-TISSUE_STRUCTURE", 72, 84], ["PRRSV", "ORGANISM", 108, 113], ["pig", "ORGANISM", 177, 180], ["cells", "CELL", 235, 240], ["lung", "ORGAN", 287, 291], ["alveolar macrophages", "CELL", 320, 340], ["alveolar macrophages", "CELL_TYPE", 320, 340], ["pig", "SPECIES", 177, 180], ["PRRSV", "SPECIES", 52, 57], ["PRRSV", "SPECIES", 108, 113], ["pig", "SPECIES", 177, 180], ["fetal infection", "PROBLEM", 11, 26], ["PRRSV diversity", "PROBLEM", 52, 67], ["acute infection", "PROBLEM", 144, 159], ["the postnatal pig", "PROBLEM", 163, 180], ["virus", "PROBLEM", 206, 211], ["virus replication", "PROBLEM", 252, 269], ["targeting alveolar macrophages", "PROBLEM", 310, 340], ["fetal", "ANATOMY", 11, 16], ["infection", "OBSERVATION", 17, 26], ["PRRSV diversity", "OBSERVATION", 52, 67], ["fetal thymus", "ANATOMY", 72, 84], ["PRRSV replication", "OBSERVATION", 108, 125], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["infection", "OBSERVATION", 150, 159], ["largest", "OBSERVATION_MODIFIER", 186, 193], ["quantity", "OBSERVATION_MODIFIER", 194, 202], ["virus", "OBSERVATION", 206, 211], ["greatest", "OBSERVATION_MODIFIER", 216, 224], ["number", "OBSERVATION_MODIFIER", 225, 231], ["cells", "OBSERVATION", 235, 240], ["virus replication", "OBSERVATION", 252, 269], ["lung", "ANATOMY", 287, 291], ["alveolar macrophages", "OBSERVATION", 320, 340]]], ["During the later stages of PRRSV infection, secondary lymphoid organs, including tonsil and lymph nodes, become sources of virus replication (Allende et al., 2000, Rossow, 1998, Rowland et al., 1999).", [["lymphoid organs", "ANATOMY", 54, 69], ["tonsil", "ANATOMY", 81, 87], ["lymph nodes", "ANATOMY", 92, 103], ["PRRSV infection", "DISEASE", 27, 42], ["PRRSV", "ORGANISM", 27, 32], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 54, 69], ["tonsil", "ORGAN", 81, 87], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 92, 103], ["PRRSV", "SPECIES", 27, 32], ["PRRSV", "SPECIES", 27, 32], ["PRRSV infection", "PROBLEM", 27, 42], ["secondary lymphoid organs", "PROBLEM", 44, 69], ["tonsil and lymph nodes", "PROBLEM", 81, 103], ["virus replication", "TREATMENT", 123, 140], ["PRRSV infection", "OBSERVATION", 27, 42], ["secondary lymphoid organs", "OBSERVATION", 44, 69], ["tonsil", "ANATOMY", 81, 87], ["lymph nodes", "OBSERVATION", 92, 103], ["virus replication", "OBSERVATION", 123, 140]]], ["Virus replication in fetal tissues was assessed using a combination of virus isolation and IHC detection of nucleocapsid antigen in formalin-fixed tissues.", [["fetal tissues", "ANATOMY", 21, 34], ["tissues", "ANATOMY", 147, 154], ["formalin", "CHEMICAL", 132, 140], ["formalin", "CHEMICAL", 132, 140], ["Virus", "ORGANISM", 0, 5], ["fetal tissues", "TISSUE", 21, 34], ["nucleocapsid antigen", "GENE_OR_GENE_PRODUCT", 108, 128], ["tissues", "TISSUE", 147, 154], ["nucleocapsid antigen", "PROTEIN", 108, 128], ["Virus replication in fetal tissues", "PROBLEM", 0, 34], ["virus isolation", "TREATMENT", 71, 86], ["IHC detection", "TEST", 91, 104], ["nucleocapsid antigen", "TEST", 108, 128], ["fetal tissues", "ANATOMY", 21, 34], ["nucleocapsid antigen", "OBSERVATION", 108, 128], ["fixed tissues", "OBSERVATION", 141, 154]]], ["As summarized in Table 4, virus was isolated from all tissues from infected fetuses, including placenta, umbilical cord, heart, lung, spleen, lymph nodes and thymus.", [["tissues", "ANATOMY", 54, 61], ["fetuses", "ANATOMY", 76, 83], ["placenta", "ANATOMY", 95, 103], ["umbilical cord", "ANATOMY", 105, 119], ["heart", "ANATOMY", 121, 126], ["lung", "ANATOMY", 128, 132], ["spleen", "ANATOMY", 134, 140], ["lymph nodes", "ANATOMY", 142, 153], ["thymus", "ANATOMY", 158, 164], ["tissues", "TISSUE", 54, 61], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 76, 83], ["placenta", "TISSUE", 95, 103], ["umbilical cord", "MULTI-TISSUE_STRUCTURE", 105, 119], ["heart", "ORGAN", 121, 126], ["lung", "ORGAN", 128, 132], ["spleen", "ORGAN", 134, 140], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 142, 153], ["thymus", "ORGAN", 158, 164], ["virus", "PROBLEM", 26, 31], ["infected fetuses", "PROBLEM", 67, 83], ["placenta, umbilical cord, heart, lung, spleen, lymph nodes and thymus", "PROBLEM", 95, 164], ["infected fetuses", "OBSERVATION", 67, 83], ["placenta", "ANATOMY", 95, 103], ["umbilical cord", "ANATOMY", 105, 119], ["heart", "ANATOMY", 121, 126], ["lung", "ANATOMY", 128, 132], ["spleen", "ANATOMY", 134, 140], ["lymph nodes", "OBSERVATION", 142, 153], ["thymus", "ANATOMY", 158, 164]]], ["Overall, the thymus contained the largest quantity of virus.", [["thymus", "ANATOMY", 13, 19], ["thymus", "ORGAN", 13, 19], ["virus", "PROBLEM", 54, 59], ["thymus", "ANATOMY", 13, 19], ["largest", "OBSERVATION_MODIFIER", 34, 41], ["quantity", "OBSERVATION_MODIFIER", 42, 50], ["virus", "OBSERVATION", 54, 59]]], ["Nine of ten fetuses yielded measurable amounts of virus with five of the ten fetal thymuses producing titers greater than 3.0.", [["fetuses", "ANATOMY", 12, 19], ["fetal thymuses", "ANATOMY", 77, 91], ["fetuses", "ORGANISM", 12, 19], ["fetal thymuses", "ORGAN", 77, 91], ["measurable amounts of virus", "PROBLEM", 28, 55], ["the ten fetal thymuses", "TEST", 69, 91], ["titers", "TEST", 102, 108], ["measurable", "OBSERVATION_MODIFIER", 28, 38], ["amounts", "OBSERVATION_MODIFIER", 39, 46], ["virus", "OBSERVATION", 50, 55], ["fetal thymuses", "ANATOMY", 77, 91]]], ["For lung, 6 of 10 fetuses were VI-positive and only one fetal lung yielded a virus titer greater than 2.0.", [["lung", "ANATOMY", 4, 8], ["fetuses", "ANATOMY", 18, 25], ["fetal lung", "ANATOMY", 56, 66], ["lung", "ORGAN", 4, 8], ["fetuses", "ORGANISM", 18, 25], ["VI", "GENE_OR_GENE_PRODUCT", 31, 33], ["fetal", "ORGAN", 56, 61], ["lung", "ORGAN", 62, 66], ["lung, 6 of 10 fetuses", "TEST", 4, 25], ["VI", "TEST", 31, 33], ["a virus titer", "TEST", 75, 88], ["lung", "ANATOMY", 4, 8], ["lung", "ANATOMY", 62, 66], ["virus", "OBSERVATION", 77, 82]]], ["The recovery of virus from a tissue can represent virus in circulating blood.", [["tissue", "ANATOMY", 29, 35], ["blood", "ANATOMY", 71, 76], ["tissue", "TISSUE", 29, 35], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["virus", "PROBLEM", 16, 21], ["virus in circulating blood", "PROBLEM", 50, 76], ["virus", "OBSERVATION", 16, 21], ["virus", "OBSERVATION", 50, 55]]], ["Therefore, to determine if cells in the thymus and other tissues were a source of PRRSV, tissue thin sections were stained with PRRSV anti-nucleocapsid antibody.", [["cells", "ANATOMY", 27, 32], ["thymus", "ANATOMY", 40, 46], ["tissues", "ANATOMY", 57, 64], ["tissue thin sections", "ANATOMY", 89, 109], ["cells", "CELL", 27, 32], ["thymus", "ORGAN", 40, 46], ["tissues", "TISSUE", 57, 64], ["PRRSV", "ORGANISM", 82, 87], ["tissue thin sections", "MULTI-TISSUE_STRUCTURE", 89, 109], ["PRRSV", "ORGANISM", 128, 133], ["anti-nucleocapsid antibody", "GENE_OR_GENE_PRODUCT", 134, 160], ["PRRSV anti-nucleocapsid antibody", "PROTEIN", 128, 160], ["PRRSV", "SPECIES", 82, 87], ["PRRSV", "SPECIES", 128, 133], ["cells in the thymus and other tissues", "PROBLEM", 27, 64], ["PRRSV", "PROBLEM", 82, 87], ["tissue thin sections", "TEST", 89, 109], ["PRRSV anti-nucleocapsid antibody", "PROBLEM", 128, 160], ["thymus", "ANATOMY", 40, 46]]], ["The IHC staining procedure included two sets of negative controls: tissue thin sections from non-infected fetuses and from infected fetuses stained with only secondary antibody.", [["tissue thin sections", "ANATOMY", 67, 87], ["fetuses", "ANATOMY", 106, 113], ["fetuses", "ANATOMY", 132, 139], ["tissue thin sections", "MULTI-TISSUE_STRUCTURE", 67, 87], ["fetuses", "ORGANISM", 106, 113], ["fetuses", "ORGANISM", 132, 139], ["secondary antibody", "PROTEIN", 158, 176], ["The IHC staining procedure", "TREATMENT", 0, 26], ["tissue thin sections", "TREATMENT", 67, 87], ["non-infected fetuses", "PROBLEM", 93, 113], ["infected fetuses stained", "PROBLEM", 123, 147], ["secondary antibody", "PROBLEM", 158, 176], ["non-infected fetuses", "OBSERVATION", 93, 113], ["infected fetuses", "OBSERVATION", 123, 139], ["secondary antibody", "OBSERVATION", 158, 176]]], ["Both controls were negative for staining (data not shown).", [["staining", "PROBLEM", 32, 40]]], ["The results in Table 4 showed the largest number of positive tissues for the thymus (8 of 10 positive), followed by spleen (2 of 8 positive) and lymph node (1 of 9 positive).", [["tissues", "ANATOMY", 61, 68], ["thymus", "ANATOMY", 77, 83], ["spleen", "ANATOMY", 116, 122], ["lymph node", "ANATOMY", 145, 155], ["tissues", "TISSUE", 61, 68], ["thymus", "ORGAN", 77, 83], ["spleen", "ORGAN", 116, 122], ["lymph node", "MULTI-TISSUE_STRUCTURE", 145, 155], ["The results in Table 4", "TEST", 0, 22], ["the thymus", "TEST", 73, 83], ["spleen", "TEST", 116, 122], ["lymph node", "TEST", 145, 155], ["largest", "OBSERVATION_MODIFIER", 34, 41], ["positive tissues", "OBSERVATION", 52, 68], ["thymus", "ANATOMY", 77, 83], ["spleen", "ANATOMY", 116, 122], ["lymph node", "OBSERVATION", 145, 155]]], ["Within the thymus, antigen-positive cells were located in both medullar and cortical regions (data not shown).", [["thymus", "ANATOMY", 11, 17], ["cells", "ANATOMY", 36, 41], ["medullar", "ANATOMY", 63, 71], ["cortical regions", "ANATOMY", 76, 92], ["thymus", "ORGAN", 11, 17], ["antigen", "GENE_OR_GENE_PRODUCT", 19, 26], ["medullar", "TISSUE", 63, 71], ["cortical regions", "MULTI-TISSUE_STRUCTURE", 76, 92], ["antigen-positive cells", "CELL_TYPE", 19, 41], ["positive cells", "PROBLEM", 27, 41], ["thymus", "ANATOMY", 11, 17], ["positive cells", "OBSERVATION", 27, 41], ["both", "ANATOMY_MODIFIER", 58, 62], ["medullar", "ANATOMY", 63, 71], ["cortical", "ANATOMY_MODIFIER", 76, 84], ["regions", "ANATOMY_MODIFIER", 85, 92]]], ["PRRSV antigen-positive cells were not detected in lung or tonsil.", [["cells", "ANATOMY", 23, 28], ["lung", "ANATOMY", 50, 54], ["tonsil", "ANATOMY", 58, 64], ["PRRSV", "ORGANISM", 0, 5], ["lung", "ORGAN", 50, 54], ["tonsil", "ORGAN", 58, 64], ["PRRSV antigen", "PROTEIN", 0, 13], ["positive cells", "CELL_TYPE", 14, 28], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV antigen", "TEST", 0, 13], ["positive cells", "PROBLEM", 14, 28], ["positive cells", "OBSERVATION", 14, 28], ["lung", "ANATOMY", 50, 54], ["tonsil", "ANATOMY", 58, 64]]], ["Taken together, the virus titration and IHC results identify the thymus as a principal source of virus replication in the PRRSV-infected fetus.Response of fetal lymph node to infection ::: ResultsIn the post-natal pig, PRRSV infection results in distinct pathology in the lung, including the appearance of interstitial pneumonia.", [["thymus", "ANATOMY", 65, 71], ["fetus", "ANATOMY", 137, 142], ["fetal lymph node", "ANATOMY", 155, 171], ["lung", "ANATOMY", 272, 276], ["interstitial", "ANATOMY", 306, 318], ["infection", "DISEASE", 175, 184], ["PRRSV infection", "DISEASE", 219, 234], ["interstitial pneumonia", "DISEASE", 306, 328], ["thymus", "ORGAN", 65, 71], ["PRRSV", "ORGANISM", 122, 127], ["fetus", "ORGANISM", 137, 142], ["fetal lymph node", "MULTI-TISSUE_STRUCTURE", 155, 171], ["pig", "ORGANISM", 214, 217], ["PRRSV", "ORGANISM", 219, 224], ["lung", "ORGAN", 272, 276], ["PRRSV", "SPECIES", 122, 127], ["pig", "SPECIES", 214, 217], ["PRRSV", "SPECIES", 122, 127], ["pig", "SPECIES", 214, 217], ["PRRSV", "SPECIES", 219, 224], ["the virus titration", "TEST", 16, 35], ["IHC", "TEST", 40, 43], ["virus replication", "PROBLEM", 97, 114], ["fetal lymph node to infection", "PROBLEM", 155, 184], ["PRRSV infection", "PROBLEM", 219, 234], ["distinct pathology in the lung", "PROBLEM", 246, 276], ["interstitial pneumonia", "PROBLEM", 306, 328], ["thymus", "ANATOMY", 65, 71], ["virus", "OBSERVATION", 97, 102], ["infected", "OBSERVATION", 128, 136], ["fetal", "ANATOMY", 155, 160], ["lymph node", "OBSERVATION", 161, 171], ["infection", "OBSERVATION", 175, 184], ["PRRSV", "OBSERVATION_MODIFIER", 219, 224], ["infection", "OBSERVATION", 225, 234], ["distinct", "OBSERVATION_MODIFIER", 246, 254], ["pathology", "OBSERVATION", 255, 264], ["lung", "ANATOMY", 272, 276], ["interstitial", "ANATOMY_MODIFIER", 306, 318], ["pneumonia", "OBSERVATION", 319, 328]]], ["Representative lymph node and lung tissues from non-infected and infected fetuses are shown in Fig. 2.", [["lymph node", "ANATOMY", 15, 25], ["lung tissues", "ANATOMY", 30, 42], ["fetuses", "ANATOMY", 74, 81], ["lymph node", "MULTI-TISSUE_STRUCTURE", 15, 25], ["lung tissues", "TISSUE", 30, 42], ["fetuses", "ORGANISM", 74, 81], ["Representative lymph node and lung tissues", "PROBLEM", 0, 42], ["non-infected and infected fetuses", "PROBLEM", 48, 81], ["lymph node", "OBSERVATION", 15, 25], ["lung", "ANATOMY", 30, 34], ["non-infected", "OBSERVATION_MODIFIER", 48, 60], ["infected", "OBSERVATION_MODIFIER", 65, 73], ["fetuses", "OBSERVATION", 74, 81], ["Fig", "OBSERVATION_MODIFIER", 95, 98]]], ["There was no discernable difference between lungs from infected and non-infected fetuses (compare Fig. 2 panels C and D).", [["lungs", "ANATOMY", 44, 49], ["fetuses", "ANATOMY", 81, 88], ["lungs", "ORGAN", 44, 49], ["fetuses", "ORGAN", 81, 88], ["discernable difference between lungs", "PROBLEM", 13, 49], ["infected and non-infected fetuses", "PROBLEM", 55, 88], ["no", "UNCERTAINTY", 10, 12], ["discernable", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION", 25, 35], ["lungs", "ANATOMY", 44, 49], ["infected", "OBSERVATION", 55, 63], ["non-infected fetuses", "OBSERVATION", 68, 88]]], ["Lymph nodes from PRRSV-negative fetuses appeared largely undeveloped and devoid of well-defined germinal centers.", [["Lymph nodes", "ANATOMY", 0, 11], ["fetuses", "ANATOMY", 32, 39], ["germinal centers", "ANATOMY", 96, 112], ["Lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["PRRSV", "ORGANISM", 17, 22], ["fetuses", "ORGANISM", 32, 39], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 96, 112], ["PRRSV", "SPECIES", 17, 22], ["Lymph nodes", "TEST", 0, 11], ["PRRSV", "TEST", 17, 22], ["Lymph nodes", "OBSERVATION", 0, 11], ["negative", "OBSERVATION_MODIFIER", 23, 31], ["fetuses", "OBSERVATION", 32, 39], ["largely", "OBSERVATION_MODIFIER", 49, 56], ["undeveloped", "OBSERVATION", 57, 68], ["well-defined", "OBSERVATION_MODIFIER", 83, 95], ["germinal centers", "OBSERVATION", 96, 112]]], ["In contrast, the lymph nodes from PRRSV-infected fetuses appeared much more pronounced and enlarged.", [["lymph nodes", "ANATOMY", 17, 28], ["fetuses", "ANATOMY", 49, 56], ["PRRSV-infected", "DISEASE", 34, 48], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 17, 28], ["PRRSV", "ORGANISM", 34, 39], ["fetuses", "ORGANISM", 49, 56], ["PRRSV", "SPECIES", 34, 39], ["the lymph nodes", "PROBLEM", 13, 28], ["infected fetuses", "PROBLEM", 40, 56], ["lymph nodes", "OBSERVATION", 17, 28], ["infected", "OBSERVATION_MODIFIER", 40, 48], ["fetuses", "OBSERVATION", 49, 56], ["much", "OBSERVATION_MODIFIER", 66, 70], ["more pronounced", "OBSERVATION_MODIFIER", 71, 86], ["enlarged", "OBSERVATION", 91, 99]]], ["At the microscopic level, the increased lymph node volume was associated with increased numbers of cells and the formation of distinct germinal centers (see Fig. 2 panels A and B).", [["lymph node", "ANATOMY", 40, 50], ["cells", "ANATOMY", 99, 104], ["germinal centers", "ANATOMY", 135, 151], ["lymph node", "MULTI-TISSUE_STRUCTURE", 40, 50], ["cells", "CELL", 99, 104], ["B", "CELL", 177, 178], ["the increased lymph node volume", "PROBLEM", 26, 57], ["increased numbers of cells", "PROBLEM", 78, 104], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["lymph node volume", "OBSERVATION", 40, 57], ["increased", "OBSERVATION_MODIFIER", 78, 87], ["numbers", "OBSERVATION_MODIFIER", 88, 95], ["cells", "OBSERVATION", 99, 104], ["distinct", "OBSERVATION_MODIFIER", 126, 134], ["germinal centers", "OBSERVATION", 135, 151]]], ["The overall appearance is consistent with an antigen-activated lymph node.", [["lymph node", "ANATOMY", 63, 73], ["lymph node", "MULTI-TISSUE_STRUCTURE", 63, 73], ["an antigen-activated lymph node", "PROBLEM", 42, 73], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["consistent with", "UNCERTAINTY", 26, 41], ["activated", "OBSERVATION_MODIFIER", 53, 62], ["lymph node", "OBSERVATION", 63, 73]]], ["To determine the source of the increased cell volume, formalin-fixed thin sections of lymph nodes were stained with T cell-specific (CD3) and B cell-specific (CDw75 and CD79\u03b1) antibodies.", [["cell", "ANATOMY", 41, 45], ["sections", "ANATOMY", 74, 82], ["lymph nodes", "ANATOMY", 86, 97], ["T cell", "ANATOMY", 116, 122], ["B cell", "ANATOMY", 142, 148], ["formalin", "CHEMICAL", 54, 62], ["cell", "CELL", 41, 45], ["thin sections", "MULTI-TISSUE_STRUCTURE", 69, 82], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 86, 97], ["T cell", "CELL", 116, 122], ["CD3", "GENE_OR_GENE_PRODUCT", 133, 136], ["B cell", "CELL", 142, 148], ["CDw75", "GENE_OR_GENE_PRODUCT", 159, 164], ["CD79\u03b1", "GENE_OR_GENE_PRODUCT", 169, 174], ["T cell", "CELL_TYPE", 116, 122], ["CD3", "PROTEIN", 133, 136], ["CDw75 and CD79\u03b1) antibodies", "PROTEIN", 159, 186], ["the increased cell volume", "PROBLEM", 27, 52], ["fixed thin sections of lymph nodes", "PROBLEM", 63, 97], ["T cell", "TEST", 116, 122], ["B cell", "TEST", 142, 148], ["CDw", "TEST", 159, 162], ["CD79", "TEST", 169, 173], ["antibodies", "TEST", 176, 186], ["increased cell volume", "OBSERVATION", 31, 52], ["lymph nodes", "OBSERVATION", 86, 97]]], ["Representative results for mandibular lymph nodes from infected and non-infected fetuses are shown in Fig. 3.", [["mandibular lymph nodes", "ANATOMY", 27, 49], ["fetuses", "ANATOMY", 81, 88], ["mandibular lymph nodes", "MULTI-TISSUE_STRUCTURE", 27, 49], ["fetuses", "ORGAN", 81, 88], ["mandibular lymph nodes", "PROBLEM", 27, 49], ["infected and non-infected fetuses", "PROBLEM", 55, 88], ["mandibular", "ANATOMY", 27, 37], ["lymph nodes", "OBSERVATION", 38, 49], ["infected", "OBSERVATION_MODIFIER", 55, 63], ["non-infected fetuses", "OBSERVATION", 68, 88], ["Fig", "OBSERVATION_MODIFIER", 102, 105]]], ["The lymph nodes from both infected and non-infected fetuses showed extensive areas of staining with anti-CD3, indicating the presence of T cells.", [["lymph nodes", "ANATOMY", 4, 15], ["fetuses", "ANATOMY", 52, 59], ["T cells", "ANATOMY", 137, 144], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 4, 15], ["fetuses", "ORGANISM", 52, 59], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 100, 108], ["T cells", "CELL", 137, 144], ["anti-CD3", "PROTEIN", 100, 108], ["T cells", "CELL_TYPE", 137, 144], ["The lymph nodes", "PROBLEM", 0, 15], ["both infected and non-infected fetuses", "PROBLEM", 21, 59], ["anti-CD3", "TREATMENT", 100, 108], ["T cells", "PROBLEM", 137, 144], ["lymph nodes", "OBSERVATION", 4, 15], ["infected", "OBSERVATION_MODIFIER", 26, 34], ["non-infected", "OBSERVATION_MODIFIER", 39, 51], ["extensive", "OBSERVATION_MODIFIER", 67, 76], ["areas", "OBSERVATION_MODIFIER", 77, 82], ["staining", "OBSERVATION", 86, 94], ["anti-CD3", "OBSERVATION", 100, 108], ["T cells", "OBSERVATION", 137, 144]]], ["Lymph nodes from non-infected fetuses were negative for CwD75 staining, but possessed some regions that were positive for CD79\u03b1.", [["Lymph nodes", "ANATOMY", 0, 11], ["fetuses", "ANATOMY", 30, 37], ["Lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["fetuses", "ORGANISM", 30, 37], ["CwD75", "GENE_OR_GENE_PRODUCT", 56, 61], ["CD79\u03b1", "GENE_OR_GENE_PRODUCT", 122, 127], ["CwD75", "PROTEIN", 56, 61], ["CD79\u03b1", "PROTEIN", 122, 127], ["Lymph nodes", "TEST", 0, 11], ["non-infected fetuses", "PROBLEM", 17, 37], ["CwD75 staining", "PROBLEM", 56, 70], ["Lymph nodes", "OBSERVATION", 0, 11], ["negative for", "UNCERTAINTY", 43, 55]]], ["The B cell receptor for antigen (BCR) signal transduction complex is composed of a heterodimer of Ig\u03b1 and Ig\u03b2 chains, which are also known as CD79\u03b1 and CD79\u03b2, respectively.", [["B cell", "ANATOMY", 4, 10], ["B cell receptor for antigen", "GENE_OR_GENE_PRODUCT", 4, 31], ["BCR", "GENE_OR_GENE_PRODUCT", 33, 36], ["Ig\u03b1", "GENE_OR_GENE_PRODUCT", 98, 101], ["Ig\u03b2", "GENE_OR_GENE_PRODUCT", 106, 109], ["CD79\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["CD79\u03b2", "GENE_OR_GENE_PRODUCT", 152, 157], ["B cell receptor for antigen (BCR) signal transduction complex", "PROTEIN", 4, 65], ["Ig\u03b1", "PROTEIN", 98, 101], ["Ig\u03b2 chains", "PROTEIN", 106, 116], ["CD79\u03b1", "PROTEIN", 142, 147], ["CD79\u03b2", "PROTEIN", 152, 157], ["The B cell receptor", "TEST", 0, 19], ["antigen (BCR) signal transduction complex", "PROBLEM", 24, 65], ["a heterodimer of Ig\u03b1 and Ig\u03b2 chains", "PROBLEM", 81, 116], ["CD79", "TEST", 142, 146], ["B cell", "OBSERVATION", 4, 10], ["chains", "OBSERVATION_MODIFIER", 110, 116]]], ["CD79\u03b1 staining in the lymph node from non-infected fetuses is consistent with the presence of pro- and pre-B cells (Lee et al., 2008).", [["lymph node", "ANATOMY", 22, 32], ["fetuses", "ANATOMY", 51, 58], ["pre-B cells", "ANATOMY", 103, 114], ["CD79\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["lymph node", "MULTI-TISSUE_STRUCTURE", 22, 32], ["fetuses", "ORGAN", 51, 58], ["pre-B cells", "CELL", 103, 114], ["CD79\u03b1", "PROTEIN", 0, 5], ["pro- and pre-B cells", "CELL_LINE", 94, 114], ["staining in the lymph node", "PROBLEM", 6, 32], ["non-infected fetuses", "PROBLEM", 38, 58], ["pro", "TEST", 94, 97], ["staining", "OBSERVATION", 6, 14], ["lymph node", "OBSERVATION", 22, 32], ["non-infected fetuses", "OBSERVATION", 38, 58], ["consistent with", "UNCERTAINTY", 62, 77]]], ["The principle difference between infected and non-infected fetuses was found in an overall increase in CD79\u03b1+ cells as well as the appearance of CDw75+ cells, which were associated with germinal centers.", [["fetuses", "ANATOMY", 59, 66], ["CD79\u03b1+ cells", "ANATOMY", 103, 115], ["CDw75+ cells", "ANATOMY", 145, 157], ["germinal centers", "ANATOMY", 186, 202], ["fetuses", "ORGANISM", 59, 66], ["CD79", "GENE_OR_GENE_PRODUCT", 103, 107], ["CD79\u03b1+ cells", "CELL_LINE", 103, 115], ["infected and non-infected fetuses", "PROBLEM", 33, 66], ["an overall increase in CD79\u03b1+ cells", "PROBLEM", 80, 115], ["difference", "OBSERVATION_MODIFIER", 14, 24], ["infected", "OBSERVATION_MODIFIER", 33, 41], ["non-infected fetuses", "OBSERVATION", 46, 66], ["overall", "OBSERVATION_MODIFIER", 83, 90], ["increase", "OBSERVATION_MODIFIER", 91, 99], ["CD79\u03b1+ cells", "OBSERVATION", 103, 115], ["+ cells", "OBSERVATION", 150, 157], ["germinal centers", "OBSERVATION", 186, 202]]], ["CDw79 is beta-galactoside alpha-2,6-sialyltransferase, which is up-regulated in activated B cells (Erikstein et al., 1992).", [["B cells", "ANATOMY", 90, 97], ["beta-galactoside alpha-2,6-sialyltransferase", "GENE_OR_GENE_PRODUCT", 9, 53], ["B cells", "CELL", 90, 97], ["beta-galactoside alpha-2,6-sialyltransferase", "PROTEIN", 9, 53], ["activated B cells", "CELL_TYPE", 80, 97], ["CDw", "TEST", 0, 3], ["beta-galactoside alpha", "TEST", 9, 31]]], ["The absence of CDw75 staining in non-infected fetuses is consistent with the overall quiescent nature of the non-stimulated fetal immune system.", [["fetuses", "ANATOMY", 46, 53], ["fetal immune system", "ANATOMY", 124, 143], ["CDw75", "GENE_OR_GENE_PRODUCT", 15, 20], ["fetuses", "ORGAN", 46, 53], ["fetal immune system", "ANATOMICAL_SYSTEM", 124, 143], ["CDw75 staining in non-infected fetuses", "PROBLEM", 15, 53], ["the non-stimulated fetal immune system", "PROBLEM", 105, 143], ["non-infected fetuses", "OBSERVATION", 33, 53], ["consistent with", "UNCERTAINTY", 57, 72], ["overall", "OBSERVATION_MODIFIER", 77, 84], ["quiescent", "OBSERVATION", 85, 94], ["non-stimulated fetal immune system", "OBSERVATION", 109, 143]]], ["The up-regulation of CDw75 after PRRSV infection is consistent with B cell activation and the formation of mature germinal centers in response to infection.", [["B cell", "ANATOMY", 68, 74], ["germinal centers", "ANATOMY", 114, 130], ["PRRSV infection", "DISEASE", 33, 48], ["infection", "DISEASE", 146, 155], ["CDw75", "GENE_OR_GENE_PRODUCT", 21, 26], ["PRRSV", "ORGANISM", 33, 38], ["B cell", "CELL", 68, 74], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 114, 130], ["PRRSV", "SPECIES", 33, 38], ["The up-regulation of CDw", "TREATMENT", 0, 24], ["PRRSV infection", "PROBLEM", 33, 48], ["B cell activation", "PROBLEM", 68, 85], ["infection", "PROBLEM", 146, 155], ["infection", "OBSERVATION", 39, 48], ["consistent with", "UNCERTAINTY", 52, 67], ["B cell activation", "OBSERVATION", 68, 85], ["mature", "OBSERVATION_MODIFIER", 107, 113], ["germinal centers", "OBSERVATION", 114, 130], ["infection", "OBSERVATION", 146, 155]]], ["It should be noted that infected fetuses showed different degrees of staining, a likely consequence of the different stages of fetal infection; i.e. less staining was the result of early infection.", [["fetuses", "ANATOMY", 33, 40], ["fetal", "ANATOMY", 127, 132], ["fetal infection", "DISEASE", 127, 142], ["infection", "DISEASE", 187, 196], ["fetuses", "ORGANISM", 33, 40], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 127, 132], ["infected fetuses", "PROBLEM", 24, 40], ["different degrees of staining", "PROBLEM", 48, 77], ["fetal infection", "PROBLEM", 127, 142], ["early infection", "PROBLEM", 181, 196], ["infected", "OBSERVATION", 24, 32], ["different degrees", "OBSERVATION_MODIFIER", 48, 65], ["different stages", "OBSERVATION_MODIFIER", 107, 123], ["fetal", "ANATOMY", 127, 132], ["infection", "OBSERVATION", 133, 142], ["less staining", "OBSERVATION_MODIFIER", 149, 162], ["early", "OBSERVATION_MODIFIER", 181, 186], ["infection", "OBSERVATION", 187, 196]]], ["Together, the overall morphology and lymphocyte marker expression results indicate that the increased volume in the lymph nodes of infected fetuses is largely the result of increased numbers of mature activated B cells, which occupy germinal centers.Cytokine gene expression ::: ResultsImmune cytokines are important factors in antiviral immunity and can influence the outcome of pregnancy (Arck et al., 1999, Basurko et al., 2009).", [["lymphocyte", "ANATOMY", 37, 47], ["lymph nodes", "ANATOMY", 116, 127], ["fetuses", "ANATOMY", 140, 147], ["B cells", "ANATOMY", 211, 218], ["germinal centers", "ANATOMY", 233, 249], ["lymphocyte", "CELL", 37, 47], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 116, 127], ["fetuses", "ORGAN", 140, 147], ["B cells", "CELL", 211, 218], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 233, 249], ["Cytokine", "GENE_OR_GENE_PRODUCT", 250, 258], ["mature activated B cells", "CELL_TYPE", 194, 218], ["Cytokine gene", "DNA", 250, 263], ["ResultsImmune cytokines", "PROTEIN", 279, 302], ["the increased volume in the lymph nodes", "PROBLEM", 88, 127], ["infected fetuses", "PROBLEM", 131, 147], ["increased numbers", "PROBLEM", 173, 190], ["mature activated B cells", "PROBLEM", 194, 218], ["ResultsImmune cytokines", "PROBLEM", 279, 302], ["overall", "OBSERVATION_MODIFIER", 14, 21], ["morphology", "OBSERVATION_MODIFIER", 22, 32], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["volume", "OBSERVATION_MODIFIER", 102, 108], ["lymph nodes", "OBSERVATION", 116, 127], ["infected fetuses", "OBSERVATION", 131, 147], ["increased", "OBSERVATION_MODIFIER", 173, 182], ["numbers", "OBSERVATION_MODIFIER", 183, 190], ["mature", "OBSERVATION_MODIFIER", 194, 200], ["activated B cells", "OBSERVATION", 201, 218], ["germinal centers", "OBSERVATION", 233, 249]]], ["The detection of cytokine gene expression in tissues was performed using a steady state RT-PCR procedure.", [["tissues", "ANATOMY", 45, 52], ["tissues", "TISSUE", 45, 52], ["cytokine gene", "DNA", 17, 30], ["cytokine gene expression in tissues", "PROBLEM", 17, 52], ["a steady state RT-PCR procedure", "TREATMENT", 73, 104], ["cytokine gene expression", "OBSERVATION", 17, 41]]], ["RT-PCR was performed on RNA isolated from four fetuses randomly chosen from the two mock-infected dams and four randomly selected PRRSV-infected fetuses.", [["fetuses", "ANATOMY", 47, 54], ["fetuses", "ANATOMY", 145, 152], ["PRRSV-infected", "DISEASE", 130, 144], ["fetuses", "ORGANISM", 47, 54], ["dams", "ORGANISM", 98, 102], ["PRRSV", "ORGANISM", 130, 135], ["fetuses", "ORGANISM", 145, 152], ["PRRSV", "SPECIES", 130, 135], ["RT-PCR", "TEST", 0, 6], ["RNA", "TEST", 24, 27], ["infected dams", "PROBLEM", 89, 102], ["infected fetuses", "PROBLEM", 136, 152], ["PRRSV", "OBSERVATION", 130, 135], ["infected fetuses", "OBSERVATION", 136, 152]]], ["The tissues selected for RT-PCR amplification were lung, lymph node and placenta.", [["tissues", "ANATOMY", 4, 11], ["lung", "ANATOMY", 51, 55], ["lymph node", "ANATOMY", 57, 67], ["placenta", "ANATOMY", 72, 80], ["tissues", "TISSUE", 4, 11], ["lung", "ORGAN", 51, 55], ["lymph node", "MULTI-TISSUE_STRUCTURE", 57, 67], ["placenta", "MULTI-TISSUE_STRUCTURE", 72, 80], ["RT-PCR amplification", "TEST", 25, 45], ["tissues", "ANATOMY", 4, 11], ["lung", "ANATOMY", 51, 55], ["lymph node", "OBSERVATION", 57, 67], ["placenta", "ANATOMY", 72, 80]]], ["Lung and lymph node represent sites cytokine alterations in the post-natal pig.", [["Lung", "ANATOMY", 0, 4], ["lymph node", "ANATOMY", 9, 19], ["sites", "ANATOMY", 30, 35], ["Lung", "ORGAN", 0, 4], ["lymph node", "MULTI-TISSUE_STRUCTURE", 9, 19], ["pig", "ORGANISM", 75, 78], ["cytokine", "PROTEIN", 36, 44], ["pig", "SPECIES", 75, 78], ["pig", "SPECIES", 75, 78], ["Lung and lymph node", "PROBLEM", 0, 19], ["cytokine alterations", "PROBLEM", 36, 56], ["lymph node", "OBSERVATION", 9, 19], ["sites", "OBSERVATION_MODIFIER", 30, 35], ["cytokine alterations", "OBSERVATION", 36, 56], ["post-natal pig", "OBSERVATION", 64, 78]]], ["Placenta was selected as an accessory tissue located at the fetal maternal interface.", [["Placenta", "ANATOMY", 0, 8], ["accessory tissue", "ANATOMY", 28, 44], ["fetal", "ANATOMY", 60, 65], ["Placenta", "ORGAN", 0, 8], ["tissue", "TISSUE", 38, 44], ["fetal maternal interface", "MULTI-TISSUE_STRUCTURE", 60, 84], ["an accessory tissue", "PROBLEM", 25, 44], ["accessory tissue", "OBSERVATION", 28, 44], ["fetal", "ANATOMY_MODIFIER", 60, 65], ["maternal interface", "OBSERVATION", 66, 84]]], ["Amplification of mRNAs included cytokines associated with inflammatory (IL-6, IL-8), Th1 (IL-12, IFN-\u03b3, IL-2) and Th2/regulatory (IL-4, IL-10) responses.", [["IL-6", "GENE_OR_GENE_PRODUCT", 72, 76], ["IL-8", "GENE_OR_GENE_PRODUCT", 78, 82], ["Th1", "GENE_OR_GENE_PRODUCT", 85, 88], ["IL-12", "GENE_OR_GENE_PRODUCT", 90, 95], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 97, 102], ["IL-2", "GENE_OR_GENE_PRODUCT", 104, 108], ["Th2", "GENE_OR_GENE_PRODUCT", 114, 117], ["IL-4", "GENE_OR_GENE_PRODUCT", 130, 134], ["IL-10", "GENE_OR_GENE_PRODUCT", 136, 141], ["mRNAs", "RNA", 17, 22], ["cytokines", "PROTEIN", 32, 41], ["IFN", "PROTEIN", 97, 100], ["cytokines", "TEST", 32, 41], ["inflammatory (IL", "TEST", 58, 74], ["IL", "TEST", 78, 80], ["Th1", "TEST", 85, 88], ["IL", "TEST", 90, 92], ["IFN", "TEST", 97, 100], ["IL", "TEST", 104, 106], ["Th2", "TEST", 114, 117], ["IL", "TEST", 130, 132], ["inflammatory", "OBSERVATION_MODIFIER", 58, 70]]], ["The amplification of \u03b22m mRNA was included as an internal control.", [["\u03b22m", "GENE_OR_GENE_PRODUCT", 21, 24], ["\u03b22m mRNA", "RNA", 21, 29], ["\u03b22m mRNA", "TREATMENT", 21, 29], ["an internal control", "TREATMENT", 46, 65]]], ["The determination of a cytokine response was based on the presence or absence of a PCR product.", [["cytokine", "PROTEIN", 23, 31], ["a PCR product", "TREATMENT", 81, 94]]], ["IL-6, IL-8, IL-12 and IL-10 products were detected in tissues from both control and infected fetuses.", [["tissues", "ANATOMY", 54, 61], ["fetuses", "ANATOMY", 93, 100], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-8", "GENE_OR_GENE_PRODUCT", 6, 10], ["IL-12", "GENE_OR_GENE_PRODUCT", 12, 17], ["IL-10", "GENE_OR_GENE_PRODUCT", 22, 27], ["tissues", "TISSUE", 54, 61], ["fetuses", "ORGANISM", 93, 100], ["IL-6, IL-8, IL-12 and IL-10 products", "PROTEIN", 0, 36], ["IL", "TEST", 0, 2], ["IL", "TEST", 6, 8], ["IL", "TREATMENT", 12, 14], ["IL", "TREATMENT", 22, 24], ["infected fetuses", "PROBLEM", 84, 100], ["infected fetuses", "OBSERVATION", 84, 100]]], ["Because of the qualitative nature of the PCR method, it was not possible to accurately determine quantitative differences between control and infected fetuses; and therefore, these cytokines were not subjected to further study (data not shown).", [["fetuses", "ANATOMY", 151, 158], ["fetuses", "ORGANISM", 151, 158], ["cytokines", "PROTEIN", 181, 190], ["the PCR method", "TEST", 37, 51], ["infected fetuses", "PROBLEM", 142, 158], ["these cytokines", "TEST", 175, 190], ["further study", "TEST", 213, 226], ["infected", "OBSERVATION_MODIFIER", 142, 150], ["fetuses", "OBSERVATION", 151, 158]]], ["IL-4 mRNA was not detected in any of the selected tissues for control and infected fetuses.", [["tissues", "ANATOMY", 50, 57], ["fetuses", "ANATOMY", 83, 90], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissues", "TISSUE", 50, 57], ["fetuses", "ORGANISM", 83, 90], ["IL-4 mRNA", "RNA", 0, 9], ["infected fetuses", "PROBLEM", 74, 90], ["infected", "OBSERVATION_MODIFIER", 74, 82], ["fetuses", "OBSERVATION", 83, 90]]], ["Marked differences in expression were observed for TNF-\u03b1 and IFN-\u03b3 mRNAs.", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 51, 56], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 61, 66], ["TNF-\u03b1 and IFN-\u03b3 mRNAs", "RNA", 51, 72], ["TNF", "TEST", 51, 54]]], ["The results for IFN-\u03b3 and TNF-\u03b1 from lung, mandibular lymph node and placenta are presented in Fig. 4.", [["lung", "ANATOMY", 37, 41], ["mandibular lymph node", "ANATOMY", 43, 64], ["placenta", "ANATOMY", 69, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 16, 21], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["lung", "ORGAN", 37, 41], ["mandibular lymph node", "MULTI-TISSUE_STRUCTURE", 43, 64], ["placenta", "ORGAN", 69, 77], ["IFN", "PROTEIN", 16, 19], ["\u03b3", "PROTEIN", 20, 21], ["TNF-\u03b1", "PROTEIN", 26, 31], ["The results", "TEST", 0, 11], ["IFN", "TEST", 16, 19], ["\u03b3", "TEST", 20, 21], ["TNF", "TEST", 26, 29], ["mandibular lymph node", "PROBLEM", 43, 64], ["lung", "ANATOMY", 37, 41], ["mandibular", "ANATOMY", 43, 53], ["lymph node", "OBSERVATION", 54, 64], ["placenta", "ANATOMY", 69, 77], ["Fig", "OBSERVATION_MODIFIER", 95, 98]]], ["The results for IL-10 are also shown.", [["IL-10", "GENE_OR_GENE_PRODUCT", 16, 21], ["IL", "PROTEIN", 16, 18], ["IL", "TEST", 16, 18]]], ["The internal control mRNA, \u03b22m, was amplified from all tissues, indicating that the RNA was intact.", [["tissues", "ANATOMY", 55, 62], ["\u03b22m", "GENE_OR_GENE_PRODUCT", 27, 30], ["tissues", "TISSUE", 55, 62], ["internal control mRNA", "RNA", 4, 25], ["\u03b22m", "PROTEIN", 27, 30], ["internal", "ANATOMY_MODIFIER", 4, 12], ["intact", "OBSERVATION", 92, 98]]], ["IL-10 was amplified from lung and mandibular lymph nodes from two of the four control fetuses and from all infected fetuses.", [["lung", "ANATOMY", 25, 29], ["mandibular lymph nodes", "ANATOMY", 34, 56], ["fetuses", "ANATOMY", 86, 93], ["fetuses", "ANATOMY", 116, 123], ["IL-10", "GENE_OR_GENE_PRODUCT", 0, 5], ["lung", "ORGAN", 25, 29], ["mandibular lymph nodes", "MULTI-TISSUE_STRUCTURE", 34, 56], ["fetuses", "ORGANISM", 86, 93], ["fetuses", "ORGANISM", 116, 123], ["IL-10", "PROTEIN", 0, 5], ["IL", "TREATMENT", 0, 2], ["lung and mandibular lymph nodes", "PROBLEM", 25, 56], ["all infected fetuses", "PROBLEM", 103, 123], ["lung", "ANATOMY", 25, 29], ["mandibular", "ANATOMY", 34, 44], ["lymph nodes", "OBSERVATION", 45, 56], ["fetuses", "OBSERVATION", 86, 93], ["all", "OBSERVATION_MODIFIER", 103, 106], ["infected", "OBSERVATION_MODIFIER", 107, 115], ["fetuses", "OBSERVATION", 116, 123]]], ["The presence of IL-10 was not unexpected, since increased IL-10 production is associated with fetal T cell responses (Lin et al., 1993, Rainsford and Reen, 2002).", [["fetal T cell", "ANATOMY", 94, 106], ["IL-10", "GENE_OR_GENE_PRODUCT", 16, 21], ["IL-10", "GENE_OR_GENE_PRODUCT", 58, 63], ["fetal T cell", "CELL", 94, 106], ["IL", "PROTEIN", 16, 18], ["IL", "PROTEIN", 58, 60], ["increased IL", "PROBLEM", 48, 60], ["IL", "OBSERVATION_MODIFIER", 16, 18], ["increased", "OBSERVATION_MODIFIER", 48, 57]]], ["As shown in Fig. 4A, IFN-\u03b3 and TNF-\u03b1 PCR products were not detected in lung, lymph node or placenta from the non-infected fetuses.", [["lung", "ANATOMY", 71, 75], ["lymph node", "ANATOMY", 77, 87], ["placenta", "ANATOMY", 91, 99], ["fetuses", "ANATOMY", 122, 129], ["4A", "GENE_OR_GENE_PRODUCT", 17, 19], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 21, 26], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 31, 36], ["lung", "ORGAN", 71, 75], ["lymph node", "MULTI-TISSUE_STRUCTURE", 77, 87], ["placenta", "ORGAN", 91, 99], ["fetuses", "ORGAN", 122, 129], ["IFN", "PROTEIN", 21, 24], ["TNF", "PROTEIN", 31, 34], ["IFN", "TEST", 21, 24], ["TNF", "TEST", 31, 34], ["PCR products", "TEST", 37, 49], ["lymph node", "PROBLEM", 77, 87], ["the non-infected fetuses", "PROBLEM", 105, 129], ["Fig", "OBSERVATION", 12, 15], ["not detected", "UNCERTAINTY", 55, 67], ["lung", "ANATOMY", 71, 75], ["lymph node", "OBSERVATION", 77, 87], ["placenta", "ANATOMY", 91, 99], ["non-infected fetuses", "OBSERVATION", 109, 129]]], ["However, IFN-\u03b3 PCR products were obtained for lung and lymph nodes from infected fetuses.", [["lung", "ANATOMY", 46, 50], ["lymph nodes", "ANATOMY", 55, 66], ["fetuses", "ANATOMY", 81, 88], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 9, 14], ["lung", "ORGAN", 46, 50], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 55, 66], ["fetuses", "ORGANISM", 81, 88], ["IFN", "PROTEIN", 9, 12], ["IFN", "TEST", 9, 12], ["PCR products", "TEST", 15, 27], ["lung and lymph nodes", "PROBLEM", 46, 66], ["infected fetuses", "PROBLEM", 72, 88], ["lung", "ANATOMY", 46, 50], ["lymph nodes", "OBSERVATION", 55, 66], ["infected fetuses", "OBSERVATION", 72, 88]]], ["One infected fetus, 4\u20133, yielded a faint IFN-\u03b3 product for placenta.", [["fetus", "ANATOMY", 13, 18], ["placenta", "ANATOMY", 59, 67], ["fetus", "ORGANISM", 13, 18], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 41, 46], ["placenta", "ORGAN", 59, 67], ["IFN", "PROTEIN", 41, 44], ["\u03b3 product", "PROTEIN", 45, 54], ["a faint IFN", "TREATMENT", 33, 44], ["infected", "OBSERVATION", 4, 12], ["faint", "OBSERVATION_MODIFIER", 35, 40], ["IFN", "OBSERVATION", 41, 44], ["placenta", "ANATOMY", 59, 67]]], ["For infected fetuses, TNF-\u03b1 mRNA was amplified from lung, but not lymph node or placenta (Fig. 4B).", [["fetuses", "ANATOMY", 13, 20], ["lung", "ANATOMY", 52, 56], ["lymph node", "ANATOMY", 66, 76], ["placenta", "ANATOMY", 80, 88], ["fetuses", "ORGANISM", 13, 20], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 22, 27], ["lung", "ORGAN", 52, 56], ["lymph node", "MULTI-TISSUE_STRUCTURE", 66, 76], ["placenta", "ORGAN", 80, 88], ["TNF-\u03b1 mRNA", "RNA", 22, 32], ["infected fetuses", "PROBLEM", 4, 20], ["TNF", "TEST", 22, 25], ["mRNA", "TEST", 28, 32], ["lymph node", "PROBLEM", 66, 76], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["fetuses", "OBSERVATION", 13, 20], ["lung", "ANATOMY", 52, 56], ["not", "UNCERTAINTY", 62, 65], ["lymph node", "OBSERVATION", 66, 76], ["placenta", "ANATOMY", 80, 88]]], ["To determine if cytokine gene expression was the direct result of PRRSV infection, RT-PCR for IFN-\u03b3 and TNF-\u03b1 was performed on the same tissues from fetuses of infected dam no. 2, which produced only PRRSV VI-negative fetuses (see Fig. 1).", [["tissues", "ANATOMY", 136, 143], ["fetuses", "ANATOMY", 149, 156], ["fetuses", "ANATOMY", 218, 225], ["PRRSV infection", "DISEASE", 66, 81], ["PRRSV", "ORGANISM", 66, 71], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 94, 99], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 104, 109], ["tissues", "TISSUE", 136, 143], ["fetuses", "ORGANISM", 149, 156], ["PRRSV", "ORGANISM", 200, 205], ["VI", "GENE_OR_GENE_PRODUCT", 206, 208], ["fetuses", "ORGANISM", 218, 225], ["cytokine gene", "DNA", 16, 29], ["IFN", "PROTEIN", 94, 97], ["TNF", "PROTEIN", 104, 107], ["PRRSV", "SPECIES", 66, 71], ["PRRSV", "SPECIES", 200, 205], ["cytokine gene expression", "PROBLEM", 16, 40], ["PRRSV infection", "PROBLEM", 66, 81], ["RT-PCR", "TEST", 83, 89], ["IFN", "TEST", 94, 97], ["TNF", "TEST", 104, 107], ["PRRSV infection", "OBSERVATION", 66, 81], ["infected dam", "OBSERVATION", 160, 172], ["negative fetuses", "OBSERVATION", 209, 225]]], ["The analysis of mRNA expression in lungs and lymph nodes from six fetuses from dam no. 2 showed only the amplification of the \u03b22m, but not TNF-\u03b1 or IFN-\u03b3 mRNAs (data not shown).", [["lungs", "ANATOMY", 35, 40], ["lymph nodes", "ANATOMY", 45, 56], ["fetuses", "ANATOMY", 66, 73], ["lungs", "ORGAN", 35, 40], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 45, 56], ["fetuses", "ORGANISM", 66, 73], ["\u03b22m", "GENE_OR_GENE_PRODUCT", 126, 129], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 139, 144], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 148, 153], ["\u03b22m, but not TNF-\u03b1 or IFN-\u03b3 mRNAs", "RNA", 126, 159], ["The analysis", "TEST", 0, 12], ["mRNA expression in lungs and lymph nodes", "PROBLEM", 16, 56], ["TNF", "TEST", 139, 142], ["IFN", "PROBLEM", 148, 151], ["mRNA expression", "OBSERVATION", 16, 31], ["lungs", "ANATOMY", 35, 40], ["lymph nodes", "OBSERVATION", 45, 56]]], ["Similar results were obtained from virus-negative fetuses located immediately adjacent to infected fetuses (data not shown).Cytokine gene expression ::: ResultsIn order to confirm that TNF-\u03b1 and IFN-\u03b3 were produced during infection, cytokine protein levels were measured in fetal sera and amniotic fluid from infected fetuses and fetuses from mock-infected dams.", [["fetuses", "ANATOMY", 50, 57], ["fetuses", "ANATOMY", 99, 106], ["fetal sera", "ANATOMY", 274, 284], ["amniotic fluid", "ANATOMY", 289, 303], ["fetuses", "ANATOMY", 318, 325], ["fetuses", "ANATOMY", 330, 337], ["infection", "DISEASE", 222, 231], ["fetuses", "ORGANISM", 50, 57], ["fetuses", "ORGANISM", 99, 106], ["Cytokine", "GENE_OR_GENE_PRODUCT", 124, 132], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 185, 190], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 195, 200], ["fetal sera", "ORGANISM_SUBSTANCE", 274, 284], ["amniotic fluid", "ORGANISM_SUBSTANCE", 289, 303], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 318, 325], ["fetuses", "ORGANISM", 330, 337], ["dams", "ORGANISM", 357, 361], ["Cytokine gene", "DNA", 124, 137], ["TNF", "PROTEIN", 185, 188], ["\u03b1", "PROTEIN", 189, 190], ["IFN-\u03b3", "PROTEIN", 195, 200], ["cytokine", "PROTEIN", 233, 241], ["virus", "TEST", 35, 40], ["infected fetuses", "PROBLEM", 90, 106], ["TNF", "TEST", 185, 188], ["IFN", "TEST", 195, 198], ["infection", "PROBLEM", 222, 231], ["cytokine protein levels", "TEST", 233, 256], ["fetal sera", "TEST", 274, 284], ["amniotic fluid", "PROBLEM", 289, 303], ["infected fetuses", "PROBLEM", 309, 325], ["infected", "OBSERVATION_MODIFIER", 90, 98], ["fetuses", "OBSERVATION", 99, 106], ["infection", "OBSERVATION", 222, 231], ["amniotic fluid", "OBSERVATION", 289, 303], ["infected fetuses", "OBSERVATION", 309, 325]]], ["As shown in Fig. 5, the concentration of TNF-\u03b1 in serum for PRRSV-infected fetuses ranged between 20 and 100 pg/ml compared to less than 30 pg/ml for control fetuses.", [["serum", "ANATOMY", 50, 55], ["fetuses", "ANATOMY", 75, 82], ["fetuses", "ANATOMY", 158, 165], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 50, 55], ["PRRSV", "ORGANISM", 60, 65], ["fetuses", "ORGANISM", 75, 82], ["fetuses", "ORGANISM", 158, 165], ["TNF-\u03b1", "PROTEIN", 41, 46], ["PRRSV", "SPECIES", 60, 65], ["TNF", "TEST", 41, 44], ["serum", "TEST", 50, 55], ["PRRSV", "PROBLEM", 60, 65], ["infected fetuses", "PROBLEM", 66, 82]]], ["Even though the maximum quantities obtained for infected fetuses were near the lower limit of detection for the ELISA test, it was clear that TNF-\u03b1 was elevated during infection.", [["fetuses", "ANATOMY", 57, 64], ["infection", "DISEASE", 168, 177], ["fetuses", "ORGANISM", 57, 64], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["TNF", "PROTEIN", 142, 145], ["the maximum quantities", "TEST", 12, 34], ["infected fetuses", "PROBLEM", 48, 64], ["the ELISA test", "TEST", 108, 122], ["TNF", "TEST", 142, 145], ["elevated", "PROBLEM", 152, 160], ["infection", "PROBLEM", 168, 177], ["infected", "OBSERVATION", 48, 56], ["lower limit", "OBSERVATION_MODIFIER", 79, 90], ["infection", "OBSERVATION", 168, 177]]], ["Detectable concentrations of TNF-\u03b1 (>23 pg/ml) were found in amniotic fluid from only two control and two infected fetuses.", [["amniotic fluid", "ANATOMY", 61, 75], ["fetuses", "ANATOMY", 115, 122], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 29, 34], ["amniotic fluid", "ORGANISM_SUBSTANCE", 61, 75], ["fetuses", "ORGANISM", 115, 122], ["TNF", "PROTEIN", 29, 32], ["TNF", "TEST", 29, 32], ["amniotic fluid", "TEST", 61, 75], ["two infected fetuses", "PROBLEM", 102, 122], ["concentrations", "OBSERVATION_MODIFIER", 11, 25], ["amniotic fluid", "OBSERVATION", 61, 75], ["infected fetuses", "OBSERVATION", 106, 122]]], ["Compared to fetuses from mock-infected dams, IFN-\u03b3 concentrations were detected in sera, with values ranging from a low of 60 to more than 500 pg/ml.", [["fetuses", "ANATOMY", 12, 19], ["sera", "ANATOMY", 83, 87], ["IFN-\u03b3", "CHEMICAL", 45, 50], ["fetuses", "ORGANISM", 12, 19], ["dams", "ORGANISM", 39, 43], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 45, 50], ["sera", "ORGANISM_SUBSTANCE", 83, 87], ["IFN", "PROTEIN", 45, 48], ["IFN", "TREATMENT", 45, 48], ["\u03b3 concentrations", "PROBLEM", 49, 65], ["sera", "TEST", 83, 87], ["values", "TEST", 94, 100]]], ["A maximum level of 60 pg/ml was obtained for a single non-infected fetus.", [["fetus", "ANATOMY", 67, 72], ["fetus", "ORGANISM", 67, 72], ["A maximum level", "TEST", 0, 15], ["a single non-infected fetus", "PROBLEM", 45, 72]]], ["IFN-\u03b3 was not detected in amniotic fluid from either the infected or control fetuses.", [["amniotic fluid", "ANATOMY", 26, 40], ["fetuses", "ANATOMY", 77, 84], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["amniotic fluid", "ORGANISM_SUBSTANCE", 26, 40], ["fetuses", "ORGANISM", 77, 84], ["IFN", "PROTEIN", 0, 3], ["\u03b3", "PROTEIN", 4, 5], ["IFN", "TEST", 0, 3], ["amniotic fluid", "PROBLEM", 26, 40], ["the infected or control fetuses", "PROBLEM", 53, 84], ["not detected", "UNCERTAINTY", 10, 22], ["amniotic fluid", "OBSERVATION", 26, 40], ["infected", "OBSERVATION", 57, 65]]], ["The presence of IFN-\u03b3 and TNF-\u03b1 in serum, but not amniotic fluid, further supports the notion that the IFN-\u03b3 and TNF-\u03b1 responses are primarily restricted to the PRRSV-infected fetus and do not extend to the accessory tissue compartments.DiscussionThis study characterizes the unique biology associated with the interaction between PRRSV and the late gestation fetus.", [["serum", "ANATOMY", 35, 40], ["amniotic fluid", "ANATOMY", 50, 64], ["fetus", "ANATOMY", 176, 181], ["tissue compartments", "ANATOMY", 217, 236], ["fetus", "ANATOMY", 360, 365], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 16, 21], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["amniotic fluid", "ORGANISM_SUBSTANCE", 50, 64], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 103, 108], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 113, 118], ["PRRSV", "ORGANISM", 161, 166], ["fetus", "ORGAN", 176, 181], ["tissue compartments", "MULTI-TISSUE_STRUCTURE", 217, 236], ["PRRSV", "ORGANISM", 331, 336], ["fetus", "ORGAN", 360, 365], ["IFN", "PROTEIN", 16, 19], ["TNF-\u03b1", "PROTEIN", 26, 31], ["IFN", "PROTEIN", 103, 106], ["TNF", "PROTEIN", 113, 116], ["PRRSV", "SPECIES", 161, 166], ["PRRSV", "SPECIES", 161, 166], ["PRRSV", "SPECIES", 331, 336], ["IFN", "TEST", 16, 19], ["TNF-\u03b1 in serum", "TEST", 26, 40], ["amniotic fluid", "PROBLEM", 50, 64], ["the IFN", "TEST", 99, 106], ["TNF", "TEST", 113, 116], ["infected fetus", "PROBLEM", 167, 181], ["This study", "TEST", 247, 257], ["not", "UNCERTAINTY", 46, 49], ["amniotic fluid", "OBSERVATION", 50, 64], ["PRRSV", "OBSERVATION", 161, 166], ["infected", "OBSERVATION", 167, 175], ["accessory tissue", "ANATOMY", 207, 223]]], ["Consistent with the body of published literature, the fetuses from the infected dams obtained in this study exhibited several anatomic pathological features typical of PRRSV infection of the fetus, including lesions associated with the accessory organs, such as umbilical cord and amniotic sac (Lager and Halbur, 1996, Mengeling et al., 1996).", [["fetuses", "ANATOMY", 54, 61], ["fetus", "ANATOMY", 191, 196], ["lesions", "ANATOMY", 208, 215], ["accessory organs", "ANATOMY", 236, 252], ["umbilical cord", "ANATOMY", 262, 276], ["amniotic sac", "ANATOMY", 281, 293], ["PRRSV infection of the fetus", "DISEASE", 168, 196], ["fetuses", "ORGANISM", 54, 61], ["dams", "ORGANISM", 80, 84], ["PRRSV", "ORGANISM", 168, 173], ["fetus", "ORGAN", 191, 196], ["lesions", "CANCER", 208, 215], ["organs", "ORGAN", 246, 252], ["umbilical cord", "TISSUE", 262, 276], ["amniotic sac", "MULTI-TISSUE_STRUCTURE", 281, 293], ["PRRSV", "SPECIES", 168, 173], ["PRRSV", "SPECIES", 168, 173], ["this study", "TEST", 97, 107], ["several anatomic pathological features", "PROBLEM", 118, 156], ["PRRSV infection of the fetus", "PROBLEM", 168, 196], ["lesions", "PROBLEM", 208, 215], ["the accessory organs", "PROBLEM", 232, 252], ["infected", "OBSERVATION", 71, 79], ["PRRSV infection", "OBSERVATION", 168, 183], ["fetus", "ANATOMY", 191, 196], ["lesions", "OBSERVATION", 208, 215], ["accessory", "ANATOMY_MODIFIER", 236, 245], ["organs", "ANATOMY", 246, 252], ["umbilical cord", "ANATOMY", 262, 276], ["amniotic sac", "ANATOMY", 281, 293]]], ["One interesting observation from this study was the apparent absence of a correlation between the presence of gross abnormalities and productive fetal infection.", [["fetal", "ANATOMY", 145, 150], ["gross abnormalities", "DISEASE", 110, 129], ["fetal infection", "DISEASE", 145, 160], ["fetal", "ORGAN", 145, 150], ["this study", "TEST", 33, 43], ["gross abnormalities", "PROBLEM", 110, 129], ["productive fetal infection", "PROBLEM", 134, 160], ["gross", "OBSERVATION_MODIFIER", 110, 115], ["abnormalities", "OBSERVATION", 116, 129], ["productive", "OBSERVATION_MODIFIER", 134, 144], ["fetal", "OBSERVATION_MODIFIER", 145, 150], ["infection", "OBSERVATION", 151, 160]]], ["For example, several fetuses from dam no. 2 exhibited several types of gross pathology, including death, growth retardation, or merconium/blood stained amniotic fluid.", [["fetuses", "ANATOMY", 21, 28], ["blood", "ANATOMY", 138, 143], ["amniotic fluid", "ANATOMY", 152, 166], ["death", "DISEASE", 98, 103], ["growth retardation", "DISEASE", 105, 123], ["fetuses", "ORGANISM", 21, 28], ["merconium", "SIMPLE_CHEMICAL", 128, 137], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["amniotic fluid", "ORGANISM_SUBSTANCE", 152, 166], ["gross pathology", "PROBLEM", 71, 86], ["death", "PROBLEM", 98, 103], ["growth retardation", "PROBLEM", 105, 123], ["merconium/blood stained amniotic fluid", "PROBLEM", 128, 166], ["several", "OBSERVATION_MODIFIER", 13, 20], ["fetuses", "OBSERVATION", 21, 28], ["gross", "OBSERVATION_MODIFIER", 71, 76], ["pathology", "OBSERVATION", 77, 86], ["blood", "ANATOMY", 138, 143], ["amniotic fluid", "OBSERVATION", 152, 166]]], ["There were also examples of productively infected fetuses that showed no evidence of gross pathology (see fetuses 1\u20132, 3\u201312, 4\u20139, 4\u201311, 4\u201313 in Fig. 1).", [["fetuses", "ANATOMY", 50, 57], ["fetuses", "ANATOMY", 106, 113], ["fetuses", "ORGANISM", 50, 57], ["productively infected fetuses", "PROBLEM", 28, 57], ["gross pathology", "PROBLEM", 85, 100], ["fetuses", "TEST", 106, 113], ["productively", "OBSERVATION_MODIFIER", 28, 40], ["infected", "OBSERVATION", 41, 49], ["no evidence of", "UNCERTAINTY", 70, 84], ["gross", "OBSERVATION_MODIFIER", 85, 90], ["pathology", "OBSERVATION", 91, 100]]], ["The mechanism for fetal pathology remains unclear, but the results suggest that the source pathology is likely result of the infection of tissues on the maternal side and damage to maternal tissues or production of maternal factors that affect the fetus.", [["fetal", "ANATOMY", 18, 23], ["tissues", "ANATOMY", 138, 145], ["tissues", "ANATOMY", 190, 197], ["fetus", "ANATOMY", 248, 253], ["infection", "DISEASE", 125, 134], ["fetal", "ANATOMICAL_SYSTEM", 18, 23], ["tissues", "TISSUE", 138, 145], ["maternal tissues", "TISSUE", 181, 197], ["fetus", "DEVELOPING_ANATOMICAL_STRUCTURE", 248, 253], ["maternal factors", "PROTEIN", 215, 231], ["fetal pathology", "PROBLEM", 18, 33], ["the source pathology", "PROBLEM", 80, 100], ["the infection of tissues on the maternal side", "PROBLEM", 121, 166], ["maternal tissues", "PROBLEM", 181, 197], ["maternal factors", "PROBLEM", 215, 231], ["likely result of", "UNCERTAINTY", 104, 120], ["infection", "OBSERVATION", 125, 134]]], ["In this study we did not observe lesions in the myometrium or placenta; however, Stockhofe-Zurwieden et al. (1995) reported PRRS virions budding from maternal vascular endothelial cells at the maternal-fetal interface.", [["lesions", "ANATOMY", 33, 40], ["myometrium", "ANATOMY", 48, 58], ["placenta", "ANATOMY", 62, 70], ["vascular endothelial cells", "ANATOMY", 159, 185], ["fetal", "ANATOMY", 202, 207], ["lesions", "PATHOLOGICAL_FORMATION", 33, 40], ["myometrium", "MULTI-TISSUE_STRUCTURE", 48, 58], ["placenta", "ORGAN", 62, 70], ["PRRS", "ORGANISM", 124, 128], ["vascular endothelial cells", "CELL", 159, 185], ["fetal interface", "MULTI-TISSUE_STRUCTURE", 202, 217], ["maternal vascular endothelial cells", "CELL_TYPE", 150, 185], ["PRRS", "SPECIES", 124, 128], ["this study", "TEST", 3, 13], ["lesions in the myometrium", "PROBLEM", 33, 58], ["PRRS virions budding", "PROBLEM", 124, 144], ["maternal vascular endothelial cells", "PROBLEM", 150, 185], ["lesions", "OBSERVATION", 33, 40], ["myometrium", "ANATOMY", 48, 58], ["placenta", "ANATOMY", 62, 70], ["vascular endothelial cells", "OBSERVATION", 159, 185], ["fetal interface", "OBSERVATION", 202, 217]]], ["Lager and Halbur (1996) reported damage to the myometrium during PRRSV infection.", [["myometrium", "ANATOMY", 47, 57], ["damage to the myometrium", "DISEASE", 33, 57], ["PRRSV infection", "DISEASE", 65, 80], ["myometrium", "MULTI-TISSUE_STRUCTURE", 47, 57], ["PRRSV", "ORGANISM", 65, 70], ["PRRSV", "SPECIES", 65, 70], ["PRRSV", "SPECIES", 65, 70], ["damage to the myometrium", "PROBLEM", 33, 57], ["PRRSV infection", "PROBLEM", 65, 80], ["myometrium", "ANATOMY", 47, 57], ["infection", "OBSERVATION", 71, 80]]], ["Virus-associated lesions in the myometrium are observed for horses infected with EAV (Coignoul and Cheville, 1984).", [["lesions", "ANATOMY", 17, 24], ["myometrium", "ANATOMY", 32, 42], ["Virus", "ORGANISM", 0, 5], ["lesions", "PATHOLOGICAL_FORMATION", 17, 24], ["myometrium", "MULTI-TISSUE_STRUCTURE", 32, 42], ["EAV", "SPECIES", 81, 84], ["Virus", "PROBLEM", 0, 5], ["associated lesions in the myometrium", "PROBLEM", 6, 42], ["lesions", "OBSERVATION", 17, 24], ["myometrium", "ANATOMY", 32, 42]]], ["The apparent discrepancy between pathology and infection helps to explain the stealthy nature of the PRRSV.", [["infection", "DISEASE", 47, 56], ["PRRSV", "DISEASE", 101, 106], ["PRRSV", "ORGANISM", 101, 106], ["PRRSV", "SPECIES", 101, 106], ["The apparent discrepancy between pathology", "PROBLEM", 0, 42], ["infection", "PROBLEM", 47, 56], ["the PRRSV", "PROBLEM", 97, 106], ["discrepancy", "OBSERVATION_MODIFIER", 13, 24], ["pathology", "OBSERVATION", 33, 42], ["infection", "OBSERVATION", 47, 56]]], ["A significant number of apparently healthy, but infected fetuses, are likely go on to become healthy growing pigs with the capacity to shed virus.DiscussionRNA viruses often exist as a population of closely related sequences, frequently referred to as a quasispecies.", [["fetuses", "ANATOMY", 57, 64], ["fetuses", "ORGANISM", 57, 64], ["pigs", "ORGANISM", 109, 113], ["pigs", "SPECIES", 109, 113], ["pigs", "SPECIES", 109, 113], ["infected fetuses", "PROBLEM", 48, 64], ["the capacity", "PROBLEM", 119, 131], ["DiscussionRNA viruses", "PROBLEM", 146, 167], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["apparently healthy", "OBSERVATION_MODIFIER", 24, 42], ["infected", "OBSERVATION_MODIFIER", 48, 56], ["fetuses", "OBSERVATION", 57, 64]]], ["The appearance or disappearance of individual gene sequences in the population over the course of infection is used as evidence for changes in fitness that result from selection.", [["infection", "DISEASE", 98, 107], ["individual gene sequences", "PROBLEM", 35, 60], ["infection", "PROBLEM", 98, 107], ["changes in fitness", "PROBLEM", 132, 150], ["disappearance", "OBSERVATION_MODIFIER", 18, 31], ["infection", "OBSERVATION", 98, 107]]], ["PRRSV variants with mutations in ORF5 typically appear during the serial passage of virus in culture and during infection of pigs (Rowland et al. 1999; Allende et al., 2000).", [["infection", "DISEASE", 112, 121], ["PRRSV", "ORGANISM", 0, 5], ["ORF5", "GENE_OR_GENE_PRODUCT", 33, 37], ["pigs", "ORGANISM", 125, 129], ["ORF5", "DNA", 33, 37], ["pigs", "SPECIES", 125, 129], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 125, 129], ["PRRSV variants", "PROBLEM", 0, 14], ["mutations in ORF5", "PROBLEM", 20, 37], ["virus in culture", "TEST", 84, 100]]], ["The significance of mutations in ORF5 as a source for increased fitness during infection is not completely understood; but is useful for following the fate of individual PRRSV subpopulations over the course of a long-term infection (Rowland et al., 1999).", [["infection", "DISEASE", 79, 88], ["infection", "DISEASE", 222, 231], ["ORF5", "GENE_OR_GENE_PRODUCT", 33, 37], ["PRRSV", "ORGANISM", 170, 175], ["ORF5", "PROTEIN", 33, 37], ["PRRSV", "SPECIES", 170, 175], ["mutations in ORF5", "PROBLEM", 20, 37], ["increased fitness during infection", "PROBLEM", 54, 88], ["individual PRRSV subpopulations", "PROBLEM", 159, 190], ["a long-term infection", "PROBLEM", 210, 231], ["infection", "OBSERVATION", 79, 88]]], ["In this study, one dam, no. 4, showed evidence of a mixed PRRSV infection as indicated by the presence of two different ORF5 sequences, which were distinguished from each other by a nucleotide substitution at position 77 in ORF5.", [["PRRSV infection", "DISEASE", 58, 73], ["nucleotide", "CHEMICAL", 182, 192], ["nucleotide", "CHEMICAL", 182, 192], ["PRRSV", "ORGANISM", 58, 63], ["ORF5", "GENE_OR_GENE_PRODUCT", 120, 124], ["ORF5", "GENE_OR_GENE_PRODUCT", 224, 228], ["ORF5 sequences", "DNA", 120, 134], ["position 77", "DNA", 209, 220], ["ORF5", "PROTEIN", 224, 228], ["PRRSV", "SPECIES", 58, 63], ["this study", "TEST", 3, 13], ["a mixed PRRSV infection", "PROBLEM", 50, 73], ["two different ORF5 sequences", "TEST", 106, 134], ["a nucleotide substitution at position", "TREATMENT", 180, 217], ["evidence of", "UNCERTAINTY", 38, 49], ["mixed", "OBSERVATION_MODIFIER", 52, 57], ["PRRSV infection", "OBSERVATION", 58, 73]]], ["The C to T change was observed in approximately 60% of the cloned plasmid products obtained from dam no. 4 (see Table 2).", [["plasmid", "ANATOMY", 66, 73], ["cloned plasmid products", "PROTEIN", 59, 82], ["The C to T change", "PROBLEM", 0, 17], ["the cloned plasmid products", "TREATMENT", 55, 82]]], ["However, the same frequency was not transferred to the individual fetuses, which included two fetuses that possessed only viruses with the T-77 mutation and a single fetus with a virus population dominated by C at position 77.", [["fetuses", "ANATOMY", 66, 73], ["fetuses", "ANATOMY", 94, 101], ["fetus", "ANATOMY", 166, 171], ["fetuses", "ORGANISM", 66, 73], ["fetuses", "ORGANISM", 94, 101], ["T-77", "GENE_OR_GENE_PRODUCT", 139, 143], ["fetus", "ORGAN", 166, 171], ["T-77", "SPECIES", 139, 143], ["the T", "TEST", 135, 140], ["a single fetus", "PROBLEM", 157, 171], ["a virus population", "PROBLEM", 177, 195]]], ["These results suggest that fetal infection can alter the selection of PRRSV variants and may represent a source of PRRSV genetic diversity.DiscussionTo identify the targets of virus replication in the fetus, a variety of tissues were assessed for the presence of virus and virus-infected cells.", [["fetal", "ANATOMY", 27, 32], ["fetus", "ANATOMY", 201, 206], ["tissues", "ANATOMY", 221, 228], ["cells", "ANATOMY", 288, 293], ["fetal infection", "DISEASE", 27, 42], ["fetal", "ANATOMICAL_SYSTEM", 27, 32], ["PRRSV", "ORGANISM", 70, 75], ["PRRSV", "ORGANISM", 115, 120], ["fetus", "ORGANISM", 201, 206], ["tissues", "TISSUE", 221, 228], ["cells", "CELL", 288, 293], ["virus-infected cells", "CELL_TYPE", 273, 293], ["PRRSV", "SPECIES", 70, 75], ["PRRSV", "SPECIES", 115, 120], ["fetal infection", "PROBLEM", 27, 42], ["PRRSV variants", "PROBLEM", 70, 84], ["PRRSV genetic diversity", "PROBLEM", 115, 138], ["virus replication", "TREATMENT", 176, 193], ["virus", "PROBLEM", 263, 268], ["virus", "PROBLEM", 273, 278], ["infected cells", "PROBLEM", 279, 293], ["infection", "OBSERVATION", 33, 42], ["PRRSV variants", "OBSERVATION", 70, 84], ["may represent", "UNCERTAINTY", 89, 102], ["virus", "OBSERVATION", 176, 181], ["fetus", "ANATOMY", 201, 206], ["infected cells", "OBSERVATION", 279, 293]]], ["VI, as opposed to more sensitive approaches, such as PCR, was selected as the means for measuring virus, because the relative insensitivity of VI avoids the possibility of false positive PCR results that might result from small amounts of contaminating maternal material.", [["VI", "GENE_OR_GENE_PRODUCT", 0, 2], ["PCR", "TEST", 53, 56], ["measuring virus", "PROBLEM", 88, 103], ["false positive PCR results", "PROBLEM", 172, 198], ["small amounts of contaminating maternal material", "PROBLEM", 222, 270], ["small", "OBSERVATION_MODIFIER", 222, 227], ["amounts", "OBSERVATION_MODIFIER", 228, 235]]], ["Within the group of selected tissues, virus could be isolated from all tissues.", [["tissues", "ANATOMY", 29, 36], ["tissues", "ANATOMY", 71, 78], ["tissues", "TISSUE", 29, 36], ["tissues", "TISSUE", 71, 78], ["virus", "PROBLEM", 38, 43], ["selected tissues", "ANATOMY", 20, 36], ["virus", "OBSERVATION", 38, 43]]], ["However, the most consistent source and largest quantity of virus were obtained from the thymus.", [["thymus", "ANATOMY", 89, 95], ["thymus", "ORGAN", 89, 95], ["largest quantity of virus", "PROBLEM", 40, 65], ["largest", "OBSERVATION_MODIFIER", 40, 47], ["virus", "OBSERVATION", 60, 65], ["thymus", "ANATOMY", 89, 95]]], ["Collectively, these data identify the thymus as a primary site of virus replication in the PRRSV-infected fetus and confirm an earlier observation for PRRSV by Benson et al. (2002).", [["thymus", "ANATOMY", 38, 44], ["fetus", "ANATOMY", 106, 111], ["thymus", "ORGAN", 38, 44], ["PRRSV", "ORGANISM", 91, 96], ["fetus", "ORGANISM", 106, 111], ["PRRSV", "ORGANISM", 151, 156], ["PRRSV", "SPECIES", 91, 96], ["PRRSV", "SPECIES", 91, 96], ["PRRSV", "SPECIES", 151, 156], ["the thymus", "PROBLEM", 34, 44], ["virus replication", "PROBLEM", 66, 83], ["an earlier observation", "TEST", 124, 146], ["PRRSV", "PROBLEM", 151, 156], ["thymus", "ANATOMY", 38, 44], ["virus", "OBSERVATION", 66, 71]]], ["The specific cell population in the thymus targeted PRRSV replication remains unknown.DiscussionThe natural predisposition of maternal immunity towards Th2-like responses aids in protecting the fetus by blocking cell-mediated Th1-related allorejection responses (Arck et al., 1999, Entrican, 2002, Raghupathy, 2001; recently reviewed in Challis et al., 2009).", [["cell", "ANATOMY", 13, 17], ["thymus", "ANATOMY", 36, 42], ["fetus", "ANATOMY", 194, 199], ["cell", "ANATOMY", 212, 216], ["cell", "CELL", 13, 17], ["thymus", "ORGAN", 36, 42], ["PRRSV", "ORGANISM", 52, 57], ["fetus", "ORGAN", 194, 199], ["cell", "CELL", 212, 216], ["PRRSV", "SPECIES", 52, 57], ["The specific cell population", "TREATMENT", 0, 28], ["the thymus targeted PRRSV replication", "TREATMENT", 32, 69], ["specific cell population", "OBSERVATION", 4, 28], ["thymus", "ANATOMY", 36, 42], ["PRRSV replication", "OBSERVATION", 52, 69]]], ["The negative influence of Th1 cytokines on fetal development can be demonstrated experimentally in mice, which show that a single injection of IL-2 or IFN-\u03b3 into certain strains induces fetal resorption (Lala, 1990, Chaouat et al., 1990).", [["fetal", "ANATOMY", 43, 48], ["fetal", "ANATOMY", 186, 191], ["IFN-\u03b3", "CHEMICAL", 151, 156], ["fetal resorption", "DISEASE", 186, 202], ["Th1", "GENE_OR_GENE_PRODUCT", 26, 29], ["fetal", "ANATOMICAL_SYSTEM", 43, 48], ["mice", "ORGANISM", 99, 103], ["IL-2", "GENE_OR_GENE_PRODUCT", 143, 147], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 151, 156], ["fetal", "ORGAN", 186, 191], ["Th1 cytokines", "PROTEIN", 26, 39], ["IL-2", "PROTEIN", 143, 147], ["IFN-\u03b3", "PROTEIN", 151, 156], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["Th1 cytokines", "PROBLEM", 26, 39], ["a single injection of IL", "TREATMENT", 121, 145], ["IFN", "TREATMENT", 151, 154], ["fetal resorption", "PROBLEM", 186, 202], ["negative", "OBSERVATION", 4, 12], ["resorption", "OBSERVATION_MODIFIER", 192, 202]]], ["TNF-\u03b1, when infected into mice is abortifacient (Clark et al., 2004).", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 5], ["mice", "ORGANISM", 26, 30], ["TNF", "PROTEIN", 0, 3], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["TNF", "TEST", 0, 3]]], ["Th1 cytokines can also have important long-term impacts.", [["Th1 cytokines", "PROTEIN", 0, 13], ["long-term impacts", "OBSERVATION_MODIFIER", 38, 55]]], ["For example, newborn mice that survive maternal infection with influenza virus exhibit behavior similar to hyperanxiety and autism.", [["infection", "DISEASE", 48, 57], ["influenza virus", "DISEASE", 63, 78], ["hyperanxiety", "DISEASE", 107, 119], ["autism", "DISEASE", 124, 130], ["mice", "ORGANISM", 21, 25], ["influenza virus", "ORGANISM", 63, 78], ["mice", "SPECIES", 21, 25], ["influenza virus", "SPECIES", 63, 78], ["mice", "SPECIES", 21, 25], ["influenza virus", "SPECIES", 63, 78], ["maternal infection", "PROBLEM", 39, 57], ["influenza virus", "PROBLEM", 63, 78], ["autism", "PROBLEM", 124, 130], ["infection", "OBSERVATION", 48, 57]]], ["The behavioral changes are a consequence of the altered distribution of dopamine and glutamine receptors during fetal brain development.", [["fetal brain", "ANATOMY", 112, 123], ["dopamine", "CHEMICAL", 72, 80], ["glutamine", "CHEMICAL", 85, 94], ["dopamine", "CHEMICAL", 72, 80], ["glutamine", "CHEMICAL", 85, 94], ["dopamine", "SIMPLE_CHEMICAL", 72, 80], ["glutamine receptors", "GENE_OR_GENE_PRODUCT", 85, 104], ["fetal brain", "MULTI-TISSUE_STRUCTURE", 112, 123], ["glutamine receptors", "PROTEIN", 85, 104], ["The behavioral changes", "PROBLEM", 0, 22], ["dopamine", "TREATMENT", 72, 80], ["glutamine receptors", "TREATMENT", 85, 104], ["fetal brain development", "PROBLEM", 112, 135], ["altered", "OBSERVATION_MODIFIER", 48, 55], ["distribution", "OBSERVATION_MODIFIER", 56, 68]]], ["The effect of influenza virus infection on the fetal brain can be mimicked by the administration of poly I:C, an inducer of IFN (Shi et al., 2003).", [["fetal brain", "ANATOMY", 47, 58], ["influenza virus infection", "DISEASE", 14, 39], ["poly I:C", "CHEMICAL", 100, 108], ["poly I:C", "CHEMICAL", 100, 108], ["influenza virus", "ORGANISM", 14, 29], ["fetal brain", "ORGAN", 47, 58], ["poly I:C", "SIMPLE_CHEMICAL", 100, 108], ["IFN", "GENE_OR_GENE_PRODUCT", 124, 127], ["IFN", "PROTEIN", 124, 127], ["influenza virus", "SPECIES", 14, 29], ["influenza virus", "SPECIES", 14, 29], ["influenza virus infection", "PROBLEM", 14, 39], ["influenza virus infection", "OBSERVATION", 14, 39], ["brain", "ANATOMY", 53, 58]]], ["Furthermore, the addition of IFN-\u03b3 to hippocampal neuron cultures alters the distribution of glutamate receptors, sufficient to affect synaptic activity between neurons (Vikman et al., 2001).", [["hippocampal neuron cultures", "ANATOMY", 38, 65], ["synaptic", "ANATOMY", 135, 143], ["neurons", "ANATOMY", 161, 168], ["IFN-\u03b3", "CHEMICAL", 29, 34], ["glutamate", "CHEMICAL", 93, 102], ["glutamate", "CHEMICAL", 93, 102], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 29, 34], ["hippocampal neuron cultures", "CELL", 38, 65], ["glutamate receptors", "GENE_OR_GENE_PRODUCT", 93, 112], ["neurons", "CELL", 161, 168], ["IFN", "PROTEIN", 29, 32], ["\u03b3", "PROTEIN", 33, 34], ["hippocampal neuron cultures", "CELL_LINE", 38, 65], ["glutamate receptors", "PROTEIN", 93, 112], ["IFN", "TREATMENT", 29, 32], ["hippocampal neuron cultures", "TEST", 38, 65], ["glutamate receptors", "TREATMENT", 93, 112]]], ["Virus infections during pregnancy present an interesting paradox: those cytokines that protect the fetus from viral infection, tend to inhibit fetal development or potentiate rejection of the fetus; while those cytokines that maintain and promote fetal development are associated with the inhibition of antiviral immune responses.", [["fetus", "ANATOMY", 99, 104], ["fetal", "ANATOMY", 143, 148], ["fetus", "ANATOMY", 192, 197], ["fetal", "ANATOMY", 247, 252], ["Virus infections", "DISEASE", 0, 16], ["viral infection", "DISEASE", 110, 125], ["Virus", "ORGANISM", 0, 5], ["fetus", "ORGAN", 99, 104], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 143, 148], ["fetus", "ORGAN", 192, 197], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 247, 252], ["cytokines", "PROTEIN", 72, 81], ["cytokines", "PROTEIN", 211, 220], ["Virus infections", "PROBLEM", 0, 16], ["those cytokines", "TREATMENT", 66, 81], ["the fetus", "PROBLEM", 95, 104], ["viral infection", "PROBLEM", 110, 125], ["fetal development", "PROBLEM", 143, 160], ["rejection of the fetus", "PROBLEM", 175, 197], ["antiviral immune responses", "TREATMENT", 303, 329], ["infections", "OBSERVATION", 6, 16], ["viral infection", "OBSERVATION", 110, 125], ["rejection", "OBSERVATION", 175, 184]]], ["Because of the potential negative impact of Th1 cytokines on fetal outcome, there is a natural predisposition for the fetus to block the induction of Th1-associated cytokines.", [["fetal", "ANATOMY", 61, 66], ["fetus", "ANATOMY", 118, 123], ["Th1", "GENE_OR_GENE_PRODUCT", 44, 47], ["fetal", "ANATOMICAL_SYSTEM", 61, 66], ["fetus", "ORGANISM", 118, 123], ["Th1", "GENE_OR_GENE_PRODUCT", 150, 153], ["Th1 cytokines", "PROTEIN", 44, 57], ["Th1-associated cytokines", "PROTEIN", 150, 174], ["the fetus", "PROBLEM", 114, 123], ["negative", "OBSERVATION_MODIFIER", 25, 33], ["impact", "OBSERVATION_MODIFIER", 34, 40], ["Th1 cytokines", "OBSERVATION", 44, 57]]], ["For example, the IFN-\u03b3 response in the developing fetus can be blocked by a combination of factors, including (1) defects in the capacity of fetal dendritic cells to express MHC class II and synthesize IL-12, (2) hypermethylation of the IFN-\u03b3 gene in fetal T cells, (3) the absence of target macrophages, and (4) the presence of an immune environment dominated by Th2/regulatory cytokines (Goriely et al., 2001, Langrish et al., 2002, Melvin et al., 1995, Marodi et al., 2001, Murphy et al., 2009, Prescott et al., 1998, White et al., 2002,).", [["fetus", "ANATOMY", 50, 55], ["fetal dendritic cells", "ANATOMY", 141, 162], ["fetal T cells", "ANATOMY", 251, 264], ["macrophages", "ANATOMY", 292, 303], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 17, 22], ["fetus", "ORGAN", 50, 55], ["fetal dendritic cells", "CELL", 141, 162], ["MHC class II", "GENE_OR_GENE_PRODUCT", 174, 186], ["IL-12", "GENE_OR_GENE_PRODUCT", 202, 207], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 237, 242], ["fetal T cells", "CELL", 251, 264], ["macrophages", "CELL", 292, 303], ["IFN", "PROTEIN", 17, 20], ["\u03b3", "PROTEIN", 21, 22], ["fetal dendritic cells", "CELL_TYPE", 141, 162], ["MHC class II", "PROTEIN", 174, 186], ["IL-12", "PROTEIN", 202, 207], ["IFN-\u03b3 gene", "DNA", 237, 247], ["fetal T cells", "CELL_TYPE", 251, 264], ["macrophages", "CELL_TYPE", 292, 303], ["Th2/regulatory cytokines", "PROTEIN", 364, 388], ["(1) defects", "PROBLEM", 110, 121], ["fetal dendritic cells", "PROBLEM", 141, 162], ["synthesize IL", "TEST", 191, 204], ["the IFN", "TEST", 233, 240], ["\u03b3 gene in fetal T cells", "PROBLEM", 241, 264], ["target macrophages", "PROBLEM", 285, 303], ["an immune environment", "PROBLEM", 329, 350], ["defects", "OBSERVATION", 114, 121], ["capacity", "OBSERVATION_MODIFIER", 129, 137], ["fetal", "ANATOMY", 141, 146], ["dendritic cells", "OBSERVATION", 147, 162], ["immune environment", "OBSERVATION", 332, 350]]], ["With this in mind, there are examples of viruses, such as Epstein\u2013Barr virus (EBV), which are capable of stimulating antigen-specific IFN-\u03b3 responses in human umbilical cord blood lymphocytes (Ito et al., 1998, Wilson and Morgan, 2002).", [["umbilical cord blood lymphocytes", "ANATOMY", 159, 191], ["Epstein\u2013Barr virus", "ORGANISM", 58, 76], ["EBV", "ORGANISM", 78, 81], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 134, 139], ["human", "ORGANISM", 153, 158], ["umbilical cord blood lymphocytes", "CELL", 159, 191], ["IFN", "PROTEIN", 134, 137], ["\u03b3", "PROTEIN", 138, 139], ["human umbilical cord blood lymphocytes", "CELL_TYPE", 153, 191], ["Barr virus", "SPECIES", 66, 76], ["human", "SPECIES", 153, 158], ["Epstein\u2013Barr virus", "SPECIES", 58, 76], ["EBV", "SPECIES", 78, 81], ["human", "SPECIES", 153, 158], ["viruses", "PROBLEM", 41, 48], ["Epstein\u2013Barr virus", "PROBLEM", 58, 76], ["stimulating antigen", "TEST", 105, 124], ["IFN", "TEST", 134, 137], ["viruses", "OBSERVATION", 41, 48], ["Barr virus", "OBSERVATION", 66, 76], ["umbilical cord", "ANATOMY", 159, 173]]], ["These and other data provide a description of the fetus as capable of initiating a robust antiviral Th1 immune response (Chaouat et al., 2002, Chipeta et al., 2000, Murphy et al., 2009).", [["fetus", "ANATOMY", 50, 55], ["fetus", "ORGANISM", 50, 55]]], ["In this study IFN-\u03b3 and TNF-\u03b1 mRNAs were identified in tissues from infected fetuses.", [["tissues", "ANATOMY", 55, 62], ["fetuses", "ANATOMY", 77, 84], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 14, 19], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 24, 29], ["tissues", "TISSUE", 55, 62], ["fetuses", "ORGANISM", 77, 84], ["IFN-\u03b3 and TNF-\u03b1 mRNAs", "RNA", 14, 35], ["this study", "TEST", 3, 13], ["IFN", "TEST", 14, 17], ["TNF", "TEST", 24, 27], ["mRNAs", "PROBLEM", 30, 35], ["infected fetuses", "PROBLEM", 68, 84], ["infected fetuses", "OBSERVATION", 68, 84]]], ["RNA message was not identified in tissues of fetuses from mock-infected dams or non-infected fetuses from infected dams.", [["tissues", "ANATOMY", 34, 41], ["fetuses", "ANATOMY", 45, 52], ["fetuses", "ANATOMY", 93, 100], ["tissues", "TISSUE", 34, 41], ["fetuses", "ORGANISM", 45, 52], ["dams", "ORGANISM", 72, 76], ["fetuses", "ORGAN", 93, 100], ["dams", "ORGANISM", 115, 119], ["infected dams", "PROBLEM", 63, 76], ["non-infected fetuses", "PROBLEM", 80, 100], ["non-infected fetuses", "OBSERVATION", 80, 100], ["infected dams", "OBSERVATION", 106, 119]]], ["This indicates that altered gene expression is the direct result of fetal infection.", [["fetal", "ANATOMY", 68, 73], ["fetal infection", "DISEASE", 68, 83], ["fetal", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 73], ["altered gene expression", "PROBLEM", 20, 43], ["fetal infection", "PROBLEM", 68, 83], ["altered", "OBSERVATION_MODIFIER", 20, 27], ["gene expression", "OBSERVATION", 28, 43], ["fetal", "ANATOMY", 68, 73], ["infection", "OBSERVATION", 74, 83]]], ["Up-regulated expression was confirmed by the presence of detectable levels of IFN-\u03b3 and TNF-\u03b1 proteins in serum.", [["serum", "ANATOMY", 106, 111], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 78, 83], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 88, 93], ["serum", "ORGANISM_SUBSTANCE", 106, 111], ["IFN-\u03b3", "PROTEIN", 78, 83], ["TNF-\u03b1 proteins", "PROTEIN", 88, 102], ["IFN", "TEST", 78, 81], ["TNF", "TEST", 88, 91], ["serum", "TEST", 106, 111]]], ["Furthermore, the results indicate that INF-\u03b1 and IFN-\u03b3 cytokines response are compartmentalized within the fetus and do not extend to other compartments, such as amniotic fluid or placenta, thus lessening the probability of allorejection by the dam.", [["fetus", "ANATOMY", 107, 112], ["compartments", "ANATOMY", 140, 152], ["amniotic fluid", "ANATOMY", 162, 176], ["placenta", "ANATOMY", 180, 188], ["allorejection", "DISEASE", 224, 237], ["INF-\u03b1", "GENE_OR_GENE_PRODUCT", 39, 44], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 49, 54], ["fetus", "ORGAN", 107, 112], ["amniotic fluid", "ORGANISM_SUBSTANCE", 162, 176], ["placenta", "ORGAN", 180, 188], ["INF", "PROTEIN", 39, 42], ["IFN", "PROTEIN", 49, 52], ["cytokines", "PROTEIN", 55, 64], ["INF-\u03b1 and IFN-\u03b3 cytokines response", "TEST", 39, 73], ["amniotic fluid or placenta", "PROBLEM", 162, 188], ["fetus", "ANATOMY", 107, 112], ["amniotic fluid", "OBSERVATION", 162, 176], ["placenta", "ANATOMY", 180, 188]]], ["From these data, it is apparent that the fetus is capable of initiating a Th1-like response; however, the capacity of IFN-\u03b3 and TNF-\u03b1 to control PRRSV infection in the fetus is not known.", [["fetus", "ANATOMY", 41, 46], ["fetus", "ANATOMY", 168, 173], ["PRRSV infection", "DISEASE", 145, 160], ["fetus", "ORGANISM", 41, 46], ["Th1", "GENE_OR_GENE_PRODUCT", 74, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 118, 123], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 128, 133], ["PRRSV", "ORGANISM", 145, 150], ["fetus", "ORGAN", 168, 173], ["IFN", "PROTEIN", 118, 121], ["TNF", "PROTEIN", 128, 131], ["\u03b1", "PROTEIN", 132, 133], ["PRRSV", "SPECIES", 145, 150], ["PRRSV", "SPECIES", 145, 150], ["IFN", "TEST", 118, 121], ["TNF", "TEST", 128, 131], ["PRRSV infection", "PROBLEM", 145, 160], ["PRRSV infection", "OBSERVATION", 145, 160], ["not known", "UNCERTAINTY", 177, 186]]], ["Additional evidence for induction of virus-specific immunity was found in the development of germinal centers containing activated (CDw75+) B cells and seroconversion in at least one fetus.DiscussionPro-inflammatory cytokines, such as TNF-\u03b1 and IFN-\u03b3 can contribute to pulmonary distress through the activation of alveolar macrophages and other cell populations.", [["germinal centers", "ANATOMY", 93, 109], ["B cells", "ANATOMY", 140, 147], ["fetus", "ANATOMY", 183, 188], ["pulmonary", "ANATOMY", 269, 278], ["alveolar macrophages", "ANATOMY", 314, 334], ["cell", "ANATOMY", 345, 349], ["pulmonary distress", "DISEASE", 269, 287], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 93, 109], ["B cells", "CELL", 140, 147], ["fetus", "ORGANISM", 183, 188], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 235, 240], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 245, 250], ["pulmonary", "ORGAN", 269, 278], ["alveolar macrophages", "CELL", 314, 334], ["cell populations", "CELL", 345, 361], ["B cells", "CELL_TYPE", 140, 147], ["Pro-inflammatory cytokines", "PROTEIN", 199, 225], ["TNF", "PROTEIN", 235, 238], ["IFN", "PROTEIN", 245, 248], ["alveolar macrophages", "CELL_TYPE", 314, 334], ["induction of virus", "PROBLEM", 24, 42], ["B cells", "PROBLEM", 140, 147], ["seroconversion", "PROBLEM", 152, 166], ["Pro-inflammatory cytokines", "TEST", 199, 225], ["TNF", "TEST", 235, 238], ["IFN", "TREATMENT", 245, 248], ["pulmonary distress", "PROBLEM", 269, 287], ["alveolar macrophages", "PROBLEM", 314, 334], ["other cell populations", "PROBLEM", 339, 361], ["evidence for", "UNCERTAINTY", 11, 23], ["germinal centers", "OBSERVATION", 93, 109], ["cells", "OBSERVATION", 142, 147], ["seroconversion", "OBSERVATION", 152, 166], ["pulmonary", "ANATOMY", 269, 278], ["distress", "OBSERVATION", 279, 287], ["alveolar macrophages", "OBSERVATION", 314, 334], ["cell populations", "OBSERVATION", 345, 361]]], ["The increased quantities of IFN-\u03b3 and TNF-\u03b1 found in the lungs of PRRSV-infected fetuses may not be sufficient to cause pulmonary damage to the fetal lung, primarily because fetal macrophages have a reduced capacity to respond to inflammatory stimuli.", [["lungs", "ANATOMY", 57, 62], ["fetuses", "ANATOMY", 81, 88], ["pulmonary", "ANATOMY", 120, 129], ["fetal lung", "ANATOMY", 144, 154], ["fetal macrophages", "ANATOMY", 174, 191], ["PRRSV-infected", "DISEASE", 66, 80], ["pulmonary damage", "DISEASE", 120, 136], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 28, 33], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 38, 43], ["lungs", "ORGAN", 57, 62], ["PRRSV", "ORGANISM", 66, 71], ["fetuses", "ORGANISM", 81, 88], ["pulmonary", "ORGAN", 120, 129], ["fetal lung", "ORGAN", 144, 154], ["fetal macrophages", "CELL", 174, 191], ["IFN", "PROTEIN", 28, 31], ["TNF-\u03b1", "PROTEIN", 38, 43], ["fetal macrophages", "CELL_TYPE", 174, 191], ["PRRSV", "SPECIES", 66, 71], ["The increased quantities of IFN", "PROBLEM", 0, 31], ["TNF", "TEST", 38, 41], ["PRRSV", "PROBLEM", 66, 71], ["infected fetuses", "PROBLEM", 72, 88], ["pulmonary damage to the fetal lung", "PROBLEM", 120, 154], ["fetal macrophages", "PROBLEM", 174, 191], ["a reduced capacity", "PROBLEM", 197, 215], ["inflammatory stimuli", "TEST", 230, 250], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["quantities", "OBSERVATION_MODIFIER", 14, 24], ["lungs", "ANATOMY", 57, 62], ["PRRSV", "OBSERVATION", 66, 71], ["infected fetuses", "OBSERVATION", 72, 88], ["may not be", "UNCERTAINTY", 89, 99], ["pulmonary", "ANATOMY", 120, 129], ["damage", "OBSERVATION", 130, 136], ["fetal", "ANATOMY_MODIFIER", 144, 149], ["lung", "ANATOMY", 150, 154], ["macrophages", "OBSERVATION", 180, 191], ["reduced", "OBSERVATION_MODIFIER", 199, 206], ["capacity", "OBSERVATION_MODIFIER", 207, 215], ["inflammatory stimuli", "OBSERVATION", 230, 250]]], ["In addition, IL-10, up-regulated in response to PRRSV infection, is a potent antagonist of IFN-\u03b3 and TNF-\u03b1 activation of macrophages (Burchett et al., 1992, Marodi et al., 2001, Johnsen et al., 2002, Thanawongnuwech et al., 2003).", [["macrophages", "ANATOMY", 121, 132], ["PRRSV infection", "DISEASE", 48, 63], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["PRRSV", "ORGANISM", 48, 53], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 91, 96], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 101, 106], ["macrophages", "CELL", 121, 132], ["IL-10", "PROTEIN", 13, 18], ["IFN", "PROTEIN", 91, 94], ["TNF", "PROTEIN", 101, 104], ["macrophages", "CELL_TYPE", 121, 132], ["PRRSV", "SPECIES", 48, 53], ["IL", "TEST", 13, 15], ["PRRSV infection", "PROBLEM", 48, 63], ["IFN", "TEST", 91, 94], ["TNF", "TEST", 101, 104], ["PRRSV infection", "OBSERVATION", 48, 63]]], ["However, within days after birth, adult macrophages, including mature alveolar and intravascular macrophages emerge into an environment already enriched in IFN-\u03b3 and TNF-\u03b1.", [["macrophages", "ANATOMY", 40, 51], ["alveolar", "ANATOMY", 70, 78], ["intravascular macrophages", "ANATOMY", 83, 108], ["macrophages", "CELL", 40, 51], ["alveolar", "CELL", 70, 78], ["intravascular macrophages", "CELL", 83, 108], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 156, 161], ["TNF-\u03b1.", "GENE_OR_GENE_PRODUCT", 166, 172], ["adult macrophages", "CELL_TYPE", 34, 51], ["mature alveolar and intravascular macrophages", "CELL_TYPE", 63, 108], ["IFN", "PROTEIN", 156, 159], ["TNF", "PROTEIN", 166, 169], ["adult macrophages", "PROBLEM", 34, 51], ["mature alveolar and intravascular macrophages", "PROBLEM", 63, 108], ["TNF", "TEST", 166, 169], ["macrophages", "OBSERVATION", 40, 51], ["alveolar", "ANATOMY_MODIFIER", 70, 78], ["intravascular macrophages", "OBSERVATION", 83, 108]]], ["The outcome is the rapid recruitment, activation, and cytopathic killing of large numbers of virus-permissive macrophages (Choi and Chae, 2002).", [["macrophages", "ANATOMY", 110, 121], ["macrophages", "CELL", 110, 121], ["virus-permissive macrophages", "CELL_TYPE", 93, 121], ["the rapid recruitment", "PROBLEM", 15, 36], ["virus", "PROBLEM", 93, 98], ["rapid", "OBSERVATION_MODIFIER", 19, 24], ["recruitment", "OBSERVATION", 25, 36], ["cytopathic", "OBSERVATION_MODIFIER", 54, 64], ["large", "OBSERVATION_MODIFIER", 76, 81], ["permissive macrophages", "OBSERVATION", 99, 121]]], ["This scenario as a cause of severe interstitial pnuemonia in the PRRSV-infected newborn requires further investigation, but has obvious implications in the etiology of postnatal pulmonary complications following virus infections of the fetus.", [["interstitial pnuemonia", "ANATOMY", 35, 57], ["pulmonary", "ANATOMY", 178, 187], ["fetus", "ANATOMY", 236, 241], ["interstitial pnuemonia", "DISEASE", 35, 57], ["PRRSV-infected", "DISEASE", 65, 79], ["pulmonary complications", "DISEASE", 178, 201], ["infections", "DISEASE", 218, 228], ["interstitial pnuemonia", "PATHOLOGICAL_FORMATION", 35, 57], ["PRRSV", "ORGANISM", 65, 70], ["pulmonary", "ORGAN", 178, 187], ["fetus", "ORGAN", 236, 241], ["PRRSV", "SPECIES", 65, 70], ["severe interstitial pnuemonia", "PROBLEM", 28, 57], ["the PRRSV", "PROBLEM", 61, 70], ["further investigation", "TEST", 97, 118], ["postnatal pulmonary complications", "PROBLEM", 168, 201], ["virus infections of the fetus", "PROBLEM", 212, 241], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["interstitial", "OBSERVATION_MODIFIER", 35, 47], ["pnuemonia", "OBSERVATION", 48, 57], ["infected", "OBSERVATION_MODIFIER", 71, 79], ["pulmonary", "ANATOMY", 178, 187], ["complications", "OBSERVATION", 188, 201], ["fetus", "ANATOMY", 236, 241]]]], "ddbef93b27ebbc2c6d9a68ab35c06d815ea5a802": [["This study examines the effects of chloroquine on hair cells using two common 31 experimental models: the zebrafish lateral line and neonatal mouse cochlear cultures.", [["hair cells", "ANATOMY", 50, 60], ["lateral line", "ANATOMY", 116, 128], ["cochlear cultures", "ANATOMY", 148, 165], ["chloroquine", "CHEMICAL", 35, 46], ["chloroquine", "CHEMICAL", 35, 46], ["chloroquine", "SIMPLE_CHEMICAL", 35, 46], ["hair cells", "CELL", 50, 60], ["zebrafish", "ORGANISM", 106, 115], ["lateral line", "CELL", 116, 128], ["mouse", "ORGANISM", 142, 147], ["cochlear cultures", "CELL", 148, 165], ["hair cells", "CELL_TYPE", 50, 60], ["zebrafish lateral line", "CELL_LINE", 106, 128], ["neonatal mouse cochlear cultures", "CELL_LINE", 133, 165], ["zebrafish", "SPECIES", 106, 115], ["mouse", "SPECIES", 142, 147], ["mouse", "SPECIES", 142, 147], ["This study", "TEST", 0, 10], ["chloroquine on hair cells", "TREATMENT", 35, 60], ["the zebrafish lateral line", "TREATMENT", 102, 128], ["neonatal mouse cochlear cultures", "TREATMENT", 133, 165]]]], "4313564fec59facf82281a6de7eb1b690603daa9": [["BackgroundNeurally adjusted ventilatory assist (NAVA) is a new method of assisted ventilation that can be used for children regardless of weight and age.", [["children", "ORGANISM", 115, 123], ["children", "SPECIES", 115, 123], ["a new method of assisted ventilation", "TREATMENT", 57, 93]]], ["This ventilation mode is controlled by diaphragmatic electrical signals through a gastric tube with specific electrodes on its surface.", [["diaphragmatic", "ANATOMY", 39, 52], ["gastric tube", "ANATOMY", 82, 94], ["surface", "ANATOMY", 127, 134], ["gastric tube", "TISSUE", 82, 94], ["surface", "CELLULAR_COMPONENT", 127, 134], ["This ventilation mode", "TREATMENT", 0, 21], ["a gastric tube", "TREATMENT", 80, 94], ["diaphragmatic", "ANATOMY", 39, 52], ["gastric", "ANATOMY", 82, 89], ["tube", "OBSERVATION", 90, 94], ["electrodes", "OBSERVATION_MODIFIER", 109, 119], ["surface", "OBSERVATION_MODIFIER", 127, 134]]], ["The collected electrical signals allow synchronization of ventilation to spontaneous breathing efforts of a child, as well as providing pressure assistance proportional to the electrical signal and thus to the output of the child's respiratory centers.BackgroundNAVA has mainly been studied in children who underwent cardiac surgery [1] [2] [3] during the period of weaning from a respirator.", [["cardiac", "ANATOMY", 317, 324], ["BackgroundNAVA", "CHEMICAL", 252, 266], ["children", "ORGANISM", 294, 302], ["children", "SPECIES", 294, 302], ["synchronization of ventilation", "TREATMENT", 39, 69], ["pressure assistance", "TREATMENT", 136, 155], ["the electrical signal", "TEST", 172, 193], ["cardiac surgery", "TREATMENT", 317, 332], ["a respirator", "TREATMENT", 379, 391], ["cardiac", "ANATOMY", 317, 324], ["surgery", "OBSERVATION", 325, 332]]], ["We report here a series of 3 children with severe respiratory distress due to respiratory syncytial virus (RSV) bronchiolitis for whom NAVA facilitated respiratory support.Case PresentationOur unit is a 12-bed tertiary care university hospital pediatric intensive care unit.", [["respiratory", "ANATOMY", 50, 61], ["respiratory", "ANATOMY", 152, 163], ["respiratory distress", "DISEASE", 50, 70], ["respiratory syncytial virus (RSV) bronchiolitis", "DISEASE", 78, 125], ["NAVA", "CHEMICAL", 135, 139], ["children", "ORGANISM", 29, 37], ["respiratory syncytial virus", "ORGANISM", 78, 105], ["RSV", "ORGANISM", 107, 110], ["children", "SPECIES", 29, 37], ["respiratory syncytial virus", "SPECIES", 78, 105], ["respiratory syncytial virus", "SPECIES", 78, 105], ["RSV", "SPECIES", 107, 110], ["severe respiratory distress", "PROBLEM", 43, 70], ["respiratory syncytial virus", "PROBLEM", 78, 105], ["RSV) bronchiolitis", "PROBLEM", 107, 125], ["NAVA", "TREATMENT", 135, 139], ["respiratory support", "TREATMENT", 152, 171], ["respiratory", "ANATOMY", 50, 61], ["distress", "OBSERVATION", 62, 70], ["respiratory", "ANATOMY", 78, 89], ["syncytial virus", "OBSERVATION", 90, 105], ["bronchiolitis", "OBSERVATION", 112, 125], ["respiratory support", "OBSERVATION", 152, 171]]], ["NAVA has been used in our unit for weaning children from a respirator who were operated * Correspondence: jeanmichel.liet@chu-nantes.fr \u2020 Contributed equally 1 Unit\u00e9 de R\u00e9animation P\u00e9diatrique, H\u00f4pital M\u00e8re-Enfant Fa\u00efencerie, CHU de Nantes, 38 Boulevard Jean-Monnet, 44093 Nantes, France Full list of author information is available at the end of the article on for congenital heart disease.", [["heart", "ANATOMY", 377, 382], ["NAVA", "CHEMICAL", 0, 4], ["congenital heart disease", "DISEASE", 366, 390], ["children", "ORGANISM", 43, 51], ["heart", "ORGAN", 377, 382], ["children", "SPECIES", 43, 51], ["NAVA", "TREATMENT", 0, 4], ["congenital heart disease", "PROBLEM", 366, 390], ["heart", "ANATOMY", 377, 382], ["disease", "OBSERVATION", 383, 390]]], ["The effectiveness of NAVA in these children led us to gradually expand the indications.", [["NAVA", "CHEMICAL", 21, 25], ["NAVA", "SIMPLE_CHEMICAL", 21, 25], ["children", "ORGANISM", 35, 43], ["children", "SPECIES", 35, 43], ["NAVA", "TREATMENT", 21, 25]]], ["We report a series of 3 children with severe respiratory distress due to RSV bronchiolitis for whom NAVA was used.", [["respiratory", "ANATOMY", 45, 56], ["respiratory distress", "DISEASE", 45, 65], ["RSV bronchiolitis", "DISEASE", 73, 90], ["NAVA", "CHEMICAL", 100, 104], ["children", "ORGANISM", 24, 32], ["RSV", "ORGANISM", 73, 76], ["children", "SPECIES", 24, 32], ["RSV", "SPECIES", 73, 76], ["severe respiratory distress", "PROBLEM", 38, 65], ["RSV bronchiolitis", "PROBLEM", 73, 90], ["NAVA", "TREATMENT", 100, 104], ["respiratory", "ANATOMY", 45, 56], ["distress", "OBSERVATION", 57, 65], ["RSV bronchiolitis", "OBSERVATION", 73, 90]]], ["The parents of all three children gave their written consent for publication.", [["children", "ORGANISM", 25, 33], ["children", "SPECIES", 25, 33]]], ["Starting NAVA requires the initial correct positioning of the \"NAVA\" gastric tube.", [["gastric tube", "ANATOMY", 69, 81], ["NAVA", "CHEMICAL", 9, 13], ["gastric tube", "TISSUE", 69, 81], ["NAVA", "TREATMENT", 9, 13], ["the \"NAVA\" gastric tube", "TREATMENT", 58, 81], ["gastric", "ANATOMY", 69, 76], ["tube", "OBSERVATION", 77, 81]]], ["This commercially available feeding tube equipped with sensors (Edi catheter, Maquet Critical Care, Solna, Sweden) permits the recording of electrical activity of the diaphragm (Edi) via a Servo-I Ventilator (Maquet Critical Care, Solna, Sweden) using a standardized method [4] .", [["diaphragm", "ANATOMY", 167, 176], ["tube", "TISSUE", 36, 40], ["diaphragm", "ORGAN", 167, 176], ["feeding tube", "TREATMENT", 28, 40], ["sensors (Edi catheter", "TREATMENT", 55, 76], ["a Servo-I Ventilator", "TREATMENT", 187, 207], ["a standardized method", "TREATMENT", 252, 273], ["diaphragm", "ANATOMY", 167, 176]]], ["Settings are relatively simple and include positive end-expiratory pressure (PEEP), fraction of inspired oxygen (FiO 2 ), and level of NAVA assistance.Case PresentationThe Edi was multiplied was multiplied by the NAVA level to adjust the pressure assistance delivered to the child.", [["oxygen", "CHEMICAL", 105, 111], ["oxygen", "CHEMICAL", 105, 111], ["FiO 2", "CHEMICAL", 113, 118], ["oxygen", "SIMPLE_CHEMICAL", 105, 111], ["NAVA", "SIMPLE_CHEMICAL", 135, 139], ["positive end-expiratory pressure", "TREATMENT", 43, 75], ["PEEP", "TREATMENT", 77, 81], ["inspired oxygen (FiO", "TREATMENT", 96, 116], ["NAVA assistance", "TREATMENT", 135, 150], ["the pressure assistance", "TREATMENT", 234, 257]]], ["The delivered pressure is equal to: NAVA level \u00d7 (Edi max -Edi min) + PEEP.", [["NAVA", "SIMPLE_CHEMICAL", 36, 40], ["NAVA level", "TEST", 36, 46], ["Edi max", "TEST", 50, 57], ["PEEP", "TREATMENT", 70, 74], ["pressure", "OBSERVATION_MODIFIER", 14, 22], ["equal", "OBSERVATION_MODIFIER", 26, 31]]], ["In clinical practice we usually started with a NAVA level of 1 cm H 2 O/\u03bcV that may have required adjustment if the Edi max signals deviated from a range between 5 and 20 \u03bcV.", [["a NAVA level", "TEST", 45, 57], ["the Edi max signals", "TEST", 112, 131]]], ["If the Edi signals turned out to be consistently greater than 20 \u03bcV, we increased the NAVA level until they are within this range.", [["Edi", "GENE_OR_GENE_PRODUCT", 7, 10], ["Edi", "DNA", 7, 10], ["NAVA", "PROTEIN", 86, 90], ["the Edi signals", "TEST", 3, 18], ["the NAVA level", "TREATMENT", 82, 96]]], ["In the three reported cases, we did not need to do so.Case PresentationDuring NAVA, the ventilator is triggered when the deflection in the Edi curve exceeds 0.5 \u03bcV.", [["the ventilator", "TREATMENT", 84, 98], ["the deflection", "TEST", 117, 131], ["the Edi curve", "TEST", 135, 148]]], ["The assist is cycled-off when the Edi decreases to 70% of its peak value.Case PresentationWe assume that pressure support, which is pneumatically triggered, should remain a means of backup ventilation in case the Edi signal cannot be collected (e.g. if the child removes his/her Edi catheter).", [["pressure support", "TREATMENT", 105, 121], ["backup ventilation", "TREATMENT", 182, 200], ["his/her Edi catheter", "TREATMENT", 271, 291], ["pressure support", "OBSERVATION", 105, 121]]], ["Therefore, we set the trigger of this pressure support high enough (typically 0 to -5 cm) so that this backup ventilation did not compete with NAVA ventilation.Case PresentationWe measured respiratory parameters (FiO 2 , tidal volume, mean airway pressure, peak inspiratory pressure, respiratory rate, and Edi max) directly from data exported from the respirator.", [["respiratory", "ANATOMY", 189, 200], ["airway", "ANATOMY", 240, 246], ["NAVA", "SIMPLE_CHEMICAL", 143, 147], ["airway", "MULTI-TISSUE_STRUCTURE", 240, 246], ["this pressure support", "TREATMENT", 33, 54], ["this backup ventilation", "TREATMENT", 98, 121], ["NAVA ventilation", "TREATMENT", 143, 159], ["respiratory parameters", "TEST", 189, 211], ["FiO", "TEST", 213, 216], ["tidal volume", "TEST", 221, 233], ["mean airway pressure", "TEST", 235, 255], ["peak inspiratory pressure", "TEST", 257, 282], ["respiratory rate", "TEST", 284, 300], ["inspiratory pressure", "OBSERVATION", 262, 282]]], ["Nurses recorded vital signs and SpO2.", [["vital signs", "TEST", 16, 27], ["SpO2", "TEST", 32, 36]]], ["The oxygenation saturation index, OSI = (FiO 2 \u00d7 mean airway pressure)/SpO 2 , was used to provide a non-invasive method of oxygenation assessment.", [["airway", "ANATOMY", 54, 60], ["airway", "MULTI-TISSUE_STRUCTURE", 54, 60], ["The oxygenation saturation index", "TEST", 0, 32], ["OSI", "TEST", 34, 37], ["FiO", "TEST", 41, 44], ["mean airway pressure", "TEST", 49, 69], ["oxygenation assessment", "TEST", 124, 146], ["oxygenation", "OBSERVATION_MODIFIER", 4, 15]]], ["This index can be used for the diagnosis of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in children when SpO 2 values are \u2264 97% [5] .", [["lung", "ANATOMY", 50, 54], ["respiratory", "ANATOMY", 78, 89], ["acute lung injury", "DISEASE", 44, 61], ["ALI", "DISEASE", 63, 66], ["acute respiratory distress syndrome", "DISEASE", 72, 107], ["ARDS", "DISEASE", 109, 113], ["lung", "ORGAN", 50, 54], ["children", "ORGANISM", 118, 126], ["children", "SPECIES", 118, 126], ["This index", "TEST", 0, 10], ["acute lung injury", "PROBLEM", 44, 61], ["ALI", "PROBLEM", 63, 66], ["acute respiratory distress syndrome", "PROBLEM", 72, 107], ["ARDS)", "PROBLEM", 109, 114], ["SpO 2 values", "TEST", 132, 144], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["lung", "ANATOMY", 50, 54], ["injury", "OBSERVATION", 55, 61], ["ALI", "ANATOMY", 63, 66], ["acute", "OBSERVATION_MODIFIER", 72, 77], ["respiratory distress syndrome", "OBSERVATION", 78, 107]]], ["Diagnosis of ALI and ARDS required an acute onset of the process, bilateral infiltrates on a chest radiograph, no evidence of left atrial hypertension, and OSI > 6.5 (ALI) or > 7.8 (ARDS).", [["chest", "ANATOMY", 93, 98], ["left atrial", "ANATOMY", 126, 137], ["ALI", "DISEASE", 13, 16], ["ARDS", "DISEASE", 21, 25], ["left atrial hypertension", "DISEASE", 126, 150], ["ALI", "DISEASE", 167, 170], ["ARDS", "DISEASE", 182, 186], ["atrial", "MULTI-TISSUE_STRUCTURE", 131, 137], ["ALI", "PROBLEM", 13, 16], ["ARDS", "PROBLEM", 21, 25], ["the process", "PROBLEM", 53, 64], ["bilateral infiltrates", "PROBLEM", 66, 87], ["a chest radiograph", "TEST", 91, 109], ["left atrial hypertension", "PROBLEM", 126, 150], ["OSI", "TEST", 156, 159], ["ALI", "TEST", 167, 170], ["ARDS", "PROBLEM", 182, 186], ["ALI", "OBSERVATION", 13, 16], ["ARDS", "OBSERVATION", 21, 25], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["bilateral", "ANATOMY_MODIFIER", 66, 75], ["infiltrates", "OBSERVATION", 76, 87], ["chest", "ANATOMY", 93, 98], ["no evidence of", "UNCERTAINTY", 111, 125], ["left atrial", "ANATOMY", 126, 137], ["hypertension", "OBSERVATION", 138, 150]]], ["Blood samples were also analyzed to provide blood pH and PCO 2 values.Case 1Shemsy was one month old (3.8 kg) without any particular risk factors.", [["Blood samples", "ANATOMY", 0, 13], ["blood", "ANATOMY", 44, 49], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 44, 49], ["Blood samples", "TEST", 0, 13], ["blood pH", "TEST", 44, 52], ["PCO 2 values", "TEST", 57, 69]]], ["Her parents referred her to the emergency room because of grunting and hypotonia.", [["grunting", "DISEASE", 58, 66], ["hypotonia", "DISEASE", 71, 80], ["grunting", "PROBLEM", 58, 66], ["hypotonia", "PROBLEM", 71, 80], ["grunting", "OBSERVATION", 58, 66], ["hypotonia", "OBSERVATION", 71, 80]]], ["She had rhinitis for several days with a cough for 48 hours following a viral contamination 3 days prior.", [["rhinitis", "DISEASE", 8, 16], ["cough", "DISEASE", 41, 46], ["rhinitis", "PROBLEM", 8, 16], ["a cough", "PROBLEM", 39, 46], ["a viral contamination", "PROBLEM", 70, 91], ["rhinitis", "OBSERVATION", 8, 16], ["cough", "OBSERVATION", 41, 46]]], ["She presented with apnea, desaturation, bradycardia and altered consciousness.", [["apnea", "DISEASE", 19, 24], ["desaturation", "DISEASE", 26, 38], ["bradycardia", "DISEASE", 40, 51], ["altered consciousness", "DISEASE", 56, 77], ["apnea", "PROBLEM", 19, 24], ["desaturation", "PROBLEM", 26, 38], ["bradycardia", "PROBLEM", 40, 51], ["altered consciousness", "PROBLEM", 56, 77], ["apnea", "OBSERVATION", 19, 24], ["desaturation", "OBSERVATION_MODIFIER", 26, 38], ["bradycardia", "OBSERVATION", 40, 51], ["altered consciousness", "OBSERVATION", 56, 77]]], ["She was intubated and ventilated immediately, and then transferred to intensive care.Case 1Ten hours later, respiratory parameters were as follows: synchronized intermittent mandatory ventilation (SIMV) with a tidal volume (VT) of 20 ml (5 ml/kg); rate, 30/min; PEEP, 5 cm H 2 O; and FiO 2 , 50%.", [["respiratory", "ANATOMY", 108, 119], ["intubated", "TREATMENT", 8, 17], ["ventilated", "TREATMENT", 22, 32], ["respiratory parameters", "TEST", 108, 130], ["synchronized intermittent mandatory ventilation", "TREATMENT", 148, 195], ["SIMV", "TREATMENT", 197, 201], ["a tidal volume", "TEST", 208, 222], ["VT", "TEST", 224, 226], ["rate", "TEST", 248, 252], ["PEEP", "TREATMENT", 262, 266], ["FiO", "TEST", 284, 287]]], ["Measured parameters (stable for 2 hours) included a SpO 2 of 91%, a mean airway pressure of 10 cm H 2 O, and a peak inspiratory pressure of 30 cm H 2 O (other parameters are also shown in Table 1 ).", [["airway", "ANATOMY", 73, 79], ["airway", "MULTI-TISSUE_STRUCTURE", 73, 79], ["a SpO", "TEST", 50, 55], ["a mean airway pressure", "TEST", 66, 88], ["a peak inspiratory pressure", "TEST", 109, 136], ["stable", "OBSERVATION_MODIFIER", 21, 27], ["inspiratory pressure", "OBSERVATION", 116, 136], ["30 cm", "OBSERVATION_MODIFIER", 140, 145]]], ["The OSI was 5.5.", [["The OSI", "TEST", 0, 7]]], ["A chest X-ray showed poorly ventilated lungs with diffuse infiltrates.", [["chest", "ANATOMY", 2, 7], ["lungs", "ANATOMY", 39, 44], ["lungs", "ORGAN", 39, 44], ["A chest X-ray", "TEST", 0, 13], ["poorly ventilated lungs", "PROBLEM", 21, 44], ["diffuse infiltrates", "PROBLEM", 50, 69], ["chest", "ANATOMY", 2, 7], ["poorly", "OBSERVATION_MODIFIER", 21, 27], ["ventilated", "OBSERVATION", 28, 38], ["lungs", "ANATOMY", 39, 44], ["diffuse", "OBSERVATION_MODIFIER", 50, 57], ["infiltrates", "OBSERVATION", 58, 69]]], ["Since the child was agitated, the options for care were to increase sedation, or to attempt ventilation using NAVA.", [["NAVA", "CHEMICAL", 110, 114], ["child", "ORGANISM", 10, 15], ["child", "SPECIES", 10, 15], ["agitated", "PROBLEM", 20, 28], ["care", "TREATMENT", 46, 50], ["sedation", "TREATMENT", 68, 76], ["ventilation", "TREATMENT", 92, 103], ["NAVA", "TREATMENT", 110, 114]]], ["A brief test was undertaken to validate the use of NAVA, which proved successful.", [["NAVA", "CHEMICAL", 51, 55], ["NAVA", "SIMPLE_CHEMICAL", 51, 55], ["A brief test", "TEST", 0, 12], ["NAVA", "TREATMENT", 51, 55]]], ["We chose to commence NAVA after a short period of decreased sedation (morphine was decreased to 8 \u03bcg/kg/h).", [["NAVA", "CHEMICAL", 21, 25], ["morphine", "CHEMICAL", 70, 78], ["NAVA", "CHEMICAL", 21, 25], ["morphine", "CHEMICAL", 70, 78], ["morphine", "SIMPLE_CHEMICAL", 70, 78], ["NAVA", "TREATMENT", 21, 25], ["decreased sedation", "TREATMENT", 50, 68], ["morphine", "TREATMENT", 70, 78]]], ["Initial NAVA settings were PEEP, 5 cm H 2 O; NAVA level, 1 cm H 2 O/\u03bcV; and FiO 2 , initially 50% was then decreased by nurses to SpO 2 > 90%.Case 1We observed a dramatic decrease in inspiratory pressure with a reduced requirement for oxygen (Figures 1 and 2 ).", [["oxygen", "CHEMICAL", 235, 241], ["oxygen", "CHEMICAL", 235, 241], ["oxygen", "SIMPLE_CHEMICAL", 235, 241], ["Initial NAVA settings", "TREATMENT", 0, 21], ["PEEP", "TREATMENT", 27, 31], ["NAVA level", "TEST", 45, 55], ["V", "TEST", 69, 70], ["FiO", "TEST", 76, 79], ["SpO", "TEST", 130, 133], ["a dramatic decrease in inspiratory pressure", "PROBLEM", 160, 203], ["dramatic", "OBSERVATION_MODIFIER", 162, 170], ["decrease", "OBSERVATION_MODIFIER", 171, 179], ["inspiratory pressure", "OBSERVATION", 183, 203], ["reduced", "OBSERVATION_MODIFIER", 211, 218]]], ["Within several minutes, the child's breathing became much more harmonious and smoother, while her respiratory parameters showed large variations from one cycle to another.", [["respiratory", "ANATOMY", 98, 109], ["her respiratory parameters", "TEST", 94, 120], ["large variations", "PROBLEM", 128, 144]]], ["SpO 2 was96%, mean airway pressure was 6 cm H 2 O, peak inspiratory pressure was 10 cm H 2 O, and minute volume was 0.6 l/min.", [["airway", "ANATOMY", 19, 25], ["airway", "MULTI-TISSUE_STRUCTURE", 19, 25], ["SpO", "TEST", 0, 3], ["mean airway pressure", "TEST", 14, 34], ["peak inspiratory pressure", "TEST", 51, 76], ["minute volume", "TEST", 98, 111], ["pressure", "OBSERVATION_MODIFIER", 26, 34], ["inspiratory pressure", "OBSERVATION", 56, 76]]], ["Twelve hours later, FiO 2 was decreased to 21% with a mean airway pressure of 6 cm H 2 O. Detailed ventilatory parameters are reported in Table 1 .", [["airway", "ANATOMY", 59, 65], ["FiO 2", "CHEMICAL", 20, 25], ["airway", "MULTI-TISSUE_STRUCTURE", 59, 65], ["FiO", "TEST", 20, 23], ["a mean airway pressure", "TEST", 52, 74], ["Detailed ventilatory parameters", "TEST", 90, 121]]], ["Since respiratory parameters were very low (Peak inspiratory pressure < 12 cm H 2 O with FiO2 < 25%) and blood gas values was normal, we extubated the child (10:30).", [["respiratory", "ANATOMY", 6, 17], ["blood", "ANATOMY", 105, 110], ["blood", "ORGANISM_SUBSTANCE", 105, 110], ["respiratory parameters", "TEST", 6, 28], ["very low", "PROBLEM", 34, 42], ["Peak inspiratory pressure", "TEST", 44, 69], ["FiO2", "TEST", 89, 93], ["blood gas values", "TEST", 105, 121], ["low", "OBSERVATION_MODIFIER", 39, 42]]], ["She needed nasal continuous positive airway pressure for 3 days after which she was able to leave intensive care.", [["nasal", "ANATOMY", 11, 16], ["airway", "ANATOMY", 37, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["nasal continuous positive airway pressure", "TREATMENT", 11, 52], ["intensive care", "TREATMENT", 98, 112], ["airway pressure", "OBSERVATION", 37, 52]]], ["Tracheal aspirate was positive for RSV and Streptococcus pneumoniae.Case 2Matteo was 3 years old (14 kg), he was prematurely born (birth weight 1650 g) and he was mechanically ventilated in the neonatal period during 10 days for pulmonary hemorrhage.Case 2He was recently hospitalized because of subcutaneous emphysema, with signs of acute respiratory failure from RSV infection.", [["Tracheal aspirate", "ANATOMY", 0, 17], ["pulmonary", "ANATOMY", 229, 238], ["subcutaneous emphysema", "ANATOMY", 296, 318], ["respiratory", "ANATOMY", 340, 351], ["Streptococcus pneumoniae", "DISEASE", 43, 67], ["pulmonary hemorrhage", "DISEASE", 229, 249], ["emphysema", "DISEASE", 309, 318], ["respiratory failure", "DISEASE", 340, 359], ["RSV infection", "DISEASE", 365, 378], ["Tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 17], ["RSV", "ORGANISM", 35, 38], ["Streptococcus pneumoniae", "ORGANISM", 43, 67], ["pulmonary", "ORGAN", 229, 238], ["RSV", "ORGANISM", 365, 368], ["Streptococcus pneumoniae", "SPECIES", 43, 67], ["RSV", "SPECIES", 35, 38], ["Streptococcus pneumoniae", "SPECIES", 43, 67], ["RSV", "SPECIES", 365, 368], ["Tracheal aspirate", "TEST", 0, 17], ["RSV", "PROBLEM", 35, 38], ["Streptococcus pneumoniae", "PROBLEM", 43, 67], ["mechanically ventilated", "TREATMENT", 163, 186], ["pulmonary hemorrhage", "PROBLEM", 229, 249], ["subcutaneous emphysema", "PROBLEM", 296, 318], ["acute respiratory failure", "PROBLEM", 334, 359], ["RSV infection", "PROBLEM", 365, 378], ["aspirate", "OBSERVATION", 9, 17], ["positive for", "UNCERTAINTY", 22, 34], ["RSV", "OBSERVATION", 35, 38], ["Streptococcus pneumoniae", "OBSERVATION", 43, 67], ["mechanically", "OBSERVATION_MODIFIER", 163, 175], ["ventilated", "OBSERVATION", 176, 186], ["pulmonary", "ANATOMY", 229, 238], ["hemorrhage", "OBSERVATION", 239, 249], ["subcutaneous", "ANATOMY", 296, 308], ["emphysema", "OBSERVATION", 309, 318], ["acute", "OBSERVATION_MODIFIER", 334, 339], ["respiratory", "ANATOMY", 340, 351], ["failure", "OBSERVATION", 352, 359], ["RSV infection", "OBSERVATION", 365, 378]]], ["Because of an increased need for oxygen, he was intubated and ventilated with an FiO 2 of 100%, and PEEP was 3.", [["oxygen", "CHEMICAL", 33, 39], ["oxygen", "CHEMICAL", 33, 39], ["oxygen", "SIMPLE_CHEMICAL", 33, 39], ["oxygen", "TREATMENT", 33, 39], ["intubated", "TREATMENT", 48, 57], ["ventilated", "TREATMENT", 62, 72], ["an FiO", "TREATMENT", 78, 84], ["PEEP", "TREATMENT", 100, 104], ["increased", "OBSERVATION_MODIFIER", 14, 23]]], ["A chest X-ray did not show pneumothorax that could be drained.", [["chest", "ANATOMY", 2, 7], ["pneumothorax", "DISEASE", 27, 39], ["A chest X-ray", "TEST", 0, 13], ["pneumothorax", "PROBLEM", 27, 39], ["chest", "ANATOMY", 2, 7], ["pneumothorax", "OBSERVATION", 27, 39], ["drained", "OBSERVATION", 54, 61]]], ["Tracheal aspirate was positive for RSV and Hemophilus influenzae.", [["Tracheal aspirate", "ANATOMY", 0, 17], ["Hemophilus influenzae", "DISEASE", 43, 64], ["Tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 0, 17], ["RSV", "ORGANISM", 35, 38], ["Hemophilus influenzae", "ORGANISM", 43, 64], ["RSV", "SPECIES", 35, 38], ["Hemophilus influenzae", "SPECIES", 43, 64], ["RSV", "SPECIES", 35, 38], ["Hemophilus influenzae", "SPECIES", 43, 64], ["Tracheal aspirate", "TEST", 0, 17], ["RSV", "PROBLEM", 35, 38], ["Hemophilus influenzae", "PROBLEM", 43, 64], ["aspirate", "OBSERVATION", 9, 17], ["positive for", "UNCERTAINTY", 22, 34], ["Hemophilus influenzae", "OBSERVATION", 43, 64]]], ["A few days later, because of emergence of an alveolar syndrome associated with persistence of subcutaneous emphysema, he was transferred to our unit for possible extracorporeal membrane oxygenation (ECMO).", [["alveolar", "ANATOMY", 45, 53], ["subcutaneous emphysema", "ANATOMY", 94, 116], ["extracorporeal membrane", "ANATOMY", 162, 185], ["alveolar syndrome", "DISEASE", 45, 62], ["subcutaneous emphysema", "DISEASE", 94, 116], ["alveolar", "ORGAN", 45, 53], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 162, 185], ["an alveolar syndrome", "PROBLEM", 42, 62], ["subcutaneous emphysema", "PROBLEM", 94, 116], ["extracorporeal membrane oxygenation", "TREATMENT", 162, 197], ["alveolar syndrome", "OBSERVATION", 45, 62], ["subcutaneous", "ANATOMY", 94, 106], ["emphysema", "OBSERVATION", 107, 116], ["membrane oxygenation", "OBSERVATION", 177, 197]]], ["Upon arrival, he had an oxygenation saturation index of 9.4 as well as with the other criteria for ARDS (bilateral infiltrates on a chest radiograph and no evidence of left atrial hypertension).", [["chest", "ANATOMY", 132, 137], ["left atrial", "ANATOMY", 168, 179], ["ARDS", "DISEASE", 99, 103], ["left atrial hypertension", "DISEASE", 168, 192], ["atrial", "MULTI-TISSUE_STRUCTURE", 173, 179], ["an oxygenation saturation index", "TEST", 21, 52], ["ARDS (bilateral infiltrates", "PROBLEM", 99, 126], ["a chest radiograph", "TEST", 130, 148], ["left atrial hypertension", "PROBLEM", 168, 192], ["ARDS", "OBSERVATION", 99, 103], ["bilateral", "ANATOMY_MODIFIER", 105, 114], ["infiltrates", "OBSERVATION", 115, 126], ["chest", "ANATOMY", 132, 137], ["no evidence of", "UNCERTAINTY", 153, 167], ["left atrial", "ANATOMY", 168, 179], ["hypertension", "OBSERVATION", 180, 192]]], ["Respiratory parameters were an SIMV with a VT of 85 ml (6 ml/kg), the rate was 25/ min, PEEP was 6 cm H 2 O, and FiO 2 was 70%.", [["Respiratory parameters", "TEST", 0, 22], ["an SIMV", "TREATMENT", 28, 35], ["a VT", "TEST", 41, 45], ["the rate", "TEST", 66, 74], ["PEEP", "TREATMENT", 88, 92], ["FiO", "TEST", 113, 116]]], ["SpO2 was 89%, mean airway pressure was 12 cm H 2 O, peak inspiratory pressure was 28 cm H 2 O, and minute volume was 2 l/min.", [["airway", "ANATOMY", 19, 25], ["airway", "MULTI-TISSUE_STRUCTURE", 19, 25], ["SpO2", "TEST", 0, 4], ["mean airway pressure", "TEST", 14, 34], ["peak inspiratory pressure", "TEST", 52, 77], ["minute volume", "TEST", 99, 112], ["pressure", "OBSERVATION_MODIFIER", 26, 34]]], ["Venous blood gas showed a pH of 7.32, and a PvCO 2 of 53 Torr (7.1 kPa).", [["Venous blood", "ANATOMY", 0, 12], ["Venous", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["Venous blood gas", "TEST", 0, 16], ["a pH", "TEST", 24, 28], ["a PvCO", "TEST", 42, 48], ["Torr", "TEST", 57, 61]]], ["Because of a slight improvement, the child was not treated by ECMO.", [["child", "ORGANISM", 37, 42], ["ECMO", "TREATMENT", 62, 66], ["slight", "OBSERVATION_MODIFIER", 13, 19], ["improvement", "OBSERVATION", 20, 31]]], ["He underwent fibroscopy to eliminate the diagnosis of foreign body inhalation, which would have explained the subcutaneous emphysema.", [["body", "ANATOMY", 62, 66], ["subcutaneous emphysema", "ANATOMY", 110, 132], ["emphysema", "DISEASE", 123, 132], ["body", "ORGANISM_SUBDIVISION", 62, 66], ["fibroscopy", "TREATMENT", 13, 23], ["foreign body inhalation", "TREATMENT", 54, 77], ["the subcutaneous emphysema", "PROBLEM", 106, 132], ["foreign body", "OBSERVATION", 54, 66], ["subcutaneous", "ANATOMY", 110, 122], ["emphysema", "OBSERVATION", 123, 132]]], ["Forty-eight hours later, because of an increase in cough, cutaneous emphysema worsened and became diffuse (cervico-thoraco-abdominal) despite the reduction in PEEP to 4 cm H 2 O (FiO 2 60%).", [["cutaneous emphysema", "ANATOMY", 58, 77], ["cervico", "ANATOMY", 107, 114], ["abdominal", "ANATOMY", 123, 132], ["cough", "DISEASE", 51, 56], ["emphysema", "DISEASE", 68, 77], ["abdominal", "ORGAN", 123, 132], ["an increase in cough", "PROBLEM", 36, 56], ["cutaneous emphysema", "PROBLEM", 58, 77], ["cervico", "TEST", 107, 114], ["the reduction in PEEP", "TREATMENT", 142, 163], ["FiO", "TEST", 179, 182], ["increase", "OBSERVATION_MODIFIER", 39, 47], ["cough", "OBSERVATION", 51, 56], ["cutaneous", "ANATOMY", 58, 67], ["emphysema", "OBSERVATION", 68, 77], ["diffuse", "OBSERVATION_MODIFIER", 98, 105], ["abdominal", "ANATOMY", 123, 132], ["reduction", "OBSERVATION_MODIFIER", 146, 155]]], ["We decided to use NAVA to improve the synchronization of mechanical ventilation with the child's spontaneous breathing.", [["NAVA", "CHEMICAL", 18, 22], ["NAVA", "SIMPLE_CHEMICAL", 18, 22], ["NAVA", "TREATMENT", 18, 22], ["mechanical ventilation", "TREATMENT", 57, 79], ["mechanical ventilation", "OBSERVATION", 57, 79]]], ["Sedation was reduced, midazolam was decreased to 80 \u03bcg/kg/h and sufentanil to 0.3 \u03bcg/kg/h.", [["midazolam", "CHEMICAL", 22, 31], ["sufentanil", "CHEMICAL", 64, 74], ["midazolam", "CHEMICAL", 22, 31], ["sufentanil", "CHEMICAL", 64, 74], ["midazolam", "SIMPLE_CHEMICAL", 22, 31], ["sufentanil", "SIMPLE_CHEMICAL", 64, 74], ["Sedation", "TREATMENT", 0, 8], ["midazolam", "TREATMENT", 22, 31], ["sufentanil", "TREATMENT", 64, 74]]], ["The child became alert.", [["child", "ORGANISM", 4, 9], ["child", "SPECIES", 4, 9]]], ["Initial NAVA settings were a PEEP of 5 cm H 2 O, NAVA level was 1.2 cm H 2 O/\u03bcV, and FiO 2 was 60%.Case 2This change reduced the requirement for oxygen and normalized blood gases ( Table 2 ).", [["blood", "ANATOMY", 167, 172], ["oxygen", "CHEMICAL", 145, 151], ["oxygen", "CHEMICAL", 145, 151], ["oxygen", "SIMPLE_CHEMICAL", 145, 151], ["blood", "ORGANISM_SUBSTANCE", 167, 172], ["Initial NAVA settings", "TREATMENT", 0, 21], ["a PEEP", "TEST", 27, 33], ["NAVA level", "TEST", 49, 59], ["V", "TEST", 78, 79], ["FiO", "TEST", 85, 88], ["oxygen", "TREATMENT", 145, 151], ["normalized blood gases", "TEST", 156, 178]]], ["The next day, the subcutaneous emphysema started to decline ( Figure 3 ).", [["subcutaneous emphysema", "ANATOMY", 18, 40], ["emphysema", "DISEASE", 31, 40], ["the subcutaneous emphysema", "PROBLEM", 14, 40], ["subcutaneous", "ANATOMY", 18, 30], ["emphysema", "OBSERVATION", 31, 40]]], ["Peak inspiratory pressure was between 10 and 19 cm H 2 O with an FiO 2 of 50% for a SpO 2 of 90%.", [["H 2 O", "CHEMICAL", 51, 56], ["Peak inspiratory pressure", "TEST", 0, 25], ["an FiO", "TEST", 62, 68], ["a SpO", "TEST", 82, 87], ["inspiratory pressure", "OBSERVATION", 5, 25]]], ["The child's level of distress was scored with the modified COMFORT scale [6] and it ranged between 11 and 14 (adequately sedated, as confirmed by the child).", [["child", "SPECIES", 4, 9], ["distress", "PROBLEM", 21, 29]]], ["This clear improvement allowed us to reassign the child to the original hospital 48 hours after initiation of NAVA.", [["NAVA", "CHEMICAL", 110, 114], ["NAVA", "TREATMENT", 110, 114]]], ["NAVA was continued at the second facility, permitting extubation 3 days later.Case 3Leane was 28 days old (3 kg) and was born at term.", [["NAVA", "CHEMICAL", 0, 4], ["NAVA", "SIMPLE_CHEMICAL", 0, 4], ["NAVA", "TREATMENT", 0, 4]]], ["She had a 2-year-old brother with bronchiolitis.", [["bronchiolitis", "DISEASE", 34, 47], ["brother", "ORGANISM", 21, 28], ["bronchiolitis", "PROBLEM", 34, 47], ["bronchiolitis", "OBSERVATION", 34, 47]]], ["After an episode of rhinorrhea, she presented with feeding difficulties and was referred to the emergency room of a local hospital.", [["rhinorrhea", "DISEASE", 20, 30], ["feeding difficulties", "DISEASE", 51, 71], ["rhinorrhea", "PROBLEM", 20, 30], ["feeding difficulties", "PROBLEM", 51, 71], ["rhinorrhea", "OBSERVATION", 20, 30]]], ["Four hours later, she progressively presented with low oxygen saturation, tachypnea, and chest retraction.", [["chest", "ANATOMY", 89, 94], ["oxygen", "CHEMICAL", 55, 61], ["tachypnea", "DISEASE", 74, 83], ["chest retraction", "DISEASE", 89, 105], ["oxygen", "CHEMICAL", 55, 61], ["oxygen", "SIMPLE_CHEMICAL", 55, 61], ["chest", "ORGANISM_SUBDIVISION", 89, 94], ["low oxygen saturation", "PROBLEM", 51, 72], ["tachypnea", "PROBLEM", 74, 83], ["chest retraction", "PROBLEM", 89, 105], ["low", "OBSERVATION_MODIFIER", 51, 54], ["oxygen saturation", "OBSERVATION", 55, 72], ["tachypnea", "OBSERVATION", 74, 83], ["chest", "ANATOMY", 89, 94], ["retraction", "OBSERVATION", 95, 105]]], ["She was placed under nasal CPAP with 30% FiO 2 , and then transferred to our unit for severe RSV bronchiolitis.", [["nasal", "ANATOMY", 21, 26], ["bronchiolitis", "DISEASE", 97, 110], ["She", "ORGANISM", 0, 3], ["RSV", "ORGANISM", 93, 96], ["RSV", "SPECIES", 93, 96], ["nasal CPAP", "TREATMENT", 21, 31], ["30% FiO", "TREATMENT", 37, 44], ["severe RSV bronchiolitis", "PROBLEM", 86, 110], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["RSV", "OBSERVATION", 93, 96], ["bronchiolitis", "OBSERVATION", 97, 110]]], ["She was intubated on arrival because of clinical signs of respiratory distress and collapse.", [["respiratory", "ANATOMY", 58, 69], ["respiratory distress", "DISEASE", 58, 78], ["intubated", "TREATMENT", 8, 17], ["respiratory distress", "PROBLEM", 58, 78], ["collapse", "PROBLEM", 83, 91], ["respiratory distress", "OBSERVATION", 58, 78], ["collapse", "OBSERVATION", 83, 91]]], ["Although we suspected concomitant bacterial pneumonia because of a major inflammatory syndrome, we did not have bacteriological confirmation.", [["bacterial pneumonia", "DISEASE", 34, 53], ["concomitant bacterial pneumonia", "PROBLEM", 22, 53], ["a major inflammatory syndrome", "PROBLEM", 65, 94], ["bacteriological confirmation", "TEST", 112, 140], ["suspected concomitant", "UNCERTAINTY", 12, 33], ["bacterial", "OBSERVATION_MODIFIER", 34, 43], ["pneumonia", "OBSERVATION", 44, 53], ["major", "OBSERVATION_MODIFIER", 67, 72], ["inflammatory syndrome", "OBSERVATION", 73, 94]]], ["Her respiratory status deteriorated rapidly.", [["respiratory", "ANATOMY", 4, 15], ["respiratory status", "OBSERVATION", 4, 22], ["deteriorated", "OBSERVATION_MODIFIER", 23, 35], ["rapidly", "OBSERVATION_MODIFIER", 36, 43]]], ["The OSI was 6.8 (with other diagnosis criteria for acute lung injury).", [["lung", "ANATOMY", 57, 61], ["acute lung injury", "DISEASE", 51, 68], ["lung", "ORGAN", 57, 61], ["The OSI", "TEST", 0, 7], ["acute lung injury", "PROBLEM", 51, 68], ["acute", "OBSERVATION_MODIFIER", 51, 56], ["lung", "ANATOMY", 57, 61], ["injury", "OBSERVATION", 62, 68]]], ["Her need for oxygen increased rapidly with bilateral infiltrates on a chest radiograph.", [["chest", "ANATOMY", 70, 75], ["oxygen", "CHEMICAL", 13, 19], ["oxygen", "CHEMICAL", 13, 19], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["oxygen", "TREATMENT", 13, 19], ["bilateral infiltrates", "PROBLEM", 43, 64], ["a chest radiograph", "TEST", 68, 86], ["bilateral", "ANATOMY_MODIFIER", 43, 52], ["infiltrates", "OBSERVATION", 53, 64], ["chest", "ANATOMY", 70, 75]]], ["We chose to use NAVA after a short period of decreased sedation (morphine was decreased to 8 \u03bcg/kg/h).", [["NAVA", "CHEMICAL", 16, 20], ["morphine", "CHEMICAL", 65, 73], ["NAVA", "CHEMICAL", 16, 20], ["morphine", "CHEMICAL", 65, 73], ["morphine", "SIMPLE_CHEMICAL", 65, 73], ["NAVA", "TREATMENT", 16, 20], ["decreased sedation", "TREATMENT", 45, 63], ["morphine", "TREATMENT", 65, 73]]], ["Initial NAVA settings were a PEEP of 5 cm H 2 O, NAVA level was 1 cm H 2 O/\u03bcV, and FiO 2 was initially 60% and was then adjusted by a nurse for a SpO 2 > 90% and < 98%.", [["Initial NAVA settings", "TREATMENT", 0, 21], ["a PEEP", "TEST", 27, 33], ["NAVA level", "TEST", 49, 59], ["V", "TEST", 76, 77], ["FiO", "TEST", 83, 86], ["a SpO", "TEST", 144, 149]]], ["Six hours later, FiO 2 was 35%, while ventilatory pressures were lower than before starting NAVA ( Table 3) .", [["FiO 2", "CHEMICAL", 17, 22], ["FiO", "TEST", 17, 20], ["ventilatory pressures", "TEST", 38, 59]]], ["As in the 2 other cases, ventilatory parameters were highly variable (Figure 4) , while chest movements of the child were smooth as if the child was not mechanically ventilated.", [["chest", "ANATOMY", 88, 93], ["chest", "ORGANISM_SUBDIVISION", 88, 93], ["child", "ORGANISM", 111, 116], ["ventilatory parameters", "TEST", 25, 47], ["mechanically ventilated", "PROBLEM", 153, 176], ["chest", "ANATOMY", 88, 93], ["mechanically ventilated", "OBSERVATION", 153, 176]]], ["Twenty-four hours after starting NAVA, FiO 2 was 21%.", [["FiO 2", "CHEMICAL", 39, 44], ["NAVA", "TREATMENT", 33, 37], ["FiO", "TEST", 39, 42]]], ["The modified COMFORT scale ranged between 7 and 13.Case 3At 36 hours of NAVA ventilation, the child was accidentally extubated during coughing.", [["child", "ORGANISM", 94, 99], ["The modified COMFORT scale", "TEST", 0, 26], ["NAVA ventilation", "TREATMENT", 72, 88], ["coughing", "PROBLEM", 134, 142]]], ["She immediately presented marked signs of respiratory distress (Silverman score: 7/10).", [["respiratory", "ANATOMY", 42, 53], ["respiratory distress", "DISEASE", 42, 62], ["respiratory distress", "PROBLEM", 42, 62], ["marked", "OBSERVATION_MODIFIER", 26, 32], ["respiratory distress", "OBSERVATION", 42, 62]]], ["We then used noninvasive ventilation with the NAVA option.", [["noninvasive ventilation", "TREATMENT", 13, 36], ["the NAVA option", "TREATMENT", 42, 57]]], ["Edi max values were initially very high (80 \u03bcV) and gradually decreased over 1 hour after the establishment of noninvasive ventilation.", [["Edi max values", "TEST", 0, 14], ["noninvasive ventilation", "TREATMENT", 111, 134], ["decreased", "OBSERVATION_MODIFIER", 62, 71]]], ["Thereafter, nasal continuous airway pressure was applied and the child left the intensive care unit 3 days later.DiscussionAs in many pediatric intensive care units, our rate of intubation of children hospitalized for bronchiolitis is tidal volume became much more variable from one cycle to another.", [["nasal", "ANATOMY", 12, 17], ["airway", "ANATOMY", 29, 35], ["bronchiolitis", "DISEASE", 218, 231], ["airway", "MULTI-TISSUE_STRUCTURE", 29, 35], ["children", "ORGANISM", 192, 200], ["children", "SPECIES", 192, 200], ["nasal continuous airway pressure", "TREATMENT", 12, 44], ["intubation", "TREATMENT", 178, 188], ["bronchiolitis", "PROBLEM", 218, 231], ["tidal volume", "TEST", 235, 247], ["nasal", "ANATOMY", 12, 17], ["airway", "ANATOMY", 29, 35], ["bronchiolitis", "OBSERVATION", 218, 231], ["tidal volume", "OBSERVATION", 235, 247]]], ["Middle panels: One of the most remarkable changes observed with switching to the NAVA mode was the immediate reduction in the mean airway pressure (C) and in the peak airway pressure (D) which decreased from 30 to 10 cm H 2 O. Bottom panels: After starting NAVA, the respiratory rate became very variable over time (E).", [["airway", "ANATOMY", 131, 137], ["airway", "ANATOMY", 167, 173], ["respiratory", "ANATOMY", 267, 278], ["airway", "MULTI-TISSUE_STRUCTURE", 131, 137], ["airway", "MULTI-TISSUE_STRUCTURE", 167, 173], ["the NAVA mode", "TREATMENT", 77, 90], ["the mean airway pressure", "TEST", 122, 146], ["the peak airway pressure", "TEST", 158, 182], ["NAVA", "TREATMENT", 257, 261], ["the respiratory rate", "TEST", 263, 283], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["mean airway pressure", "OBSERVATION", 126, 146], ["peak airway", "ANATOMY", 162, 173], ["pressure", "OBSERVATION_MODIFIER", 174, 182], ["respiratory", "ANATOMY", 267, 278]]], ["From a mandatory frequency set at 30 breaths per minute, respiratory rate increased to 40 and 60 breaths per minute.", [["respiratory", "ANATOMY", 57, 68], ["respiratory rate", "TEST", 57, 73]]], ["Clinically, the breathing became easier with harmonious chest movements.", [["chest", "ANATOMY", 56, 61], ["chest", "ORGANISM_SUBDIVISION", 56, 61], ["chest", "ANATOMY", 56, 61]]], ["(F) Edi max that it is the sum of inspiratory Edi and Edi min corresponds to the peak of electrical activity of the diaphragm.", [["diaphragm", "ANATOMY", 116, 125], ["diaphragm", "ORGAN", 116, 125], ["peak", "OBSERVATION_MODIFIER", 81, 85], ["electrical activity", "OBSERVATION", 89, 108], ["diaphragm", "ANATOMY", 116, 125]]], ["In SIMV, this activity is depressed, and in NAVA, the inspiratory Edi (Edi max -Edi min) drives ventilation.", [["depressed", "DISEASE", 26, 35], ["SIMV", "TREATMENT", 3, 7], ["depressed", "PROBLEM", 26, 35], ["ventilation", "TREATMENT", 96, 107], ["depressed", "OBSERVATION", 26, 35]]], ["Abbreviations: FiO 2 , fraction of inspired oxygen; Edi, electrical activity of the diaphragm; SIMV, synchronized intermittent mandatory ventilation.", [["diaphragm", "ANATOMY", 84, 93], ["oxygen", "CHEMICAL", 44, 50], ["FiO 2", "CHEMICAL", 15, 20], ["oxygen", "CHEMICAL", 44, 50], ["FiO 2", "SIMPLE_CHEMICAL", 15, 20], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["Edi", "SIMPLE_CHEMICAL", 52, 55], ["diaphragm", "ORGAN", 84, 93], ["inspired oxygen", "TREATMENT", 35, 50], ["SIMV", "TREATMENT", 95, 99], ["synchronized intermittent mandatory ventilation", "TREATMENT", 101, 148], ["inspired oxygen", "OBSERVATION", 35, 50], ["diaphragm", "ANATOMY", 84, 93]]], ["Other data are measured parameters that depend both on the ventilatory settings and the respiratory status of the child. * Data expressed in parentheses represent measurements that were very variable over time, and hence an estimate of the measured parameter is provided.", [["respiratory", "ANATOMY", 88, 99], ["Other data", "TEST", 0, 10], ["the ventilatory settings", "TREATMENT", 55, 79], ["respiratory status", "OBSERVATION", 88, 106]]], ["Abbreviations: SIMV, synchronized intermittent mandatory ventilation; NAVA, neurally adjusted ventilatory assist; PEEP, positive end-expiratory pressure; FiO 2 , fraction of inspired oxygen; Edi, electrical activity of the diaphragm Figure 2 Screenshot with trends over 24 hours (case 1).", [["diaphragm", "ANATOMY", 223, 232], ["oxygen", "CHEMICAL", 183, 189], ["FiO 2", "CHEMICAL", 154, 159], ["oxygen", "CHEMICAL", 183, 189], ["oxygen", "SIMPLE_CHEMICAL", 183, 189], ["SIMV", "TREATMENT", 15, 19], ["synchronized intermittent mandatory ventilation", "TREATMENT", 21, 68], ["NAVA", "TREATMENT", 70, 74], ["ventilatory assist", "TREATMENT", 94, 112], ["PEEP", "TREATMENT", 114, 118], ["expiratory pressure", "TEST", 133, 152], ["FiO", "TREATMENT", 154, 157], ["inspired oxygen", "TREATMENT", 174, 189], ["inspired oxygen", "OBSERVATION", 174, 189], ["diaphragm", "ANATOMY", 223, 232]]], ["In the window untitled \"Courbes de tendances\" (Trend curves), three panels report trends over 24 hours of peak inspiratory pressure (cm H 2 O), respiratory rate (resp/mn), and minute volume (l/min).", [["respiratory", "ANATOMY", 144, 155], ["peak inspiratory pressure", "TEST", 106, 131], ["cm H", "TEST", 133, 137], ["respiratory rate", "TEST", 144, 160], ["minute volume", "TEST", 176, 189]]], ["On the right of these panels, the values of these ventilatory parameters were collected to the vertical bar (at 18:57 while the child was not receiving NAVA).", [["these panels", "TEST", 16, 28], ["these ventilatory parameters", "TEST", 44, 72], ["NAVA", "TREATMENT", 152, 156], ["right", "ANATOMY_MODIFIER", 7, 12], ["ventilatory parameters", "OBSERVATION", 50, 72]]], ["The downward vertical arrow indicates the switch from SIMV to NAVA (at 20:30).", [["NAVA", "CHEMICAL", 62, 66], ["The downward vertical arrow", "PROBLEM", 0, 27], ["SIMV", "TREATMENT", 54, 58], ["NAVA", "TREATMENT", 62, 66], ["downward", "OBSERVATION_MODIFIER", 4, 12], ["vertical", "OBSERVATION_MODIFIER", 13, 21]]], ["Outside the window untitled \"Courbes de tendances\", on the right of the scrennshot, ventilatory parameters were collected the next day at 10:15 while the child was receiving NAVA.", [["NAVA", "CHEMICAL", 174, 178], ["NAVA", "CHEMICAL", 174, 178], ["ventilatory parameters", "TEST", 84, 106], ["NAVA", "TREATMENT", 174, 178], ["right", "ANATOMY_MODIFIER", 59, 64]]], ["The upper pannel showed a decrease in peak inspiratory pressure after the switch of ventilation.", [["The upper pannel", "TEST", 0, 16], ["a decrease in peak inspiratory pressure", "PROBLEM", 24, 63], ["the switch of ventilation", "TREATMENT", 70, 95], ["upper", "ANATOMY_MODIFIER", 4, 9], ["decrease", "OBSERVATION_MODIFIER", 26, 34], ["peak", "OBSERVATION_MODIFIER", 38, 42], ["inspiratory pressure", "OBSERVATION", 43, 63]]], ["The middle pannel showed the extreme variability of the respiratory ratein NAVA (the white area under the curve corresponds to the mandatory respiratory rate, while the black area corresponds to the spontaneous respiratory rate).", [["respiratory", "ANATOMY", 211, 222], ["The middle pannel", "TEST", 0, 17], ["the respiratory ratein NAVA", "PROBLEM", 52, 79], ["the mandatory respiratory rate", "TEST", 127, 157], ["the black area", "PROBLEM", 165, 179], ["the spontaneous respiratory rate", "TEST", 195, 227], ["middle", "ANATOMY_MODIFIER", 4, 10], ["extreme", "OBSERVATION_MODIFIER", 29, 36], ["variability", "OBSERVATION_MODIFIER", 37, 48], ["respiratory ratein NAVA", "OBSERVATION", 56, 79]]], ["The lower pannel showed minute volume that remained unchanged.", [["The lower pannel", "TEST", 0, 16], ["minute volume", "TEST", 24, 37], ["lower", "ANATOMY_MODIFIER", 4, 9], ["minute volume", "OBSERVATION", 24, 37], ["unchanged", "OBSERVATION_MODIFIER", 52, 61]]], ["When comparing values of ventilatory parameters in SIMV (at 18:57) with those in NAVA (next day at 10:15), peak inspiratory pressure decreased from 29 to 6 cm H 2 O, mean airway pressure decreased from 10 to 4 cm H 2 O, spontaneous respiratory rate varied from 0 to 29 breaths/min.", [["airway", "ANATOMY", 171, 177], ["respiratory", "ANATOMY", 232, 243], ["airway", "MULTI-TISSUE_STRUCTURE", 171, 177], ["ventilatory parameters", "TEST", 25, 47], ["SIMV", "TREATMENT", 51, 55], ["peak inspiratory pressure", "TEST", 107, 132], ["mean airway pressure", "TEST", 166, 186], ["spontaneous respiratory rate", "TEST", 220, 248], ["inspiratory pressure", "OBSERVATION", 112, 132], ["airway", "ANATOMY", 171, 177], ["pressure", "OBSERVATION_MODIFIER", 178, 186]]], ["Abbreviations: SIMV, synchronized intermittent mandatory ventilation; PEP, positive end-expiratory pressure; P cr\u00eate, peak inspiratory pressure; P moyen, mean airway pressure; FR spont, spontaneous respiratory rate; F resp, respiratory rate; VM, minute volume; FiO 2 , fraction of inspired oxygen. low (< 20%) [7] .", [["airway", "ANATOMY", 159, 165], ["oxygen", "CHEMICAL", 290, 296], ["oxygen", "CHEMICAL", 290, 296], ["airway", "MULTI-TISSUE_STRUCTURE", 159, 165], ["oxygen", "SIMPLE_CHEMICAL", 290, 296], ["SIMV", "TREATMENT", 15, 19], ["synchronized intermittent mandatory ventilation", "TREATMENT", 21, 68], ["PEP", "TEST", 70, 73], ["expiratory pressure", "TEST", 88, 107], ["P cr\u00eate", "TEST", 109, 116], ["peak inspiratory pressure", "TEST", 118, 143], ["P moyen", "TEST", 145, 152], ["mean airway pressure", "TEST", 154, 174], ["FR spont", "TEST", 176, 184], ["spontaneous respiratory rate", "TEST", 186, 214], ["resp", "TEST", 218, 222], ["respiratory rate", "TEST", 224, 240], ["VM", "TEST", 242, 244], ["minute volume", "TEST", 246, 259], ["FiO", "TEST", 261, 264], ["inspired oxygen", "TREATMENT", 281, 296], ["inspiratory pressure", "OBSERVATION", 123, 143], ["airway pressure", "OBSERVATION", 159, 174], ["inspired oxygen", "OBSERVATION", 281, 296]]], ["However, the severity of lung disease in some children still necessitates invasive mechanical ventilation.", [["lung", "ANATOMY", 25, 29], ["lung disease", "DISEASE", 25, 37], ["lung", "ORGAN", 25, 29], ["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54], ["lung disease", "PROBLEM", 25, 37], ["invasive mechanical ventilation", "TREATMENT", 74, 105], ["severity", "OBSERVATION_MODIFIER", 13, 21], ["lung", "ANATOMY", 25, 29], ["disease", "OBSERVATION", 30, 37], ["invasive", "OBSERVATION_MODIFIER", 74, 82], ["mechanical ventilation", "OBSERVATION", 83, 105]]], ["Our unit recruitment is both medical and surgical, and we therefore acquired expertise in NAVA through the weaning of children treated after cardiac surgery.", [["cardiac", "ANATOMY", 141, 148], ["NAVA", "CANCER", 90, 94], ["children", "ORGANISM", 118, 126], ["cardiac", "ORGAN", 141, 148], ["children", "SPECIES", 118, 126], ["NAVA", "TREATMENT", 90, 94], ["cardiac surgery", "TREATMENT", 141, 156], ["cardiac", "ANATOMY", 141, 148], ["surgery", "OBSERVATION", 149, 156]]], ["We then expanded the indications of this mode of ventilation in children with severe respiratory disease.", [["respiratory", "ANATOMY", 85, 96], ["respiratory disease", "DISEASE", 85, 104], ["children", "ORGANISM", 64, 72], ["children", "SPECIES", 64, 72], ["this mode of ventilation", "TREATMENT", 36, 60], ["severe respiratory disease", "PROBLEM", 78, 104], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["respiratory disease", "OBSERVATION", 85, 104]]], ["The positive results in the present study may be explained by the specific selection of children to whom we applied NAVA.", [["children", "ORGANISM", 88, 96], ["children", "SPECIES", 88, 96], ["the present study", "TEST", 24, 41], ["NAVA", "TREATMENT", 116, 120]]], ["First, there should be no specific contraindication to the placement of a nasogastric tube.", [["nasogastric tube", "MULTI-TISSUE_STRUCTURE", 74, 90], ["a nasogastric tube", "TREATMENT", 72, 90], ["nasogastric tube", "OBSERVATION", 74, 90]]], ["Second, there should be no alkalosis or hypocapnia (in such cases there would not be sufficient diaphragmatic electrical activity).", [["diaphragmatic", "ANATOMY", 96, 109], ["alkalosis", "DISEASE", 27, 36], ["hypocapnia", "DISEASE", 40, 50], ["alkalosis", "PROBLEM", 27, 36], ["hypocapnia", "PROBLEM", 40, 50], ["no", "UNCERTAINTY", 24, 26], ["alkalosis", "OBSERVATION", 27, 36], ["hypocapnia", "OBSERVATION", 40, 50]]], ["During alkalosis, the ventilatory brain centers no longer stimulate the diaphragm, and the respirator works on a backup mode, which is simply conventional ventilation.", [["brain", "ANATOMY", 34, 39], ["diaphragm", "ANATOMY", 72, 81], ["alkalosis", "DISEASE", 7, 16], ["brain", "ORGAN", 34, 39], ["diaphragm", "ORGAN", 72, 81], ["alkalosis", "PROBLEM", 7, 16], ["a backup mode", "TREATMENT", 111, 124], ["conventional ventilation", "TREATMENT", 142, 166], ["alkalosis", "OBSERVATION", 7, 16], ["diaphragm", "ANATOMY", 72, 81]]], ["Finally, the level of sedation should not be too high, so that it does not depress brain centers that control breathing.", [["brain", "ANATOMY", 83, 88], ["brain", "ORGAN", 83, 88], ["sedation", "TREATMENT", 22, 30]]], ["If the sedation is too high, the Edi signal cannot be collected and the respirator works again in a backup mode.", [["the sedation", "TREATMENT", 3, 15]]], ["Likewise, neuromuscular connection from the respiratory center to the diaphragm must be intact.", [["neuromuscular", "ANATOMY", 10, 23], ["respiratory center", "ANATOMY", 44, 62], ["diaphragm", "ANATOMY", 70, 79], ["diaphragm", "ORGAN", 70, 79], ["neuromuscular", "ANATOMY", 10, 23], ["respiratory center", "OBSERVATION", 44, 62], ["diaphragm", "ANATOMY", 70, 79], ["intact", "OBSERVATION", 88, 94]]], ["For example, NAVA cannot be used in case of post-surgical lesion of the two phrenic nerves [3] or diaphragmatic paralysis secondary to botulism [8] .DiscussionThe main benefit observed in our cases was an improvement in oxygenation associated with a normalization of blood pH.", [["lesion", "ANATOMY", 58, 64], ["phrenic nerves", "ANATOMY", 76, 90], ["diaphragmatic", "ANATOMY", 98, 111], ["blood", "ANATOMY", 267, 272], ["NAVA", "CHEMICAL", 13, 17], ["diaphragmatic paralysis", "DISEASE", 98, 121], ["botulism", "DISEASE", 135, 143], ["NAVA", "SIMPLE_CHEMICAL", 13, 17], ["phrenic nerves", "MULTI-TISSUE_STRUCTURE", 76, 90], ["diaphragmatic", "ORGAN", 98, 111], ["blood", "ORGANISM_SUBSTANCE", 267, 272], ["NAVA", "TREATMENT", 13, 17], ["post-surgical lesion of the two phrenic nerves", "PROBLEM", 44, 90], ["diaphragmatic paralysis", "PROBLEM", 98, 121], ["botulism", "PROBLEM", 135, 143], ["a normalization of blood pH", "PROBLEM", 248, 275], ["NAVA", "OBSERVATION", 13, 17], ["post-surgical", "OBSERVATION_MODIFIER", 44, 57], ["lesion", "OBSERVATION", 58, 64], ["two", "ANATOMY_MODIFIER", 72, 75], ["phrenic nerves", "ANATOMY", 76, 90], ["diaphragmatic", "ANATOMY", 98, 111], ["paralysis", "OBSERVATION", 112, 121], ["improvement", "OBSERVATION_MODIFIER", 205, 216]]], ["This was achieved with marked decrease in peak airway pressure.", [["airway", "ANATOMY", 47, 53], ["airway", "MULTI-TISSUE_STRUCTURE", 47, 53], ["peak airway pressure", "TEST", 42, 62], ["marked", "OBSERVATION_MODIFIER", 23, 29], ["decrease", "OBSERVATION_MODIFIER", 30, 38], ["peak airway pressure", "OBSERVATION", 42, 62]]], ["This effect has been previously found in crossover studies reporting NAVA in weaning children from a respirator who were operated on for congenital heart disease and comparing NAVA with pressure support [1] [2] [3] .", [["heart", "ANATOMY", 148, 153], ["NAVA", "CHEMICAL", 69, 73], ["congenital heart disease", "DISEASE", 137, 161], ["NAVA", "SIMPLE_CHEMICAL", 69, 73], ["children", "ORGANISM", 85, 93], ["heart", "ORGAN", 148, 153], ["children", "SPECIES", 85, 93], ["congenital heart disease", "PROBLEM", 137, 161], ["NAVA with pressure support", "TREATMENT", 176, 202], ["heart", "ANATOMY", 148, 153], ["disease", "OBSERVATION", 154, 161]]], ["Clinically, breathing becomes easier with harmonious chest movements.", [["chest", "ANATOMY", 53, 58], ["chest", "ORGANISM_SUBDIVISION", 53, 58], ["chest", "ANATOMY", 53, 58]]], ["In one of our cases, NAVA was very effective for ventilation in a child who had both ARDS and extensive cutaneous emphysema.", [["cutaneous emphysema", "ANATOMY", 104, 123], ["NAVA", "CHEMICAL", 21, 25], ["ARDS", "DISEASE", 85, 89], ["emphysema", "DISEASE", 114, 123], ["NAVA", "CHEMICAL", 21, 25], ["NAVA", "SIMPLE_CHEMICAL", 21, 25], ["cutaneous emphysema", "PATHOLOGICAL_FORMATION", 104, 123], ["NAVA", "TREATMENT", 21, 25], ["ventilation", "TREATMENT", 49, 60], ["ARDS", "PROBLEM", 85, 89], ["extensive cutaneous emphysema", "PROBLEM", 94, 123], ["ARDS", "OBSERVATION", 85, 89], ["extensive", "OBSERVATION_MODIFIER", 94, 103], ["cutaneous", "ANATOMY", 104, 113], ["emphysema", "OBSERVATION", 114, 123]]], ["The excellent synchronization of mechanical ventilation with the spontaneous breathing of the child improved oxygenation without aggravating the emphysema.DiscussionSeveral factors could explain the beneficial effects observed with NAVA in these three children who had severe respiratory distress.", [["respiratory", "ANATOMY", 276, 287], ["emphysema", "DISEASE", 145, 154], ["NAVA", "CHEMICAL", 232, 236], ["respiratory distress", "DISEASE", 276, 296], ["NAVA", "CHEMICAL", 232, 236], ["emphysema", "PATHOLOGICAL_FORMATION", 145, 154], ["NAVA", "SIMPLE_CHEMICAL", 232, 236], ["children", "ORGANISM", 252, 260], ["children", "SPECIES", 252, 260], ["mechanical ventilation", "TREATMENT", 33, 55], ["the emphysema", "PROBLEM", 141, 154], ["NAVA", "TREATMENT", 232, 236], ["severe respiratory distress", "PROBLEM", 269, 296], ["excellent", "OBSERVATION_MODIFIER", 4, 13], ["synchronization", "OBSERVATION_MODIFIER", 14, 29], ["mechanical ventilation", "OBSERVATION", 33, 55], ["emphysema", "OBSERVATION", 145, 154], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["respiratory distress", "OBSERVATION", 276, 296]]], ["First, asynchrony is associated with increased morbidity, a longer duration of ventilation, and a longer hospital stay [9] [10] [11] .", [["increased morbidity", "PROBLEM", 37, 56], ["ventilation", "TREATMENT", 79, 90], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["morbidity", "OBSERVATION", 47, 56]]], ["There are few pediatric data published regarding the adverse effects of long-term asynchrony between mandatory ventilation and the respiratory efforts of children, but it has been shown that infant-ventilator asynchrony (both inspiratory and expiratory asynchrony) may affect more than 50% of the total breath duration [12] .", [["respiratory", "ANATOMY", 131, 142], ["children", "ORGANISM", 154, 162], ["children", "SPECIES", 154, 162], ["long-term asynchrony", "TREATMENT", 72, 92], ["mandatory ventilation", "TREATMENT", 101, 122], ["ventilator asynchrony", "PROBLEM", 198, 219], ["few", "OBSERVATION_MODIFIER", 10, 13], ["long-term asynchrony", "OBSERVATION_MODIFIER", 72, 92], ["ventilator asynchrony", "OBSERVATION", 198, 219], ["expiratory asynchrony", "OBSERVATION", 242, 263]]], ["Second, NAVA provides assistance in synchronization, as well as in pressure assistance in Recording began with the establishment of NAVA.", [["NAVA", "CHEMICAL", 8, 12], ["NAVA", "PROTEIN", 8, 12], ["NAVA", "TREATMENT", 8, 12], ["pressure assistance", "TREATMENT", 67, 86], ["NAVA", "TREATMENT", 132, 136], ["NAVA", "OBSERVATION", 132, 136]]], ["Upper panels: After starting NAVA, (A) FiO 2 gradually decreased to 35%, and (B) tidal volume became variable from one cycle to another ranging from 5 to 30 ml.", [["NAVA", "TREATMENT", 29, 33], ["FiO", "TEST", 39, 42], ["tidal volume", "TEST", 81, 93]]], ["Middle panels: Variability was also observed in measurements of pressure: (C) mean airway pressure, (D) peak inspiratory pressure.", [["airway", "ANATOMY", 83, 89], ["airway", "MULTI-TISSUE_STRUCTURE", 83, 89], ["pressure", "TEST", 64, 72], ["mean airway pressure", "TEST", 78, 98], ["peak inspiratory pressure", "TEST", 104, 129], ["Variability", "OBSERVATION_MODIFIER", 15, 26], ["airway pressure", "OBSERVATION", 83, 98], ["inspiratory pressure", "OBSERVATION", 109, 129]]], ["Bottom panels: (E) After starting NAVA, the respiratory rate became very variable over time.", [["respiratory", "ANATOMY", 44, 55], ["NAVA", "TREATMENT", 34, 38], ["the respiratory rate", "TEST", 40, 60], ["respiratory", "ANATOMY", 44, 55], ["very", "OBSERVATION_MODIFIER", 68, 72], ["variable", "OBSERVATION_MODIFIER", 73, 81]]], ["(F) Edi max corresponds to the peak of electrical activity of the diaphragm.", [["diaphragm", "ANATOMY", 66, 75], ["diaphragm", "ORGAN", 66, 75], ["electrical activity", "OBSERVATION", 39, 58], ["diaphragm", "ANATOMY", 66, 75]]], ["The highest Edi values (recorded between 19:00 and 22:00) drove assistance with the highest pressures.", [["The highest Edi values", "TEST", 0, 22], ["the highest pressures", "TEST", 80, 101]]], ["A decrease in signal intensity was accompanied by a decrease in pressure, corresponding to an improvement in lung function.", [["lung", "ANATOMY", 109, 113], ["lung", "ORGAN", 109, 113], ["A decrease in signal intensity", "PROBLEM", 0, 30], ["a decrease in pressure", "PROBLEM", 50, 72], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["signal intensity", "OBSERVATION", 14, 30], ["decrease", "OBSERVATION_MODIFIER", 52, 60], ["pressure", "OBSERVATION_MODIFIER", 64, 72], ["improvement", "OBSERVATION_MODIFIER", 94, 105], ["lung", "ANATOMY", 109, 113], ["function", "OBSERVATION", 114, 122]]], ["The requirement for oxygen decreased at the same time.", [["oxygen", "CHEMICAL", 20, 26], ["oxygen", "CHEMICAL", 20, 26], ["oxygen", "SIMPLE_CHEMICAL", 20, 26], ["oxygen", "TREATMENT", 20, 26], ["oxygen", "OBSERVATION_MODIFIER", 20, 26], ["decreased", "OBSERVATION_MODIFIER", 27, 36]]], ["Abbreviations: FiO 2 , fraction of inspired oxygen; Edi, electrical activity of the diaphragm; NAVA, neurally adjusted ventilatory assist.Discussionproportion to the measured electrical activity of the diaphragm.", [["diaphragm", "ANATOMY", 84, 93], ["diaphragm", "ANATOMY", 202, 211], ["oxygen", "CHEMICAL", 44, 50], ["FiO 2", "CHEMICAL", 15, 20], ["oxygen", "CHEMICAL", 44, 50], ["oxygen", "SIMPLE_CHEMICAL", 44, 50], ["Edi", "SIMPLE_CHEMICAL", 52, 55], ["diaphragm", "ORGAN", 84, 93], ["diaphragm", "ORGAN", 202, 211], ["inspired oxygen", "TREATMENT", 35, 50], ["NAVA", "TREATMENT", 95, 99], ["ventilatory assist", "TREATMENT", 119, 137], ["inspired oxygen", "OBSERVATION", 35, 50], ["diaphragm", "ANATOMY", 84, 93], ["NAVA", "ANATOMY", 95, 99], ["ventilatory assist", "OBSERVATION", 119, 137], ["diaphragm", "ANATOMY", 202, 211]]], ["This helps to limit the periods of insufficient assist delivery that could induce respiratory muscle fatigue with increased oxygen consumption, and periods of overassistance that can generate intrinsic PEEP with an inadequate increase in intrathoracic pressure [13] .", [["respiratory muscle", "ANATOMY", 82, 100], ["intrathoracic", "ANATOMY", 238, 251], ["respiratory muscle fatigue", "DISEASE", 82, 108], ["oxygen", "CHEMICAL", 124, 130], ["oxygen", "CHEMICAL", 124, 130], ["muscle", "ORGAN", 94, 100], ["oxygen", "SIMPLE_CHEMICAL", 124, 130], ["insufficient assist delivery", "TREATMENT", 35, 63], ["respiratory muscle fatigue", "PROBLEM", 82, 108], ["increased oxygen consumption", "TREATMENT", 114, 142], ["intrinsic PEEP", "TREATMENT", 192, 206], ["intrathoracic pressure", "TEST", 238, 260], ["respiratory muscle", "ANATOMY", 82, 100], ["oxygen consumption", "OBSERVATION", 124, 142], ["inadequate", "OBSERVATION_MODIFIER", 215, 225], ["increase", "OBSERVATION_MODIFIER", 226, 234], ["intrathoracic pressure", "OBSERVATION", 238, 260]]], ["NAVA can also prevent air swallowing and gastric distension by optimization of patient-ventilator synchrony [14] .", [["gastric", "ANATOMY", 41, 48], ["NAVA", "CHEMICAL", 0, 4], ["NAVA", "SIMPLE_CHEMICAL", 0, 4], ["gastric", "ORGAN", 41, 48], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["NAVA", "TREATMENT", 0, 4], ["air swallowing", "PROBLEM", 22, 36], ["gastric distension", "PROBLEM", 41, 59], ["ventilator synchrony", "TREATMENT", 87, 107], ["air swallowing", "OBSERVATION", 22, 36], ["gastric", "ANATOMY", 41, 48], ["distension", "OBSERVATION", 49, 59]]], ["Third, it is likely that NAVA can help clinician avoiding inappropriate ventilator settings that overload (or underload) respiratory muscles, preventing recovery.", [["respiratory muscles", "ANATOMY", 121, 140], ["NAVA", "SIMPLE_CHEMICAL", 25, 29], ["muscles", "ORGAN", 133, 140], ["NAVA", "TREATMENT", 25, 29], ["inappropriate ventilator settings", "TREATMENT", 58, 91], ["overload", "PROBLEM", 97, 105], ["underload) respiratory muscles", "PROBLEM", 110, 140], ["is likely", "UNCERTAINTY", 10, 19], ["overload", "OBSERVATION", 97, 105], ["respiratory muscles", "ANATOMY", 121, 140]]], ["Finally, improvements in pulmonary gas exchange, systemic blood flow and oxygen supply to tissues which have been observed when spontaneous breathing has been maintained during mechanical ventilation with clinical improvement in the patient's condition [15] , are assumed to occur in NAVA, when breathing efforts by the patient and the initiated breaths are in synchrony.DiscussionCost effectiveness studies are required, as NAVA requires probes that are single-patient use.", [["pulmonary", "ANATOMY", 25, 34], ["blood", "ANATOMY", 58, 63], ["tissues", "ANATOMY", 90, 97], ["oxygen", "CHEMICAL", 73, 79], ["oxygen", "CHEMICAL", 73, 79], ["pulmonary", "ORGAN", 25, 34], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["oxygen", "SIMPLE_CHEMICAL", 73, 79], ["tissues", "TISSUE", 90, 97], ["patient", "ORGANISM", 233, 240], ["patient", "ORGANISM", 320, 327], ["patient", "ORGANISM", 462, 469], ["patient", "SPECIES", 233, 240], ["patient", "SPECIES", 320, 327], ["patient", "SPECIES", 462, 469], ["pulmonary gas exchange", "TEST", 25, 47], ["systemic blood flow", "TREATMENT", 49, 68], ["oxygen supply", "TREATMENT", 73, 86], ["spontaneous breathing", "PROBLEM", 128, 149], ["mechanical ventilation", "TREATMENT", 177, 199], ["Cost effectiveness studies", "TEST", 381, 407], ["pulmonary", "ANATOMY", 25, 34], ["gas exchange", "OBSERVATION", 35, 47], ["oxygen supply", "OBSERVATION", 73, 86]]], ["It is possible that improving comfort provided by better synchronization between spontaneous breathing and mechanical ventilation could reduce the sedation and thus shorten duration of ventilation.ConclusionsBased on three individual cases, NAVA appears to be a useful mode for weaning from a respirator and is an effective alternative treatment for children with severe respiratory distress.", [["respiratory", "ANATOMY", 371, 382], ["NAVA", "CHEMICAL", 241, 245], ["respiratory distress", "DISEASE", 371, 391], ["NAVA", "CHEMICAL", 241, 245], ["NAVA", "SIMPLE_CHEMICAL", 241, 245], ["children", "ORGANISM", 350, 358], ["children", "SPECIES", 350, 358], ["spontaneous breathing", "TREATMENT", 81, 102], ["mechanical ventilation", "TREATMENT", 107, 129], ["the sedation", "TREATMENT", 143, 155], ["ventilation", "TREATMENT", 185, 196], ["NAVA", "TREATMENT", 241, 245], ["a respirator", "TREATMENT", 291, 303], ["an effective alternative treatment", "TREATMENT", 311, 345], ["severe respiratory distress", "PROBLEM", 364, 391], ["mechanical ventilation", "OBSERVATION", 107, 129], ["severe", "OBSERVATION_MODIFIER", 364, 370], ["respiratory distress", "OBSERVATION", 371, 391]]], ["NAVA provides a respiratory support that is in harmony with the spontaneous efforts of breathing, allowing a decrease in inspiratory pressures and oxygen needs.", [["NAVA", "CHEMICAL", 0, 4], ["oxygen", "CHEMICAL", 147, 153], ["oxygen", "CHEMICAL", 147, 153], ["NAVA", "SIMPLE_CHEMICAL", 0, 4], ["oxygen", "SIMPLE_CHEMICAL", 147, 153], ["NAVA", "TREATMENT", 0, 4], ["a respiratory support", "TREATMENT", 14, 35], ["a decrease in inspiratory pressures", "PROBLEM", 107, 142], ["oxygen needs", "TREATMENT", 147, 159], ["respiratory support", "OBSERVATION", 16, 35], ["decrease", "OBSERVATION_MODIFIER", 109, 117], ["inspiratory pressures", "OBSERVATION", 121, 142], ["oxygen needs", "OBSERVATION", 147, 159]]], ["Larger studies are required to compare NAVA with conventional respiratory support in children with various etiologies of respiratory distress.", [["respiratory", "ANATOMY", 62, 73], ["respiratory", "ANATOMY", 121, 132], ["respiratory distress", "DISEASE", 121, 141], ["children", "ORGANISM", 85, 93], ["children", "SPECIES", 85, 93], ["Larger studies", "TEST", 0, 14], ["NAVA", "TREATMENT", 39, 43], ["conventional respiratory support", "TREATMENT", 49, 81], ["respiratory distress", "PROBLEM", 121, 141], ["respiratory distress", "OBSERVATION", 121, 141]]]], "cf27e2301131c5cb6d5b67e2dd29eff6f31ead18": [], "09ab3556208e8fd5284870dc441bf0324973d230": [["IntroductionThe emergence of the Severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 has boosted related research and led to the discovery of many novel coronaviruses (CoVs) from different hosts such as equines, whales, birds, and bats; the latter species are considered as the potential reservoir of SARS-CoV Li et al., 2005; Marra et al., 2003; Mihindukulasuriya et al., 2008; Woo et al., 2007 Woo et al., , 2009 Zhang et al., 2007) .", [["acute respiratory syndrome coronavirus", "DISEASE", 40, 78], ["SARS", "DISEASE", 80, 84], ["SARS", "DISEASE", 314, 318], ["Severe acute respiratory syndrome coronavirus", "ORGANISM", 33, 78], ["SARS-CoV", "ORGANISM", 80, 88], ["coronaviruses", "ORGANISM", 166, 179], ["CoVs", "CANCER", 181, 185], ["birds", "ORGANISM", 233, 238], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 33, 78], ["SARS-CoV", "SPECIES", 80, 88], ["the Severe acute respiratory syndrome coronavirus", "PROBLEM", 29, 78], ["many novel coronaviruses (CoVs)", "PROBLEM", 155, 186], ["the latter species", "PROBLEM", 250, 268], ["Severe", "OBSERVATION_MODIFIER", 33, 39], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["respiratory syndrome coronavirus", "OBSERVATION", 46, 78], ["coronaviruses", "OBSERVATION", 166, 179]]], ["In the past few years, also two novel human CoVs, NL63 and HKU1, have been identified causing rather severe symptoms in infants and the elderly (van der Hoek et al., 2004; Woo et al., 2005) .", [["human", "ORGANISM", 38, 43], ["CoVs", "GENE_OR_GENE_PRODUCT", 44, 48], ["NL63", "GENE_OR_GENE_PRODUCT", 50, 54], ["HKU1", "GENE_OR_GENE_PRODUCT", 59, 63], ["infants", "ORGANISM", 120, 127], ["human CoVs", "PROTEIN", 38, 48], ["NL63", "PROTEIN", 50, 54], ["HKU1", "PROTEIN", 59, 63], ["human", "SPECIES", 38, 43], ["infants", "SPECIES", 120, 127], ["human", "SPECIES", 38, 43], ["rather severe symptoms in infants", "PROBLEM", 94, 127], ["severe", "OBSERVATION_MODIFIER", 101, 107]]], ["The discovery of so many novel CoVs calls for a better understanding of the phylogeny of CoVs.IntroductionBased on serological patterns and genome organization, the genus Coronavirus has been classified into three major groups: group I, II and III (Lai and Cavanagh, 1997; Brian and Baric, 2005) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 31, 35], ["CoVs", "GENE_OR_GENE_PRODUCT", 89, 93], ["CoVs", "PROTEIN", 31, 35], ["CoVs", "DNA", 89, 93], ["serological patterns", "TEST", 115, 135], ["the genus Coronavirus", "PROBLEM", 161, 182], ["genus Coronavirus", "OBSERVATION", 165, 182]]], ["More recently, these groups have been further subdivided into, in total, 9 subgroups, based upon amino acid similarity of structural and non-structural proteins (nsp) (Snijder et al., 2003; Woo et al., 2006 Woo et al., , 2007 Woo et al., 2006 Woo et al., , 2007 .", [["amino acid", "CHEMICAL", 97, 107], ["amino acid", "CHEMICAL", 97, 107], ["amino acid", "AMINO_ACID", 97, 107], ["structural and non-structural proteins", "PROTEIN", 122, 160], ["nsp", "PROTEIN", 162, 165], ["amino acid", "TEST", 97, 107], ["non-structural proteins", "OBSERVATION", 137, 160]]], ["However, other studies propose at least 5 distinct lineages (Tang et al., 2006; Dong et al., 2007; Vijaykrishna et al., 2007) , and even for SARS-CoV there is discussion whether it represents a separate lineage or is an early split-off of group II CoVs (Snijder et al., 2003; Gibbs et al., 2004) .", [["SARS", "DISEASE", 141, 145], ["SARS-CoV", "ORGANISM", 141, 149], ["SARS-CoV", "SPECIES", 141, 149], ["other studies", "TEST", 9, 22], ["SARS", "PROBLEM", 141, 145]]], ["Thus, in addition to the conventional pair-wise comparison of viral protein sequences, other genetic or structural features may be helpful in the classification of CoVs.IntroductionIn the genome of CoVs, like that of most RNA viruses, the 5\u2032 and 3\u2032 untranslated regions (UTRs) usually harbor important structural elements which are involved in replication and/or translation (Chang et al., 1994; Raman et al., 2003; Raman and Brian, 2005; Goebel et al., 2007; Z\u00fcst et al., 2008; Liu et al., 2009) .", [["CoVs", "CANCER", 164, 168], ["CoVs", "GENE_OR_GENE_PRODUCT", 198, 202], ["5\u2032", "GENE_OR_GENE_PRODUCT", 239, 241], ["viral protein sequences", "DNA", 62, 85], ["CoVs", "DNA", 164, 168], ["CoVs", "DNA", 198, 202], ["5\u2032 and 3\u2032 untranslated regions", "DNA", 239, 269], ["UTRs", "DNA", 271, 275], ["viral protein sequences", "TEST", 62, 85], ["CoVs", "PROBLEM", 164, 168], ["CoVs", "PROBLEM", 198, 202], ["most RNA viruses", "PROBLEM", 217, 233], ["CoVs", "OBSERVATION", 198, 202], ["structural elements", "OBSERVATION", 302, 321]]], ["In Mouse hepatitis virus (MHV), a group II CoV, a bulged stem-loop and a pseudoknot structure were identified in the 3\u2032 UTR (Goebel et al., 2004a) .", [["Mouse hepatitis virus", "DISEASE", 3, 24], ["Mouse hepatitis virus", "ORGANISM", 3, 24], ["MHV", "ORGANISM", 26, 29], ["CoV", "ORGANISM", 43, 46], ["UTR", "DNA", 120, 123], ["Mouse hepatitis virus", "SPECIES", 3, 24], ["Mouse hepatitis virus", "SPECIES", 3, 24], ["MHV", "SPECIES", 26, 29], ["II CoV", "SPECIES", 40, 46], ["Mouse hepatitis virus", "PROBLEM", 3, 24], ["a group II CoV", "TREATMENT", 32, 46], ["a bulged stem-loop", "TREATMENT", 48, 66], ["a pseudoknot structure", "PROBLEM", 71, 93], ["hepatitis virus", "OBSERVATION", 9, 24], ["bulged stem", "OBSERVATION", 50, 61], ["loop", "OBSERVATION_MODIFIER", 62, 66], ["pseudoknot structure", "OBSERVATION", 73, 93]]], ["Similar pseudoknot structures were found in other group I and II CoVs, showing structural conservations of the CoV 3\u2032 UTR (Goebel et al., 2004a) .", [["CoVs", "GENE_OR_GENE_PRODUCT", 65, 69], ["group I and II CoVs", "PROTEIN", 50, 69], ["CoV 3\u2032 UTR", "DNA", 111, 121], ["Similar pseudoknot structures", "PROBLEM", 0, 29], ["II CoVs", "PROBLEM", 62, 69], ["structural conservations of the CoV", "PROBLEM", 79, 114], ["pseudoknot structures", "OBSERVATION", 8, 29], ["structural conservations", "OBSERVATION", 79, 103]]], ["However, the 3\u2032 UTR of MHV could be functionally replaced by the 3\u2032 UTR of group II SARS-CoV but not by that of the group I Transmissible gastroenteritis virus (TGEV) or the group III Avian infectious bronchitis virus (IBV), indicating certain group-specific functions for the 3\u2032 UTR (Goebel et al., 2004b) .IntroductionIn this study the secondary structures of the 5\u2032 UTRs and the 5\u2032proximal sequences of the ORF1ab gene in all known CoVs were predicted.", [["SARS", "DISEASE", 84, 88], ["Transmissible gastroenteritis", "DISEASE", 124, 153], ["infectious bronchitis", "DISEASE", 190, 211], ["MHV", "ORGANISM", 23, 26], ["Transmissible gastroenteritis virus", "ORGANISM", 124, 159], ["TGEV", "ORGANISM", 161, 165], ["group III", "ORGANISM", 174, 183], ["Avian infectious bronchitis virus", "ORGANISM", 184, 217], ["IBV", "ORGANISM", 219, 222], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 410, 416], ["CoVs", "GENE_OR_GENE_PRODUCT", 435, 439], ["3\u2032 UTR", "DNA", 13, 19], ["UTR", "DNA", 68, 71], ["3\u2032 UTR", "DNA", 277, 283], ["5\u2032 UTRs", "DNA", 366, 373], ["5\u2032proximal sequences", "DNA", 382, 402], ["ORF1ab gene", "DNA", 410, 421], ["CoVs", "DNA", 435, 439], ["Transmissible gastroenteritis virus", "SPECIES", 124, 159], ["Avian infectious bronchitis virus", "SPECIES", 184, 217], ["MHV", "SPECIES", 23, 26], ["SARS-CoV", "SPECIES", 84, 92], ["I Transmissible gastroenteritis virus", "SPECIES", 122, 159], ["TGEV", "SPECIES", 161, 165], ["Avian infectious bronchitis virus", "SPECIES", 184, 217], ["IBV", "SPECIES", 219, 222], ["the 3\u2032 UTR of MHV", "TREATMENT", 9, 26], ["UTR of group II SARS", "PROBLEM", 68, 88], ["CoV", "PROBLEM", 89, 92], ["Transmissible gastroenteritis virus (TGEV", "PROBLEM", 124, 165], ["the group III Avian infectious bronchitis virus", "PROBLEM", 170, 217], ["this study", "TEST", 323, 333], ["the 5\u2032proximal sequences", "TEST", 378, 402], ["MHV", "ANATOMY", 23, 26], ["group II", "OBSERVATION_MODIFIER", 75, 83], ["infectious", "OBSERVATION_MODIFIER", 190, 200], ["bronchitis", "OBSERVATION", 201, 211]]], ["The structural features of this region turned out to reflect the known grouping of CoVs, which is based on amino acid similarity.", [["amino acid", "CHEMICAL", 107, 117], ["amino acid", "CHEMICAL", 107, 117], ["CoVs", "GENE_OR_GENE_PRODUCT", 83, 87], ["amino acid", "AMINO_ACID", 107, 117], ["CoVs", "PROTEIN", 83, 87], ["amino acid similarity", "TEST", 107, 128], ["CoVs", "OBSERVATION", 83, 87]]], ["The unique and conserved features were further investigated in detail.Results and discussionThe clustering of the 5\u2032-proximal sequence of CoV RNAs shows group specificityResults and discussionThe clustering of the CoV 5\u2032-proximal 420 nucleotides (nts) obtained from the Kalign webserver (see Materials and methods) basically resembled the current grouping system for CoVs (Fig. 1) , though group I CoVs may be further subdivided into 4 subgroups, groups Ia to Id, according to their relatively large phylogenetic distances ( Fig. 1 ).", [["nucleotides", "CHEMICAL", 234, 245], ["CoV", "GENE_OR_GENE_PRODUCT", 138, 141], ["Id", "GENE_OR_GENE_PRODUCT", 460, 462], ["5\u2032-proximal sequence", "DNA", 114, 134], ["CoV RNAs", "RNA", 138, 146], ["CoV 5\u2032-proximal 420 nucleotides", "DNA", 214, 245], ["Id", "PROTEIN", 460, 462], ["CoV RNAs", "TEST", 138, 146], ["group specificity", "TEST", 153, 170], ["the CoV", "TEST", 210, 217], ["CoVs", "PROBLEM", 367, 371], ["group I CoVs", "PROBLEM", 390, 402], ["CoV", "ANATOMY", 214, 217]]], ["Sequence comparison further showed conserved and unique features for each CoV group, including: (i) the relative location of the core sequence of the leader transcription-regulating sequence (L-TRS) is quite conserved in all CoVs, except for the one in group Ia CoVs which has a rather long leader sequence upstream of the core TRS; (ii) the potentially translatable short ORF upstream of the genomic ORF1ab, the uORF, is present in most CoVs except for group IId, IIIb, IIIc, and IIId CoVs; (iii) the 5\u2032 UTR in group III CoVs is substantially longer than that in group I and II CoVs, while group IIa CoVs have an exclusively short 5\u2032 UTR (Fig. 1) .", [["CoVs", "PATHOLOGICAL_FORMATION", 225, 229], ["CoVs", "GENE_OR_GENE_PRODUCT", 262, 266], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 401, 407], ["CoVs", "CANCER", 438, 442], ["IIIc", "GENE_OR_GENE_PRODUCT", 471, 475], ["IIId CoVs", "GENE_OR_GENE_PRODUCT", 481, 490], ["II CoVs", "GENE_OR_GENE_PRODUCT", 576, 583], ["IIa CoVs", "GENE_OR_GENE_PRODUCT", 597, 605], ["leader transcription-regulating sequence", "DNA", 150, 190], ["TRS", "DNA", 194, 197], ["CoVs", "DNA", 225, 229], ["group Ia CoVs", "DNA", 253, 266], ["long leader sequence", "DNA", 286, 306], ["core TRS", "DNA", 323, 331], ["short ORF upstream", "DNA", 367, 385], ["genomic ORF1ab", "DNA", 393, 407], ["uORF", "DNA", 413, 417], ["CoVs", "DNA", 438, 442], ["IIIc", "DNA", 471, 475], ["IIId CoVs", "DNA", 481, 490], ["5\u2032 UTR", "DNA", 502, 508], ["group IIa CoVs", "PROTEIN", 591, 605], ["UTR", "DNA", 635, 638], ["translatable short ORF upstream", "PROBLEM", 354, 385], ["substantially", "OBSERVATION_MODIFIER", 530, 543], ["longer", "OBSERVATION_MODIFIER", 544, 550]]], ["It has to be noted that in order to obtain a higher threshold of the phylogenetic distance, strains with the highest sequence variation were used for analysis (selected from the genomic sequences of all CoVs available in GenBank).", [["genomic sequences", "DNA", 178, 195], ["CoVs", "DNA", 203, 207], ["the highest sequence variation", "TEST", 105, 135], ["analysis", "TEST", 150, 158]]], ["To further examine if particular features found in the RNA sequence in each group are relevant to specific organization of the 5\u2032 cis-acting elements, we globally predicted the secondary structures of the CoV 5\u2032 UTRs, predominantly using computational calculations at the mfold webserver (Zuker, 2003) .", [["RNA sequence", "DNA", 55, 67], ["5\u2032 cis-acting elements", "DNA", 127, 149], ["CoV 5\u2032 UTRs", "DNA", 205, 216], ["particular features", "PROBLEM", 22, 41], ["the RNA sequence", "TEST", 51, 67], ["computational calculations", "TEST", 238, 264], ["CoV", "ANATOMY", 205, 208]]], ["We have identified several conserved stemloop (SL) structures in this region, some of which are organized in a group-specific manner (see Figs.", [["stemloop", "GENE_OR_GENE_PRODUCT", 37, 45], ["stemloop (SL) structures", "DNA", 37, 61], ["several conserved stemloop (SL) structures in this region", "PROBLEM", 19, 76], ["several", "OBSERVATION_MODIFIER", 19, 26], ["conserved", "OBSERVATION_MODIFIER", 27, 36], ["stemloop", "OBSERVATION_MODIFIER", 37, 45], ["SL", "OBSERVATION_MODIFIER", 47, 49], ["region", "ANATOMY_MODIFIER", 70, 76]]], ["The universal presence of SL1 and SL2 in CoV 5\u2032 UTRResults and discussionThe very 5\u2032 nts of CoV RNAs fold into a hairpin of low thermodynamic stability, SL1, which is supported by many co-variations (Figs.", [["SL1", "GENE_OR_GENE_PRODUCT", 26, 29], ["SL2", "GENE_OR_GENE_PRODUCT", 34, 37], ["CoV 5", "ORGANISM", 41, 46], ["CoV", "ORGANISM", 92, 95], ["SL1", "DNA", 26, 29], ["SL2", "DNA", 34, 37], ["CoV RNAs", "RNA", 92, 100], ["SL1", "DNA", 153, 156], ["CoV RNAs", "TREATMENT", 92, 100], ["low thermodynamic stability", "PROBLEM", 124, 151], ["SL1", "ANATOMY_MODIFIER", 26, 29], ["low thermodynamic stability", "OBSERVATION_MODIFIER", 124, 151]]], ["2-4), particularly in group IIa and IIIc CoVs.", [["IIIc CoVs", "GENE_OR_GENE_PRODUCT", 36, 45], ["group IIa", "OBSERVATION_MODIFIER", 22, 31], ["IIIc CoVs", "OBSERVATION", 36, 45]]], ["The loop sequences are not strongly conserved although a YRYR tetra-loop seems to be preferred in most SL1s.", [["YRYR", "GENE_OR_GENE_PRODUCT", 57, 61], ["SL1s", "CANCER", 103, 107], ["YRYR tetra-loop", "DNA", 57, 72], ["SL1s", "PROTEIN", 103, 107], ["The loop sequences", "TEST", 0, 18], ["a YRYR tetra-loop", "PROBLEM", 55, 72]]], ["A general feature of SL1 is the presence of mismatches, bulges (e.g. in group I and II CoV RNAs) and a high number of A-U and U-A base pairs (bps) (e.g. in group IIIa, b, and d CoV RNAs).Results and discussionRecent data by Li et al. (2008) suggest that the low thermodynamic stability of SL1 is important for the replication of MHV.Results and discussionAnother conserved hairpin is SL2 which consists of a 5-bp stem and a highly conserved loop sequence, 5\u2032-CUUGY-3\u2032, which has an important role in MHV replication , though the motif is less conserved in SL2 of group I and III CoVs (Figs.", [["SL1", "GENE_OR_GENE_PRODUCT", 21, 24], ["II CoV", "GENE_OR_GENE_PRODUCT", 84, 90], ["A-U", "GENE_OR_GENE_PRODUCT", 118, 121], ["U-A", "GENE_OR_GENE_PRODUCT", 126, 129], ["b", "GENE_OR_GENE_PRODUCT", 168, 169], ["d CoV", "GENE_OR_GENE_PRODUCT", 175, 180], ["SL1", "GENE_OR_GENE_PRODUCT", 289, 292], ["MHV", "ORGANISM", 329, 332], ["SL2", "GENE_OR_GENE_PRODUCT", 384, 387], ["5\u2032-CUUGY-3", "GENE_OR_GENE_PRODUCT", 456, 466], ["MHV", "ORGANISM", 500, 503], ["III CoVs", "GENE_OR_GENE_PRODUCT", 575, 583], ["SL1", "DNA", 21, 24], ["group I and II CoV RNAs", "RNA", 72, 95], ["bps", "DNA", 142, 145], ["group IIIa, b, and d CoV RNAs", "RNA", 156, 185], ["SL1", "DNA", 289, 292], ["SL2", "DNA", 384, 387], ["5-bp stem", "DNA", 408, 417], ["highly conserved loop sequence", "DNA", 424, 454], ["5\u2032-CUUGY-3\u2032", "DNA", 456, 467], ["SL2", "DNA", 556, 559], ["MHV", "SPECIES", 329, 332], ["MHV", "SPECIES", 500, 503], ["mismatches", "PROBLEM", 44, 54], ["bulges (e.g. in group I and II CoV RNAs", "PROBLEM", 56, 95], ["A base pairs", "TEST", 128, 140], ["bps", "TEST", 142, 145], ["the low thermodynamic stability of SL1", "PROBLEM", 254, 292], ["the replication of MHV", "TREATMENT", 310, 332], ["a 5-bp stem", "TREATMENT", 406, 417], ["MHV replication", "TREATMENT", 500, 515], ["SL1", "OBSERVATION", 21, 24], ["mismatches", "OBSERVATION", 44, 54], ["bulges", "OBSERVATION_MODIFIER", 56, 62], ["high", "OBSERVATION_MODIFIER", 103, 107], ["MHV replication", "OBSERVATION", 500, 515]]], ["Downstream of SL2, an additional hairpin, SL2.1, with the stable UUCG tetra-loop, was predicted in group Ia CoVs.", [["SL2", "GENE_OR_GENE_PRODUCT", 14, 17], ["SL2.1", "GENE_OR_GENE_PRODUCT", 42, 47], ["UUCG", "GENE_OR_GENE_PRODUCT", 65, 69], ["CoVs", "GENE_OR_GENE_PRODUCT", 108, 112], ["SL2", "DNA", 14, 17], ["SL2.1", "DNA", 42, 47], ["UUCG tetra-loop", "DNA", 65, 80], ["group Ia CoVs", "CELL_LINE", 99, 112], ["an additional hairpin, SL2.1", "PROBLEM", 19, 47], ["SL2", "ANATOMY", 14, 17], ["hairpin", "OBSERVATION", 33, 40], ["stable", "OBSERVATION_MODIFIER", 58, 64]]], ["Interestingly, the CUUGY loop was recently shown to adopt the YNMG-type of tetra-loop-folds (Liu et al., 2009) .The diversity of SL3 and SL4 in CoVsPreviously, the core L-TRS in CoVs has either been proposed to be non-structured (Stirrups et al., 2000; Wang and Zhang, 2000) or to form a hairpin structure (Shieh et al., 1987; Chang et al., 1996) .", [["CoVs", "CHEMICAL", 178, 182], ["CUUGY", "GENE_OR_GENE_PRODUCT", 19, 24], ["SL3", "GENE_OR_GENE_PRODUCT", 129, 132], ["SL4", "GENE_OR_GENE_PRODUCT", 137, 140], ["CoVs", "GENE_OR_GENE_PRODUCT", 178, 182], ["CUUGY loop", "PROTEIN", 19, 29], ["YNMG", "PROTEIN", 62, 66], ["tetra-loop", "PROTEIN", 75, 85], ["SL3", "DNA", 129, 132], ["SL4", "DNA", 137, 140], ["core L-TRS", "DNA", 164, 174], ["CoVs", "DNA", 178, 182], ["CoVs", "PROBLEM", 178, 182], ["diversity", "OBSERVATION_MODIFIER", 116, 125], ["SL3", "ANATOMY", 129, 132], ["hairpin", "OBSERVATION", 288, 295]]], ["We found that the core L-TRS and the adjacent sequence may fold into SL3 in some CoVs, e.g. the group II Bovine coronavirus (BCoV), SARS-CoV and Bat coronavirus HKU4 (BatCoV-HKU4), and the group III coronavirus SW1 (CoV-SW1), Bulbul coronavirus HKU11 (BuCoV-HKU11), and Munia coronavirus HKU13 (MuCoV-HKU13) (Figs.", [["SL3", "GENE_OR_GENE_PRODUCT", 69, 72], ["CoVs", "GENE_OR_GENE_PRODUCT", 81, 85], ["Bovine coronavirus", "ORGANISM", 105, 123], ["BCoV", "GENE_OR_GENE_PRODUCT", 125, 129], ["SARS-CoV", "ORGANISM", 132, 140], ["Bat coronavirus HKU4", "ORGANISM", 145, 165], ["BatCoV-HKU4", "GENE_OR_GENE_PRODUCT", 167, 178], ["coronavirus SW1", "ORGANISM", 199, 214], ["CoV-SW1", "ORGANISM", 216, 223], ["Bulbul coronavirus", "ORGANISM", 226, 244], ["HKU11", "ORGANISM", 245, 250], ["BuCoV-HKU11", "GENE_OR_GENE_PRODUCT", 252, 263], ["Munia coronavirus", "ORGANISM", 270, 287], ["HKU13", "ORGANISM", 288, 293], ["MuCoV-HKU13", "GENE_OR_GENE_PRODUCT", 295, 306], ["core L-TRS", "DNA", 18, 28], ["SL3", "PROTEIN", 69, 72], ["BatCoV", "PROTEIN", 167, 173], ["HKU13", "DNA", 301, 306], ["Bovine coronavirus", "SPECIES", 105, 123], ["Bat coronavirus", "SPECIES", 145, 160], ["coronavirus", "SPECIES", 199, 210], ["Bulbul coronavirus", "SPECIES", 226, 244], ["Munia coronavirus", "SPECIES", 270, 287], ["Bovine coronavirus", "SPECIES", 105, 123], ["BCoV", "SPECIES", 125, 129], ["SARS-CoV", "SPECIES", 132, 140], ["Bat coronavirus", "SPECIES", 145, 160], ["Bulbul coronavirus", "SPECIES", 226, 244], ["Munia coronavirus", "SPECIES", 270, 287], ["the adjacent sequence", "TEST", 33, 54], ["some CoVs", "PROBLEM", 76, 85], ["the group II Bovine coronavirus", "TEST", 92, 123], ["BCoV", "TEST", 125, 129], ["SARS", "PROBLEM", 132, 136], ["CoV", "TEST", 137, 140], ["Bat coronavirus HKU4", "TEST", 145, 165], ["BatCoV", "TEST", 167, 173], ["HKU4", "TEST", 174, 178], ["the group III coronavirus", "TEST", 185, 210], ["CoV", "TEST", 216, 219], ["SW1", "TEST", 220, 223], ["Bulbul coronavirus", "TEST", 226, 244], ["BuCoV", "TEST", 252, 257], ["HKU11", "TEST", 258, 263], ["Munia", "TEST", 270, 275], ["coronavirus", "TEST", 276, 287], ["MuCoV", "TEST", 295, 300], ["some CoVs", "OBSERVATION", 76, 85]]], ["However, the sequence variations found in group IIa CoVs are partially in conflict with the lower part of SL3, while in other CoVs there are no co-variations to support the formation of SL3.", [["group IIa CoVs", "GENE_OR_GENE_PRODUCT", 42, 56], ["SL3", "GENE_OR_GENE_PRODUCT", 106, 109], ["CoVs", "CANCER", 126, 130], ["SL3", "GENE_OR_GENE_PRODUCT", 186, 189], ["group IIa CoVs", "PROTEIN", 42, 56], ["SL3", "PROTEIN", 106, 109], ["SL3", "PROTEIN", 186, 189], ["the sequence variations", "TEST", 9, 32], ["group IIa CoVs", "PROBLEM", 42, 56], ["co-variations", "PROBLEM", 144, 157], ["the formation of SL3", "PROBLEM", 169, 189], ["lower", "ANATOMY_MODIFIER", 92, 97], ["no", "UNCERTAINTY", 141, 143], ["co-variations", "OBSERVATION", 144, 157]]], ["Thus, the CoV SL3 may not structurally resemble the L-TRS Hairpin (LTH) found in the related arterivirus, the Equine arteritis virus (EAV), which directs discontinuous transcription (van den Born et al., 2004 Born et al., , 2005 .", [["Equine arteritis", "DISEASE", 110, 126], ["CoV", "ORGANISM", 10, 13], ["SL3", "GENE_OR_GENE_PRODUCT", 14, 17], ["L-TRS Hairpin", "GENE_OR_GENE_PRODUCT", 52, 65], ["LTH", "GENE_OR_GENE_PRODUCT", 67, 70], ["arterivirus", "GENE_OR_GENE_PRODUCT", 93, 104], ["Equine arteritis virus", "ORGANISM", 110, 132], ["EAV", "ORGANISM", 134, 137], ["CoV SL3", "PROTEIN", 10, 17], ["L-TRS Hairpin", "DNA", 52, 65], ["LTH", "PROTEIN", 67, 70], ["Equine arteritis virus", "SPECIES", 110, 132], ["Equine arteritis virus", "SPECIES", 110, 132], ["EAV", "SPECIES", 134, 137], ["the CoV SL3", "PROBLEM", 6, 17], ["the L-TRS Hairpin (LTH)", "PROBLEM", 48, 71], ["the related arterivirus", "PROBLEM", 81, 104], ["the Equine arteritis virus", "PROBLEM", 106, 132], ["Equine arteritis", "OBSERVATION", 110, 126]]], ["In some other CoVs, e.g. TGEV and the Human coronavirus-229E (HCoV-229E), the core L-TRS was predicted to participate in the stem of SL4 (Figs.", [["stem", "ANATOMY", 125, 129], ["CoVs", "GENE_OR_GENE_PRODUCT", 14, 18], ["TGEV", "ORGANISM", 25, 29], ["Human coronavirus-229E", "ORGANISM", 38, 60], ["HCoV-229E", "ORGANISM", 62, 71], ["SL4", "GENE_OR_GENE_PRODUCT", 133, 136], ["core L-TRS", "DNA", 78, 88], ["TGEV", "SPECIES", 25, 29], ["Human", "SPECIES", 38, 43], ["coronavirus", "SPECIES", 44, 55], ["TGEV", "SPECIES", 25, 29], ["Human coronavirus-229E (HCoV-229E", "SPECIES", 38, 71], ["TGEV", "TEST", 25, 29], ["the Human coronavirus", "TEST", 34, 55], ["HCoV", "TEST", 62, 66], ["stem", "ANATOMY_MODIFIER", 125, 129]]], ["2A and B), although sequence variations found in group Ib CoVs do not strongly support the involvement of the core L-TRS in the SL4 stem (Fig. 2B) .", [["SL4 stem", "ANATOMY", 128, 136], ["2A", "GENE_OR_GENE_PRODUCT", 0, 2], ["B", "GENE_OR_GENE_PRODUCT", 7, 8], ["SL4 stem", "CELL", 128, 136], ["B", "PROTEIN", 7, 8], ["group Ib CoVs", "CELL_LINE", 49, 62], ["core L-TRS", "DNA", 110, 120], ["SL4 stem", "CELL_LINE", 128, 136], ["sequence variations", "TEST", 20, 39], ["group Ib CoVs", "PROBLEM", 49, 62], ["SL4 stem", "ANATOMY", 128, 136]]], ["All in all, based on the structural-phylogenetic survey, it can be concluded that the core L-TRS and the flanking sequences are poorly structured in CoVs.The diversity of SL3 and SL4 in CoVsDownstream of the L-TRS, a long hairpin, SL4, was predicted for all CoVs (Figs.", [["CoVs", "CANCER", 149, 153], ["SL3", "GENE_OR_GENE_PRODUCT", 171, 174], ["SL4", "GENE_OR_GENE_PRODUCT", 179, 182], ["SL4", "GENE_OR_GENE_PRODUCT", 231, 234], ["CoVs", "GENE_OR_GENE_PRODUCT", 258, 262], ["core L-TRS", "DNA", 86, 96], ["flanking sequences", "DNA", 105, 123], ["CoVs", "DNA", 149, 153], ["SL3", "DNA", 171, 174], ["SL4", "DNA", 179, 182], ["CoVsDownstream", "DNA", 186, 200], ["L-TRS", "DNA", 208, 213], ["long hairpin", "DNA", 217, 229], ["SL4", "DNA", 231, 234], ["CoVs", "DNA", 258, 262], ["the flanking sequences", "TEST", 101, 123], ["SL3", "PROBLEM", 171, 174], ["a long hairpin, SL4", "PROBLEM", 215, 234], ["diversity", "OBSERVATION_MODIFIER", 158, 167], ["SL3", "ANATOMY_MODIFIER", 171, 174], ["L", "ANATOMY_MODIFIER", 208, 209], ["-TRS", "ANATOMY_MODIFIER", 209, 213], ["long", "OBSERVATION_MODIFIER", 217, 221], ["hairpin", "OBSERVATION", 222, 229]]], ["The presence of a large number of co-variations seems to support the existence of SL4 strongly, particularly the upper half of this structure.", [["SL4", "GENE_OR_GENE_PRODUCT", 82, 85], ["SL4", "PROTEIN", 82, 85], ["a large number of co-variations", "PROBLEM", 16, 47], ["large", "OBSERVATION_MODIFIER", 18, 23], ["number", "OBSERVATION_MODIFIER", 24, 30], ["co-variations", "OBSERVATION", 34, 47], ["upper half", "ANATOMY_MODIFIER", 113, 123]]], ["Raman et al. (2003) have shown that the structural integrity, in positive or negative strands or both, of the upper part of SL4 (the SL-III in their study) is important for replication of BCoV DI RNA.", [["SL4", "GENE_OR_GENE_PRODUCT", 124, 127], ["SL-III", "GENE_OR_GENE_PRODUCT", 133, 139], ["BCoV DI", "GENE_OR_GENE_PRODUCT", 188, 195], ["SL4", "PROTEIN", 124, 127], ["BCoV DI RNA", "RNA", 188, 199], ["BCoV", "SPECIES", 188, 192], ["BCoV DI RNA", "PROBLEM", 188, 199], ["structural", "OBSERVATION_MODIFIER", 40, 50], ["integrity", "OBSERVATION_MODIFIER", 51, 60], ["negative strands", "OBSERVATION", 77, 93], ["both", "OBSERVATION_MODIFIER", 97, 101], ["upper", "ANATOMY_MODIFIER", 110, 115], ["DI RNA", "OBSERVATION", 193, 199]]], ["We also found that the uORF predominantly terminates within the SL4 (data not shown), even for those uORFs that are in-frame with the downstream ORF1ab (Fig. 1) .The diversity of SL3 and SL4 in CoVsThere has no direct evidence for the translation of uORF in CoV infected cells, although Raman et al. (2003) have suggested a positive correlation between maintenance of the uORF and maximal BCoV DI RNA accumulation.", [["cells", "ANATOMY", 271, 276], ["SL4", "GENE_OR_GENE_PRODUCT", 64, 67], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 145, 151], ["SL3", "GENE_OR_GENE_PRODUCT", 179, 182], ["SL4", "GENE_OR_GENE_PRODUCT", 187, 190], ["CoVsThere", "GENE_OR_GENE_PRODUCT", 194, 203], ["CoV", "ORGANISM", 258, 261], ["cells", "CELL", 271, 276], ["uORF", "DNA", 23, 27], ["SL4", "DNA", 64, 67], ["uORFs", "DNA", 101, 106], ["ORF1ab", "DNA", 145, 151], ["SL3", "DNA", 179, 182], ["SL4", "DNA", 187, 190], ["CoVsThere", "DNA", 194, 203], ["uORF", "DNA", 250, 254], ["CoV infected cells", "CELL_TYPE", 258, 276], ["uORF", "DNA", 372, 376], ["the uORF", "PROBLEM", 19, 27], ["those uORFs", "PROBLEM", 95, 106], ["uORF in CoV infected cells", "PROBLEM", 250, 276], ["the uORF", "TREATMENT", 368, 376], ["maximal BCoV DI RNA accumulation", "PROBLEM", 381, 413], ["uORF", "OBSERVATION_MODIFIER", 23, 27], ["predominantly", "OBSERVATION_MODIFIER", 28, 41], ["terminates", "OBSERVATION_MODIFIER", 42, 52], ["diversity", "OBSERVATION_MODIFIER", 166, 175], ["SL3", "ANATOMY", 179, 182], ["no direct evidence for", "UNCERTAINTY", 208, 230], ["infected cells", "OBSERVATION", 262, 276], ["DI RNA accumulation", "OBSERVATION", 394, 413]]], ["They have also shown that a DI RNA in which this uORF was replaced by a totally unrelated uORF could be replicated.", [["DI RNA", "RNA", 28, 34], ["uORF", "DNA", 49, 53], ["uORF", "DNA", 90, 94], ["a DI RNA", "PROBLEM", 26, 34], ["a totally unrelated uORF", "TREATMENT", 70, 94]]], ["Our phylogenetic analysis showed that the sequence variations located in SL4, which were found to maintain the integrity of the RNA secondary structure, are not always silent at the amino acid level (data not shown).", [["amino acid", "CHEMICAL", 182, 192], ["amino acid", "CHEMICAL", 182, 192], ["SL4", "GENE_OR_GENE_PRODUCT", 73, 76], ["amino acid", "AMINO_ACID", 182, 192], ["SL4", "DNA", 73, 76], ["Our phylogenetic analysis", "TEST", 0, 25], ["the sequence variations", "PROBLEM", 38, 61], ["the amino acid level", "TEST", 178, 198], ["RNA", "OBSERVATION", 128, 131], ["secondary structure", "OBSERVATION", 132, 151]]], ["Although features of uORFs seem to be conserved and group-specific (Fig. 1) , the necessity of translation of this ORF needs to be determined in the future to understand why certain groups of CoVs do need uORF for their propagation and others do not.The diversity of SL3 and SL4 in CoVsWe noticed that the sequence of SL4 is included in the hotspot of the 5\u2032-proximal genomic acceptor (Wu et al., 2006) , suggesting that SL4 may play a role in directing the subgenomic RNA synthesis and thereby compensates for the absence of a structured L-TRS hairpin (see above).Features of the inserted sequence in SL5 reflect the lineage of CoVsA fifth structural element, SL5, was predicted downstream of SL4 in all CoVs (Figs.", [["SL4", "CHEMICAL", 421, 424], ["CoVs", "GENE_OR_GENE_PRODUCT", 192, 196], ["SL3", "GENE_OR_GENE_PRODUCT", 267, 270], ["SL4", "GENE_OR_GENE_PRODUCT", 275, 278], ["SL4", "GENE_OR_GENE_PRODUCT", 318, 321], ["SL4", "GENE_OR_GENE_PRODUCT", 421, 424], ["SL5", "GENE_OR_GENE_PRODUCT", 602, 605], ["CoVsA", "GENE_OR_GENE_PRODUCT", 629, 634], ["SL5", "GENE_OR_GENE_PRODUCT", 661, 664], ["SL4", "GENE_OR_GENE_PRODUCT", 694, 697], ["CoVs", "PATHOLOGICAL_FORMATION", 705, 709], ["uORFs", "DNA", 21, 26], ["ORF", "DNA", 115, 118], ["CoVs", "DNA", 192, 196], ["uORF", "DNA", 205, 209], ["SL3", "DNA", 267, 270], ["SL4", "DNA", 275, 278], ["CoVsWe", "DNA", 282, 288], ["SL4", "DNA", 318, 321], ["5\u2032-proximal genomic acceptor", "DNA", 356, 384], ["SL4", "PROTEIN", 421, 424], ["subgenomic RNA", "RNA", 458, 472], ["L-TRS hairpin", "DNA", 539, 552], ["SL5", "DNA", 602, 605], ["CoVsA fifth structural element", "DNA", 629, 659], ["SL5", "DNA", 661, 664], ["SL4", "DNA", 694, 697], ["CoVs", "DNA", 705, 709], ["uORFs", "PROBLEM", 21, 26], ["this ORF", "TREATMENT", 110, 118], ["the subgenomic RNA synthesis", "TREATMENT", 454, 482], ["a structured L-TRS hairpin", "PROBLEM", 526, 552], ["the inserted sequence", "TEST", 577, 598], ["uORFs", "OBSERVATION", 21, 26], ["diversity", "OBSERVATION_MODIFIER", 254, 263], ["SL3", "ANATOMY", 267, 270], ["proximal", "ANATOMY_MODIFIER", 359, 367], ["lineage", "OBSERVATION_MODIFIER", 618, 625], ["fifth", "OBSERVATION_MODIFIER", 635, 640], ["structural element", "OBSERVATION", 641, 659], ["all CoVs", "ANATOMY", 701, 709]]], ["SL5 is a homologue of SL-IV of BCoV reported by Brian and coworkers (Raman and Brian, 2005; Brown et al., 2007) and is supported by co-variations in almost all CoV groups with the exception of group Ia, and IIIa, b, and d CoVs, where sequence variation is low.", [["SL5", "GENE_OR_GENE_PRODUCT", 0, 3], ["SL-IV", "GENE_OR_GENE_PRODUCT", 22, 27], ["BCoV", "GENE_OR_GENE_PRODUCT", 31, 35], ["IIIa", "GENE_OR_GENE_PRODUCT", 207, 211], ["b", "GENE_OR_GENE_PRODUCT", 213, 214], ["CoVs", "GENE_OR_GENE_PRODUCT", 222, 226], ["SL5", "PROTEIN", 0, 3], ["CoVs", "PROTEIN", 222, 226], ["sequence variation", "TEST", 234, 252], ["IIIa", "ANATOMY", 207, 211], ["low", "OBSERVATION_MODIFIER", 256, 259]]], ["Compared to group IIa and III CoVs, the other CoVs have sequence insertions in the top of SL5, which are about 110-nt long in group I CoVs and between 55 and 94 nt in group IIb, c, and d CoVs (Figs.", [["CoVs", "GENE_OR_GENE_PRODUCT", 30, 34], ["CoVs", "GENE_OR_GENE_PRODUCT", 46, 50], ["SL5", "GENE_OR_GENE_PRODUCT", 90, 93], ["CoVs", "GENE_OR_GENE_PRODUCT", 134, 138], ["IIb, c", "GENE_OR_GENE_PRODUCT", 173, 179], ["d CoVs", "GENE_OR_GENE_PRODUCT", 185, 191], ["group IIa and III CoVs", "DNA", 12, 34], ["CoVs", "DNA", 46, 50], ["SL5", "DNA", 90, 93], ["group I CoVs", "DNA", 126, 138], ["sequence insertions", "TREATMENT", 56, 75], ["group IIa", "OBSERVATION_MODIFIER", 12, 21], ["top", "OBSERVATION_MODIFIER", 83, 86], ["SL5", "ANATOMY", 90, 93], ["group IIb", "OBSERVATION_MODIFIER", 167, 176], ["d CoVs", "OBSERVATION", 185, 191]]], ["Secondary structure predictions of these inserts revealed hairpins displaying the conserved 5\u2032-UUYCGU-3\u2032 loop motif (Fig. 5) .", [["5\u2032-UUYCGU-3\u2032 loop motif", "DNA", 92, 115], ["these inserts", "TREATMENT", 35, 48], ["hairpins", "PROBLEM", 58, 66], ["UUYCGU", "TEST", 95, 101], ["loop motif", "TREATMENT", 105, 115], ["hairpins", "OBSERVATION", 58, 66]]], ["We note that some of these hairpins resemble the predicted structures for four group I CoVs and SARS-CoV reported by Raman and Brian (2005) , which were proposed to be homologues of BCoV SL5 (SL-IV in their report).", [["CoVs", "GENE_OR_GENE_PRODUCT", 87, 91], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 96, 104], ["SL-IV", "GENE_OR_GENE_PRODUCT", 192, 197], ["BCoV SL5", "PROTEIN", 182, 190], ["SL-IV", "PROTEIN", 192, 197], ["SARS-CoV", "SPECIES", 96, 104], ["these hairpins", "PROBLEM", 21, 35], ["SARS", "PROBLEM", 96, 100], ["hairpins", "OBSERVATION", 27, 35]]], ["Nevertheless, our comprehensive structural-phylogenetic analysis indicates that these conserved structural motifs are not SL5 homologues as such but are substructural hairpins within SL5 (Figs.", [["SL5", "GENE_OR_GENE_PRODUCT", 122, 125], ["SL5", "GENE_OR_GENE_PRODUCT", 183, 186], ["SL5 homologues", "DNA", 122, 136], ["our comprehensive structural-phylogenetic analysis", "TEST", 14, 64], ["SL5 homologues", "PROBLEM", 122, 136], ["substructural hairpins", "PROBLEM", 153, 175], ["hairpins", "OBSERVATION", 167, 175]]], ["2, 3, and 5) .Features of the inserted sequence in SL5 reflect the lineage of CoVsIn group I CoVs, a large number of co-variations, particularly in group Ib CoVs, was observed, supporting the existence of these substructural hairpins at the top of SL5 (Fig. 5) .", [["SL5", "GENE_OR_GENE_PRODUCT", 51, 54], ["CoVsIn group I CoVs", "GENE_OR_GENE_PRODUCT", 78, 97], ["CoVs", "GENE_OR_GENE_PRODUCT", 157, 161], ["SL5", "DNA", 51, 54], ["CoVsIn group I CoVs", "PROTEIN", 78, 97], ["group Ib CoVs", "PROTEIN", 148, 161], ["SL5", "PROTEIN", 248, 251], ["the inserted sequence", "TEST", 26, 47], ["a large number of co-variations", "PROBLEM", 99, 130], ["group Ib CoVs", "PROBLEM", 148, 161], ["these substructural hairpins", "PROBLEM", 205, 233], ["lineage", "OBSERVATION_MODIFIER", 67, 74], ["large", "OBSERVATION_MODIFIER", 101, 106], ["number", "OBSERVATION_MODIFIER", 107, 113], ["co-variations", "OBSERVATION_MODIFIER", 117, 130], ["Ib CoVs", "OBSERVATION", 154, 161], ["substructural hairpins", "OBSERVATION", 211, 233], ["top", "OBSERVATION_MODIFIER", 241, 244]]], ["We noticed that 4 different patterns of the SL5 substructural hairpins were found in group I CoVs.", [["SL5", "GENE_OR_GENE_PRODUCT", 44, 47], ["SL5", "DNA", 44, 47], ["group I CoVs", "PROTEIN", 85, 97], ["the SL5 substructural hairpins", "PROBLEM", 40, 70], ["4 different", "OBSERVATION_MODIFIER", 16, 27], ["substructural hairpins", "OBSERVATION", 48, 70]]], ["This finding supports the idea that group I CoVs may be clustered into 4 subgroups, groups Ia to d.", [["CoVs", "GENE_OR_GENE_PRODUCT", 44, 48], ["group I CoVs", "PROBLEM", 36, 48]]], ["Nonetheless, the structural homology of SL5 within the lineage of the group I CoVs is still higher than that of the group II CoVs; three hairpins, SL5a, b, and c, with mainly the conserved 5\u2032-UUCCGU-3\u2032 loop sequence, were found in all group I CoVs.", [["SL5", "GENE_OR_GENE_PRODUCT", 40, 43], ["CoVs", "GENE_OR_GENE_PRODUCT", 78, 82], ["CoVs", "GENE_OR_GENE_PRODUCT", 125, 129], ["SL5a", "GENE_OR_GENE_PRODUCT", 147, 151], ["b", "GENE_OR_GENE_PRODUCT", 153, 154], ["c", "GENE_OR_GENE_PRODUCT", 160, 161], ["SL5", "PROTEIN", 40, 43], ["group I CoVs", "PROTEIN", 70, 82], ["group II CoVs", "PROTEIN", 116, 129], ["SL5a", "PROTEIN", 147, 151], ["c", "PROTEIN", 160, 161], ["5\u2032", "PROTEIN", 189, 191], ["UUCCGU", "PROTEIN", 192, 198], ["group I CoVs", "PROTEIN", 235, 247], ["three hairpins", "TEST", 131, 145], ["SL5a", "TEST", 147, 151], ["lineage", "OBSERVATION_MODIFIER", 55, 62], ["higher", "OBSERVATION_MODIFIER", 92, 98]]], ["This is in agreement with the shorter phylogenetic distances found between each subgroup (group Ia-d) in group I CoVs compared to group II CoVs, which feature more diverse sequence insertions, in terms of length, the presence of 5\u2032-UUYCGU-3\u2032 motifs, and secondary structure.", [["group II CoVs", "CELL_LINE", 130, 143], ["5\u2032-UUYCGU-3\u2032 motifs", "DNA", 229, 248], ["group I CoVs", "PROBLEM", 105, 117], ["group II CoVs", "PROBLEM", 130, 143], ["UUYCGU", "TEST", 232, 238], ["secondary structure", "OBSERVATION", 254, 273]]], ["The greater structural variation in SL5 of group II CoVs is as follows: (i) the substructural hairpins are replaced by an 8-nt sequence in group IIa CoVs (Fig. 5E) ; (ii) one of the three substructural hairpins in SL5, SL5c, contains a GNRA tetra-loop sequence (group IIb) or a non-conserved hepta-loop sequence (group IIc) but not the UUYCGU motif (Figs.", [["group II CoVs", "GENE_OR_GENE_PRODUCT", 43, 56], ["SL5", "GENE_OR_GENE_PRODUCT", 214, 217], ["SL5c", "GENE_OR_GENE_PRODUCT", 219, 223], ["GNRA", "GENE_OR_GENE_PRODUCT", 236, 240], ["SL5", "PROTEIN", 36, 39], ["group II CoVs", "PROTEIN", 43, 56], ["substructural hairpins", "RNA", 80, 102], ["8-nt sequence", "DNA", 122, 135], ["group IIa CoVs", "PROTEIN", 139, 153], ["substructural hairpins", "PROTEIN", 188, 210], ["SL5", "PROTEIN", 214, 217], ["SL5c", "PROTEIN", 219, 223], ["GNRA tetra-loop sequence", "PROTEIN", 236, 260], ["group IIb", "PROTEIN", 262, 271], ["non-conserved hepta-loop sequence", "PROTEIN", 278, 311], ["group IIc", "PROTEIN", 313, 322], ["UUYCGU motif", "PROTEIN", 336, 348], ["the substructural hairpins", "TREATMENT", 76, 102], ["an 8-nt sequence", "TEST", 119, 135], ["the three substructural hairpins in SL5", "PROBLEM", 178, 217], ["a GNRA tetra-loop sequence", "TEST", 234, 260], ["a non-conserved hepta-loop sequence", "TEST", 276, 311], ["greater", "OBSERVATION_MODIFIER", 4, 11], ["structural", "OBSERVATION_MODIFIER", 12, 22], ["variation", "OBSERVATION_MODIFIER", 23, 32], ["hairpins", "OBSERVATION", 94, 102], ["substructural hairpins", "OBSERVATION", 188, 210]]], ["5F and G); (iii) only two substructural hairpins are folded on top of SL5 in group IId CoVs, yet an additional conserved UUCCGU motif is present in SL5.1 located further upstream, in between the L-TRS and SL4 (Figs.", [["SL5", "GENE_OR_GENE_PRODUCT", 70, 73], ["CoVs", "GENE_OR_GENE_PRODUCT", 87, 91], ["UUCCGU", "GENE_OR_GENE_PRODUCT", 121, 127], ["SL5.1", "GENE_OR_GENE_PRODUCT", 148, 153], ["L-TRS", "GENE_OR_GENE_PRODUCT", 195, 200], ["SL5", "PROTEIN", 70, 73], ["CoVs", "PROTEIN", 87, 91], ["UUCCGU motif", "DNA", 121, 133], ["SL5.1", "PROTEIN", 148, 153], ["TRS", "DNA", 197, 200], ["SL4", "DNA", 205, 208], ["5F and G)", "TREATMENT", 0, 9], ["two substructural hairpins", "PROBLEM", 22, 48], ["substructural hairpins", "OBSERVATION", 26, 48], ["folded", "OBSERVATION_MODIFIER", 53, 59], ["L", "ANATOMY_MODIFIER", 195, 196]]], ["Thus, the pattern of the SL5 substructures is strongly related to the lineage and the phylogenetic distance of the group I and II CoVs.Features of the inserted sequence in SL5 reflect the lineage of CoVsSimilar hairpins with a conserved loop motif could not be identified in group III CoVs (Fig. 4) .", [["SL5", "GENE_OR_GENE_PRODUCT", 25, 28], ["II CoVs", "GENE_OR_GENE_PRODUCT", 127, 134], ["SL5", "GENE_OR_GENE_PRODUCT", 172, 175], ["CoVsSimilar", "GENE_OR_GENE_PRODUCT", 199, 210], ["SL5", "PROTEIN", 25, 28], ["group I and II CoVs", "PROTEIN", 115, 134], ["SL5", "DNA", 172, 175], ["CoVsSimilar hairpins", "RNA", 199, 219], ["group III CoVs", "CELL_LINE", 275, 289], ["the SL5 substructures", "PROBLEM", 21, 42], ["the inserted sequence", "TEST", 147, 168], ["CoVsSimilar hairpins", "TREATMENT", 199, 219], ["a conserved loop motif", "TREATMENT", 225, 247], ["CoVsSimilar hairpins", "OBSERVATION", 199, 219], ["could not be", "UNCERTAINTY", 248, 260]]], ["Here, SL5 has a rod-like shape as in group IIa.", [["SL5", "CHEMICAL", 6, 9], ["SL5", "GENE_OR_GENE_PRODUCT", 6, 9], ["SL5", "PROTEIN", 6, 9], ["a rod-like shape", "PROBLEM", 14, 30], ["rod", "OBSERVATION_MODIFIER", 16, 19], ["like shape", "OBSERVATION_MODIFIER", 20, 30], ["group IIa", "OBSERVATION_MODIFIER", 37, 46]]], ["Also in the remainder of the 5\u2032 UTR of group III CoVs no hairpins could be identified that featured a UUYCGU sequence or another motif.Structure probing of the SL5 substructure in HCoV-229E and SARS-CoVTo verify the secondary structures of the proposed substructural hairpins in group I and II CoVs, the corresponding RNA transcripts of HCoV-229E and SARS-CoV were subjected to enzymatic and chemical structure probing (see Materials and methods).", [["SL5", "GENE_OR_GENE_PRODUCT", 160, 163], ["HCoV-229E", "CELL", 180, 189], ["SARS-CoVTo", "GENE_OR_GENE_PRODUCT", 194, 204], ["II CoVs", "GENE_OR_GENE_PRODUCT", 291, 298], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 337, 346], ["SARS-CoV", "ORGANISM", 351, 359], ["5\u2032 UTR", "DNA", 29, 35], ["UUYCGU sequence", "DNA", 102, 117], ["SL5", "PROTEIN", 160, 163], ["HCoV-229E and SARS-CoVTo", "DNA", 180, 204], ["substructural hairpins", "DNA", 253, 275], ["group I and II CoVs", "DNA", 279, 298], ["RNA transcripts", "RNA", 318, 333], ["HCoV", "PROTEIN", 337, 341], ["HCoV-229E", "SPECIES", 337, 346], ["SARS-CoV", "SPECIES", 351, 359], ["hairpins", "PROBLEM", 57, 65], ["a UUYCGU sequence", "TEST", 100, 117], ["HCoV", "TEST", 180, 184], ["SARS", "TEST", 194, 198], ["the proposed substructural hairpins in group I and II CoVs", "PROBLEM", 240, 298], ["HCoV", "TEST", 337, 341], ["SARS", "PROBLEM", 351, 355], ["CoV", "PROBLEM", 356, 359], ["enzymatic and chemical structure probing", "PROBLEM", 378, 418], ["hairpins", "OBSERVATION", 57, 65], ["substructural hairpins", "OBSERVATION", 253, 275], ["RNA transcripts", "OBSERVATION", 318, 333], ["chemical structure", "OBSERVATION", 392, 410]]], ["Clearly, the singlestranded 5\u2032-UUUCGU-3\u2032-hexa-loop sequences in HCoV-229E SL5a, SL5b, and SL5c can be recognized by the single-strand specific probes, DMS, RNase A, S1 nuclease and/or RNase T1 (Fig. 6A) , suggesting that these nucleotides are unpaired.", [["nucleotides", "CHEMICAL", 227, 238], ["HCoV-229E SL5a", "GENE_OR_GENE_PRODUCT", 64, 78], ["SL5b", "GENE_OR_GENE_PRODUCT", 80, 84], ["SL5c", "GENE_OR_GENE_PRODUCT", 90, 94], ["RNase A", "GENE_OR_GENE_PRODUCT", 156, 163], ["S1 nuclease", "GENE_OR_GENE_PRODUCT", 165, 176], ["RNase T1", "GENE_OR_GENE_PRODUCT", 184, 192], ["Fig. 6A", "GENE_OR_GENE_PRODUCT", 194, 201], ["singlestranded 5\u2032-UUUCGU-3\u2032-hexa-loop sequences", "DNA", 13, 60], ["HCoV-229E SL5a", "DNA", 64, 78], ["SL5b", "DNA", 80, 84], ["SL5c", "DNA", 90, 94], ["single-strand specific probes", "DNA", 120, 149], ["RNase A", "PROTEIN", 156, 163], ["S1 nuclease", "DNA", 165, 176], ["RNase T1", "PROTEIN", 184, 192], ["Fig. 6A", "PROTEIN", 194, 201], ["HCoV-229E SL5a", "SPECIES", 64, 78], ["UUUCGU", "TEST", 31, 37], ["loop sequences", "TEST", 46, 60], ["HCoV", "TEST", 64, 68]]], ["The presence of RNase V1 cuts, an enzyme that cuts double-stranded RNA, in the predicted stem regions is also in agreement with the model.", [["stem regions", "ANATOMY", 89, 101], ["RNase", "GENE_OR_GENE_PRODUCT", 16, 21], ["RNase V1", "PROTEIN", 16, 24], ["double-stranded RNA", "RNA", 51, 70], ["RNase V1 cuts", "PROBLEM", 16, 29], ["an enzyme", "TEST", 31, 40], ["double-stranded RNA", "PROBLEM", 51, 70], ["RNase V1", "OBSERVATION", 16, 24], ["stranded RNA", "OBSERVATION", 58, 70], ["stem", "ANATOMY_MODIFIER", 89, 93]]], ["Probing results of SARS-CoV were also in agreement with the existence of SL5a, b, and c (Fig. 6B) .Structure probing of the SL5 substructure in HCoV-229E and SARS-CoVNotably, the U:U mismatches located in the stems of these substructures seem to form non-canonical base pairs since RNAse V1 recognized U222 and U221 in HCoV-229E SL5b, as well as U193 in SARS-CoV SL5a.", [["HCoV-229E SL5b", "ANATOMY", 319, 333], ["SARS", "DISEASE", 19, 23], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["SL5a", "GENE_OR_GENE_PRODUCT", 73, 77], ["b", "GENE_OR_GENE_PRODUCT", 79, 80], ["c (Fig. 6B", "GENE_OR_GENE_PRODUCT", 86, 96], ["SL5", "GENE_OR_GENE_PRODUCT", 124, 127], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 144, 153], ["U:U", "GENE_OR_GENE_PRODUCT", 179, 182], ["RNAse V1", "GENE_OR_GENE_PRODUCT", 282, 290], ["U222", "GENE_OR_GENE_PRODUCT", 302, 306], ["U221", "GENE_OR_GENE_PRODUCT", 311, 315], ["HCoV-229E SL5b", "GENE_OR_GENE_PRODUCT", 319, 333], ["SARS-CoV SL5a", "ORGANISM", 354, 367], ["SL5a", "PROTEIN", 73, 77], ["SL5 substructure", "DNA", 124, 140], ["HCoV-229E and SARS-CoVNotably", "DNA", 144, 173], ["RNAse V1", "DNA", 282, 290], ["U222", "DNA", 302, 306], ["U221", "DNA", 311, 315], ["HCoV-229E SL5b", "DNA", 319, 333], ["U193", "DNA", 346, 350], ["SARS-CoV", "SPECIES", 19, 27], ["HCoV-229E", "SPECIES", 144, 153], ["HCoV-229E SL5b", "SPECIES", 319, 333], ["SARS-CoV", "SPECIES", 354, 362], ["HCoV", "TEST", 144, 148], ["SARS", "PROBLEM", 158, 162], ["U mismatches", "PROBLEM", 181, 193], ["HCoV", "TEST", 319, 323], ["mismatches", "OBSERVATION", 183, 193], ["stems", "ANATOMY_MODIFIER", 209, 214], ["base", "ANATOMY_MODIFIER", 265, 269]]], ["In fact, several (tandem) U:U mismatches were identified in the SL5 substructural hairpins, e.g. the SL5a in the group Ic Porcine epidemic diarrhea virus (PEDV) (Fig. 5C ) and the group Id Bat coronavirus 1A (BtCoV-1A) (Fig. 5D) , as well as in other 5\u2032 cis-acting elements, e.g. the MHV SL1 (Li et al., 2008) .", [["Porcine epidemic diarrhea", "DISEASE", 122, 147], ["U:U", "GENE_OR_GENE_PRODUCT", 26, 29], ["SL5", "GENE_OR_GENE_PRODUCT", 64, 67], ["SL5a", "GENE_OR_GENE_PRODUCT", 101, 105], ["Ic Porcine epidemic diarrhea virus", "ORGANISM", 119, 153], ["Fig. 5C", "ORGANISM", 162, 169], ["Bat coronavirus 1A", "ORGANISM", 189, 207], ["BtCoV-1A", "GENE_OR_GENE_PRODUCT", 209, 217], ["SL5 substructural hairpins", "DNA", 64, 90], ["SL5a", "DNA", 101, 105], ["BtCoV", "PROTEIN", 209, 214], ["5\u2032 cis-acting elements", "DNA", 251, 273], ["MHV SL1", "DNA", 284, 291], ["Porcine epidemic diarrhea virus", "SPECIES", 122, 153], ["Bat coronavirus", "SPECIES", 189, 204], ["Porcine epidemic diarrhea virus", "SPECIES", 122, 153], ["PEDV", "SPECIES", 155, 159], ["Bat coronavirus", "SPECIES", 189, 204], ["MHV", "SPECIES", 284, 287], ["U mismatches", "PROBLEM", 28, 40], ["the SL5 substructural hairpins", "PROBLEM", 60, 90], ["the SL5a", "PROBLEM", 97, 105], ["Porcine epidemic diarrhea virus", "PROBLEM", 122, 153], ["the group Id Bat coronavirus", "TEST", 176, 204], ["BtCoV", "TEST", 209, 214], ["substructural hairpins", "OBSERVATION", 68, 90], ["MHV", "ANATOMY", 284, 287]]], ["Interestingly, co-variations were frequently found at the positions of these tandem U:U mismatches, e.g. SL4 (Figs.", [["U:U", "GENE_OR_GENE_PRODUCT", 84, 87], ["SL4", "GENE_OR_GENE_PRODUCT", 105, 108], ["tandem U:U mismatches", "DNA", 77, 98], ["SL4", "DNA", 105, 108], ["U mismatches", "TEST", 86, 98], ["U mismatches", "OBSERVATION", 86, 98]]], ["2B, 3C, 4C) and SL5a-c (Figs.", [["SL5a-c", "SIMPLE_CHEMICAL", 16, 22], ["SL5a", "PROTEIN", 16, 20]]], ["5B, C, D, and H).", [["5B, C, D, and H", "CHEMICAL", 0, 15], ["C", "SIMPLE_CHEMICAL", 4, 5], ["D", "SIMPLE_CHEMICAL", 7, 8]]], ["This suggests the formation of (tandem) U:U base pairs similar to what has been reported for the 5\u2032-CU-3\u2032/5\u2032-UU-3\u2032 non-canonical base pairs found in the Y stem of polio-like enterovirus 3\u2032 UTRs (Lescrinier et al., 2003) .Structure probing of the SL5 substructure in HCoV-229E and SARS-CoVAre the SL5 substructural hairpins the counterparts of the group IIa packaging signal?Structure probing of the SL5 substructure in HCoV-229E and SARS-CoVIt has been generally found that a strong packaging signal (PS) or encapsidation signal, which directs specific packaging or encapsidation of genomic RNA, usually encompasses repetitions of conserved (structural) motifs (Hellendoorn et al., 1996 .", [["Y stem", "ANATOMY", 153, 159], ["HCoV-229E", "CHEMICAL", 266, 275], ["HCoV-229E", "CHEMICAL", 419, 428], ["SARS", "DISEASE", 433, 437], ["polio-like enterovirus 3", "ORGANISM", 163, 187], ["SL5", "GENE_OR_GENE_PRODUCT", 246, 249], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 266, 275], ["SARS-CoVAre", "GENE_OR_GENE_PRODUCT", 280, 291], ["SL5", "GENE_OR_GENE_PRODUCT", 296, 299], ["SL5", "GENE_OR_GENE_PRODUCT", 399, 402], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 419, 428], ["5\u2032-CU-3\u2032/5\u2032-UU-3\u2032 non-canonical base pairs", "DNA", 97, 139], ["UTRs", "DNA", 189, 193], ["HCoV-229E and SARS-CoVAre the SL5 substructural hairpins", "DNA", 266, 322], ["SL5", "PROTEIN", 399, 402], ["genomic RNA", "RNA", 583, 594], ["HCoV-229E", "SPECIES", 266, 275], ["HCoV-229E", "SPECIES", 419, 428], ["U base pairs", "TEST", 42, 54], ["CU", "TEST", 100, 102], ["UU", "TEST", 109, 111], ["non-canonical base pairs", "PROBLEM", 115, 139], ["polio", "PROBLEM", 163, 168], ["enterovirus", "PROBLEM", 174, 185], ["the SL5 substructure", "TEST", 242, 262], ["HCoV", "TEST", 266, 270], ["SARS", "TEST", 280, 284], ["the SL5 substructure", "TEST", 395, 415], ["HCoV", "TEST", 419, 423], ["SARS-CoVIt", "TEST", 433, 443], ["encapsidation signal", "PROBLEM", 508, 528], ["encapsidation of genomic RNA", "PROBLEM", 566, 594], ["base", "ANATOMY_MODIFIER", 129, 133], ["Y stem", "ANATOMY", 153, 159], ["substructural hairpins", "OBSERVATION", 300, 322], ["group IIa", "OBSERVATION_MODIFIER", 347, 356], ["encapsidation", "OBSERVATION_MODIFIER", 566, 579], ["genomic RNA", "OBSERVATION", 583, 594]]], ["This leads us to propose that the SL5 substructures bearing the highly conserved UUYCGU repeats function as genomic PS for group I and II CoVs, including SARS-CoV.Structure probing of the SL5 substructure in HCoV-229E and SARS-CoVStudies of the genomic PSs in CoVs have been mainly focused on group IIa CoVs in the past, e.g. MHV and BCoV (Fosmire et al., 1992; Makino et al., 1990; van der Most et al., 1991; Woo et al., 1997; Chen et al., 2007; Cologna and Hogue, 2000) .", [["HCoV-229E", "CHEMICAL", 208, 217], ["SL5", "GENE_OR_GENE_PRODUCT", 34, 37], ["UUYCGU", "GENE_OR_GENE_PRODUCT", 81, 87], ["II CoVs", "GENE_OR_GENE_PRODUCT", 135, 142], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 154, 162], ["SL5", "GENE_OR_GENE_PRODUCT", 188, 191], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 208, 217], ["CoVs", "CANCER", 260, 264], ["CoVs", "GENE_OR_GENE_PRODUCT", 303, 307], ["UUYCGU repeats", "DNA", 81, 95], ["group I and II CoVs", "PROTEIN", 123, 142], ["HCoV-229E and SARS-CoVStudies", "DNA", 208, 237], ["CoVs", "DNA", 260, 264], ["group IIa CoVs", "PROTEIN", 293, 307], ["SARS-CoV", "SPECIES", 154, 162], ["MHV", "SPECIES", 326, 329], ["BCoV", "SPECIES", 334, 338], ["the SL5 substructures", "TREATMENT", 30, 51], ["genomic PS", "TEST", 108, 118], ["group I and II CoVs", "PROBLEM", 123, 142], ["SARS", "PROBLEM", 154, 158], ["HCoV", "TEST", 208, 212], ["SARS", "PROBLEM", 222, 226], ["the genomic PSs in CoVs", "PROBLEM", 241, 264], ["genomic PSs", "OBSERVATION", 245, 256], ["MHV", "ANATOMY", 326, 329]]], ["For other groups of CoVs, e.g. SARS-CoV, the identification of a putative PS has been reported by Hsieh et al. (2005) .", [["SARS", "DISEASE", 31, 35], ["CoVs", "GENE_OR_GENE_PRODUCT", 20, 24], ["SARS-CoV", "ORGANISM", 31, 39], ["SARS-CoV", "SPECIES", 31, 39], ["CoVs", "PROBLEM", 20, 24], ["a putative PS", "TREATMENT", 63, 76], ["CoVs", "OBSERVATION", 20, 24]]], ["This PS was thought to be a homologue of the MHV PS located in the corresponding region near the 3\u2032 end of ORF1ab.", [["MHV PS", "ORGANISM", 45, 51], ["ORF1ab", "GENE_OR_GENE_PRODUCT", 107, 113], ["MHV PS", "PROTEIN", 45, 51], ["3\u2032 end", "DNA", 97, 103], ["ORF1ab", "DNA", 107, 113], ["MHV", "SPECIES", 45, 48], ["the MHV PS", "TREATMENT", 41, 51], ["thought to be", "UNCERTAINTY", 12, 25], ["MHV", "OBSERVATION", 45, 48], ["region", "ANATOMY_MODIFIER", 81, 87]]], ["However, it has to be noted that the specificity of the proposed SARS-CoV PS to direct RNA packaging was not determined in their study, and the predicted secondary structure of their \"homologue of MHV PS\" lacks the conserved features of the MHV PS structure reported by Chen et al. (2007) .", [["SARS", "DISEASE", 65, 69], ["SARS-CoV PS", "ORGANISM", 65, 76], ["MHV PS", "ORGANISM", 197, 203], ["MHV PS structure", "PROTEIN", 241, 257], ["SARS-CoV", "SPECIES", 65, 73], ["MHV", "SPECIES", 241, 244], ["the proposed SARS", "PROBLEM", 52, 69], ["CoV PS", "TREATMENT", 70, 76], ["direct RNA packaging", "TREATMENT", 80, 100], ["their study", "TEST", 123, 134], ["MHV PS", "TREATMENT", 197, 203], ["MHV", "OBSERVATION", 241, 244]]], ["Also we doubt the possibility of identifying a MHVlike PS in the \"corresponding region\" of SARS-CoV genomic RNA because an alignment of nsp15 sequences clearly shows that the sequence corresponding to the MHV PS is absent in SARS and other non-group IIa CoVs (Fig. 7) .Structure probing of the SL5 substructure in HCoV-229E and SARS-CoVInterestingly, the presence or absence of the region corresponding to the group IIa PS may not interfere with the function of nsp15 as the functional domains remain intact in both MHV and SARS-CoV nsp15 (Joseph et al., 2007) .", [["SARS", "DISEASE", 91, 95], ["SARS", "DISEASE", 225, 229], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["nsp15", "GENE_OR_GENE_PRODUCT", 136, 141], ["MHV PS", "ORGANISM", 205, 211], ["SL5", "GENE_OR_GENE_PRODUCT", 294, 297], ["HCoV-229E", "CELL", 314, 323], ["nsp15", "GENE_OR_GENE_PRODUCT", 462, 467], ["MHV", "ORGANISM", 516, 519], ["SARS-CoV nsp15", "ORGANISM", 524, 538], ["MHVlike PS", "DNA", 47, 57], ["SARS-CoV genomic RNA", "RNA", 91, 111], ["nsp15 sequences", "DNA", 136, 151], ["MHV PS", "DNA", 205, 211], ["group IIa PS", "PROTEIN", 410, 422], ["nsp15", "PROTEIN", 462, 467], ["SARS-CoV", "SPECIES", 91, 99], ["MHV", "SPECIES", 205, 208], ["HCoV-229E", "SPECIES", 314, 323], ["MHV", "SPECIES", 516, 519], ["SARS-CoV", "SPECIES", 524, 532], ["a MHVlike PS", "PROBLEM", 45, 57], ["SARS", "PROBLEM", 91, 95], ["CoV genomic RNA", "PROBLEM", 96, 111], ["an alignment of nsp15 sequences", "TEST", 120, 151], ["the sequence", "TEST", 171, 183], ["the MHV PS", "TEST", 201, 211], ["SARS", "PROBLEM", 225, 229], ["HCoV", "TEST", 314, 318], ["SARS", "PROBLEM", 328, 332], ["the group IIa PS", "TREATMENT", 406, 422], ["nsp15", "TREATMENT", 462, 467], ["doubt the possibility of", "UNCERTAINTY", 8, 32], ["SARS", "OBSERVATION", 91, 95], ["MHV", "OBSERVATION", 205, 208], ["intact", "OBSERVATION", 501, 507], ["both MHV", "ANATOMY", 511, 519]]], ["There seems to be however a strong correlation between the lack of a MHV PS-corresponding region and the presence of SL5 substructures and vice versa (Fig. 5) .", [["SL5", "GENE_OR_GENE_PRODUCT", 117, 120], ["MHV PS-corresponding region", "PROTEIN", 69, 96], ["SL5", "PROTEIN", 117, 120], ["SL5 substructures", "PROBLEM", 117, 134]]], ["This correlation strongly suggests that the SL5 substructural hairpins located in the 5\u2032 UTR are the counterparts of the genomic PS present in group IIa CoVs, and presumably the UUCCGU structural repeats (Fig. 5A) are responsible for the packaging activity reported by Escors et al. (2003) for the first 649 nts of TGEV genomic RNA.ConclusionsThe diversity of the genomic RNA sequence provides a wealth of structural and phylogenetic information on the lineage of CoVs and improves our understanding of the evolution of the 5\u2032 cis-acting elements.", [["CoVs", "GENE_OR_GENE_PRODUCT", 153, 157], ["TGEV", "ORGANISM", 315, 319], ["CoVs", "GENE_OR_GENE_PRODUCT", 464, 468], ["SL5", "DNA", 44, 47], ["UTR", "DNA", 89, 92], ["group IIa CoVs", "DNA", 143, 157], ["UUCCGU structural repeats", "DNA", 178, 203], ["TGEV genomic RNA", "RNA", 315, 331], ["genomic RNA sequence", "DNA", 364, 384], ["CoVs", "DNA", 464, 468], ["5\u2032 cis-acting elements", "DNA", 524, 546], ["TGEV", "SPECIES", 315, 319], ["the SL5 substructural hairpins", "PROBLEM", 40, 70], ["UTR", "PROBLEM", 89, 92], ["TGEV genomic RNA", "PROBLEM", 315, 331], ["CoVs", "PROBLEM", 464, 468], ["substructural hairpins", "OBSERVATION", 48, 70], ["genomic PS", "OBSERVATION", 121, 131], ["group IIa", "OBSERVATION_MODIFIER", 143, 152], ["genomic RNA", "OBSERVATION", 320, 331]]], ["We have shown that the pattern of these cis-acting elements in the 5\u2032 UTR is highly related to the phylogenetic distance based on the viral protein sequences, suggesting that the viral proteins and the RNA sequence evolved simultaneously, possibly to maintain functional RNA-protein interactions.ConclusionsThe unique and conserved features of the 5\u2032 UTR and SL5 highlight the role of RNA structure in the evolution of CoVs and may serve as a roadmap for further studies.", [["SL5", "GENE_OR_GENE_PRODUCT", 359, 362], ["CoVs", "GENE_OR_GENE_PRODUCT", 419, 423], ["cis-acting elements", "DNA", 40, 59], ["5\u2032 UTR", "DNA", 67, 73], ["viral protein sequences", "DNA", 134, 157], ["viral proteins", "PROTEIN", 179, 193], ["RNA sequence", "DNA", 202, 214], ["5\u2032 UTR", "DNA", 348, 354], ["SL5", "DNA", 359, 362], ["CoVs", "DNA", 419, 423], ["the viral protein sequences", "TEST", 130, 157], ["the viral proteins", "PROBLEM", 175, 193], ["the RNA sequence", "TEST", 198, 214], ["the 5\u2032 UTR", "TREATMENT", 344, 354], ["RNA structure", "PROBLEM", 385, 398], ["CoVs", "PROBLEM", 419, 423], ["further studies", "TEST", 455, 470], ["cis-acting elements", "OBSERVATION", 40, 59], ["highly related to", "UNCERTAINTY", 77, 94], ["RNA structure", "OBSERVATION", 385, 398], ["CoVs", "OBSERVATION", 419, 423]]], ["Future experiments should also verify whether the conserved UUYCGU motifs in SL5 function as PS in group I and II CoVs by interacting with nucleocapsid and/or membrane proteins (Molenkamp and Spaan, 1997; Narayanan and Makino, 2001; Narayanan et al., 2003) .", [["membrane", "ANATOMY", 159, 167], ["UUYCGU", "GENE_OR_GENE_PRODUCT", 60, 66], ["SL5", "GENE_OR_GENE_PRODUCT", 77, 80], ["II CoVs", "GENE_OR_GENE_PRODUCT", 111, 118], ["membrane", "CELLULAR_COMPONENT", 159, 167], ["UUYCGU motifs", "DNA", 60, 73], ["SL5", "DNA", 77, 80], ["group I and II CoVs", "PROTEIN", 99, 118], ["nucleocapsid and/or membrane proteins", "PROTEIN", 139, 176], ["the conserved UUYCGU motifs", "PROBLEM", 46, 73]]], ["The absence of these or other conserved motifs in the 5\u2032 UTR of group III CoVs suggests that their PSs are located elsewhere in the genome.", [["group III CoVs", "GENE_OR_GENE_PRODUCT", 64, 78], ["PSs", "GENE_OR_GENE_PRODUCT", 99, 102], ["genome", "CELLULAR_COMPONENT", 132, 138], ["UTR", "DNA", 57, 60], ["group III", "OBSERVATION_MODIFIER", 64, 73], ["PSs", "OBSERVATION", 99, 102], ["genome", "ANATOMY", 132, 138]]], ["This possibility is currently being explored.Structural-phylogenetic analysisMultiple alignment of all CoV 5\u2032-proximal sequences available in GenBank was used to select coronaviruses with the highest sequence diversity.", [["coronaviruses", "ORGANISM", 169, 182], ["CoV 5\u2032-proximal sequences", "DNA", 103, 128], ["all CoV 5\u2032-proximal sequences", "TEST", 99, 128], ["coronaviruses", "PROBLEM", 169, 182], ["phylogenetic analysisMultiple", "OBSERVATION", 56, 85]]], ["Sequences of the 5\u2032 420 nts of these variants were clustered by ClustalW2 on EBI webserver (Larkin et al., 2007) .", [["5\u2032 420 nts", "DNA", 17, 27], ["Sequences", "TEST", 0, 9]]], ["Secondary structures of this region were predicted by the Mfold webserver (Zuker, 2003) .", [["Secondary structures of this region", "PROBLEM", 0, 35]]], ["The alignment of CoV nsp15 was done by Kalign webserver (Lassmann and Sonnhammer, 2006) (Fig. 7) .Structure probing and primer extensionThe RNA transcripts encompassing the entire HCoV-229E and SARS-CoV SL5 region (about 180 nt) were synthesized in vitro using Ribomax TM RNA production system (Promega).", [["CoV", "ORGANISM", 17, 20], ["nsp15", "GENE_OR_GENE_PRODUCT", 21, 26], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 180, 189], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 194, 202], ["CoV nsp15", "PROTEIN", 17, 26], ["RNA transcripts", "RNA", 140, 155], ["HCoV-229E and SARS-CoV SL5 region", "DNA", 180, 213], ["180 nt", "DNA", 221, 227], ["SARS-CoV", "SPECIES", 194, 202], ["CoV nsp15", "TEST", 17, 26], ["Structure probing", "PROBLEM", 98, 115], ["the entire HCoV", "TEST", 169, 184], ["SARS", "PROBLEM", 194, 198], ["CoV SL5 region", "PROBLEM", 199, 213], ["RNA transcripts", "OBSERVATION", 140, 155]]], ["The corresponding cDNA templates with an upstream T7 promoter were amplified by PCR using oligo-nucleotides 5\u2032-TAATACGACTCACTATAGGGCATGCC-TAGTGCACCTACGCAG-3\u2032 (the T7 promoter sequence is underlined) and 5\u2032-CAAACTGAGTTGGACGTGTG-3\u2032 for SARS-CoV SL5 and oligonucleotides 5\u2032-TAATACGACTCACTATAGGGTAATTGAAATTTCATTTG-GG-3\u2032 (the T7 promoter sequence is underlined) and 5\u2032-GTGTGACAC-TTGCCGTAGC-3\u2032 for HCoV-229E SL5.", [["T7", "GENE_OR_GENE_PRODUCT", 50, 52], ["SARS-CoV SL5", "GENE_OR_GENE_PRODUCT", 234, 246], ["HCoV-229E SL5", "GENE_OR_GENE_PRODUCT", 392, 405], ["cDNA templates", "DNA", 18, 32], ["upstream T7 promoter", "DNA", 41, 61], ["oligo-nucleotides 5\u2032-TAATACGACTCACTATAGGGCATGCC-TAGTGCACCTACGCAG-3\u2032", "DNA", 90, 157], ["T7 promoter sequence", "DNA", 163, 183], ["SARS-CoV SL5 and oligonucleotides 5\u2032-TAATACGACTCACTATAGGGTAATTGAAATTTCATTTG-GG-3\u2032", "DNA", 234, 315], ["T7 promoter sequence", "DNA", 321, 341], ["HCoV-229E SL5", "DNA", 392, 405], ["SARS-CoV", "SPECIES", 234, 242], ["HCoV-229E SL5", "SPECIES", 392, 405], ["The corresponding cDNA templates", "TREATMENT", 0, 32], ["an upstream T7 promoter", "TREATMENT", 38, 61], ["oligo-nucleotides", "TREATMENT", 90, 107], ["TAATACGACTCACTATAGGGCATGCC-TAGTGCACCTACGCAG", "TREATMENT", 111, 154], ["the T7 promoter sequence", "TREATMENT", 159, 183], ["CAAACTGAGTTGGACGTGTG", "TEST", 206, 226], ["SARS", "TEST", 234, 238], ["CoV SL5 and oligonucleotides", "TREATMENT", 239, 267], ["TAATACGACTCACTATAGGGTAATTGAAATTTCATTTG", "TEST", 271, 309], ["the T7 promoter sequence", "TREATMENT", 317, 341], ["GTGTGACAC", "TEST", 364, 373], ["TTGCCGTAGC", "TEST", 374, 384], ["HCoV", "TEST", 392, 396]]], ["Purified RNA transcripts were subjected to chemical and enzymatic probing as described in Chen et al. (2007) .", [["Purified RNA transcripts", "RNA", 0, 24], ["RNA transcripts", "OBSERVATION", 9, 24]]], ["In general, 0.001% dimethylsulfate (DMS), 1 pg Rnase A, 0.001 U RNase T1, 0.1 U RNase V1, and 0.8 U S1 nuclease were used for the probing reactions (1\u00d7), followed by serial dilutions with a factor 1/5 (1/5\u00d7 and 1/25\u00d7) or 1/8 (1/8\u00d7 and 1/64\u00d7).", [["dimethylsulfate", "CHEMICAL", 19, 34], ["DMS", "CHEMICAL", 36, 39], ["dimethylsulfate", "CHEMICAL", 19, 34], ["DMS", "CHEMICAL", 36, 39], ["Rnase A", "CHEMICAL", 47, 54], ["dimethylsulfate", "SIMPLE_CHEMICAL", 19, 34], ["DMS", "SIMPLE_CHEMICAL", 36, 39], ["RNase", "GENE_OR_GENE_PRODUCT", 64, 69], ["RNase", "GENE_OR_GENE_PRODUCT", 80, 85], ["U S1", "GENE_OR_GENE_PRODUCT", 98, 102], ["0.001 U RNase T1", "TEST", 56, 72], ["U RNase V1", "TEST", 78, 88], ["U S1 nuclease", "TEST", 98, 111], ["the probing reactions", "PROBLEM", 126, 147], ["serial dilutions", "TEST", 166, 182], ["a factor", "TEST", 188, 196]]], ["The primer extension was carried out with 0.01 \u00b5g of treated transcripts, 0.5 \u00b5l of a 0.1 mM concentration of the MHV1 primer, 1 \u00b5l of 5 mM dGAT, 1 \u00b5l of 25 \u00b5M dCTP, 0.1 \u00b5l of \u03b1-32 P-labeled dCTP (10 mCi/ml), 1 \u00b5l of 5\u00d7 reverse transcriptase buffer, and 20 U of Moloney murine leukemia virus reverse transcriptase (Promega).", [["dGAT", "CHEMICAL", 140, 144], ["dCTP", "CHEMICAL", 160, 164], ["\u03b1-32 P", "CHEMICAL", 176, 182], ["dCTP", "CHEMICAL", 191, 195], ["dGAT", "CHEMICAL", 140, 144], ["dCTP", "CHEMICAL", 160, 164], ["dCTP", "CHEMICAL", 191, 195], ["dGAT", "SIMPLE_CHEMICAL", 140, 144], ["dCTP", "SIMPLE_CHEMICAL", 160, 164], ["\u03b1-32 P", "SIMPLE_CHEMICAL", 176, 182], ["dCTP", "SIMPLE_CHEMICAL", 191, 195], ["Moloney murine leukemia virus", "ORGANISM", 262, 291], ["Promega", "ORGANISM", 315, 322], ["reverse transcriptase", "PROTEIN", 220, 241], ["Moloney murine leukemia virus reverse transcriptase", "PROTEIN", 262, 313], ["murine", "SPECIES", 270, 276], ["leukemia virus", "SPECIES", 277, 291], ["Moloney murine leukemia virus", "SPECIES", 262, 291], ["The primer extension", "PROBLEM", 0, 20], ["a 0.1 mM concentration of the MHV1 primer", "TREATMENT", 84, 125], ["P-labeled dCTP", "TREATMENT", 181, 195], ["reverse transcriptase buffer", "TREATMENT", 220, 248], ["Moloney murine leukemia virus", "TREATMENT", 262, 291], ["transcriptase (Promega)", "TREATMENT", 300, 323], ["Moloney murine leukemia virus", "OBSERVATION", 262, 291]]]], "9761018c62f5d80401031e5af5690f44f3185d0d": [["Introduction 57Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide 58Introduction 57Papilloma Virus (HPV) [24] , and Herpes simplex-1 (HSV-1) [25] .", [["acute respiratory syndrome coronavirus", "DISEASE", 22, 60], ["Herpes simplex", "DISEASE", 147, 161], ["57Severe acute respiratory syndrome coronavirus 2", "ORGANISM", 13, 62], ["SARS-CoV-2", "ORGANISM", 64, 74], ["58Introduction 57Papilloma Virus", "ORGANISM", 97, 129], ["HPV", "ORGANISM", 131, 134], ["Herpes simplex-1", "ORGANISM", 147, 163], ["HSV-1", "ORGANISM", 165, 170], ["58Introduction 57Papilloma Virus", "SPECIES", 97, 129], ["Herpes simplex-1", "SPECIES", 147, 163], ["HSV-1", "SPECIES", 165, 170], ["57Severe acute respiratory syndrome coronavirus", "SPECIES", 13, 60], ["SARS-CoV-2", "SPECIES", 64, 74], ["HPV", "SPECIES", 131, 134], ["Herpes simplex-1", "SPECIES", 147, 163], ["HSV-1", "SPECIES", 165, 170], ["acute respiratory syndrome coronavirus", "PROBLEM", 22, 60], ["SARS", "TEST", 64, 68], ["CoV", "TEST", 69, 72], ["Herpes simplex", "TEST", 147, 161], ["HSV", "TEST", 165, 168], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["respiratory syndrome", "OBSERVATION", 28, 48]]], ["Furthermore, CK2 88 also regulates a number of signaling cascades such as NF-\u03baB [26] , JAK / STAT [27] , and 89 PTEN / PI3K / Akt-PKB [28] , that viruses hijacked to guaranteed their propagation.", [["CK2 88", "GENE_OR_GENE_PRODUCT", 13, 19], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 74, 79], ["JAK", "GENE_OR_GENE_PRODUCT", 87, 90], ["STAT", "GENE_OR_GENE_PRODUCT", 93, 97], ["27", "GENE_OR_GENE_PRODUCT", 99, 101], ["PTEN", "GENE_OR_GENE_PRODUCT", 112, 116], ["PI3K", "GENE_OR_GENE_PRODUCT", 119, 123], ["Akt", "GENE_OR_GENE_PRODUCT", 126, 129], ["PKB", "GENE_OR_GENE_PRODUCT", 130, 133], ["CK2 88", "PROTEIN", 13, 19], ["NF-\u03baB", "PROTEIN", 74, 79], ["JAK", "PROTEIN", 87, 90], ["STAT", "PROTEIN", 93, 97], ["PTEN", "PROTEIN", 112, 116], ["PI3K", "PROTEIN", 119, 123], ["Akt", "PROTEIN", 126, 129], ["PKB", "PROTEIN", 130, 133], ["CK2", "TEST", 13, 16], ["signaling cascades", "PROBLEM", 47, 65], ["NF", "TEST", 74, 76], ["JAK / STAT", "TEST", 87, 97], ["PTEN", "TEST", 112, 116], ["PI3K", "TEST", 119, 123], ["Akt", "TEST", 126, 129], ["PKB", "TEST", 130, 133], ["viruses", "PROBLEM", 146, 153], ["PKB", "ANATOMY", 130, 133]]], ["90 Therefore, it is expected that pharmacological intervention of CK2 may impact on viral 91Introduction 57replication.", [["CK2", "GENE_OR_GENE_PRODUCT", 66, 69], ["CK2", "PROTEIN", 66, 69], ["pharmacological intervention of CK2", "TREATMENT", 34, 69]]], ["Recently, CK2 has been found to be directly targeted by the SARS-Cov2 92 nucleocapsid protein and they both co-localize along the filopodia protrusions that 93 promote virus egress and rapid cell-to-cell spread across epithelial mono-layers of 94 infected cells [29] .", [["filopodia", "ANATOMY", 130, 139], ["cell", "ANATOMY", 191, 195], ["cell", "ANATOMY", 199, 203], ["epithelial mono-layers", "ANATOMY", 218, 240], ["cells", "ANATOMY", 256, 261], ["CK2", "GENE_OR_GENE_PRODUCT", 10, 13], ["Cov2", "GENE_OR_GENE_PRODUCT", 65, 69], ["filopodia", "CELLULAR_COMPONENT", 130, 139], ["cell", "CELL", 191, 195], ["cell", "CELL", 199, 203], ["epithelial mono-layers", "CELL", 218, 240], ["cells", "CELL", 256, 261], ["CK2", "PROTEIN", 10, 13], ["SARS-Cov2 92 nucleocapsid protein", "PROTEIN", 60, 93], ["epithelial mono-layers", "CELL_TYPE", 218, 240], ["CK2", "TEST", 10, 13], ["the SARS", "TEST", 56, 64], ["nucleocapsid protein", "TEST", 73, 93], ["the filopodia protrusions", "PROBLEM", 126, 151], ["virus egress", "PROBLEM", 168, 180], ["rapid cell", "TEST", 185, 195], ["epithelial mono-layers", "TEST", 218, 240], ["infected cells", "PROBLEM", 247, 261], ["filopodia protrusions", "OBSERVATION", 130, 151], ["virus egress", "OBSERVATION", 168, 180], ["rapid cell", "OBSERVATION", 185, 195], ["epithelial", "ANATOMY_MODIFIER", 218, 228]]], ["Additionally, inhibition of CK2 in those experiments demonstrated 95 the instrumental role of this protein kinase for SARS-Cov2 infection in vitro [29] .", [["infection", "DISEASE", 128, 137], ["CK2", "GENE_OR_GENE_PRODUCT", 28, 31], ["SARS-Cov2", "GENE_OR_GENE_PRODUCT", 118, 127], ["CK2", "PROTEIN", 28, 31], ["protein kinase", "PROTEIN", 99, 113], ["CK2", "TEST", 28, 31], ["those experiments", "TEST", 35, 52], ["this protein kinase", "TEST", 94, 113], ["SARS", "PROBLEM", 118, 122], ["Cov2 infection", "PROBLEM", 123, 137]]], ["96Introduction 57Considering the scientific rationality of inhibiting CK2 in SARS-Cov2 infection and 97 taking advance of CIGB-325 (formerly CIGB-300) as an anti-CK2 synthetic peptide 98 previously already assessed in different Phase I-II in cancer patients, we investigated the 99 putative clinical benefit of this peptide in Covid-19 patients.", [["cancer", "ANATOMY", 242, 248], ["SARS-Cov2 infection", "DISEASE", 77, 96], ["CIGB-325", "CHEMICAL", 122, 130], ["CIGB-300", "CHEMICAL", 141, 149], ["cancer", "DISEASE", 242, 248], ["CIGB-325", "CHEMICAL", 122, 130], ["CIGB-300", "CHEMICAL", 141, 149], ["CK2", "GENE_OR_GENE_PRODUCT", 70, 73], ["SARS-Cov2", "ORGANISM", 77, 86], ["CIGB-325", "SIMPLE_CHEMICAL", 122, 130], ["CIGB-300", "SIMPLE_CHEMICAL", 141, 149], ["cancer", "CANCER", 242, 248], ["patients", "ORGANISM", 249, 257], ["patients", "ORGANISM", 336, 344], ["CK2", "PROTEIN", 70, 73], ["Phase I-II", "PROTEIN", 228, 238], ["patients", "SPECIES", 249, 257], ["patients", "SPECIES", 336, 344], ["inhibiting CK2", "PROBLEM", 59, 73], ["SARS", "PROBLEM", 77, 81], ["Cov2 infection", "PROBLEM", 82, 96], ["CIGB", "TEST", 122, 126], ["CIGB", "TEST", 141, 145], ["an anti-CK2 synthetic peptide", "TEST", 154, 183], ["this peptide", "TREATMENT", 311, 323], ["cancer", "OBSERVATION", 242, 248]]], ["Particularly, safety and 100 tolerability of intravenous delivery of CIGB-325 has been previously assessed from 0.2 101 to 12.8 mg/kg [30, 31] as well as the consecutive-5 day regimen of administration.", [["intravenous", "ANATOMY", 45, 56], ["CIGB-325", "CHEMICAL", 69, 77], ["CIGB-325", "CHEMICAL", 69, 77], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 56], ["CIGB-325", "SIMPLE_CHEMICAL", 69, 77], ["intravenous delivery of CIGB", "TREATMENT", 45, 73]]], ["102Introduction 57In this clinical study we administered intravenous CIGB-325 at 2.5 mg/kg along with 103 standard-of-care for treating SARS-Cov2 positive patients in Cuba which is based on 104 alpha 2b-IFN plus kaletra/hydroxyquinoline.", [["intravenous", "ANATOMY", 57, 68], ["CIGB-325", "CHEMICAL", 69, 77], ["SARS-Cov2 positive", "DISEASE", 136, 154], ["104 alpha 2b-IFN", "CHEMICAL", 190, 206], ["kaletra/hydroxyquinoline", "CHEMICAL", 212, 236], ["CIGB-325", "CHEMICAL", 69, 77], ["hydroxyquinoline", "CHEMICAL", 220, 236], ["CIGB-325", "SIMPLE_CHEMICAL", 69, 77], ["patients", "ORGANISM", 155, 163], ["alpha 2b-IFN", "GENE_OR_GENE_PRODUCT", 194, 206], ["kaletra/hydroxyquinoline", "SIMPLE_CHEMICAL", 212, 236], ["IFN", "PROTEIN", 203, 206], ["patients", "SPECIES", 155, 163], ["intravenous CIGB", "TREATMENT", 57, 73], ["SARS", "PROBLEM", 136, 140], ["alpha 2b", "TREATMENT", 194, 202], ["IFN", "TREATMENT", 203, 206], ["kaletra", "TREATMENT", 212, 219], ["hydroxyquinoline", "TREATMENT", 220, 236]]], ["Preliminary data indicated that combination 105 of CIGB-325 with standard-of-care improved chest-CT outcomes in Covid-19 patients 106 with pneumonia at day 7.", [["chest", "ANATOMY", 91, 96], ["CIGB-325", "CHEMICAL", 51, 59], ["pneumonia", "DISEASE", 139, 148], ["CIGB-325", "CHEMICAL", 51, 59], ["CIGB-325", "SIMPLE_CHEMICAL", 51, 59], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Preliminary data", "TEST", 0, 16], ["CIGB", "TEST", 51, 55], ["CT outcomes", "TEST", 97, 108], ["Covid", "TEST", 112, 117], ["pneumonia", "PROBLEM", 139, 148], ["chest", "ANATOMY", 91, 96], ["pneumonia", "OBSERVATION", 139, 148]]], ["Other signs of clinical benefit for this therapeutic regimen were 107 also registered in our study.", [["this therapeutic regimen", "TREATMENT", 36, 60], ["our study", "TEST", 89, 98]]], ["This is the first clinical study where an anti-CK2 approach is 108 investigated in Covid-19 disease.", [["Covid-19 disease", "CANCER", 83, 99], ["the first clinical study", "TEST", 8, 32], ["an anti-CK2 approach", "TEST", 39, 59]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroduction 57The copyright holder for this this version posted September 15, 2020 . . https://doi.org/10.1101 size, the difference between groups (for clinical and chest-CT evaluations, proportion of 154 patients with reduction of score and number of lesions) was estimated from the Bayesian 155 point of view, performing 10,000 simulations and specifying non-informative prior 156 distributions.", [["lesions", "ANATOMY", 464, 471], ["CC", "CHEMICAL", 0, 2], ["patients", "ORGANISM", 417, 425], ["lesions", "PATHOLOGICAL_FORMATION", 464, 471], ["patients", "SPECIES", 417, 425], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["clinical and chest-CT evaluations", "TEST", 364, 397], ["score", "TEST", 444, 449], ["lesions", "PROBLEM", 464, 471], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["size", "OBSERVATION_MODIFIER", 323, 327], ["chest", "ANATOMY", 377, 382], ["lesions", "OBSERVATION", 464, 471]]], ["The analysis was performed using SPSS 25.0 software and EPIDAT 3.1.", [["The analysis", "TEST", 0, 12], ["SPSS", "TEST", 33, 37], ["EPIDAT", "TEST", 56, 62]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintIntroduction 57The copyright holder for this this version posted September 15, 2020. .Baseline characteristics of Covid-19 patients 159Between June 1, 2020, and June 16, 2020, twenty SARS-Cov2 positive patients 160 underwent randomization in the hospital \"Luis Diaz Soto\" in Havana, Cuba.", [["CC", "CHEMICAL", 0, 2], ["SARS-Cov2 positive", "DISEASE", 394, 412], ["patients", "ORGANISM", 334, 342], ["patients", "ORGANISM", 413, 421], ["patients", "SPECIES", 334, 342], ["patients", "SPECIES", 413, 421], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Covid", "TEST", 325, 330], ["twenty SARS", "TEST", 387, 398], ["randomization", "TREATMENT", 436, 449], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Ten were 161 assigned to receive intravenous CIGB-325 + standard-of-care (Group I) and 10 to receive 162 standard-of-care as control (Group II).", [["intravenous", "ANATOMY", 33, 44], ["CIGB-325", "CHEMICAL", 45, 53], ["CIGB-325", "CHEMICAL", 45, 53], ["intravenous CIGB", "TREATMENT", 33, 49]]], ["To diminish the chance of disease progression, the 163 Cuban Program for managing Covid-19 patients is based on the application of standard-164 of-care immediately upon confirmation of nasopharyngeal SARS-Cov2 diagnosis 165 irrespectively of having symptoms or not.", [["nasopharyngeal", "ANATOMY", 185, 199], ["nasopharyngeal SARS-Cov2", "DISEASE", 185, 209], ["patients", "ORGANISM", 91, 99], ["nasopharyngeal", "ORGAN", 185, 199], ["patients", "SPECIES", 91, 99], ["disease progression", "PROBLEM", 26, 45], ["Covid", "TEST", 82, 87], ["nasopharyngeal SARS", "PROBLEM", 185, 204], ["symptoms", "PROBLEM", 249, 257], ["disease", "OBSERVATION", 26, 33], ["nasopharyngeal", "ANATOMY", 185, 199]]], ["The median number of days between SARS-166 Cov2 diagnosis, hospitalization and treatment initiation was 2 days.", [["SARS", "DISEASE", 34, 38], ["treatment initiation", "TREATMENT", 79, 99]]], ["All the patients 167 completed the treatment as planned except one patient from Group I who experienced 168 some concomitant moderate histaminergic adverse events during the first CIGB-325 169 intravenous delivery and dose was decreased to 1.6 mg/kg for remaining days as 170 indicated in the clinical protocol.", [["intravenous", "ANATOMY", 193, 204], ["CIGB-325", "CHEMICAL", 180, 188], ["CIGB-325", "CHEMICAL", 180, 188], ["patients", "ORGANISM", 8, 16], ["patient", "ORGANISM", 67, 74], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 193, 204], ["patients", "SPECIES", 8, 16], ["patient", "SPECIES", 67, 74], ["the treatment", "TREATMENT", 31, 44], ["some concomitant moderate histaminergic adverse events", "PROBLEM", 108, 162], ["intravenous delivery", "TREATMENT", 193, 213], ["moderate", "OBSERVATION_MODIFIER", 125, 133], ["histaminergic adverse", "OBSERVATION", 134, 155]]], ["171Baseline characteristics of Covid-19 patients 159The mean age of patients was 45.35 years and 70% were male (Table 1) .", [["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 68, 76], ["Covid", "TEST", 31, 36]]], ["Fourteen 172 patients (70%) were asymptomatic at the enrollment and 9 (45%) at the starting day of 173 treatment.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["asymptomatic", "PROBLEM", 33, 45]]], ["Fifty percent of patients (5/10) had moderate disease and 20% (2/10) were 174 severe in the CIGB-325 group while 40% of patients (4/10) had moderate disease and 175 none severe case at the starting day of treatment (Table 1) .", [["CIGB-325", "CHEMICAL", 92, 100], ["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 120, 128], ["moderate disease", "PROBLEM", 37, 53], ["the CIGB", "TEST", 88, 96], ["moderate disease", "PROBLEM", 140, 156], ["treatment", "TREATMENT", 205, 214], ["moderate", "OBSERVATION_MODIFIER", 37, 45], ["disease", "OBSERVATION", 46, 53], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["moderate", "OBSERVATION_MODIFIER", 140, 148], ["disease", "OBSERVATION", 149, 156]]], ["176Baseline characteristics of Covid-19 patients 159Overall, 25% of patients had hypertension, 25% had obesity and none had type 2 177 diabetes.", [["hypertension", "DISEASE", 81, 93], ["obesity", "DISEASE", 103, 110], ["diabetes", "DISEASE", 135, 143], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 68, 76], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 68, 76], ["Covid", "TEST", 31, 36], ["hypertension", "PROBLEM", 81, 93], ["obesity", "PROBLEM", 103, 110], ["type 2 177 diabetes", "PROBLEM", 124, 143], ["hypertension", "OBSERVATION", 81, 93]]], ["Other comorbidities were anemia (1/20), glaucoma (1/20), hypothyroidism 178Baseline characteristics of Covid-19 patients 159(1/20), cancer (1/20).", [["glaucoma", "ANATOMY", 40, 48], ["cancer", "ANATOMY", 132, 138], ["anemia", "DISEASE", 25, 31], ["glaucoma", "DISEASE", 40, 48], ["hypothyroidism", "DISEASE", 57, 71], ["cancer", "DISEASE", 132, 138], ["patients", "ORGANISM", 112, 120], ["cancer", "CANCER", 132, 138], ["patients", "SPECIES", 112, 120], ["Other comorbidities", "PROBLEM", 0, 19], ["anemia", "PROBLEM", 25, 31], ["glaucoma", "PROBLEM", 40, 48], ["hypothyroidism", "PROBLEM", 57, 71], ["Covid", "TEST", 103, 108], ["cancer", "PROBLEM", 132, 138], ["comorbidities", "OBSERVATION", 6, 19], ["anemia", "OBSERVATION", 25, 31], ["glaucoma", "OBSERVATION", 40, 48], ["hypothyroidism", "OBSERVATION", 57, 71], ["cancer", "OBSERVATION", 132, 138]]], ["The most substantial imbalance in baseline characteristics was 179 observed between the CIGB-325 group and control respect to age and coexisting high 180 risk conditions which were more unfavorable in the CIGB-325 group (Table 1) .", [["CIGB-325", "CHEMICAL", 88, 96], ["CIGB-325", "CHEMICAL", 205, 213], ["CIGB-325", "CHEMICAL", 88, 96], ["CIGB-325", "CHEMICAL", 205, 213], ["the CIGB", "TEST", 84, 92], ["coexisting high 180 risk conditions", "PROBLEM", 134, 169], ["most", "OBSERVATION_MODIFIER", 4, 8], ["substantial", "OBSERVATION_MODIFIER", 9, 20], ["imbalance", "OBSERVATION", 21, 30]]], ["181Baseline characteristics of Covid-19 patients 159Data from baseline chest-CT analysis showed that 80% of patients in the CIGB-325 182 group had positive chest-CT according to presence of ground-glass opacity, 183 consolidation, mixed pattern and affectation of more than three pulmonary lobules.", [["pulmonary lobules", "ANATOMY", 280, 297], ["CIGB-325", "CHEMICAL", 124, 132], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 108, 116], ["pulmonary lobules", "MULTI-TISSUE_STRUCTURE", 280, 297], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 108, 116], ["Covid", "TEST", 31, 36], ["baseline chest", "TEST", 62, 76], ["CT analysis", "TEST", 77, 88], ["the CIGB", "TEST", 120, 128], ["positive chest-CT", "TEST", 147, 164], ["ground-glass opacity", "PROBLEM", 190, 210], ["consolidation", "PROBLEM", 216, 229], ["affectation of more than three pulmonary lobules", "PROBLEM", 249, 297], ["chest", "ANATOMY", 71, 76], ["chest", "ANATOMY", 156, 161], ["ground", "OBSERVATION", 190, 196], ["glass opacity", "OBSERVATION", 197, 210], ["183", "OBSERVATION_MODIFIER", 212, 215], ["consolidation", "OBSERVATION", 216, 229], ["mixed", "OBSERVATION_MODIFIER", 231, 236], ["pattern", "OBSERVATION_MODIFIER", 237, 244], ["affectation", "OBSERVATION_MODIFIER", 249, 260], ["more", "OBSERVATION_MODIFIER", 264, 268], ["pulmonary", "ANATOMY", 280, 289], ["lobules", "ANATOMY_MODIFIER", 290, 297]]], ["In the 184 control group, 50% of patients had positive chest-CT with presence of consolidation, 185 mixed pattern and affectation of less than two pulmonary lobules.", [["pulmonary lobules", "ANATOMY", 147, 164], ["patients", "ORGANISM", 33, 41], ["pulmonary lobules", "MULTI-TISSUE_STRUCTURE", 147, 164], ["patients", "SPECIES", 33, 41], ["positive chest-CT", "TEST", 46, 63], ["consolidation", "PROBLEM", 81, 94], ["affectation of less than two pulmonary lobules", "PROBLEM", 118, 164], ["chest", "ANATOMY", 55, 60], ["consolidation", "OBSERVATION", 81, 94], ["185 mixed", "OBSERVATION_MODIFIER", 96, 105], ["pattern", "OBSERVATION_MODIFIER", 106, 113], ["affectation", "OBSERVATION_MODIFIER", 118, 129], ["less", "OBSERVATION_MODIFIER", 133, 137], ["pulmonary", "ANATOMY", 147, 156], ["lobules", "ANATOMY_MODIFIER", 157, 164]]], ["186Baseline characteristics of Covid-19 patients 159Concerning hematological and biochemical baseline parameters in all patients, abnormal 187 levels were observed in hemoglobin (25%), platelets (15%), neutrophils (50%), 188 .", [["platelets", "ANATOMY", 185, 194], ["neutrophils", "ANATOMY", 202, 213], ["patients", "ORGANISM", 40, 48], ["patients", "ORGANISM", 120, 128], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 167, 177], ["platelets", "CELL", 185, 194], ["neutrophils", "CELL", 202, 213], ["hemoglobin", "PROTEIN", 167, 177], ["platelets", "CELL_TYPE", 185, 194], ["neutrophils", "CELL_TYPE", 202, 213], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 120, 128], ["Covid", "TEST", 31, 36], ["biochemical baseline parameters", "TEST", 81, 112], ["abnormal 187 levels", "PROBLEM", 130, 149], ["hemoglobin", "TEST", 167, 177], ["platelets", "TEST", 185, 194], ["neutrophils", "TEST", 202, 213]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintBaseline characteristics of Covid-19 patients 159The copyright holder for this this version posted September 15, 2020. . lymphocytes (40%), aspartate aminotransferase (ASAT) (20%), alanine aminotransferase 189 (ALAT)(40%), ferritin (35%), creatinine (20%), and glycemia (30%).", [["lymphocytes", "ANATOMY", 332, 343], ["CC", "CHEMICAL", 0, 2], ["aspartate", "CHEMICAL", 351, 360], ["alanine", "CHEMICAL", 392, 399], ["creatinine", "CHEMICAL", 450, 460], ["aspartate", "CHEMICAL", 351, 360], ["alanine", "CHEMICAL", 392, 399], ["creatinine", "CHEMICAL", 450, 460], ["patients", "ORGANISM", 248, 256], ["lymphocytes", "CELL", 332, 343], ["aspartate aminotransferase", "GENE_OR_GENE_PRODUCT", 351, 377], ["ASAT", "SIMPLE_CHEMICAL", 379, 383], ["alanine aminotransferase 189", "GENE_OR_GENE_PRODUCT", 392, 420], ["ALAT", "SIMPLE_CHEMICAL", 422, 426], ["ferritin", "GENE_OR_GENE_PRODUCT", 434, 442], ["creatinine", "SIMPLE_CHEMICAL", 450, 460], ["lymphocytes", "CELL_TYPE", 332, 343], ["aspartate aminotransferase", "PROTEIN", 351, 377], ["ASAT", "PROTEIN", 379, 383], ["ALAT", "PROTEIN", 422, 426], ["ferritin", "PROTEIN", 434, 442], ["patients", "SPECIES", 248, 256], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["Covid", "TEST", 239, 244], ["lymphocytes", "TEST", 332, 343], ["aspartate aminotransferase", "TEST", 351, 377], ["ASAT", "TEST", 379, 383], ["alanine aminotransferase", "TEST", 392, 416], ["ALAT)", "TEST", 422, 427], ["ferritin", "TEST", 434, 442], ["creatinine", "TEST", 450, 460], ["glycemia", "TEST", 472, 480], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Other parameters 190 were in the normal range.", [["Other parameters", "TEST", 0, 16], ["normal range", "OBSERVATION_MODIFIER", 33, 45]]], ["191Primary and exploratory efficacy end points 192The dynamic conversion from positive to negative of SARS-Cov2 RT-PCR results was 193 analyzed in both groups of treatments at 0, 3, 7, and 14 days.", [["SARS", "DISEASE", 102, 106], ["The dynamic conversion", "TEST", 50, 72], ["SARS", "TEST", 102, 106], ["PCR", "TEST", 115, 118], ["treatments", "TREATMENT", 162, 172]]], ["No significant differences 194 were observed in the median time, 11 days \uf0b1 8.0 for CIGB-325 plus standard care and 12 195 days \uf0b1 6 for standard care alone (p = 0.614).", [["CIGB-325", "CHEMICAL", 83, 91], ["CIGB", "TEST", 83, 87], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["Thus, time to SARS-Cov2 viral clearance in 196 the nasopharynx swabs behaved similarly for both treatments over the time.", [["nasopharynx swabs", "ANATOMY", 51, 68], ["nasopharynx swabs", "ORGAN", 51, 68], ["SARS", "TEST", 14, 18], ["viral clearance", "TEST", 24, 39], ["the nasopharynx swabs", "TEST", 47, 68], ["nasopharynx", "ANATOMY", 51, 62]]], ["197Primary and exploratory efficacy end points 192The clinical status was classified in categories of asymptomatic, mild, moderate or severe 198 disease and it was followed up until ending treatment and thereafter for both groups.", [["asymptomatic, mild, moderate or severe 198 disease", "PROBLEM", 102, 152], ["treatment", "TREATMENT", 189, 198], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["moderate", "OBSERVATION_MODIFIER", 122, 130], ["severe", "OBSERVATION_MODIFIER", 134, 140], ["198 disease", "OBSERVATION", 141, 152]]], ["In 199 the intent-to-treat population of CIGB-325 group at day 6 there were 2/10 patients that 200 remained asymptomatic since initiation of treatment, 2/10 changed from severe to 201 moderate, 1/10 from moderate to asymptomatic, 1/10 from mild to asymptomatic and 202 4/10 did not change their clinical status during the treatment.", [["CIGB-325", "CHEMICAL", 41, 49], ["CIGB-325", "CHEMICAL", 41, 49], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["CIGB", "TEST", 41, 45], ["treatment", "TREATMENT", 141, 150], ["mild to asymptomatic", "PROBLEM", 240, 260], ["the treatment", "TREATMENT", 318, 331], ["201 moderate", "OBSERVATION_MODIFIER", 180, 192]]], ["Otherwise, in the control 203 6/10 patients remained asymptomatic since initiation of treatment, 1/10 changed from 204 mild to asymptomatic and 3/10 did not change their clinical status during the treatment.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43], ["asymptomatic", "PROBLEM", 53, 65], ["treatment", "TREATMENT", 86, 95], ["the treatment", "TREATMENT", 193, 206], ["asymptomatic", "OBSERVATION", 53, 65], ["mild", "OBSERVATION_MODIFIER", 119, 123]]], ["205Primary and exploratory efficacy end points 192Additionally, chest-CT analysis was performed to investigate the effect of CIGB-325 206 over the Covid-19 pulmonary lesions.", [["pulmonary lesions", "ANATOMY", 156, 173], ["CIGB-325 206", "CHEMICAL", 125, 137], ["pulmonary lesions", "DISEASE", 156, 173], ["CIGB-325 206", "CHEMICAL", 125, 137], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 156, 173], ["chest-CT analysis", "TEST", 64, 81], ["CIGB", "TEST", 125, 129], ["the Covid", "TEST", 143, 152], ["pulmonary lesions", "PROBLEM", 156, 173], ["chest", "ANATOMY", 64, 69], ["pulmonary", "ANATOMY", 156, 165], ["lesions", "OBSERVATION", 166, 173]]], ["For that purpose, both number and lesion's extent 207 at day 0 and after treatment (day 7) were compared just in those patients analyzed per 208 protocol (Table 2) .", [["lesion", "ANATOMY", 34, 40], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["lesion's extent", "TEST", 34, 49], ["treatment", "TREATMENT", 73, 82], ["lesion", "OBSERVATION", 34, 40]]], ["Importantly, CIGB-325 treatment significantly reduced the median 209 number of pulmonary lesions from 9.5 \uf0b1 10 (day 0) to 5.5 \uf0b1 10 (day 7) (p = 0.042).", [["pulmonary lesions", "ANATOMY", 79, 96], ["CIGB-325", "CHEMICAL", 13, 21], ["pulmonary lesions", "DISEASE", 79, 96], ["CIGB-325", "CHEMICAL", 13, 21], ["CIGB-325", "SIMPLE_CHEMICAL", 13, 21], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 79, 96], ["CIGB", "TEST", 13, 17], ["pulmonary lesions", "PROBLEM", 79, 96], ["pulmonary", "ANATOMY", 79, 88], ["lesions", "OBSERVATION", 89, 96]]], ["210Primary and exploratory efficacy end points 192Conversely, no substantial change was observed in the control group.", [["substantial change", "PROBLEM", 65, 83], ["no", "UNCERTAINTY", 62, 64], ["substantial", "OBSERVATION_MODIFIER", 65, 76], ["change", "OBSERVATION", 77, 83]]], ["Proportion of 211 patients with reduction of pulmonary lesions was higher in the CIGB-325 group 212 compared with control according to the Bayesian analysis (pDif > 0; 0.951) ( Table 2) .", [["pulmonary lesions", "ANATOMY", 45, 62], ["reduction of pulmonary lesions", "DISEASE", 32, 62], ["CIGB-325", "CHEMICAL", 81, 89], ["CIGB-325", "CHEMICAL", 81, 89], ["patients", "ORGANISM", 18, 26], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 45, 62], ["patients", "SPECIES", 18, 26], ["pulmonary lesions", "PROBLEM", 45, 62], ["the Bayesian analysis", "TEST", 135, 156], ["Dif", "TEST", 159, 162], ["pulmonary", "ANATOMY", 45, 54], ["lesions", "OBSERVATION", 55, 62], ["higher", "OBSERVATION_MODIFIER", 67, 73]]], ["213Primary and exploratory efficacy end points 192The effect over lesion's extent showed in Table 3 including those patients analyzed per 214 protocol indicates that CIGB-325 treatment also reduced the median of lesion's extent 215 after consecutive-5 day regimen although not significantly.", [["lesion", "ANATOMY", 66, 72], ["lesion", "ANATOMY", 212, 218], ["CIGB-325", "CHEMICAL", 166, 174], ["CIGB-325", "CHEMICAL", 166, 174], ["patients", "ORGANISM", 116, 124], ["CIGB-325", "SIMPLE_CHEMICAL", 166, 174], ["patients", "SPECIES", 116, 124], ["The effect over lesion", "PROBLEM", 50, 72], ["CIGB", "TEST", 166, 170], ["treatment", "TREATMENT", 175, 184], ["consecutive-5 day regimen", "TREATMENT", 238, 263], ["lesion", "OBSERVATION", 66, 72], ["lesion", "OBSERVATION", 212, 218]]], ["Importantly, proportion of patients with 217 reduction of lesion's extent was higher in the CIGB-325 group (4/7) compared with 218 control (1/9) (pDif > 0; 0.982) (Bayesian analysis).", [["lesion", "ANATOMY", 58, 64], ["CIGB-325", "CHEMICAL", 92, 100], ["CIGB-325", "CHEMICAL", 92, 100], ["patients", "ORGANISM", 27, 35], ["lesion", "CANCER", 58, 64], ["patients", "SPECIES", 27, 35], ["lesion's extent", "PROBLEM", 58, 73], ["Dif", "TEST", 147, 150], ["Bayesian analysis", "TEST", 164, 181], ["lesion", "OBSERVATION", 58, 64], ["higher", "OBSERVATION_MODIFIER", 78, 84]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintPrimary and exploratory efficacy end points 192The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.03.20187112 doi: medRxiv preprintPrimary and exploratory efficacy end points 192The overall chest-CT response was also analyzed considering the number of lesions, 220 lesion's extent and the pattern of Covid-19 typical chest-CT abnormalities ( Table 4 ).", [["chest", "ANATOMY", 454, 459], ["lesions", "ANATOMY", 516, 523], ["lesion", "ANATOMY", 529, 535], ["CC", "CHEMICAL", 0, 2], ["chest-CT abnormalities", "DISEASE", 581, 603], ["chest", "ORGAN", 454, 459], ["lesions", "PATHOLOGICAL_FORMATION", 516, 523], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintPrimary", "TREATMENT", 379, 402], ["The overall chest-CT response", "TEST", 442, 471], ["lesions", "PROBLEM", 516, 523], ["Covid", "TEST", 564, 569], ["typical chest-CT abnormalities", "PROBLEM", 573, 603], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["chest", "ANATOMY", 454, 459], ["lesions", "OBSERVATION", 516, 523], ["chest", "ANATOMY", 581, 586], ["abnormalities", "OBSERVATION", 590, 603]]], ["The 221 analysis per protocol showed that 50% (3/6) of patients in the CIGB-325 group had a 222 favorable overall chest-CT response compared with 28.6% (2/7) in the control (pDif > 0; 223 0.796) (Bayesian analysis).", [["CIGB-325", "CHEMICAL", 71, 79], ["CIGB-325", "CHEMICAL", 71, 79], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["the CIGB", "TEST", 67, 75], ["Dif", "TEST", 175, 178], ["Bayesian analysis", "TEST", 196, 213], ["chest", "ANATOMY", 114, 119]]], ["Importantly, any patient had progression in the CIGB-325 224 group and 28.6% (2/7) in the control group did it.", [["CIGB-325 224", "CHEMICAL", 48, 60], ["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["the CIGB", "TEST", 44, 52]]], ["Representative images of chest-CT 225 evolution from one CIGB-325 treated patient are shown in Figure 1 .", [["CIGB-325", "CHEMICAL", 57, 65], ["CIGB-325", "CHEMICAL", 57, 65], ["patient", "ORGANISM", 74, 81], ["patient", "SPECIES", 74, 81], ["Representative images of chest", "TEST", 0, 30], ["CT", "TEST", 31, 33], ["CIGB", "TEST", 57, 61], ["chest", "ANATOMY", 25, 30]]], ["Data from safety analysis indicated that intravenous CIGB-325 added to standard-of-care 235 did increase both frequency of adverse events and patients with adverse events (Table 5) .", [["intravenous", "ANATOMY", 41, 52], ["CIGB-325", "CHEMICAL", 53, 61], ["CIGB-325", "CHEMICAL", 53, 61], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 41, 52], ["CIGB-325", "SIMPLE_CHEMICAL", 53, 61], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["Data from safety analysis", "TEST", 0, 25], ["intravenous CIGB", "TREATMENT", 41, 57], ["adverse events", "PROBLEM", 123, 137], ["adverse events", "PROBLEM", 156, 170]]], ["236Primary and exploratory efficacy end points 192Particularly, pruritus, flushing and rash were increased by CIGB-325 treatment in the 237 100, 80 and 60 % of patients respectively.", [["pruritus", "DISEASE", 64, 72], ["flushing", "DISEASE", 74, 82], ["rash", "DISEASE", 87, 91], ["CIGB-325", "CHEMICAL", 110, 118], ["CIGB-325", "CHEMICAL", 110, 118], ["CIGB-325", "SIMPLE_CHEMICAL", 110, 118], ["patients", "ORGANISM", 160, 168], ["patients", "SPECIES", 160, 168], ["pruritus", "PROBLEM", 64, 72], ["flushing", "PROBLEM", 74, 82], ["rash", "PROBLEM", 87, 91], ["CIGB", "TEST", 110, 114], ["pruritus", "OBSERVATION_MODIFIER", 64, 72], ["flushing", "OBSERVATION_MODIFIER", 74, 82], ["rash", "OBSERVATION", 87, 91], ["increased", "OBSERVATION_MODIFIER", 97, 106]]], ["As previously observed during CIGB-325 238 intravenous administration, intensity of this kind of adverse events was mild and/or 239 moderate in all of the patients.", [["intravenous", "ANATOMY", 43, 54], ["CIGB-325", "CHEMICAL", 30, 38], ["CIGB-325", "CHEMICAL", 30, 38], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 43, 54], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["CIGB", "TEST", 30, 34], ["intravenous administration", "TREATMENT", 43, 69], ["adverse events", "PROBLEM", 97, 111], ["mild", "OBSERVATION_MODIFIER", 116, 120], ["moderate", "OBSERVATION_MODIFIER", 132, 140]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. protective effect from tissue damage.", [["tissue", "ANATOMY", 185, 191], ["CC", "CHEMICAL", 0, 2], ["tissue damage", "DISEASE", 185, 198], ["tissue", "TISSUE", 185, 191], ["ND", "PROBLEM", 9, 11], ["tissue damage", "PROBLEM", 185, 198], ["med", "ANATOMY", 105, 108], ["tissue", "ANATOMY", 185, 191], ["damage", "OBSERVATION", 192, 198]]], ["High serum CPK levels have been associated to 284 rhabdomyolysis, weakness and heart injury in Covid-19 patients; therefore, these findings 285 also support the clinical benefit of using CIGB-325 in this viral disease.", [["serum", "ANATOMY", 5, 10], ["heart", "ANATOMY", 79, 84], ["rhabdomyolysis", "DISEASE", 50, 64], ["weakness", "DISEASE", 66, 74], ["heart injury", "DISEASE", 79, 91], ["CIGB-325", "CHEMICAL", 187, 195], ["viral disease", "DISEASE", 204, 217], ["CIGB-325", "CHEMICAL", 187, 195], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["CPK", "GENE_OR_GENE_PRODUCT", 11, 14], ["heart", "ORGAN", 79, 84], ["patients", "ORGANISM", 104, 112], ["CIGB-325", "SIMPLE_CHEMICAL", 187, 195], ["CPK", "PROTEIN", 11, 14], ["patients", "SPECIES", 104, 112], ["High serum CPK levels", "TEST", 0, 21], ["rhabdomyolysis", "PROBLEM", 50, 64], ["weakness", "PROBLEM", 66, 74], ["heart injury", "PROBLEM", 79, 91], ["Covid", "TEST", 95, 100], ["CIGB", "TEST", 187, 191], ["this viral disease", "PROBLEM", 199, 217], ["rhabdomyolysis", "OBSERVATION", 50, 64], ["weakness", "OBSERVATION", 66, 74], ["heart", "ANATOMY", 79, 84], ["injury", "OBSERVATION", 85, 91], ["viral disease", "OBSERVATION", 204, 217]]], ["Accordingly, 286 LDH and CRP serum levels which are considered inflammatory markers were also 287 reduced after CIGB-325 treatment although no significantly.", [["serum", "ANATOMY", 29, 34], ["CIGB-325", "CHEMICAL", 112, 120], ["CIGB-325", "CHEMICAL", 112, 120], ["LDH", "GENE_OR_GENE_PRODUCT", 17, 20], ["CRP", "GENE_OR_GENE_PRODUCT", 25, 28], ["serum", "ORGANISM_SUBSTANCE", 29, 34], ["CIGB-325", "SIMPLE_CHEMICAL", 112, 120], ["LDH", "PROTEIN", 17, 20], ["CRP", "PROTEIN", 25, 28], ["LDH", "TEST", 17, 20], ["CRP serum levels", "TEST", 25, 41], ["inflammatory markers", "TEST", 63, 83], ["CIGB", "TREATMENT", 112, 116], ["inflammatory", "OBSERVATION_MODIFIER", 63, 75]]], ["288 Improvement of the clinical status at day 7 also trended to be superior by adding CIGB-289 325 to the standard care where 50% (4/8) patients experienced change towards a more 290 favorable clinical category.", [["CIGB-289", "CHEMICAL", 86, 94], ["patients", "ORGANISM", 136, 144], ["patients", "SPECIES", 136, 144], ["CIGB", "TEST", 86, 90]]], ["However, as this analysis takes into account only symptomatic patients in 292 both groups, confirmation of the CIGB-325 effect in larger size population must be of 293 major priority in future studies of this anti-CK2 peptide in The dynamic conversion from positive to negative of SARS-Cov2 RT-PCR at the 295 nasopharyngeal swabs was very similar for both groups of treatments over the time.", [["nasopharyngeal swabs", "ANATOMY", 309, 329], ["CIGB-325", "CHEMICAL", 111, 119], ["SARS", "DISEASE", 281, 285], ["CIGB-325", "CHEMICAL", 111, 119], ["patients", "ORGANISM", 62, 70], ["anti-CK2 peptide", "SIMPLE_CHEMICAL", 209, 225], ["nasopharyngeal swabs", "ORGAN", 309, 329], ["patients", "SPECIES", 62, 70], ["this analysis", "TEST", 12, 25], ["the CIGB", "TEST", 107, 115], ["larger size population", "PROBLEM", 130, 152], ["this anti-CK2 peptide", "TREATMENT", 204, 225], ["SARS", "TEST", 281, 285], ["Cov2 RT", "TEST", 286, 293], ["PCR", "TEST", 294, 297], ["nasopharyngeal swabs", "TEST", 309, 329], ["treatments", "TREATMENT", 366, 376], ["symptomatic", "OBSERVATION_MODIFIER", 50, 61], ["larger", "OBSERVATION_MODIFIER", 130, 136], ["size", "OBSERVATION_MODIFIER", 137, 141], ["nasopharyngeal", "ANATOMY", 309, 323]]], ["296Primary and exploratory efficacy end points 192Addition of CIGB-325 to the standard care did not shorten the time to viral clearance 297 respect to the standard care at least in the regimen tested in our clinical trial.", [["CIGB-325", "CHEMICAL", 62, 70], ["CIGB-325", "CHEMICAL", 62, 70], ["CIGB-325", "SIMPLE_CHEMICAL", 62, 70], ["CIGB", "TEST", 62, 66], ["viral clearance", "TEST", 120, 135], ["the regimen", "TREATMENT", 181, 192]]], ["Other 298 protocols with higher frequency of CIGB-325 administration merit to be explored for that 299 purpose in future trials.", [["CIGB-325", "CHEMICAL", 45, 53], ["CIGB-325", "CHEMICAL", 45, 53], ["CIGB-325", "SIMPLE_CHEMICAL", 45, 53], ["CIGB", "TREATMENT", 45, 49]]], ["Nonetheless, the usefulness and feasibility of the viral end point 300 .", [["the usefulness", "TEST", 13, 27]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review) preprintThe copyright holder for this this version posted September 15, 2020 . . https://doi.org/10.1101 in nasopharyngeal swabs to assess anti-SARS-Cov2 drugs has not been established yet.", [["nasopharyngeal swabs", "ANATOMY", 310, 330], ["CC", "CHEMICAL", 0, 2], ["nasopharyngeal swabs", "CANCER", 310, 330], ["anti-SARS-Cov2", "GENE_OR_GENE_PRODUCT", 341, 355], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["nasopharyngeal swabs", "TEST", 310, 330], ["anti-SARS", "TEST", 341, 350], ["Cov2 drugs", "TREATMENT", 351, 361], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["nasopharyngeal", "ANATOMY", 310, 324]]], ["302(which was not certified by peer review) preprintThe safety profile of CIGB-325 plus standard care was very similar to that observed for 303 CIGB-325 alone in which a predominant pattern of transient histaminergic-like side 304 effects has been observed [30] .", [["CIGB-325", "CHEMICAL", 74, 82], ["CIGB-325", "CHEMICAL", 144, 152], ["CIGB-325", "CHEMICAL", 74, 82], ["CIGB-325", "CHEMICAL", 144, 152], ["CIGB-325", "SIMPLE_CHEMICAL", 74, 82], ["CIGB", "TEST", 74, 78], ["CIGB", "TEST", 144, 148], ["transient histaminergic-like side 304 effects", "PROBLEM", 193, 238]]], ["However, intensity of the side effects was mild and/or 305 moderate in all the patients and total resolution of them was achieved in no more than one 306 hour after CIGB-325 administration.", [["CIGB-325", "CHEMICAL", 165, 173], ["CIGB-325", "CHEMICAL", 165, 173], ["patients", "ORGANISM", 79, 87], ["CIGB-325", "SIMPLE_CHEMICAL", 165, 173], ["patients", "SPECIES", 79, 87], ["the side effects", "PROBLEM", 22, 38], ["CIGB", "TREATMENT", 165, 169], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["moderate", "OBSERVATION_MODIFIER", 59, 67]]], ["Thus, our study confirms that combination of 307 intravenous CIGB-325 at 2.5 mg/kg with standard care for Covid-19 is a manageable and 308 safe strategy to treat patients with this infectious disease.", [["intravenous", "ANATOMY", 49, 60], ["CIGB-325", "CHEMICAL", 61, 69], ["Covid-19", "CHEMICAL", 106, 114], ["infectious disease", "DISEASE", 181, 199], ["CIGB-325", "CHEMICAL", 61, 69], ["CIGB-325", "SIMPLE_CHEMICAL", 61, 69], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["our study", "TEST", 6, 15], ["307 intravenous CIGB", "TREATMENT", 45, 65], ["Covid", "TEST", 106, 111], ["this infectious disease", "PROBLEM", 176, 199], ["infectious", "OBSERVATION", 181, 191]]], ["309(which was not certified by peer review) preprintAll in all, our study gave important clues suggesting a potential quick clinical benefit at 310 day 7 by using our anti-CK2 approach which has not been reported so far in Recently, a clinical trial with RDV has reported clinical benefit in terms of the number of 312 days to recovery of the hospitalized Covid-19 patients with lower respiratory tract 313 involvement in 11 days (95% confidence interval [CI], 9 to 12), [15] , however evidences 314 of chest-CT improvement at day 7 were not provided.", [["lower respiratory tract", "ANATOMY", 379, 402], ["RDV", "CHEMICAL", 255, 258], ["patients", "ORGANISM", 365, 373], ["tract", "ORGANISM_SUBDIVISION", 397, 402], ["patients", "SPECIES", 365, 373], ["RDV", "SPECIES", 255, 258], ["our study", "TEST", 64, 73], ["our anti-CK2 approach", "TREATMENT", 163, 184], ["lower respiratory tract", "PROBLEM", 379, 402], ["CI", "TEST", 456, 458], ["chest-CT", "TEST", 503, 511], ["lower", "ANATOMY_MODIFIER", 379, 384], ["respiratory tract", "ANATOMY", 385, 402], ["chest", "ANATOMY", 503, 508]]], ["315(which was not certified by peer review) preprintFinally, integration of our data leads to the speculation that CIGB-325 might prevent 316 COVID-19 getting worse by inducing an antiviral effect in the lungs and preventing 317 damage caused by the virus.", [["lungs", "ANATOMY", 204, 209], ["CIGB-325", "CHEMICAL", 115, 123], ["CIGB-325", "CHEMICAL", 115, 123], ["CIGB-325", "SIMPLE_CHEMICAL", 115, 123], ["lungs", "ORGAN", 204, 209], ["our data", "TEST", 76, 84], ["CIGB", "TEST", 115, 119], ["COVID", "TEST", 142, 147], ["an antiviral effect in the lungs", "PROBLEM", 177, 209], ["317 damage", "PROBLEM", 225, 235], ["the virus", "PROBLEM", 246, 255], ["antiviral effect", "OBSERVATION", 180, 196], ["lungs", "ANATOMY", 204, 209]]], ["This notion merits further verification in future larger 318 clinical trials of CIGB-325 in Covid-19 patients.", [["CIGB-325", "CHEMICAL", 80, 88], ["CIGB-325", "CHEMICAL", 80, 88], ["CIGB-325", "SIMPLE_CHEMICAL", 80, 88], ["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["further verification", "TEST", 19, 39], ["CIGB", "TEST", 80, 84], ["Covid", "TEST", 92, 97]]], ["319(which was not certified by peer review) preprintLimitations 320(which was not certified by peer review) preprintIn this exploratory study with a small sample size, randomization allowed a balance 321 between the groups regarding the allocation of treatments but not regarding the 322 prognostic variables.", [["this exploratory study", "TEST", 119, 141], ["a small sample size", "PROBLEM", 147, 166], ["treatments", "TREATMENT", 251, 261], ["small", "OBSERVATION_MODIFIER", 149, 154], ["size", "OBSERVATION_MODIFIER", 162, 166]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint(which was not certified by peer review) preprintThe copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.03.20187112 doi: medRxiv preprintConclusions 324Combination of CIGB-325 anti-CK2 peptide with standard-of-care based on alpha 2b-325 IFN/kaletra/hydroxychloroquine was adequately tolerated and superior in improving a 326 quick chest-CT response in Covid-19 patients.", [["CC", "CHEMICAL", 0, 2], ["CIGB-325", "CHEMICAL", 427, 435], ["alpha 2b-325 IFN", "CHEMICAL", 484, 500], ["hydroxychloroquine", "CHEMICAL", 509, 527], ["hydroxychloroquine", "CHEMICAL", 509, 527], ["CIGB-325", "SIMPLE_CHEMICAL", 427, 435], ["CK2", "GENE_OR_GENE_PRODUCT", 441, 444], ["alpha 2b-325 IFN", "SIMPLE_CHEMICAL", 484, 500], ["kaletra", "SIMPLE_CHEMICAL", 501, 508], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 509, 527], ["patients", "ORGANISM", 621, 629], ["CK2", "PROTEIN", 441, 444], ["IFN", "PROTEIN", 497, 500], ["patients", "SPECIES", 621, 629], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprintConclusions", "TREATMENT", 381, 408], ["CIGB", "TREATMENT", 427, 431], ["anti-CK2 peptide", "TREATMENT", 436, 452], ["alpha 2b", "TREATMENT", 484, 492], ["kaletra", "TREATMENT", 501, 508], ["hydroxychloroquine", "TREATMENT", 509, 527], ["Covid", "TEST", 612, 617], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108], ["chest", "ANATOMY", 591, 596]]], ["On the contrary, SARS-Cov2 dynamics in 327 nasopharyngeal swabs was similar for both groups over the time.", [["nasopharyngeal swabs", "ANATOMY", 43, 63], ["SARS", "DISEASE", 17, 21], ["nasopharyngeal swabs", "ORGAN", 43, 63], ["nasopharyngeal swabs", "TEST", 43, 63]]], ["Our clinical findings 328 support future studies to continue to improve patient outcomes in Covid-19 by optimizing 329 CIGB-325 regimens and combining with other antiviral agents.", [["CIGB-325", "CHEMICAL", 119, 127], ["CIGB-325", "CHEMICAL", 119, 127], ["patient", "ORGANISM", 72, 79], ["patient", "SPECIES", 72, 79], ["future studies", "TEST", 34, 48], ["Covid", "TEST", 92, 97], ["CIGB", "TEST", 119, 123], ["other antiviral agents", "TREATMENT", 156, 178]]], ["This is the first clinical 330 study using an anti-CK2 approach in Covid-19 and our findings suggest that CK2 331 inhibition can be an antiviral strategy with favorable risk-benefit to fight SARS-Cov2 332 infection.", [["SARS-Cov2 332", "CHEMICAL", 191, 204], ["infection", "DISEASE", 205, 214], ["Covid-19", "CELL", 67, 75], ["CK2 331", "GENE_OR_GENE_PRODUCT", 106, 113], ["SARS-Cov2 332", "ORGANISM", 191, 204], ["CK2", "PROTEIN", 106, 109], ["SARS-Cov2 332", "SPECIES", 191, 204], ["an anti-CK2 approach", "TREATMENT", 43, 63], ["Covid", "TEST", 67, 72], ["CK2", "TEST", 106, 109], ["an antiviral strategy", "TREATMENT", 132, 153], ["fight SARS", "PROBLEM", 185, 195], ["Cov2 332 infection", "PROBLEM", 196, 214], ["infection", "OBSERVATION", 205, 214]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintConclusions 324The copyright holder for this this version posted September 15, 2020 . . https://doi.org/10.1101 .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020 . . https://doi.org/10.1101 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020 . . https://doi.org/10.1101 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020. . ( .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020. . * Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment.Legends Figures 457.", [["CC", "CHEMICAL", 0, 2], ["TAC", "CHEMICAL", 410, 413], ["TAC", "CHEMICAL", 410, 413], ["patients", "ORGANISM", 339, 347], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 339, 347], ["patients", "SPECIES", 391, 399], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["TAC", "TREATMENT", 410, 413], ["treatment", "TREATMENT", 449, 458], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020. . * Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment .", [["CC", "CHEMICAL", 0, 2], ["TAC", "CHEMICAL", 410, 413], ["TAC", "CHEMICAL", 410, 413], ["patients", "ORGANISM", 339, 347], ["patients", "ORGANISM", 391, 399], ["patients", "SPECIES", 339, 347], ["patients", "SPECIES", 391, 399], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["TAC", "TREATMENT", 410, 413], ["treatment", "TREATMENT", 449, 458], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["0.796 * Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment.Legends Figures 457.", [["TAC", "CHEMICAL", 114, 117], ["TAC", "CHEMICAL", 114, 117], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 95, 103], ["TAC", "TREATMENT", 114, 117], ["treatment", "TREATMENT", 153, 162]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020. . https://doi.org/10.1101/2020.09.03.20187112 doi: medRxiv preprint .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["medRxiv preprint", "TREATMENT", 351, 367], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprintLegends Figures 457The copyright holder for this this version posted September 15, 2020 . . https://doi.org/10.1101", [["CC", "CHEMICAL", 0, 2], ["https://doi.org/10.1101", "CHEMICAL", 303, 326], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]]], "acca1e0d37ab842b631c45c8c7d0069befad344a": [["Escherichia coli is the most common organism isolated.", [["Escherichia coli", "ORGANISM", 0, 16], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "SPECIES", 0, 16], ["Escherichia coli", "PROBLEM", 0, 16], ["coli", "OBSERVATION", 12, 16], ["most common", "OBSERVATION_MODIFIER", 24, 35]]], ["Treat with antibiotics.", [["antibiotics", "TREATMENT", 11, 22]]], ["Blood or urine can be cultured to guide therapy; penicillins and cephalosporins are appropriate empirical choices pending culture results.", [["Blood", "ANATOMY", 0, 5], ["urine", "ANATOMY", 9, 14], ["penicillins", "CHEMICAL", 49, 60], ["cephalosporins", "CHEMICAL", 65, 79], ["penicillins", "CHEMICAL", 49, 60], ["cephalosporins", "CHEMICAL", 65, 79], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["urine", "ORGANISM_SUBSTANCE", 9, 14], ["penicillins", "SIMPLE_CHEMICAL", 49, 60], ["cephalosporins", "SIMPLE_CHEMICAL", 65, 79], ["Blood or urine", "TEST", 0, 14], ["therapy", "TREATMENT", 40, 47], ["penicillins", "TREATMENT", 49, 60], ["cephalosporins", "TREATMENT", 65, 79], ["culture", "TEST", 122, 129]]], ["Adjunctive therapy with fluids and oxygen may be required. \u2022 Neonatal isoerythrolysis occurs in kittens born to a dam with a blood type different from their own.", [["blood", "ANATOMY", 125, 130], ["oxygen", "CHEMICAL", 35, 41], ["isoerythrolysis", "DISEASE", 70, 85], ["oxygen", "CHEMICAL", 35, 41], ["oxygen", "SIMPLE_CHEMICAL", 35, 41], ["kittens", "ORGANISM", 96, 103], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["Adjunctive therapy", "TREATMENT", 0, 18], ["fluids", "TREATMENT", 24, 30], ["oxygen", "TREATMENT", 35, 41], ["Neonatal isoerythrolysis", "PROBLEM", 61, 85]]], ["Antibodies ingested in the colostrum destroy the neonate's red blood cells (RBCs).", [["colostrum", "ANATOMY", 27, 36], ["neonate", "ANATOMY", 49, 56], ["red blood cells", "ANATOMY", 59, 74], ["RBCs", "ANATOMY", 76, 80], ["colostrum", "ORGANISM_SUBSTANCE", 27, 36], ["neonate", "ORGANISM", 49, 56], ["red blood cells", "CELL", 59, 74], ["RBCs", "CELL", 76, 80], ["red blood cells", "CELL_TYPE", 59, 74], ["RBCs", "CELL_TYPE", 76, 80], ["Antibodies", "TEST", 0, 10], ["red blood cells", "TEST", 59, 74], ["RBCs", "TEST", 76, 80]]], ["Treat by removing the kitten from its dam and performing a blood transfusion; the dam serves as a good donor because her RBCs are not affected by her serum antibodies. \u2022 Canine herpesvirus causes fulminating hemorrhagic necrosis of the internal organs in puppies exposed during the first 3 weeks oflife.", [["blood", "ANATOMY", 59, 64], ["RBCs", "ANATOMY", 121, 125], ["serum", "ANATOMY", 150, 155], ["internal organs", "ANATOMY", 236, 251], ["hemorrhagic necrosis", "DISEASE", 208, 228], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["RBCs", "CELL", 121, 125], ["serum", "ORGANISM_SUBSTANCE", 150, 155], ["Canine herpesvirus", "ORGANISM", 170, 188], ["organs", "ORGAN", 245, 251], ["puppies", "ORGANISM_SUBDIVISION", 255, 262], ["RBCs", "CELL_TYPE", 121, 125], ["serum antibodies", "PROTEIN", 150, 166], ["Canine", "SPECIES", 170, 176], ["Canine herpesvirus", "SPECIES", 170, 188], ["a blood transfusion", "TREATMENT", 57, 76], ["her RBCs", "TEST", 117, 125], ["her serum antibodies", "TEST", 146, 166], ["Canine herpesvirus", "PROBLEM", 170, 188], ["fulminating hemorrhagic necrosis of the internal organs in puppies", "PROBLEM", 196, 262], ["fulminating", "OBSERVATION_MODIFIER", 196, 207], ["hemorrhagic", "OBSERVATION_MODIFIER", 208, 219], ["necrosis", "OBSERVATION", 220, 228], ["internal organs", "ANATOMY", 236, 251], ["puppies", "OBSERVATION", 255, 262]]], ["Treatment generally is unrewarding. \u2022 Internal and external parasites can be present. \u2022 \"Fading\" puppies and kittens are sometimes observed.", [["kittens", "ORGANISM", 109, 116], ["Internal and external parasites", "TREATMENT", 38, 69], ["Fading\" puppies", "PROBLEM", 89, 104], ["external parasites", "OBSERVATION", 51, 69]]], ["Causes include septicemia, inadequate environment, low birth weight, congenital abnormalities, maternal neglect or trauma, lack of ingestion of colostrum, and inadequate milk. \u2022 Feeding oforphan puppies and kittens \u2022 Use a commercial milk replacer.", [["colostrum", "ANATOMY", 144, 153], ["milk", "ANATOMY", 170, 174], ["septicemia", "DISEASE", 15, 25], ["birth weight", "DISEASE", 55, 67], ["congenital abnormalities", "DISEASE", 69, 93], ["maternal neglect", "DISEASE", 95, 111], ["trauma", "DISEASE", 115, 121], ["colostrum", "ORGANISM", 144, 153], ["milk", "ORGANISM_SUBSTANCE", 170, 174], ["kittens", "ORGANISM", 207, 214], ["milk", "ORGANISM_SUBSTANCE", 234, 238], ["septicemia", "PROBLEM", 15, 25], ["inadequate environment", "PROBLEM", 27, 49], ["low birth weight", "PROBLEM", 51, 67], ["congenital abnormalities", "PROBLEM", 69, 93], ["maternal neglect", "PROBLEM", 95, 111], ["trauma", "PROBLEM", 115, 121], ["ingestion of colostrum", "PROBLEM", 131, 153], ["a commercial milk replacer", "TREATMENT", 221, 247], ["septicemia", "OBSERVATION", 15, 25], ["low", "OBSERVATION_MODIFIER", 51, 54], ["congenital", "OBSERVATION_MODIFIER", 69, 79], ["abnormalities", "OBSERVATION", 80, 93], ["neglect", "OBSERVATION", 104, 111]]]]}